

10510026rtr

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Expanded

Q₂ - ALL , L₁, L₂, Z, Q₁, R₁, R₂ - ALL

L₃ - ALL

X, Y = CH

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 21 NOV 20 CAS Registry Number crossover limit increased to 300,000 in
additional databases
NEWS 22 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased
to 50,000
NEWS 23 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 24 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 25 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 26 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and
functionality
NEWS 27 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 28 DEC 18 CA/CAplus patent kind codes updated
NEWS 29 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased
to 50,000
NEWS 30 DEC 18 MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

10510026rtr

NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:02:27 ON 21 DEC 2006

=> fil reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:03:05 ON 21 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0
DICTIONARY FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>
Uploading C:\Program Files\Stnexp\Queries\10510026RTRExpand.str

10510026rtr



chain nodes :

7 9 18 19 22 23

ring nodes :

1 2 3 4 5 10 11 12 13 14 15

chain bonds :

1-22 1-23 2-7 4-18 4-19 5-9 9-10

ring bonds :

1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-2 1-5 1-22 1-23 2-3 2-7 3-4 4-5 4-18 4-19 5-9

exact bonds :

9-10

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15

G1:H,CH3

G2:O,S

G3:O,S,N

G4:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 9:CLASS 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 18:CLASS 19:CLASS 22:CLASS 23:CLASS


L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

10510026rtr



G1 H, Me
G2 O, S
G3 O, S, N
G4 H, Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:03:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 68 TO ITERATE

100.0% PROCESSED 68 ITERATIONS 50 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 866 TO 1854
PROJECTED ANSWERS: 576 TO 1424

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:03:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1124 TO ITERATE

100.0% PROCESSED 1124 ITERATIONS 766 ANSWERS
SEARCH TIME: 00.00.01

L3 766 SEA SSS FUL L1

=> fil hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	166.94	167.15

FILE 'HCAPLUS' ENTERED AT 14:03:44 ON 21 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

10510026rtr

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 20 Dec 2006 (20061220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 33 L3

=> d ed ibib abs hitstr 1-33

10510026rtr

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 03 Aug 2006
 ACCESSION NUMBER: 2006:765251 HCAPLUS
 DOCUMENT NUMBER: 145:211037
 TITLE: Preparation of pyrazolyl aryl ureas as modulators of the protein kinase activation state for treatment of inflammation and hyperproliferative diseases
 INVENTOR(S): Flynn, Daniel L.; Pettilio, Peter A.
 PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, LLC, USA
 SOURCE: PCT Int. Appl., 305pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006081034	A2	20060803	WO 2005-US47597	20051223
WO 2006081034	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-638987P P 20041223


OTHER SOURCE(S): HARPAT 145:211037
 GI



AB Novel compds. and methods of using those compds. for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred


L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 embodiment, the compds. of the invention modulate the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein. The compds. of the invention I have general formula (R1-(X))m-A-NH-L-NH-D-(E)q-(Y)t-O wherein R1 = aryl, heteroaryl, and heterocyclyl; X and Y = individually O, S, alkynyl, alkenyl, etc.; A = an arom., monocycloheterocyclic, or bicycloheterocyclic ring; D = Ph or a 5-6-membered heterocyclic ring; E = Ph, pyridinyl, or pyrimidinyl; L = -C(O)- or -S(O)2-; j,m,q,t = 0-1; and Q = a substituted ring or ring system. Over 500 compds. were prepd. For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester provided the propionate, which was subsequently converted to the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentenenitrile afforded Me
 3-[3-(3-tert-butyl-5-amino-1H-pyrazole-1-yl)phenyl]propionate, which was coupled with 1-naphthyl isocyanate and reduced to provide urea II. In a competition assay with SKF 86002 as a fluorescent probe, II inhibited p38 MAP kinase with IC50 of 45 nM.
 IT 872171-35-2P, 1-[5-tert-Butyl-2-[3-[(S)-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-37-4P, 1-[5-tert-Butyl-2-[3-[(R)-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-57-8P, N-[3-tert-Butyl-1-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-2-naphthalenecarboxamide 872171-62-5P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-chlorophenyl)urea 872171-63-6P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-methoxynaphthalen-1-yl)urea 872171-73-8P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-methoxynaphthalen-1-yl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflammation and hyperproliferative diseases)
 RN 872171-35-2 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[(S)-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 872171-37-4 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[(R)-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872171-57-8 HCAPLUS
 CN 2-Naphthalenecarboxamide, N-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 872171-62-5 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 872171-63-6 HCAPLUS
 CN Urea, N-(4-chlorophenyl)-N'-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 872171-73-8 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-methoxy-1-naphthalenyl)]- (9CI) (CA INDEX NAME)




IT 872171-36-3P, 1-[5-tert-Butyl-2-[3-[[5-(4-methoxybenzyl)-(R)-3-methyl-1,1,4-trioxo-(1,2,5)thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-39-6P, 1-[5-tert-Butyl-2-[3-[[5-(4-methoxybenzyl)-1,1,4-trioxo-(1,2,5)thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea 872171-49-8P, 1-[5-tert-Butyl-2-[3-[[1,1,4-trioxo-(1,2,5)thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea
 RL: RCT (Reactant); SPW (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflammation and hyperproliferative diseases)
 RN 872171-36-3 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[[3R)-5-[(4-methoxyphenyl)methyl]-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-methoxy-1-naphthalenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872171-39-6 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)]- (9CI) (CA INDEX NAME)



RN 872171-49-8 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



10510026rtr

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 28 Jul 2006

ACCESSION NUMBER: 2006:739358 HCAPLUS

DOCUMENT NUMBER: 145:377543

TITLE: Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure-activity relationships of a peptide

scaffold
AUTHOR(S): Yue, Eddy W.; Wayland, Brian; Doury, Brent; Crawley, Matthew L.; McLaughlin, Erin; Takvorian, Amy; Wasserman, Zeld; Bower, Michael J.; Wei, Min; Li, Yanlong; Ala, Paul J.; Gonnevillie, Lucie; Wynn, Richard; Burn, Timothy C.; Liu, Phillip C. C.; Combs, Andrew P.

CORPORATE SOURCE: Discovery Chemistry, Experimental Station, Incyte Corporation, Wilmington, DE, 19800, USA

SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(17), 5833-5849


CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB Oxo- and trioxo-substituted isothiazolidinylphenylalanines are prepared as tyrosine mimetics by Suzuki coupling reactions of chloroisothiazolidinones and chlorodioxoisothiazolidinones with N-Boc-4-borono-L-phenylalanine derivs. the isothiazolidinylphenylalanines (with or without subsequent hydrogenation) are incorporated into dipeptides prepared as human protein tyrosine phosphatase 1B (PTP1B) inhibitors such as I. Of the compds. tested, I is the most potent inhibitor of PTP1B with an IC50 value of 40 nM; the corresponding mixture of isothiazolidinone diastereomers inhibits PTP1B with an IC50 value of 80 nM, and the separated (R)-isothiazolidinone diastereomer inhibits PTP1B with an IC50 value of 15.5 µM; the related dipeptides prepared inhibit PTP1B less potently than either I or the mixture of isothiazolidinone diastereomers containing I. Crystal structures of a


L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
dioxothiazolidinone-substituted dipeptide and a dioxoisothiazolidinone-substituted dipeptide bound to PTP1B are detd. by X-ray crystallog.; the low energy conformation found by ab initio calcns. for the said heterocycle more closely approaches the conformation obtained upon binding to PTP1B than that of the unsaid heterocycle.

IT 850315-22-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of isothiazolone- and dioxoisothiazolone-substituted phenylalanine-containing dipeptide amides and their activities as human PTP1B inhibitors)

RN 850315-22-9 HCAPLUS

CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 850315-20-7P 850315-21-8P 850315-23-0P
910606-95-OP 910606-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of isothiazolone- and dioxoisothiazolone-substituted phenylalanine-containing dipeptide amides and their activities as human PTP1B inhibitors)

RN 850315-20-7 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 850315-21-8 HCAPLUS

CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850315-23-0 HCAPLUS

CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 910606-95-0 HCAPLUS


CN Benzeneprapanamide, α-amino-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 910606-94-9

CMF C23 H30 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




10510026rtr

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 910606-97-2 HCAPLUS
 CN L-Phenylalaninamide.
 L-phenylalanyl-4-[[1,1-dioxido-4-oxo-5-(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl]-N-pentyl-, mono(trifluoroacetate) (9CI) (CA
 INDEX NAME)

CM 1
 CRN 910606-96-1
 CMP C32 H39 N5 O5 S

Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CMP C2 H F3 O2



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 29 Dec 2005
 ACCESSION NUMBER: 2005:1346235 HCAPLUS
 DOCUMENT NUMBER: 144:88279
 TITLE: Preparation of 1-pyrazolyl-3-phenylurea p38 MAP
 kinase
 INVENTOR(S): inhibitors as antiinflammatory medicaments
 Flynn, Daniel L.; Petillo, Peter A.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 214 pp., Cont.-in-part of U.S.
 Ser. No. 746,460.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288286	A1	20051229	US 2004-886329	20040706
US 2004180906	A1	20040916	US 2003-746460	20031224
US 7144911	B2	20061205		
WO 2006014290	A2	20060209	WO 2005-US23100	20050630
WO 2006014290	A3	20060427		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LG, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2003-746460 A2 20031224
 US 2002-437304P P 20021231
 US 2002-437403P P 20021231
 US 2002-437415P P 20021231
 US 2002-437487P P 20021231
 US 2003-463804P P 20030418
 US 2004-886329 A 20040706

OTHER SOURCE(S): MARPAT 144:88279
 GI

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. (R1X)ma(NH)pLn(NH)pDEqYtO [I; wherein R1 = (un)substituted (hetero)aryl; X, Y = independently O, S, NR6, NR6SO2, NR6CO, alkynyl, alkenyl, alkylene, O(CH2)h, NR6(CH2)h, wherein for each alkylene, O(CH2)h, and NR6(CH2)h, one of the methylene groups may be substituted with CO; h = 1-4; A = (un)substituted aryl, hetero(bi)cyclyl; D = (un)substituted Ph, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, pyrimidyl; E = (un)substituted Ph, pyridinyl, pyrimidinyl; L = CO, SO2; m, n, p, q, t = independently O, 1; Q = (un)substituted heterocyclyl, Ph, etc.; R6 = independently H, alkyl, allyl, TMS(CH2)2; with exceptions]

were prepared as p38 MAP kinase inhibitors. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the α-C helix, the α-D helix, the catalytic loop, the switch control ligand sequence, or the C-lobe residues of the kinase protein with I (no data). Although the methods of preparation are not claimed, prepn. and/or characterization data for .apprx.150 examples of I and many intermediates are included. For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester using 10% Pd/C in EtOH provided the propionate, which was treated with NaNH2 in the presence of 6N HCl and SnCl2·2H2O to give the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentanonitrile in EtOH and 6N HCl afforded Me 3-(3-(3-tert-butyl-5-amino-1H-pyrazol-1-yl)phenyl)propionate. Coupling of the amine with 1-naphthyl isocyanate in CH2Cl2, followed by reduction with LiOH in THF/MeOH/H2O provided the urea II. In a competition assay with SKF 86002 as a fluorescent probe, the latter inhibited p38 MAP kinase with IC50 of 45 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory conditions (no data).


IT 872171-35-2P, 1-[5-tert-Butyl-2-[3-[[[3-(3-methyl-1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-37-4P, 1-[5-tert-Butyl-2-[3-[[[3-(3-methyl-1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-57-8P, N-[3-(3-tert-Butyl-1-[3-[[[3-(3-methyl-1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]-9CI) (CA INDEX NAME)

[[1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-63-6P, 1-[5-tert-Butyl-2-[3-

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


[[1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-chlorophenyl)urea 872171-73-8P, 1-[5-tert-Butyl-2-[3-[[[3-(3-methyl-1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-methoxynaphthalen-1-yl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; prepn. of [pyrazolyl](phenyl)urea p38 kinase inhibitors as antiinflammatory agents)
 RN 872171-35-2 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[[[3-(3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]-9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 872171-37-4 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[[[3-(3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]-9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872171-57-8 HCAPLUS

10510026rtr


L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Naphthalenecarboxamide, N-[3-([1,1-dimethylethyl]-1-[3-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



```


RN      872171-62-5  HCAPLUS
CN      Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-
        thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl-
        (9CI)  (CA INDEX NAME)

```




RN 872171-63-6 HCAPLUS
CN Urea, N-(4-chlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT	872171-36-3P, 1-[5-tert-Butyl-2-{3-[(5-(4-methoxybenzyl)-(R)-3-methyl-1,4,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl}-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-39-6P, 1-[5-tert-Butyl-2-{3-[(5-(4-methoxybenzyl)-1,1,4,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl}-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea 872171-49-8P, 1-[5-tert-Butyl-2-{3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl}-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea
RL	RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
	(preparation of (pyrazolyl)(phenyl)urea p38 kinase inhibitors as antiinflammatory agents)
RN	872171-36-3 HCAPUS
CN	Urea N-[3-(1,1-dimethylethyl)-1-[3-[(3R)-5-[4-methoxyphenyl)methyl]-3-methyl-1,4-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl)-N'-1-naphthalenyl (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 072171-39-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[[5-[(4-methoxyphenyl)methyl]-1,1-

1.4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 072171-73-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

dioxide-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 872171-49-8 HCAPLUS
CN Urea, N-{3-[1,1-dimethylethyl]-1-[3-{{1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl}phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)

PAGE 1-A



10510026rtr

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 26 Aug 2005

ACCESSION NUMBER: 2005:904352 HCAPLUS

DOCUMENT NUMBER: 143:248386

TITLE: Preparation of substituted azole derivatives for

treating diseases mediated by PTPase activity

Mjallil, Adnan M. M.; Poliseti, Dharma R.;

Subramanian, Govindan; Quada, James C.; Arimilli,

Murty N.; Yarragunta, Ravindra R.; Andrews, Robert

C.:

Xie, Rongyuan

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 204 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187277	A1	20050825	US 2005-56498	20050211
AU 2005214349	A1	20050901	AU 2005-214349	20050211
CA 2551909	A1	20050901	CA 2005-2551909	20050211
WO 2005080346	A1	20050901	WO 2005-US4590	20050211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1730118	A1	20061213	EP 2005-723026	20050211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRIORITY APPLN. INFO.:				
				US 2004-543971P P 20040212
				WO 2005-US4590 W 20050211

OTHER SOURCE(S): MARPAT 143:248386

GI



L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

AB The title compds. I [a, b = 0-2; W = O, S, NR2 (wherein R2 = alkyl, etc.)];

R1 = H, halo, CN, etc.; L1 = a direct bond, (un)substituted NHCO, NHSO2, etc.; Ar1 = (un)substituted (hetero)aryl, fused cycloalkylaryl, etc.; Ar2 = (un)substituted (hetero)arylene, fused arylcycloalkylene, etc.; L2 = CH2, O, alkylene, etc.] which can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity such as type I diabetes and type II diabetes, were prepared

Thus, treating 4-(2,4-dichlorophenyl)-2-[2-(4-methoxyphenyl)-(E)-vinyl]-1H-imidazole with Me bromoacetate followed by ester hydrolysis afforded 56% 4-(2,4-dichlorophenyl)-2-[2-(4-methoxyphenyl)-(E)-vinyl]-1H-imidazol-1-yl]acetic acid. The representative compds. I were tested for inhibition of PTP-1B. In general, the exemplified compds. I may inhibit PTP-1B with IC50 of less than 20 μ M. The pharmaceutical compns. comprising the compds. I, and their use in treating human or animal disorders are also disclosed.


IT 863243-91-8P 863245-57-2P 863245-74-3P

863246-05-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (preparation of substituted azole derivs. for treating diseases mediated by PTPase activity)

RN 863243-91-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-4,4-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-57-2 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


Double bond geometry as shown.



RN 863245-74-3 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-05-3 HCAPLUS

CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 863243-80-5P 863243-92-9P 863243-93-0P
 863243-94-1P 863243-95-2P 863244-05-7P
 863244-06-8P 863244-07-9P 863244-08-0P
 863244-13-7P 863244-47-7P 863244-51-3P
 863244-52-4P 863244-53-5P 863245-25-4P
 863245-56-1P 863245-58-3P 863245-59-4P
 863245-60-7P 863245-61-8P 863245-62-9P
 863245-63-0P 863245-64-1P 863245-66-3P
 863245-67-4P 863245-68-5P 863245-69-6P
 863245-70-9P 863245-71-0P 863245-72-1P
 863245-75-4P 863245-78-7P 863245-80-1P
 863245-82-3P 863246-03-1P 863246-04-2P
 863246-06-4P 863246-07-5P 863246-09-7P
 863246-10-0P 863246-11-1P 863246-12-2P
 863246-13-3P 863246-15-5P 863246-16-6P
 863287-03-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of substituted azole derivs. for treating diseases
 mediated by
 PTPase activity)
 RN 863243-80-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-difluorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)
 Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Double bond geometry as shown.




PAGE 1-A




PAGE 2-A

RN 863243-94-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2-chlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)
 Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863243-92-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)
 Double bond geometry as shown.




RN 863243-93-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-phenyl-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863243-95-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(4-chlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)
 Double bond geometry as shown.



RN 863244-05-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)
 Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863244-06-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(3,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-07-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(3,4-difluorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-1-yl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 863244-47-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 863244-51-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.




RN 863244-08-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2-chloro-4-fluorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-13-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,1-dioxide (9CI) (CA INDEX NAME)




RN 863244-52-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 863244-53-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[4-(2,4-dichlorophenyl)-2-{2-[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 863245-25-4 HCAPLUS
 CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-{(1E)-2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)]1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-56-1 HCAPLUS


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[2-{(1E)-2-[3'-chloro[1,1'-biphenyl]-4-yl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-60-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[4-(2,4-dichlorophenyl)-2-{(1E)-2-[3'-(1-methylethoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-61-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[4-(2,4-dichlorophenyl)-2-{(1E)-2-[4'-(1-methylethyl)thio][1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[2-{(1E)-2-[3',5'-bis(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-58-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[4-(2,4-dichlorophenyl)-2-{(1E)-2-(2'-fluoro-5'-propoxy[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-59-4 HCAPLUS


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[2-{(1E)-2-[3'-chloro[1,1'-biphenyl]-4-yl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-62-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[4-(2,4-dichlorophenyl)-2-{(1E)-2-[4'-(1,1-dimethylethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-63-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-{4-[[4-(2,4-dichlorophenyl)-2-{(1E)-2-[3'-(1,1-dimethylethyl)-5'-methyl[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-64-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-66-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-[4-(5-acetyl-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-67-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[2'-fluoro-5'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-68-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(3,3-dimethylbutoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-69-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(4,4,4-trifluorobutoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-70-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-fluoro-4'-(4,4,4-trifluorobutoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-71-0 HCAPLUS
CN Carbamic acid, [4'-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-1H-imidazol-2-yl]ethenyl]-4-fluoro[1,1'-biphenyl]-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-72-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-4-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-75-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-78-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(4,4-trifluorobutoxy)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


(trifluoromethyl)phenoxy]phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863246-03-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-04-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(2,4-dichlorophenyl)-1-ethyl]-1H-imidazol-2-yl]ethenyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.




RN 863245-80-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dimethylethyl)phenoxy]phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-82-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(4-tert-butylphenoxy)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-06-4 HCAPLUS
CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-07-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-09-7 HCAPLUS
CN Carbamic acid, [4'-[(1E)-2-{4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl][1,1'-biphenyl]-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-10-0 HCAPLUS
CN Carbamic acid, [4'-[(1E)-2-{4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl][1,1'-biphenyl]-3-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



RN 863246-13-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(4-phenoxyphenyl)ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-15-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(3-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863246-11-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(3-(1-methylethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-12-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(3-(1-methyl[1,1'-biphenyl]-4-yl]ethenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-16-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(3-(1-methyl[1,1'-biphenyl]-4-yl]ethenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863287-03-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(3-(1-methyl[1,1'-biphenyl]-4-yl]ethenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 863247-41-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of substituted azole derivs. for treating diseases mediated by PTPase activity)
 RN 863247-41-0 HCAPLUS
 CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.




L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-89-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692764-94-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[1,1'-biphenyl]-3-yl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 852835-44-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 03 May 2005

ACCESSION NUMBER: 2005:378875 HCAPLUS
 DOCUMENT NUMBER: 143:19267

TITLE: Structure-based design of protein tyrosine phosphatase-1B inhibitors

AUTHOR(S): Black, Emma; Breed, Jason; Breese, Alexander L.; Embrey, Kevin; Garcia, Robert; Gero, Thomas W.; Godfrey, Linda; Kenny, Peter W.; Morley, Andrew D.; Minshull, Claire A.; Pannifer, Andrew D.; Read, Jon; Rees, Amanda; Russell, Daniel J.; Toader, Dorin; Tucker, Julie

CORPORATE SOURCE: AstraZeneca, Cheshire, SK10 4TG, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(10), 2503-2507

CODEN: BMCLEB; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:19267

AB Using structure-based design, a new class of inhibitors of protein tyrosine phosphatase-1B (PTP1B) has been identified, which incorporate the

1,2,5-thiadiazolidin-3-one-1,1-dioxide template.


IT 692765-80-3P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(structure-based design of protein tyrosine phosphatase-1B inhibitors)

RN 692765-80-3 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-(3-bromophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



IT 612530-44-6P 692764-89-9P 692764-94-6P

852835-44-0P 852835-45-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(structure-based design of protein tyrosine phosphatase-1B inhibitors)


RN 612530-44-6 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 852835-45-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

FORMAT

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ED Entered STN: 22 Apr 2005
 ACCESSION NUMBER: 2005:347030 HCAPLUS
 DOCUMENT NUMBER: 142:411350
 TITLE: Preparation of 1-oxo and 1,1-dioxoisothiazolone and related modulators of proteins such as phosphatases that bind phosphorylated peptides and proteins
 INVENTOR(S): Combs, Andrew P.; Yue, Eddy Wai Tsun; Bower, Michael Jason; Zhu, Wenyu; Crawley, Matthew Lantz; Sparks, Richard Bruce; Pruitt, James Russell; Takvorian, Amy Incyte Corporation, USA
 PATENT ASSIGNEE(S): PCT Int. Appl., 529 pp.
 SOURCE: CODEN: PIXX22
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035551	A2	20050421	WO 2004-US33212	20041007
WO 2005035551	A3	20060908		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 2005272778	A1	20051208	US 2004-960344	20041007
US 7141596	B2	20061128		
PRIORITY APPLN. INFO.: US 2003-510002P P 20031008				
US 2003-529372P P 20031211				
US 2004-600506P P 20040811				
OTHER SOURCE(S): CASREACT 142:411350; MARPAT 142:411350				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides 1-oxo and 1,1-dioxoisothiazolones (shown as
 I-IV; also isothiazolidinone analogs of I-IV with R16 and R17 in place of R15 and R2 as a substituent at the 5 position of the isothiazolidinone ring; variables defined below; e.g. V) and related compds. that can modulate (no data) the activity of a target protein, such as a phosphatase, that selectively binds phosphorylated peptides or proteins. The present compds. can be useful (no data) in treating diseases or

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]biphenyl-4-sulfonamide 850315-36-5P
 850315-40-1P, 4-Bromo-N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)benzenesulfonamide trifluoroacetate 850315-44-5P, N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-bis(trifluoromethyl)benzenesulfonamide trifluoroacetate 850315-48-9P, N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)benzenesulfonamide trifluoroacetate 850315-63-8P, N-[(1S)-2-[3-Chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]biphenyl-4-sulfonamide trifluoroacetate 850315-65-0P 850315-69-4P

4-Bromo-N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)benzenesulfonamide trifluoroacetate 850315-73-0P, N-[(1S)-2-[3-Chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-bis(trifluoromethyl)benzenesulfonamide trifluoroacetate 850327-65-0P 850327-72-2P, N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyanobenzenesulfonamide trifluoroacetate 850327-69-4P, N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyanobenzenesulfonamide trifluoroacetate 850327-71-8P,

N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxybenzenesulfonamide trifluoroacetate 850327-73-0P, N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenylbenzenesulfonamide trifluoroacetate 850327-75-2P, N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethylbenzenesulfonamide trifluoroacetate 850327-77-4P,

N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]benzenesulfonamide trifluoroacetate 850327-79-6P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyanobenzenesulfonamide trifluoroacetate 850327-81-0P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyanobenzenesulfonamide trifluoroacetate 850327-83-2P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxybenzenesulfonamide trifluoroacetate 850327-85-4P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxybenzenesulfonamide trifluoroacetate 850327-87-6P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethylbenzenesulfonamide trifluoroacetate 850327-89-8P, 3-Chloro-N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]benzenesulfonamide trifluoroacetate 850327-91-2P, N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluorobenzenesulfonamide trifluoroacetate

benzimidazol-2-yl)phenyl]-3-fluorobenzenesulfonamide trifluoroacetate

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 disorders, including, for example, diabetes and obesity, that are connected directly or indirectly to the activity of the target protein. Methods of prepn. are claimed and hundreds of example prepn. are included. For example, V was prepd. in 12 steps (50, 62, 100, 59, not detd., 100, 100, 99, not detd., not detd., 43, and 25 % yield) starting from N-tert-butyl-3-[2-(tert-butylcarbamoyl)ethyl]sulfonylpropionamide. For I-IV: a dashed line indicates an optional bond; Sc1 is a 1st mol. scaffold or is absent; Sc2 is a 2nd mol. scaffold or is absent, wherein

at least one of Sc1 and Sc2 is present; or Sc1 and Sc2 together with X1 and X2 or X4 and X5 form a 5-, 6-, or 7-membered fused carbocyclic ring or a 5-, 6-, or 7-membered fused heterocarbocyclic ring; X1 is C or N when Sc1 is present; X1 is CR1, N, NR2, CO, CS, SO, or SO2 when Sc1 is absent; X2 is C or N when Sc2 is present; X2 is CR1, N, NR2, CO, CS, SO, or SO2 when Sc2 is absent; X3 is C or N when each D1, D2, and D3 = CR1, N, NR2, CO, CS, SO, or SO2, wherein the ring formed by X1, X2, X3, D1, D2, and D3 is an arom. ring; X4 is C or N when Sc1 is present; X4 is O, S, CR3, N, NR4, CO, CS, SO, or SO2 when Sc1 is absent; X5 is C or N when Sc2 is present; X5 is O, S, CR3, N, NR4, CO, CS, SO, or SO2 when Sc2 is absent; X6 is C or N. Each E1 and E2 = O, S, CR3, N, NR4, CO, CS, SO, or SO2, wherein the ring formed by X4, X5, X6, E1, and E2 is an arom. ring; R2 is H, halo, C1-C4 alkyl, C3-C6 cycloalkyl, haloalkyl, OR28, SR28, NO2, CN, SOR29, SO2R29, COR30, COOR31, NR32R33, a 5- or 6-membered heterocarbocycli group, or tetrazolyl. R15 is H, halo, C1-C4 alkyl, C3-C6 cycloalkyl, haloalkyl, OH,

CS, SO, or SO2 when Sc1 is absent; X5 is C or N when Sc2 is present; X5 is O, S, CR3, N, NR4, CO, CS, SO, or SO2 when Sc2 is absent; X6 is C or N.

Each E1 and E2 = O, S, CR3, N, NR4, CO, CS, SO, or SO2, wherein the ring formed by X4, X5, X6, E1, and E2 is an arom. ring; R2 is H, halo, C1-C4 alkyl, C3-C6 cycloalkyl, haloalkyl, OR28, SR28, NO2, CN, SOR29, SO2R29, COR30, COOR31, NR32R33, a 5- or 6-membered heterocarbocycli group, or tetrazolyl. R15 is H, halo, C1-C4 alkyl, C3-C6 cycloalkyl, haloalkyl, OH,

C1-C4 alkoxy, C1-C4 haloalkoxy, SH, C1-C4-thioalkoxy, CN, NO2, SO(C1-C4 alkyl), SO(C1-C4 haloalkyl), SO(C3-C6 cycloalkyl), SONH2, SO3H, SO2(C1-C4 alkyl), SO2(C1-C4 haloalkyl), SO2(C3-C6 cycloalkyl), CO(C1-C4 haloalkyl), CO(C1-C4 alkoxy), CO(C1-C4 haloalkyl), CO(C3-C6 cycloalkyl), CO(C1-C4 haloalkyl), CONH2, CONH(C1-C4 alkyl), CON(C1-C4 alkyl), CONH(C3-C6 cycloalkyl), CON(C3-C6 cycloalkyl), NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl), N(C3-C6 cycloalkyl), or N(C3-C6 cycloalkyl)2. R16 and R17 = H, halo, C1-C4 alkyl, C3-C6 cycloalkyl, haloalkyl, OH, C1-C4 alkoxy, C1-C4 haloalkoxy, SH, C1-C4 thioalkoxy, CN, NO2, SO(C1-C4 alkyl), SO(C1-C4 haloalkyl), SO(C3-C6 cycloalkyl), SONH2, SO3H, SO2(C1-C4 alkyl),

SO2(C1-C4 haloalkyl), SO2(C3-C6 cycloalkyl), SO2NH2, CHO, COOH, CO(C1-C4 alkyl), CO(C3-C6 cycloalkyl), CO(C1-C4 haloalkyl), CO(heterocarbocycli), CO(C1-C4 alkyl), CO(C3-C6 cycloalkyl), CO(C1-C4 haloalkyl), CONH2, CONH(C1-C4 alkyl), CON(C1-C4 alkyl), CONH(C3-C6 cycloalkyl), CON(C3-C6 cycloalkyl)2, NH2, NH(C1-C4 alkyl), N(C1-C4 alkyl)2, NH(C3-C6 cycloalkyl)2, or R16 and R17 together with the C atom to which they are attached form a C3-C6 cycloalkyl group or a 3-7 membered heterocarbocycli group; and q1 is 1 or 2; addnl. details are given in the claims.

or N(C3-C6 cycloalkyl)2; or R16 and R17 together with the C atom to which they are attached form a C3-C6 cycloalkyl group or a 3-7 membered heterocarbocycli group; and q1 is 1 or 2; addnl. details are given in the claims.

IT 850315-19-4P, [(1S)-1-[(1S)-1-(Pentylcarbamoyl)-2-[4-(1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]ethyl]carbamoyl]-2-phenylethyl]carbamate acid tert-butyl ester 850315-22-9P, (2S)-2-[(2S)-2-[(2-(4-Methoxyphenyl)acetyl)amino]-3-phenylpropionyl]amino]-N-pentyl-3-[4-(1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]propionamide 850315-24-1P, N-[(1S)-2-[4-(1,1-Dioxido-4-


L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 850327-93-4P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-chlorobenzenesulfonamide trifluoroacetate 850327-95-6P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluorobenzenesulfonamide trifluoroacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; prepn. of 1-oxo and 1,1-dioxoisothiazolone and related modulators of proteins such as phosphatases that bind phosphorylated peptides and proteins)


RN 850315-19-4 HCAPLUS
 CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850315-22-9 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850315-24-1 HCAPLUS
 CN [1,1'-Biphenyl]-4-sulfonamide, N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 850315-36-5 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-4-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-35-4
CMF C25 H19 F6 N5 O5 S2

Absolute stereochemistry.



CM 2


CRN 76-05-1

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzenesulfonamide,
N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-43-4
CMF C26 H18 F9 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-48-9 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-47-8
CMF C25 H19 F6 N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C2 H F3 O2




RN 850315-40-1 HCAPLUS
CN Benzenesulfonamide, 4-bromo-N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-39-8
CMF C25 H18 Br F6 N5 O6 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-44-5 HCAPLUS

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-63-8 HCAPLUS
CN [1,1'-Biphenyl]-4-sulfonamide, N-[(1S)-2-[3-chloro-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 850315-62-7
CMF C30 H23 Cl F3 N5 O5 S2

Absolute stereochemistry.

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 850315-65-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-4-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-64-9
CMF C25 H18 Cl F6 N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 850315-69-4 HCAPLUS
CN Benzenesulfonamide, 4-bromo-N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-68-3
CMF C25 H17 Br Cl F6 N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2


RN 850315-73-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-72-9
CMF C26 H17 Cl F9 N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 850327-65-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-64-9
CMF C23 H19 Cl2 N5 O5 S2

Absolute stereochemistry.



CM 2

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CRN 76-05-1
CMF C2 H F3 O2



RN 850327-67-2 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyano-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-66-1
CMF C24 H18 Cl2 N6 O5 S2

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-69-4 HCAPLUS

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-73-0 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxy-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-72-9
CMF C25 H23 Cl2 N5 O7 S2


Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyano-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-68-3
CMF C24 H18 Cl2 N6 O5 S2

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-71-8 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxy-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-70-7
CMF C29 H23 Cl2 N5 O6 S2

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850327-75-2 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethyl-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-74-1
CMF C25 H23 Cl2 N5 O5 S2

Absolute stereochemistry.

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-77-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-76-3
CMF C23 H20 Cl N5 O5 S2


Absolute stereochemistry.



L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-80-9
CMF C24 H19 Cl N6 O5 S2

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-83-2 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-82-1
CMF C29 H24 Cl N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-79-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-78-5
CMF C24 H19 Cl N6 O5 S2

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-81-0 HCAPLUS

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-85-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-84-3
CMF C25 H24 Cl N5 O7 S2

Absolute stereochemistry.



10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 850327-87-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-86-5
CMF C25 H24 Cl N5 O5 S2


Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2


CRN 76-05-1
CMF C2 H F3 O2

RN 850327-93-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-92-3
CMF C23 H19 Cl2 N5 O5 S2

Absolute stereochemistry.



CM 2

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 850327-89-8 HCAPLUS

CN Benzenesulfonamide, 3-chloro-N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-88-7
CMF C23 H18 Cl3 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 850327-91-2 HCAPLUS

CN Benzenesulfonamide, N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-90-1
CMF C23 H18 Cl2 F N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2


RN 850327-95-6 HCAPLUS

CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-94-5
CMF C23 H19 Cl F N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 850315-20-7P, [(S)-2-[4-(5-Benzyl-1,1,4-


trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]-1-(pentylcarbamoyl)ethyl]carbamic acid tert-butyl ester 850315-21-8P, [(1S)-1-[(1S)-2-[4-(5-Benzyl-1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]-1-(pentylcarbamoyl)ethyl]carbamoyl]-2-phenylethyl]carbamic acid tert-butyl

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ester 850315-21-0P. (2S)-3-[(4-(5-Benzyl-1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl)-2-[(2S)-2-[(4-methoxyphenyl)acetyl]amino]-N-pentylpropionamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 1-oxo and 1,1-dioxoisothiazolone and related modulators of proteins such as phosphatases that bind phosphorylated peptides and proteins)


RN 850315-20-7 HCAPLUS
 CN Carbamic acid, [(1S)-1-[(4-(1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)phenyl)methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 850315-21-8 HCAPLUS
 CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850315-23-0 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 11 Apr 2005
 ACCESSION NUMBER: 2005:308290 HCAPLUS
 DOCUMENT NUMBER: 143:7658
 TITLE: Expedient syntheses of sulfonylhydantoins and two six-membered analogs
 AUTHOR(S): Campbell, Andrew D.; Birch, Alan M.
 CORPORATE SOURCE: Research and Development, AstraZeneca, Cheshire, SK10 4TG, UK
 SOURCE: Synlett (2005), (5), 834-838
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:7658
 GI




AB A range of α-amino esters can be turned into sulfonylhydantoins in a single, atom-economic step using sulfamide and DBU. E.g., reaction of BnNHCH₂CO₂Et with sulfamide and DBU gave 65% sulfonylhydantoin 1. This procedure obviates the need for a three- or four-step sequence utilized by traditional procedures. Two new six-membered analogs [5-aryl-1,2,6-thiadiazinan-3-one 1,1-dioxides and 5-aryl-1,2-thiazinan-3-one 1,1-dioxides], e.g. II and III, have also been prepared utilizing novel synthetic protocols.
 IT 612528-23-1P 612529-46-1P 612530-69-5P
 852358-50-0P 852358-51-1P 852358-53-3P
 852358-54-4P 852358-56-6P 852358-57-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)


L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of sulfonylhydantoins via reaction of amino acid esters with sulfamide and DBU)
 RN 612528-23-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-46-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-69-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 852358-50-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr


L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852358-51-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 852358-53-3 HCAPLUS
CN Benzonitrile, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 852358-54-4 HCAPLUS

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 852358-56-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(1,1'-biphenyl)-3-ylmethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 852358-57-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-methyl-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 08 Mar 2005
ACCESSION NUMBER: 2005:202894 HCAPLUS
DOCUMENT NUMBER: 142:366767
TITLE: 1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides are potent inhibitors of human trypsin
AUTHOR(S): Wong, Tzutshin; Groutas, Christopher S.; Mohan, Swathi; Lai, Zhong; Alliston, Kevin R.; Vu, Nga; Schechter, Norman M.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Archives of Biochemistry and Biophysics (2005), 436(1), 1-7
CODEN: ABBIA4; ISSN: 0003-9861
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors describe herein the design, synthesis, and in vitro biochem. evaluation of a series of potent, time-dependent inhibitors of the mast cell-derived serine protease trypsin. The inhibitors were readily obtained by attaching various heterocyclic thiols, as well as a basic primary specificity residue P1, to the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold. The inhibitors were found to be devoid of any inhibitory activity toward a neutral (elastase) or cysteine (papain) protease, however they were also fairly efficient inhibitors of bovine trypsin. The differential inhibition observed with trypsin suggests that enzyme selectivity can be optimized by exploiting differences in the S' subsites of the two enzymes. The results described herein demonstrate


the versatility of the heterocyclic scaffold in fashioning mechanism-based inhibitors of neutral, basic, and acidic (chymo)trypsin-like serine proteases.

IT 849415-30-1P 849415-31-2P 849415-32-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides are potent inhibitors of human trypsin)

RN 849415-30-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(4-aminobutyl)-2-[(2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-31-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(4-aminobutyl)-5-(phenylmethyl)-2-[(2-phenyl-1,3,4-oxadiazol-2-yl)thio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 849415-32-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((4-aminobutyl)-5-(phenylmethyl)-2-[[3-phenyl-1,2,4-oxadiazol-5-yl]thio]methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 849415-24-3P 849415-25-4P 849415-26-5P
849415-27-6P 849415-28-7P 849415-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides

are potent inhibitors of human cryptase)
RN 849415-24-3 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 849415-28-7 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[[5-phenyl-1,3,4-oxadiazol-2-yl]thio]methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-29-8 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[[5-phenyl-1,2,4-oxadiazol-5-yl]thio]methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 849415-25-4 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[[phenylthio]methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849415-26-5 HCAPLUS
CN Carbamic acid, [4-[(3S)-5-(chloromethyl)-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-27-6 HCAPLUS
CN Carbamic acid, [4-[(3S)-5-[(2-benzoxazolylthio)methyl]-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Aug 2004
ACCESSION NUMBER: 2004:677210 HCAPLUS
DOCUMENT NUMBER: 141:235669
TITLE: Potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-3-one 1,1-dioxide-based
sulfonamide derivatives
AUTHOR(S): Lai, Zhong; Gan, Xiangdong; Wei, Liqing; Alliston,
Kevin R.; Yu, Hongyi; Li, Yue H.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University,
Wichita, KS, 67260, USA
SOURCE: Archives of Biochemistry and Biophysics (2004),
429(2), 191-197
CODEN: ABBIA4; ISSN: 0003-9861
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:235669
AB The design, synthesis, and in vitro biochem. evaluation of a class of
mechanism-based inhibitors of human leukocyte elastase (HLE) that
incorporate in their structure a 1,2,5-thiadiazolidin-3-one 1,1-dioxide
scaffold with appropriate recognition and reactivity elements appended to
it is described. The synthesized compds. were found to be efficient,
time-dependent inhibitors of HLE. The interaction of the inhibitors with
HLE is postulated to lead to the formation of a highly reactive
N-sulfonyl
imine (a Michael acceptor) that arises from an enzyme-induced sulfonamide
fragmentation cascade. Subsequent reaction ultimately leads to the
formation of a relatively stable acyl enzyme. The results cited herein
demonstrate convincingly the superiority of the
1,2,5-thiadiazolidin-3-one
1,1-dioxide scaffold over other scaffolds (e.g., saccharin) in the design
of inhibitors of (chymo)trypsin-like serine proteases.
IT 749866-31-7P 749866-32-8P 749866-33-9P
749866-34-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-
3-one 1,1-dioxide-based sulfonamide derivs.)
RN 749866-31-7 HCAPLUS
CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]-, methyl ester
(9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).


L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 212331-99-2P 749866-30-6P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-
3-one 1,1-dioxide-based sulfonamide derivs.)
RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-
(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 749866-30-6 HCAPLUS
CN Ethanethioic acid, S-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl] ester (9CI) (CA INDEX
NAME)
Absolute stereochemistry.




IT 220869-64-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-
3-one 1,1-dioxide-based sulfonamide derivs.)
RN 220869-64-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-,


L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 749866-32-8 HCAPLUS
CH D-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]-, methyl ester
(9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).




RN 749866-33-9 HCAPLUS
CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]-, phenylmethyl
ester (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).



RN 749866-34-0 HCAPLUS
CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA
INDEX NAME)
Absolute stereochemistry. Rotation (-).

L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


10510026rtr

L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 30 Jul 2004
 ACCESSION NUMBER: 2004:610081 HCAPLUS
 DOCUMENT NUMBER: 141:157120
 TITLE: Preparation of sulfahydantoin as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
 INVENTOR(S): Saunders, Jeffrey O.; Miknis, Gregory F.; Blake, James
 PATENT ASSIGNEE(S): F. Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062664	A1	20040729	WO 2003-US41630	20031230
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,			
TG	CA 2511818, AU 2003300447, US 2004167187, EP 1594497	A1, A1, A1, A1	20040729, 20040810, 20040826, 20051116	20031230, 20031230, 20031230, 20031230
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006514960	T	20060518	JP 2004-566641	20031230
PRIORITY APPLN. INFO.:			US 2002-437572P	P 20021230
			WO 2003-US41630	W 20031230

OTHER SOURCE(S): MARPAT 141:157120
 GI

L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 4-((1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)benzoic acid methyl ester 729600-47-9P 729600-48-0P 729600-49-1P 729600-50-4P 729600-51-5P 729600-52-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of sulfahydantoin as phosphate isosteres for use as protein phosphatase inhibitors in treatment of cancer and autoimmune disorders)
 RN 612527-99-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612530-69-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 729600-44-6 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB The invention relates to compds. having a sulfahydantoin or a reverse sulfahydantoin moiety (I) and (II) or pharmaceutically acceptable salts thereof [Q = each (un)substituted C1-8 aliphatic group, C6-10 aryl, heteroaryl having 5-10 ring atoms, heterocyclyl having 3-10 ring atoms; T = C1-6 alkylidene chain wherein one or two nonadjacent methylene units of T are optionally and independently replaced by O, NR, S, CO, CONR, NRCOR, NRCONR, SO, SO2, NRSO2, SO2NR, or NRSO2NR; m = 0,1; X = CH2, CO, CF2; R = H or (un)substituted C1-8 aliphatic group or two R groups bound to the nitrogen are taken together with the nitrogen to form a 3-7 membered heterocyclic ring having 0-2 heteroatoms in addition to the nitrogen, wherein said heteroatoms are independently selected from N, O, or S], uses thereof, and related methods. These compds. are inhibitors of phosphatases, particularly inhibitors of protein tyrosine phosphatase SHP-2 and are used in the treatment of various phosphatase mediated diseases such as proliferative diseases, autoimmune disorders, angiogenic disorders, and cancer. The autoimmune disease is selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease. The proliferative disease is selected from acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HTLV-1-mediated tumorigenesis. The angiogenic disorder is selected from solid tumors, ocular neovascularization, and infantile haemangiomas. The cancer is selected from colon, breast, stomach, and ovarian cancer. Thus, N-alkylation of Me 4-aminobenzoate by Et bromosuccinate in the presence of Et3N at 60° for 2.5 days gave 4-[[[(ethoxycarbonyl)methyl]amino]benzoic acid Me ester which underwent N-sulfamoylation by sulfamoyl chloride in the presence of Et3N in CH2Cl2 at room temperature overnight to give 4-[N-[[[(ethoxycarbonyl)methyl]-N-sulfamoyl]amino]benzoic acid Me ester (III)]. Cyclization of III by treatment with NaOMe/MeOH at room temperature overnight gave 4-[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)benzoic acid Me ester (IV)]. IV showed IC50 of 1.0-100 µM against protein tyrosine phosphatase SHP-2.

IT 612527-99-8P 612530-69-5P 729600-44-6P,


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 729600-47-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-naphthalenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 729600-48-0 HCAPLUS
 CN Benzoic acid, 3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 729600-49-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3-phenyl-2-propenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 729600-50-4 HCAPLUS
 CN Benzanide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 729600-51-5 HCAPLUS
 CN Benzanide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 729600-52-6 HCAPLUS
 CN Benzanide, N-butyl-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 23 Jul 2004

ACCESSION NUMBER: 2004:589375 HCAPLUS

DOCUMENT NUMBER: 141:140459

TITLE: Preparation of sulfamides as anti-cancer agents

INVENTOR(S): Flynn, Daniel L.; Petricillo, Peter A.

PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 168 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060305	A2	20040722	WO 2003-US41425	20031226
WO 2004060305	A3	20050210		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
US 2004171075	A1	20040902	US 2003-746545	20031224
US 2004176395	A1	20040909	US 2003-746607	20031224
CA 2511840	A1	20040722	CA 2003-2511840	20031226
AU 2003303639	A1	20040729	AU 2003-303639	20031226
EP 1590344	A2	20051102	EP 2003-814980	20031226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017863	A	20051206	BR 2003-17863	20031226
CN 1756849	A	20060405	CN 2003-80110049	20031226
CN 1791596	A	20060621	CN 2003-80110048	20031226
JP 2006519765	T	20060831	JP 2005-508623	20031226
PRIORITY APPL. INFO.:				
			US 2002-437304P	P 20021231
			US 2002-437403P	P 20021231
			US 2002-437415P	P 20021231
			US 2002-437487P	P 20021231
			US 2003-463804P	P 20030418
			US 2003-746545	A 20031224
			US 2003-746607	A 20031224
			WO 2003-US41425	W 20031226


OTHER SOURCE(S): MARPAT 141:140459

GI


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




AB Sulfamides, such as I, were prepared for use as anticancer agents which
 act by modulating the activation states of abl or bcr-abl α -kinase proteins. Thus, 4-HO2CC6H4CH2NH2NHCO (R = pyrrolidino), prepared from 4-MeO2CC6H4CH2NH2 and pyrrolidine, was treated with the pyrimidinylaminoaniline fragment to give I, which showed 10% inhibition of non-phosphorylated abl kinase at 10 μ M.
 IT 726192-44-5P 726192-45-6P 726192-60-5P
 726192-61-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of sulfamides as anti-cancer agents)
 RN 726192-44-5 HCAPLUS
 CN Benzanide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)-N-(4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 726192-45-6 HCAPLUS


10510026rtr

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[4-methyl-3-[(4-phenyl-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 726192-60-5 HCAPLUS
 CN Benzamide, 4-[(3,3-dimethyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[4-methyl-3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726192-61-6 HCAPLUS
 CN Urea, N-[4-[(3,3-dimethyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N'-[4-methyl-3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 612527-99-8P 612528-00-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of sulfamides as anti-cancer agents)
 RN 612527-99-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-00-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 18 Jun 2004
 ACCESSION NUMBER: 2004:493693 HCAPLUS
 DOCUMENT NUMBER: 141:54340
 TITLE: Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives as inhibitors of protein tyrosine phosphatase 1B
 INVENTOR(S): Kenny, Peter Wedderburn; Morley, Andrew David; Russell, Daniel John; Toader, Dorin
 PATENT ASSIGNEE(S): AstraZeneca AB, Sued.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050646	A1	20040617	WO 2003-GB5120	20031126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD				
TG AU 2003302626 A1 20040623 AU 2003-302626 20031126 GB 2002-27813 A 20021129 WO 2003-GB5120 W 20031126				

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 141:54340
 GI




AB Title compds. I [wherein R1 = H, (halogeno)alkyl, (hydroxy)alkoxy, alkylamino, etc.; R2 = H, (halogeno)alkyl, halogeno, alkoxy; R3 = alkylamido or (un)substituted alkyl; R4 = H, alkyl, (hetero)aryl; R5 = H


L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-61-7 HCAPLUS
 CN Butanamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 705256-67-3 HCAPLUS
 CN Benzenepropanamide, 4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 or alkyl; and pharmaceutically acceptable salts thereof] were prep. as inhibitors of protein tyrosine phosphatase 1B (PTB1B). For example, 5-[[4-(acetamidomethyl)-2-methoxyphenyl]-1,2,5-thiadiazolidin-3-one 1,1-dioxide (II) was given in multi-step synthesis starting from 3-methoxy-4-nitrobenzyl alc. II showed inhibition of human PTB1B with IC50 value of 44µM. Thus, I and their pharmaceutical compns. are useful as inhibitors of protein tyrosine phosphatase 1B for the treatment of diabetes mellitus.

IT 705256-50-4P 705256-54-8P 705256-55-9P
 705256-61-7P 705256-67-3P 705256-72-0P
 705256-78-6P 705256-82-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Preparation of 5-phenyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide

derivs. as inhibitors of protein tyrosine phosphatase 1B)
 RN 705256-50-4 HCAPLUS
 CN Acetamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 705256-54-8 HCAPLUS
 CN Benzenecetonitrile, 4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)




RN 705256-55-9 HCAPLUS


L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 705256-72-0 HCAPLUS
 CN Benzenepentanamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-78-6 HCAPLUS
 CN Acetamide, N-[[4-(3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-82-2 HCAPLUS
 CN Acetamide, N-[[2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 May 2004
ACCESSION NUMBER: 2004:412929 HCAPLUS
DOCUMENT NUMBER: 140:423678
TITLE: Preparation of 5-(substituted
phenyl)thiadiazolidin-3-
ones as inhibitors of protein tyrosine phosphatase 1B
INVENTOR(S): Birch, Alan Martin; Kenny, Peter Wedderburn; Morley,
Andrew David; Russell, Daniel John; Toader, Dorin
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041799	A1	20040521	WO 2003-GB4721	20031103
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RM:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003278392	A1	20040607	AU 2003-278392	20031103
PRIORITY APPLN. INFO.:			GB 2002-25986	A 20021107
			WO 2003-GB4721	W 20031103

OTHER SOURCE(S): MARPAT 140:423678
G1



AB The title compds. (I) or pharmaceutically acceptable salts thereof [R1 = H, halo, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylthio, halo-Cl-6 alkyl, halo-Cl-6 alkoxy, halo-Cl-6 alkylthio, hydroxy-Cl-6 alkoxy, dihydroxy-Cl-6

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
alkoxy, Cl-6 alkoxy-Cl-6 alkoxy, aryloxy, aryl-Cl-6 alkoxy, aryloxy-Cl-6 alkoxy, heteroaryl-Cl-6 alkoxy, heteroaryloxy, heteroaryloxy-Cl-6 alkoxy, Cl-6 alkoxy-Cl-6 alkylthio, Cl-6 alkylthio-Cl-6 alkoxy, Cl-6 alkylsulfinyl-Cl-6 alkoxy, Cl-6 alkylsulfonyl-Cl-6 alkoxy, aryl-Cl-6 alkylthio, aryloxy-Cl-6 alkylthio, etc.; R2 = H, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylthio, halo; or R1 and R2 together with the carbon atoms to

which they are attached form a 5-7 membered carbocyclic or heterocyclic ring;

R3 and R4 are selected such that (i) R3 = hydrogen, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylthio or halo and R4 = aryl, biaryl, heteroaryl, C2-6 alkynyl, C3-7 cycloalkyl, arylcarbonyl, heteroarylcarbonyl, aryl-C2-6 alkenyl, aryl-C2-6 alkynyl or heteroaryl-C2-6 alkenyl; or (ii) R4 = H, Cl-6 alkyl, Cl-6 alkoxy, Cl-6 alkylthio, or halo and R3 = aryl, biaryl, heteroaryl, C2-6 alkynyl, C3-7 cycloalkyl, arylcarbonyl, heteroarylcarbonyl, alkenyl, aryl-C2-6 alkynyl or heteroaryl-C2-6 alkenyl; R5 = H, Cl-6 alkyl.


Cl-6 alkoxy, Cl-6 alkylthio, halo-Cl-6 alkyl, halo; R6 = H, Cl-6 alkyl; wherein any aryl, biaryl or heteroaryl group is optionally substituted] are prepd. These compds. are useful as inhibitors of protein tyrosine phosphatase PTP1B for the treatment of diabetes mellitus. Thus, 4-tolylboronic acid was coupled with 5-(4-bromophenyl)-1,2,5-thiadiazolidin-3-one in the presence of tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] and cesium carbonate in a mixt. of DMF, DME, EtOH, and H2O at 170° for 600 s to give 5-(4'-Methyl-1,1'-biphenyl-4-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide.

IT 692765-08-5P 692765-17-6P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of phenylthiadiazolidinones as inhibitors of protein

tyrosine phosphatase 1B (PTP1B) for treatment of diabetes mellitus)

RN 692765-08-5 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)



RN 692765-17-6 HCAPLUS

CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 692764-76-4P 692764-77-5P 692764-78-6P
692764-79-7P 692764-80-0P 692764-81-1P
692764-82-2P 692764-83-3P 692764-84-4P
692764-85-5P 692764-86-6P 692764-87-7P
692764-88-8P 692764-89-9P 692764-90-2P
692764-91-3P 692764-92-4P 692764-93-5P
692764-94-6P 692764-95-7P 692764-96-8P
692764-97-9P 692764-98-0P 692764-99-1P
692765-00-7P 692765-01-8P 692765-02-9P
692765-03-0P 692765-04-1P 692765-05-2P
692765-06-3P 692765-07-4P 692765-09-6P
692765-10-9P 692765-11-0P 692765-12-1P
692765-13-2P 692765-14-3P 692765-15-4P
692765-16-5P 692765-18-7P 692765-19-8P
692765-20-1P 692765-21-2P 692765-22-3P
692765-23-4P 692765-24-5P 692765-25-6P
692765-26-7P 692765-27-8P 692765-28-9P
692765-29-0P 692765-30-3P 692765-31-4P
692765-32-5P 692765-33-6P 692765-34-7P
692765-35-8P 692765-36-9P 692765-37-0P
692765-38-1P 692765-39-2P 692765-40-5P
692765-41-6P 692765-42-7P 692765-43-8P
692765-44-9P 692765-45-0P 692765-46-1P
692765-47-2P 692765-48-3P 692765-49-4P
692765-50-7P 692765-51-8P 692765-52-9P
692765-53-0P 692765-54-1P 692765-55-2P
692765-56-3P 692765-57-4P 692765-58-5P
692765-59-6P 692765-60-9P 692765-61-0P
692765-62-1P 692765-63-2P 692765-64-3P
692765-65-4P 692765-66-5P 692765-67-6P
692765-68-7P 692765-69-8P 692765-70-1P
692765-71-2P 692765-72-3P 692765-73-4P
692765-74-5P 692765-75-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(Preparation of phenylthiadiazolidinones as inhibitors of protein tyrosine phosphatase 1B (PTP1B) for treatment of diabetes mellitus)

RN 692764-76-4 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-methyl[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-77-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-nitro[1,1'-biphenyl]-4-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-78-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-81-1 HCAPLUS
CN Acetamide, N-{4'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)[1,1'-
biphenyl]-3-yl}- (9CI) (CA INDEX NAME)




RN 692764-82-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-83-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-methyl[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-79-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-methyl[1,1'-biphenyl]-4-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-80-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-methyl[1,1'-biphenyl]-4-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-84-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-85-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-methyl[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-86-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-methyl[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-87-7 HCAPLUS
CN Acetamide, N-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)][1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 692764-88-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-(2-benzofuranyl)phenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-89-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-93-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(1,1'-biphenyl)-4-yl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-94-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(1,1'-biphenyl)-3-yl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-95-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-90-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[3-(5-oxazolyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-91-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-cyclohexylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-92-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-benzoylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-96-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4,4'-dimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-97-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-4'-phenoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-98-0 HCAPLUS
CN [1,1'-Biphenyl]-3-carbonitrile, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxy-3'-nitro[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-00-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-01-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3'-hydroxy-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-05-2 HCAPLUS
CN Acetamide, N-[3'-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 692765-06-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxy-3'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-07-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-02-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3',4',4'-trimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-03-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-04-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(5-(1,3-benzodioxol-5-yl)-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-09-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methoxy-5-[(1E)-2-phenylethenyl]phenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 692765-10-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methoxy-5-[(2-naphthalenyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-11-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4'-(hydroxymethyl)-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-12-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[4-methoxy-3'-(methoxymethyl)[1,1'-biphenyl]-
3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-13-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[4-methoxy-3'-(phenylmethoxy)[1,1'-biphenyl]-
3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-14-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[4-methoxy-4'-(phenylmethoxy)[1,1'-biphenyl]-
3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-19-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[4-methoxy-3'-(methylthio)[1,1'-biphenyl]-3-
yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-20-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-21-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-15-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[2-methoxy-5-[(1Z)-2-phenylethenyl]phenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 692765-16-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-{4'-[(1,1-dimethylethoxy)methyl]-4-
methoxy[1,1'-biphenyl]-3-yl}-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-18-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[4-methoxy-4'-(methoxymethyl)[1,1'-biphenyl]-
3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-22-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[3',5'-difluoro-4-methoxy[1,1'-biphenyl]-3-
yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-23-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5'-fluoro-2',4-dimethoxy[1,1'-biphenyl]-3-
yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-24-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1':3',1''-terphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-25-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-26-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-4'-(methylthio)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-27-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-(1,1-dimethylethyl)-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-31-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-32-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-[(1E)-2-(4-chlorophenyl)ethenyl]-2-methoxyphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 692765-33-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-ethenyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-28-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1':4',1''-terphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-29-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-chloro-4'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-30-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-fluoro-4-methoxy[1,1':4',1''-terphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-34-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-(2-furanyl)-2-methoxyphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-35-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-benzo[b]thien-2-yl-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-36-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-(2-benzofuranyl)-2-methoxyphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-37-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-38-1 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide,
3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-
2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-39-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(1H-pyrazol-4-yl)phenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-40-5 HCAPLUS
CN Pyrrolidine, 1-[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-
methoxy[1,1'-biphenyl]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-44-9 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-3'-(1,1-dioxido-4-oxo-1,2,5-
thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-45-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-amino-4-methoxy[1,1'-biphenyl]-3-yl)-,
1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 692765-46-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[4'-(dimethylamino)-4-methoxy[1,1'-biphenyl]-
3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-41-6 HCAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-
thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-42-7 HCAPLUS
CN Carbamic acid, [[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-
methoxy[1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)




RN 692765-43-8 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide,
3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-
2-yl)-4'-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-47-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(4-pyridinyl)phenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-48-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-(4'-hydroxy-4-methoxy[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-49-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-(1H-indol-6-yl)-2-methoxyphenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-50-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(2-thienyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-51-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(phenylethynyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-52-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(3-phenyl-1-propynyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-53-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-ethynyl-2-methoxyphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-54-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-55-2 HCAPLUS
CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-56-3 HCAPLUS
CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-57-4 HCAPLUS
CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-58-5 HCAPLUS
CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-59-6 HCAPLUS
CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-60-9 HCAPLUS
CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-61-0 HCAPLUS
CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-62-1 HCAPLUS
CN Benzoic acid, 2-[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)propoxy]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-63-2 HCAPLUS
CN Benzoic acid, 2-[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)methoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-64-3 HCAPLUS
CN Benzoic acid, 2-[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl)propoxy]-6-hydroxy- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-68-7 HCAPLUS
CN Benzoic acid, 2-[[2-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-69-8 HCAPLUS
CN Benzoic acid, 2-[[3'-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-70-1 HCAPLUS
CN Benzoic acid, 2-[[5'-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]pentyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-65-4 HCAPLUS
CN Benzoic acid, 2-[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl)propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-66-5 HCAPLUS
CN Benzoic acid, 2-[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)methoxy]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-67-6 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-71-2 HCAPLUS
CN Benzoic acid, 2-[[6'-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]hexyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-72-3 HCAPLUS
CN Benzoic acid, 2-[[2-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-73-4 HCAPLUS
CN Benzoic acid, 2-[[3'-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-74-5 HCAPLUS
CN Benzoic acid,
2-[[[5-[[[3'-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]pentyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-75-6 HCAPLUS
CN Benzoic acid,
2-[[[6-[[[3'-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]hexyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




IT 692765-79-0P 692765-80-3P 692765-84-7P
692765-85-8P 692765-86-9P 692766-02-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylthiadiazolidinones as inhibitors of protein tyrosine


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-86-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)




RN 692766-02-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-iodo-2-methoxyphenyl)-, 1,1-dioxido (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phosphatase 1B (PTP1B) for treatment of diabetes mellitus)
RN 692765-79-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-bromophenyl)-, 1,1-dioxido (9CI) (CA INDEX NAME)



RN 692765-80-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-bromophenyl)-, 1,1-dioxido (9CI) (CA INDEX NAME)



RN 692765-84-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-bromo-2-methoxyphenyl)-, 1,1-dioxido (9CI) (CA INDEX NAME)



RN 692765-85-8 HCAPLUS
CN Boronic acid, [3-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4-

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 10 Oct 2003
ACCESSION NUMBER: 2003:796679 HCAPLUS
DOCUMENT NUMBER: 139:307766
TITLE: Preparation of substituted 1,1-dioxo-1,2,5-thiadiazolidine-3-ones as protein tyrosine phosphatase


1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis
INVENTOR(S): Coppola, Gary Mark; Davies, John William; Jewell, Charles Francis, Jr.; Li, Yu-Chin; Wareing, James Richard; Sperbeck, Donald Mark; Stams, Travis Mathew; Topiol, Sidney Wolf; Viattas, Isidoros
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082841	A1	20031009	WO 2003-EP3466	20030402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TH, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2480562	A1	20031009	CA 2003-2480562	20030402
AU 2003224030	A1	20031013	AU 2003-224030	20030402
US 2004023974	A1	20040205	US 2003-405728	20030402
EP 1492780	A1	20050105	EP 2003-720412	20030402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008974	A	20050215	BR 2003-8974	20030402
US 2005090502	A1	20050428	US 2003-510026	20030402
CN 1646508	A	20050727	CN 2003-807887	20030402
JP 2005535568	T	20051124	JP 2003-580308	20030402
NO 2004004745	A	20041214	NO 2004-4745	20041102
PRIORITY APPLN. INFO.:			US 2002-369779P	P 20020403
			US 2002-369930P	P 20020403
			WO 2003-EP3466	W 20030402


OTHER SOURCE(S): MARPAT 139:307766
GI

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



I



II

AB Substituted thiazolidine triones I [L1 = L2 = single bond; Q1 = single bond, H, (un)substituted alkyl, cycloalkyl, or aminocarbonyl, carboxy, R10C(:O), R10OC(:O), R10S(:O)Q; Q2 = O, S, R3N; R, R2 = (un)substituted alkyl, alkynyl, heteroalkyl, aryl, heteroaryl, aralkyl, alkoxy, aralkoxy, or aralkylthio, amino, halogen, nitro, carboxy, trifluoromethyl, etc.; R1 = (un)substituted alkyl, alkynyl, heteroalkyl, aryl, heteroaryl, aralkyl, alkoxy, aralkoxy, aralkylthio; R3 = H, HO, alkyl; R10 = (un)substituted alkyl, aryl, heteroaryl, aralkyl, heteroalkyl; R14 = H, (un)substituted alkyl, alkoxy, carbonyl, acyl, aryloxy, carbonyl, heteroaryloxy, carbonyl, carbamoyl, or sulfonyl; X, Y = CH, N, O, S, R14N; Z = (un)substituted alkyl, alkoxy, alkylthio, alkylamino, alkyl; Z1, Z2, Z3 = CH, N, N(:O), CR1, CR2; R1 and R2 can form an (un)substituted 5- or 6-membered aromatic or heteroarom. ring; R1 and L1 can form an (un)substituted 5-


6- or 7-membered ring interrupted by nitrogen, oxygen or sulfur atoms] such as II are prepared as inhibitors of protein tyrosine phosphatase 1b and T-cell

protein tyrosine phosphatase for overcoming insulin resistance and modulating glucose levels in the treatment or prevention of metabolic diseases, such as diabetes, or atherosclerosis. II is prepared by treatment


of Et bromoacetate with 1-naphthalenemethanamine, N-sulfamoylation with sulfamoyl chloride, and base-mediated cyclocondensation. No biol. data is provided.

IT 612530-89-9P 612530-90-2P 612530-92-4P
612530-93-5P 612530-94-6P 612530-95-7P
612530-96-8P 612530-98-0P 612530-99-1P
612531-00-7P 612531-01-8P 612531-02-9P
612531-03-0P 612531-05-2P 612531-10-9P
612531-13-2P 612531-22-3P 612531-23-4P
612531-24-5P 612531-30-3P 612531-31-4P
612531-32-5P 612531-34-7P 612531-35-8P
612531-36-9P 612531-61-0P 612531-62-2P
612531-64-3P 612531-65-4P 612531-66-5P

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-92-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-[(2,4-dimethoxyphenyl)methyl]-5-[(4-methoxy-7-quinolinyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-93-5 HCAPLUS
CN Benzoic acid,
4-[(5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-(methylthio)phenyl)methyl ester (9CI)
(CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

612531-67-6P 612531-68-7P 612531-69-8P
612531-70-1P 612531-71-2P 612531-72-3P
612531-73-4P 612531-75-6P 612531-76-7P
612531-77-8P 612531-78-9P 612531-79-0P
612531-80-3P 612534-94-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of thiazolidine triones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)
RN 612530-89-9 HCAPLUS
CN Carbamic acid, [4-[(5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI)
(CA INDEX NAME)

PAGE 1-A




OMe

PAGE 2-A


RN 612530-90-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-[(2,4-dimethoxyphenyl)methyl]-5-[(1-ethyl-2-methyl-1H-benzimidazol-5-yl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612530-94-6 HCAPLUS
CN Benzoic acid,
4-[(5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-(methylsulfonyl)phenyl)methyl ester (9CI)
(CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-95-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-(bromomethyl)phenyl)methyl]-2-[(2,4-dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-96-8 HCAPLUS
CN Acetic acid, [[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-98-0 HCAPLUS
CN Acetic acid, [[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]methyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-iodophenyl)methyl]-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-00-7 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-01-8 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-05-2 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-10-9 HCAPLUS
CN Benzaldehyde, 4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-02-9 HCAPLUS
CN Carbamic acid, [(1S)-1-[[3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-03-0 HCAPLUS
CN Benzenepropanamide, α-amino-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-13-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2,4-dimethoxyphenyl)methyl]-5-[[4-[(4-phenylmethyl)-1-piperazinyl)methyl]phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


PAGE 1-A



10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612531-22-3 HCAPLUS
CN Carbamic acid, [[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 612531-23-4 HCAPLUS


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2,5-Thiadiazolidin-3-one, 5-[[[4-(aminomethyl)phenyl)methyl]-2-[(2,4-dimethoxyphenyl)methyl]-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)



RN 612531-24-5 HCAPLUS
CN Carbamic acid, [2-[[[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 612531-30-3 HCAPLUS
CN Benzoic acid, 4-[[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 612531-31-4 HCAPLUS
CN Benzoic acid, 4-[[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-32-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-[(1,1-dimethylethoxy)carbonyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612531-34-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2,4-dimethoxyphenyl)methyl]-5-(2,4-dinitrophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-35-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-2-[(2,4-dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612531-36-9 HCAPLUS
CN Benzoic acid, 3-[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-61-0 HCAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-(phenylmethoxy)phenyl]methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 612531-63-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-iodophenyl)-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-64-3 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-65-4 HCAPLUS
CN D-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-68-7 HCAPLUS
CN Benzenepropanamide, α-amino-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-69-8 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-66-5 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-67-6 HCAPLUS
CN Carbamic acid, [(1S)-1-[[4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-70-1 HCAPLUS
CN L-Phenylalanine, 4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-71-2 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-72-3 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-73-4 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-N-[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethyl]phenyl]ethyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-77-8 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612531-78-9 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-75-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-iodophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612531-76-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-iodophenyl)-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-79-0 HCAPLUS
CN Carbamic acid, [(1S)-1-[[[3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-80-3 HCAPLUS
CN Benzenepropanamide, alpha-amino-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612534-94-8 HCAPLUS
 CN 1-Phenylalaninamide, N-acetyl-1-phenylalanyl-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 612527-93-2P 612530-46-8P 612530-49-1P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (invention compound; preparation of thiazolidinediones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)
 RN 612527-93-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

612527-90-7P 612527-99-8P 612528-00-4P
 612528-01-5P 612528-02-6P 612528-07-1P
 612528-08-2P 612528-09-3P 612528-10-6P
 612528-11-7P 612528-12-8P 612528-13-9P
 612528-14-0P 612528-15-1P 612528-16-2P
 612528-17-3P 612528-18-4P 612528-19-5P
 612528-20-6P 612528-21-9P 612528-22-0P
 612528-23-1P 612528-25-3P 612528-26-4P
 612528-27-5P 612528-28-6P 612528-29-7P
 612528-32-2P 612528-33-3P 612528-34-4P
 612528-35-5P 612528-36-6P 612528-37-7P
 612528-38-8P 612528-39-9P 612528-40-2P
 612528-41-3P 612528-42-4P 612528-43-5P
 612528-44-6P 612528-45-7P 612528-46-8P
 612528-47-9P 612528-48-0P 612528-49-1P
 612528-50-4P 612528-51-5P 612528-52-6P
 612528-53-7P 612528-54-8P 612528-55-9P
 612528-56-0P 612528-57-1P 612528-58-2P
 612528-59-3P 612528-60-6P 612528-61-7P
 612528-62-8P 612528-63-9P 612528-64-0P
 612528-65-1P 612528-66-2P 612528-67-3P
 612528-68-4P 612528-69-5P 612528-70-6P
 612528-71-9P 612528-72-0P 612528-73-1P
 612528-74-2P 612528-75-3P 612528-76-4P
 612528-77-5P 612528-78-6P 612528-79-7P
 612528-80-0P 612528-82-2P 612528-83-3P
 612528-84-4P 612528-85-5P 612528-86-6P
 612528-87-7P 612528-88-8P 612528-89-9P
 612528-97-9P 612528-98-0P 612528-99-1P
 612529-00-7P 612529-01-8P 612529-02-9P
 612529-03-0P 612529-04-1P 612529-05-2P
 612529-06-3P 612529-07-4P 612529-08-5P
 612529-09-6P 612529-10-9P 612529-11-0P
 612529-12-1P 612529-13-2P 612529-14-3P
 612529-15-4P 612529-16-5P 612529-17-6P
 612529-18-7P 612529-19-8P 612529-20-1P
 612529-21-2P 612529-22-3P 612529-23-4P
 612529-24-5P 612529-26-7P 612529-27-8P
 612529-28-9P 612529-29-0P 612529-30-1P
 612529-31-4P 612529-32-5P 612529-33-6P
 612529-36-9P 612529-37-0P 612529-38-1P
 612529-39-2P 612529-40-5P 612529-41-6P
 612529-42-7P 612529-43-8P 612529-44-9P
 612529-45-0P 612529-46-1P 612529-47-2P
 612529-48-3P 612529-49-4P 612529-50-7P
 612529-51-8P 612529-52-9P 612529-53-0P
 612529-54-1P 612529-56-3P 612529-57-4P
 612529-58-5P 612529-59-6P 612529-60-9P
 612529-61-0P 612529-62-1P 612529-63-2P
 612529-64-3P 612529-65-4P 612529-67-6P
 612529-68-7P 612529-69-8P 612529-70-1P
 612529-73-4P 612529-74-5P 612529-75-6P
 612529-76-7P 612529-77-8P 612529-78-9P
 612529-79-0P 612529-80-3P 612529-81-4P
 612529-82-5P 612529-83-6P 612529-84-7P
 612529-85-8P 612529-86-9P 612529-87-0P
 612529-90-5P 612529-91-6P 612529-93-8P
 612529-94-9P 612529-95-0P 612529-96-1P
 612529-97-2P 612529-98-3P 612529-99-4P
 612530-01-5P 612530-02-6P 612530-03-7P


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-46-8 HCAPLUS
 CN Benzoic acid, 3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 612530-49-1 HCAPLUS
 CN Benzeneacetic acid, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)




IT 612527-84-1P 612527-85-2P 612527-86-3P
 612527-87-4P 612527-88-5P 612527-89-6P
 612527-90-9P 612527-91-0P 612527-92-1P
 612527-94-3P 612527-96-5P 612527-97-6P


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

612530-04-8P 612530-05-9P 612530-06-0P
 612530-08-2P 612530-09-3P 612530-10-6P
 612530-11-7P 612530-12-8P 612530-13-9P
 612530-16-2P 612530-17-3P 612530-18-4P
 612530-19-5P 612530-20-8P 612530-21-9P
 612530-22-0P 612530-23-1P 612530-25-3P
 612530-26-4P 612530-27-5P 612530-28-6P
 612530-29-7P 612530-30-0P 612530-31-1P
 612530-32-2P 612530-33-3P 612530-34-4P
 612530-35-5P 612530-36-6P 612530-37-7P
 612530-38-8P 612530-39-9P 612530-40-2P
 612530-41-3P 612530-42-4P 612530-43-5P
 612530-44-6P 612530-45-7P 612530-47-9P
 612530-48-0P 612530-50-4P 612530-51-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (invention compd.; prepn. of thiazolidinediones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)

RN 612527-84-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(1-naphthalenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-85-2 HCAPLUS
 CN Acetamide, N-[(3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]- (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612527-86-3 HCAPLUS
CN Carbamic acid, [[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 612527-87-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-88-5 HCAPLUS
CN Acetamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612527-89-6 HCAPLUS
CN Carbamic acid, [[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 612527-90-9 HCAPLUS
CN Benzenepropanamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612527-91-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-iodophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-92-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-94-3 HCAPLUS
CN Acetamide, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612527-96-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-97-6 HCAPLUS
CN Butanamide, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 612527-98-7 HCAPLUS
CN Urea, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N'-

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
propyl- (9CI) (CA INDEX NAME)




RN 612527-99-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612528-00-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 612528-07-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-08-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-amino-2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-09-3 HCAPLUS
CN Acetamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-01-5 HCAPLUS
CN Benzoic acid, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612528-02-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-10-6 HCAPLUS
CN Methanesulfonamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 612528-11-7 HCAPLUS
CN Methanesulfonamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-12-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-13-9 HCAPLUS
CN Benzeneacetic acid, alpha-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-16-2 HCAPLUS
CN Benzeneacetamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl-alpha-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)




RN 612528-17-3 HCAPLUS
CN Benzeneacetamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-alpha-[(methylsulfonyl)amino]-N-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-14-0 HCAPLUS
CN Benzeneacetamide, alpha-amino-2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-15-1 HCAPLUS
CN Benzeneacetamide, alpha-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-18-4 HCAPLUS
CN Benzenepropanamide, alpha-(acetylamino)-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-19-5 HCAPLUS
CN Propanedioic acid, (acetylamino)[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-20-8 HCAPLUS
CN Benzenepropanamide, α-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-21-9 HCAPLUS
CN Phenylalanine, N-acetyl-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-26-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(2-chlorophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-27-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(4-aminophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-22-0 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-α-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-23-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-25-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(3,4-dimethoxyphenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-28-6 HCAPLUS
CN Acetamide, N-[4-[2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)ethyl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 612528-29-7 HCAPLUS
CN Butanamide, N-[4-[2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-32-2 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-u-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-33-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(3-aminophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-34-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-(aminomethyl)-1-naphthalenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-35-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(1-ethyl-2-methyl-1H-benzimidazol-5-yl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-36-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methyl-1-(3-methylbutyl)-1H-benzimidazol-5-yl]methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-37-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxy-7-quinolinyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-38-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxy-7-quinolinyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-39-9 HCAPLUS
CN Glycine, N-[2-(butylamino)-2-oxo-1-phenylethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-40-2 HCAPLUS
CN Glycine, N-[2-(butylamino)-1-(4-ethylphenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 612528-41-3 HCAPLUS
 CN Glycine, N-[2-(butylamino)-2-oxo-1-(3-phenoxyphenyl)ethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 612528-42-4 HCAPLUS
 CN Glycine, N-[2-(butylamino)-1-(4-methoxyphenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-43-5 HCAPLUS
 CN Glycine, N-[1-(2-bromophenyl)-2-(butylamino)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612528-44-6 HCAPLUS
 CN Glycine, N-[2-(butylamino)-1-(2-naphthalenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 612528-45-7 HCAPLUS
 CN Glycine, N-[2-(butylamino)-1-(4-chlorophenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612528-46-8 HCAPLUS
 CN Glycine, N-[2-(butylamino)-2-oxo-1-(3-(phenylmethoxy)phenyl)ethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-47-9 HCAPLUS
CN Glycine,
N-[(2E)-1-[(butylamino)carbonyl]-3-phenyl-2-propenyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 612528-48-0 HCAPLUS
CN Glycine,
N-[1-[(butylamino)carbonyl]-3-phenylpropyl]-N-[4-[(1,1-dioxido-4-


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612528-50-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612528-51-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-butyphenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 612528-49-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(methylsulfonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612528-52-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(hydroxymethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612528-53-7 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [2-(2-phenylethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-54-8 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [1,1'-biphenyl]-2-ylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-55-9 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(4-(difluoromethoxy)phenyl)methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 612528-56-0 HCAPLUS
CN 2-Thiopheneacetic acid, 5-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]-α,α-difluoro- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-57-1 HCAPLUS
CN Acetic acid, [[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




RN 612528-58-2 HCAPLUS
CN Acetic acid, [[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




RN 612528-59-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]thio]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-60-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-ethylbutyl ester (9CI) (CA INDEX NAME)




RN 612528-61-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclobutylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-64-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 612528-65-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclohexylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-66-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 1,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-62-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclopentylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-63-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpentyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-67-3 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 612528-68-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 612528-69-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(methylthio)ethyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-70-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-[(carboxymethyl)thio]ethyl ester (9CI) (CA INDEX NAME)




RN 612528-71-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(hydroxymethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-72-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 612528-73-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(hydroxymethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-74-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(methylsulfonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612528-75-3 HCAPLUS
CN Benzenesulfonic acid, 4-[(4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl)amino]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612528-76-4 HCAPLUS
 CN Benzenecetic acid, 4-[[[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 612528-77-5 HCAPLUS
 CN Benzoic acid, 4-[[[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-[[dimethylamino)methyl]-2-furanyl]methyl ester (9CI) (CA INDEX NAME)




RN 612528-78-6 HCAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-[[[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612528-79-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(1H-indol-5-ylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-80-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[[3,4,5-trimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612528-82-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[[4-[(phenylmethyl)-1-piperazinyl]methyl]phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-83-3 HCAPLUS
 CN Benzenecetic acid, 4-[[[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612528-84-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[[4-benzoylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-85-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-naphthalenyl)methyl]-, 1,1-dioxide (9CI)
(CA INDEX NAME)




RN 612528-86-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(4-methyl-1-oxopentyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

RN 612528-89-9 HCAPLUS
CN 2(1H)-Quinolinone, 6-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-1-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 612528-97-9 HCAPLUS
CN Acetamide, 2-amino-N-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 612528-98-0 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-carboxyphenyl)methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-87-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(2-fluorophenoxy)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-88-8 HCAPLUS
CN Benzoic acid, 3-[2-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612528-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(phenoxy)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 612529-00-7 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 612529-01-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(hydroxymethyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-02-9 HCAPLUS
 CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-05-2 HCAPLUS
 CN Benzoic acid, 5-amino-2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-06-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-methoxy-5-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-03-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-04-1 HCAPLUS
 CN Benzoic acid, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-5-nitro- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 612529-07-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-08-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-methyl-2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-09-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-10-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-phenylpropyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-11-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-butoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-12-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-13-2 HCAPLUS
CN Benzoic acid, 3-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-16-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methyl-3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-17-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(5-methyl-2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-18-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-14-3 HCAPLUS
CN Benzenebutanoic acid, 5-amino-2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-15-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methyl-3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-19-8 HCAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612529-20-1 HCAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612529-21-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5,5'-[1,4-phenylenebis(methylene)]bis-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-22-3 HCAPLUS
CN Acetic acid, [[2-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 612529-23-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-24-5 HCAPLUS
CN Benzoic acid, 2-amino-4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-28-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-amino-5-(hydroxymethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-29-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-amino-4-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-30-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-amino-3-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-26-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-fluoro-2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-27-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(hydroxymethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-31-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-amino-2-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-32-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-amino-5-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-33-6 HCAPLUS
CN Acetamide, N-[[4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-36-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3,4-dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-37-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-amino-5-hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-41-6 HCAPLUS
CN Benzoic acid, 2-amino-5-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-42-7 HCAPLUS
CN Benzoic acid, 2-(acetamido)-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-43-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-(phenylmethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-38-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3,5-dimethylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-39-2 HCAPLUS
CN L-Phenylalanine, N-[(3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612529-40-5 HCAPLUS
CN L-Phenylalanine, N-[(4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-44-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-bis(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-45-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4,6-trifluorophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-46-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-47-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5,5'-bis-([1,1'-biphenyl]-2,2'-diylbis(methylene)bis-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)




RN 612529-48-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-([4-((ethylamino)methyl)phenyl]methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-49-4 HCAPLUS

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




Ph-CH₂-CH₂-NH-CH₂


RN 612529-52-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-([4-((diethylamino)methyl)phenyl]methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-53-0 HCAPLUS
CN Benzoic acid, 2-amino-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-(acetylamino)-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-50-7 HCAPLUS
CN Benzoic acid, 2-amino-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 612529-51-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-([4-([2-phenylethyl]amino)methyl]phenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612529-54-1 HCAPLUS
CN Benzanide, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 612529-56-3 HCAPLUS
CN Benzanide, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[2-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)



PAGE 1-A


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 612529-57-4 HCAPLUS
CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 612529-58-5 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-α-(phenylmethyl)-, 1,1-dioxide, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612529-59-6 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-α-(phenylmethyl)-, 1,1-dioxide, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-63-2 HCAPLUS
CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-64-3 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-60-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 612529-61-0 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 612529-62-1 HCAPLUS

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-65-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(carboxymethoxy)phenyl]methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612529-67-6 HCAPLUS
CN Benzoic acid, 4-[2-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612529-68-7 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-69-8 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 612529-70-1 HCAPLUS
CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-73-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-74-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-75-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-76-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-ethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-77-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-78-9 HCAPLUS
CN Benzenecetic acid, 4-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612529-79-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-80-3 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(phenylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 612529-81-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-methoxyphenyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612529-82-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 612529-83-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-84-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-methoxy-2,2-dimethyl-3-oxopropyl ester (9CI) (CA INDEX NAME)




RN 612529-85-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,2,4-trimethylpentyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-86-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-(dimethylamino)-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 612529-87-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3aR,4S,5R,6aS)-5-(benzoyloxy)hexahydro-2-oxo-2H-cyclopenta[b]furan-4-yl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-90-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-methyl-4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612529-91-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-methyl-4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



PAGE 1-A




PAGE 2-A

RN 612529-93-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 6-ethoxy-6-oxohexyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-94-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-[(3-chlorophenyl)ethyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612529-95-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-[(3-methylphenyl)ethyl] ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612529-96-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-[(3-trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-A




RN 612529-97-2 HCAPLUS
CN D-Phenylalanine, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612529-98-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(phenylmethyl)amino]methyl]phenyl]meth

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-99-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-methylphenyl)methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 612530-01-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(methoxycarbonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612530-02-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-cyclohexyl-2-methylpropyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612530-03-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-phenoxypentyl ester (9CI) (CA INDEX NAME)




RN 612530-04-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612530-05-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 612530-06-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(4-carboxyphenyl)ethyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-08-2 HCAPLUS
CN Benzoic acid, 3-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-09-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[[[4-[[[(2-methylpropylamino)methyl]phenyl]me
thyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-10-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[[[4-[[[(2,2-dimethylpropyl)amino]methyl]pheny
l)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-11-7 HCAPLUS
CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
1-naphthalenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612530-12-8 HCAPLUS
CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
(4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-13-9 HCAPLUS
CN Benzeneacetic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-16-2 HCAPLUS
CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612530-17-3 HCAPLUS
CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- 3-[[carboxymethyl]amino]-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-18-4 HCAPLUS

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 2-Thiophenecarboxylic acid, 5-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 612530-19-5 HCAPLUS
CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (1,1'-biphenyl)-4-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 612530-20-8 HCAPLUS


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-(acetylamino)phenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612530-21-9 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [2-(phenylmethyl)phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-22-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (2-methylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 612530-23-1 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (2-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (2-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612530-25-3 HCAPLUS
 CN Benzoic acid, 3-[(4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl)oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612530-26-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-27-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-fluoro-2-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-28-6 HCAPLUS
CN Benzoic acid, 4-[(5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B

OMe


RN 612530-29-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl ester (9CI) (CA INDEX NAME)



RN 612530-30-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (5-methyl-2-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Me


RN 612530-31-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylphenyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-32-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-[(carboxymethyl)methylamino]-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-33-3 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-37-7 HCAPLUS
CN 1-Piperazineacetic acid, 4-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 612530-38-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-naphthalenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-34-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-[(2-methylpropyl)amino]carbonyl]-2-thienylmethyl ester (9CI) (CA INDEX NAME)




RN 612530-35-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-naphthalenylmethyl ester (9CI) (CA INDEX NAME)




RN 612530-36-6 HCAPLUS
CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-39-9 HCAPLUS
CN 2-Thiophenecarboxylic acid, 5-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-40-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-(aminocarbonyl)-2-thienyl]methyl ester (9CI) (CA INDEX NAME)




RN 612530-41-3 HCAPLUS
CN Piperazine, 1-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-42-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-(1-oxo-3-phenylpropyl)-2-thienyl]methyl ester (9CI) (CA INDEX NAME)




RN 612530-43-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-[[[(phenylmethyl)amino]carbonyl]-2-thienyl]methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-48-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-(aminomethyl)phenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-50-4 HCAPLUS
CN Benzenecetic acid, 2-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)




RN 612530-51-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-dimethoxyphenyl)-, 1,1-dioxide, potassium salt (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-44-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-45-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-47-9 HCAPLUS
CN Benzoic acid, 3-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● K

IT 612530-52-6P 612530-53-7P 612530-54-8P
612530-55-9P 612530-56-0P 612530-57-1P
612530-58-2P 612530-59-3P 612530-60-6P
612530-61-7P 612530-62-8P 612530-63-9P
612530-64-0P 612530-65-1P 612530-66-2P
612530-67-3P 612530-68-4P 612530-69-5P
612530-71-9P 612530-72-0P 612530-73-1P
612530-74-2P 612530-75-3P 612530-77-5P
612530-78-6P 612534-93-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compound; preparation of thiazolidinetriones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)


RN 612530-52-6 HCAPLUS
CN Acetamide, 2-(4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-methylphenoxy)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 612530-53-7 HCAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-hydroxyphenyl]methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-54-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-iodophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-55-9 HCAPLUS
CN L-Phenylalanine, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612530-56-0 HCAPLUS
CN L-Phenylalanine, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 612530-60-6 HCAPLUS
CN L-Phenylalaninamide, N-benzoyl-O-(dicarboxymethyl)-L-tyrosyl-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-61-7 HCAPLUS
CN Benzenepropanamide, α-([1,1'-biphenyl]-4-ylsulfonyl)amino]-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-57-1 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-58-2 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612530-59-3 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-2-([4-(carboxymethyl)phenyl]ethyl)-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-62-8 HCAPLUS
CN Benzenepropanamide, α-([1,1'-biphenyl]-4-ylsulfonyl)amino]-4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-(4-phenylbutyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-63-9 HCAPLUS
CN Benzenepropanamide, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl)-α-([phenylsulfonyl]amino)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-64-0 HCAPLUS
CN Benzenepropanamide, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-(4-phenylbutyl)-α-([phenylsulfonyl]amino)-, (αS)- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-65-1 HCAPLUS
CN Benzenepropanamide, 3-bromo-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(3,3-diphenylpropyl)-u-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-66-2 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-bromo-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-aminophenyl)methyl]-, 1,1-dioxide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612527-96-5
CMF C9 H11 N3 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612530-72-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(1-ethyl-2-methyl-1H-benzimidazol-5-yl)methyl]-, 1,1-dioxide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 612528-35-5
CMF C13 H16 N4 O3 S



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 612530-67-3 HCAPLUS
CN Benzenepropanamide, 3-bromo-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)-u-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-68-4 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-bromo-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-69-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-71-9 HCAPLUS


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612530-73-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(Z)-(3-oxo-2(3H)-benzofuranylidene)methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 612530-74-2 HCAPLUS
CN Ethanedione, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]phenyl- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-75-3 HCAPLUS
CN 9,10-Anthracenedione, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 612530-77-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 612530-78-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-, 1,1-dioxide, trifluoroacetate (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 4
THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 612530-45-7
CMF C8 H10 N4 O3 S




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 612534-93-7 HCAPLUS
CN L-Phenylalanyl-L-phenylalanyl-3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 31 Jul 2002
ACCESSION NUMBER: 2002:565367 HCAPLUS
DOCUMENT NUMBER: 137:232603
TITLE: Efficient Solid-Phase Synthesis of Sulfahydantoins
AUTHOR(S): Tremblay, Melanie; Voyer, Normand; Boujabi, Sihem; Dawynter, Georges F.
CORPORATE SOURCE: Centre de Recherche sur la Fonction, la Structure et l'Ingenierie des Proteines, Departement de Chimie, Faculte des Sciences et de Genie, Universite Laval, Quebec, QC, G1K 7P4, Can.
SOURCE: Journal of Combinatorial Chemistry (2002), 4(5), 429-435
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:232603
GI




AB A novel solid-phase strategy allows the efficient preparation of traceless sulfahydantoins. A total of 28 derivs., with crude purity generally higher than 85%, were prepared by parallel synthesis. Through reductive alkylations, Mitsunobu reactions, and sulfamoylation reactions on oxime resin, the synthetic strategy affords sulfahydantoin derivs. selectively substituted at N2, e.g., I, N5, e.g., II, and N2, N5, e.g., III, positions, although yields of disubstituted compds. are lower. The mild reaction conditions involved, lead to sulfahydantoins without racemization.

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 459831-33-5P 459831-34-6P 459831-35-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of N2,N5-disubstituted sulfahydantoins)


via reductive alkylation of resin-bound phenylalanine with substituted benzaldehydes and subsequent sulfamoylation, Mitsunobu reaction, resin-cleavage, and cyclization)
RN 459831-33-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-butyl-5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-34-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-butyl-5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-35-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-, (3-phenylpropyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 283587-14-4P 459831-30-2P 459831-31-3P
459831-32-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of N5-substituted sulfahydantoins via reductive alkylation of resin-bound phenylalanine with substituted benzaldehydes and subsequent sulfamoylation, resin-cleavage, and cyclization)


RN 283587-14-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-30-2 HCAPLUS
CN Benzonitrile, 4-[(3S)-1,1-dioxido-4-oxo-3-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459831-31-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-nitrophenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459831-32-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 09 Oct 2001

ACCESSION NUMBER: 2001:735235 HCAPLUS

DOCUMENT NUMBER: 136:85785

TITLE: A one-step protocol for the N-chloromethylation of heterocyclic imides
AUTHOR(S): He, Shu; Yu, Hongyi; Fu, Qinghong; Kuang, Rongze; Epp,

Jeff B.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA

SOURCE: Synthetic Communications (2001), 31(20), 3055-3058
CODEN: SYNCAV; ISSN: 0039-7911

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:85785

AB A convenient single step methodol. for the N-chloromethylation of heterocyclic imides using a mixture of formaldehyde sodium bisulfite adduct and thionyl chloride is described. For example, the chloromethylation of


5-Butyl-3-propyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide gave.

IT 387859-83-8 387859-86-1


RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-(chloromethyl)-1,2,5-thiadiazolidin-3-one by chloromethylation of 1,2,5-thiadiazolidin-3-one using thionyl chloride and formaldehyde sodium bisulfite adduct)

RN 387859-83-8 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 387859-86-1 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 4-oxo-2-(phenylmethyl)-, phenylmethyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




IT 300553-85-9P 387859-88-3P


RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2-(chloromethyl)-1,2,5-thiadiazolidin-3-one by

10510026rtr

L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 chloromethylation of 1,2,5-thiadiazolidin-3-one using thionyl chloride
 and formaldehyde sodium bisulfite adduct)
 RN 300553-85-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-
 (phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 307859-88-3 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 5-(chloromethyl)-4-oxo-2-
 (phenylmethyl)-, phenylmethyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 13 Jun 2001
 ACCESSION NUMBER: 2001:426029 HCAPLUS
 DOCUMENT NUMBER: 135:202665
 TITLE: Inhibition of serine proteases by functionalized
 sulfonamides coupled to the
 1,2,5-thiadiazolidin-3-one
 1,1 dioxide scaffold
 AUTHOR(S): Groutas, W. C.; He, S.; Kuang, R.; Ruan, S.; Tu, J.;
 Chan, H.-K.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University,
 Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(6),
 1543-1548
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A challenge associated with drug design is the development of selective
 inhibitors of proteases (serine or cysteine) that exhibit the same
 primary

substrate specificity, i.e., show a preference for the same P1 residue.
 While these proteases have similar active sites, nevertheless there are
 subtle differences in their S and S' subsites which can be exploited. We
 describe herein for the first time the use of functionalized sulfonamides
 as a design and diversity element which, when coupled to the
 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold yields potent,
 time-dependent inhibitors of the serine proteases human leukocyte
 elastase
 (HLE), proteinase 3 (PR 3) and cathepsin G (Cat G). Our preliminary
 findings suggest that (a) appending to the 1,2,5-thiadiazolidin-3-one 1,1
 dioxide scaffold recognition and diversity elements that interact with
 both the S and S' subsites of a target protease may result in optimal
 enzyme selectivity and potency and, (b) functionalized sulfonamides
 constitute a powerful design and diversity element with low intrinsic
 chemical reactivity and potentially wide applicability. Potent
 inhibitors of
 human leukocyte elastase, proteinase 3 and cathepsin G that interact with
 the S and S' subsites are realized by using functional sulfonamides
 coupled to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold.
 IT 220869-05-6P 220869-07-8P 220869-14-7P
 220869-16-9P 365216-39-3P 365216-41-7P
 365216-42-8P 365216-43-9P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (inhibition of serine proteases by functionalized sulfonamides coupled
 to 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold)
 RN 220869-05-6 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, methyl ester (9CI) (CA
 INDEX NAME)


L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-07-8 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl](methylsulfonyl)-, butyl ester (9CI) (CA
 INDEX NAME)




RN 220869-14-7 HCAPLUS
 CN Carbamic acid,
 [2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 220869-16-9 HCAPLUS
 CN Carbamic acid,
 [2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-


L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-,
 phenylmethyl ester (9CI) (CA INDEX NAME)



RN 365216-39-3 HCAPLUS
 CN Benzamide,
 N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 365216-41-7 HCAPLUS
 CN Glycine,
 N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]carbonyl]-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 365216-42-8 HCAPLUS


10510026rtr

L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, butyl ester (9CI) (CA INDEX NAME)




RN 365216-43-9 HCAPLUS
 CN L-Phenylalanine, N-[[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




RN 283587-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dichlorophenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-16-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(1-methylethyl)-5-[(3-methylphenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-18-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(1-methylethyl)-5-[[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-19-9 HCAPLUS

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 24 Apr 2001
 ACCESSION NUMBER: 2001:288468 HCAPLUS
 DOCUMENT NUMBER: 135:76831
 TITLE: Synthesis of a Sulfahydantoin Library
 AUTHOR(S): Albericio, Fernando; Bryman, Lois M.; Garcia, Javier; Michelotti, Enrique L.; Nicolas, Ernesto; Tice, Colin M.
 CORPORATE SOURCE: Department of Organic Chemistry, University of Barcelona, Barcelona, 08028, Spain
 SOURCE: Journal of Combinatorial Chemistry (2001), 3(3), 290-300
 CODEN: JCCHFF; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:76831
 AB A five-step solid-phase synthesis of sulfahydantoins from α -amino acids and aldehydes was developed. The synthetic method allows the use of

hindered amino acids, including Val, Phe, and Aib, and use of aromatic aldehydes substituted with electron-withdrawing and -donating groups. Some limitations were encountered with amino acids with reactive side chains. A small but diverse library of compds. was produced for biol. testing.


IT 283587-14-4P 283587-15-5P 283587-16-6P
 283587-18-8P 283587-19-9P 283587-21-3P
 283587-22-4P 283587-24-6P 346697-35-6P
 346697-36-7P 346697-37-8P 346697-38-9P
 346697-39-0P 346697-40-3P 346697-41-4P
 346697-42-5P 346697-43-6P 346697-44-7P
 346697-45-8P 346697-46-9P 346697-47-0P
 346697-48-1P 346697-49-2P 346697-50-5P
 346697-51-6P 346697-53-8P 346697-54-9P
 346697-55-0P 346697-56-1P 346697-57-2P
 346697-58-3P 346697-59-4P 346697-60-7P
 346697-62-9P 346697-63-0P 346697-64-1P
 346697-65-2P 346697-69-6P 346697-71-0P
 346697-72-1P 346697-73-2P 346697-74-3P
 346697-75-4P 346697-76-5P 346697-77-6P
 346697-78-9P 346697-80-1P 346697-81-2P
 346697-82-3P 346697-83-4P 346697-84-5P
 346697-85-6P 346697-86-7P 346697-87-8P
 346697-88-9P 346697-89-0P 346697-90-3P
 346697-91-4P 346697-92-5P 346697-93-6P
 346697-97-0P 346697-98-1P 346697-99-2P
 346698-00-8P 346698-03-1P 346698-04-2P
 346698-05-3P 346698-06-4P 346698-12-2P
 346698-14-4P
 RL: SPW (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of a sulfahydantoin library from amino acids and

aldehydes)

RN 283587-14-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-21-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-22-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4,4-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 283587-24-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-35-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(3-chlorophenyl)methyl]-4-(1-methylethyl)-,
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-36-7 HCAPLUS
CN Acetamide, N-[4-[[[(3S)-3-(1-methylethyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-37-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
4-(1-methylethyl)-5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-42-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-43-6 HCAPLUS
CN Acetamide, N-[4-[[[(3S)-1,1-dioxido-4-oxo-3-[[4-(phenylmethoxy)phenyl]methyl]-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-44-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 346697-38-9 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-39-0 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one,
5-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-
4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-40-3 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-41-4 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chlorophenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 346697-45-8 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-46-9 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one,
5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-47-0 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-48-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-49-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-50-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-55-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-56-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-57-2 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(3-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-58-3 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-(acetylamino)phenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-51-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-53-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-54-9 HCAPLUS
CN Acetamide, N-(4-[[3R]-1,1-dioxido-4-oxo-3-[(phenylmethyl)thio]methyl]-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-59-4 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-chloro-3-nitrophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-60-7 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-62-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-63-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((1-methylethyl)-5-((2-(trifluoromethyl)phenyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-64-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((1-methylethyl)-5-((3-(trifluoromethyl)phenyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-65-2 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-((1-methylethyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-73-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-chloro-5-((trifluoromethyl)phenyl)methyl]-4-[[4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-74-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methylphenyl)methyl]-4-[[1-(phenylmethyl)-1H-imidazol-4-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-75-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[1-(phenylmethyl)-1H-imidazol-4-yl)methyl]-

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-69-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methylphenyl)methyl]-4-[[4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-71-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[4-(phenylmethoxy)phenyl)methyl]-5-[[4-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-72-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-[[4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
5-[[4-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-76-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-[[1-(phenylmethyl)-1H-imidazol-4-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-77-6 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[[3-methylphenyl)methyl]-4-oxo-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-79-8 HCAPLUS

10510026rtr


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 4-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-80-1 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-oxo-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-81-2 HCAPLUS
 CN Acetamide, N-[4-[[[(3S)-3-[2-(methylthio)ethyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-82-3 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-one, 4-[2-(methylthio)ethyl]-5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-86-7 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-87-8 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-88-9 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-83-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chlorophenyl)methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-84-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-85-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-89-0 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-90-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(phenylmethoxy)methyl]-5-[[2-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-91-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(phenylmethoxy)methyl]-5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-92-5 HCAPLUS
CN Benzoic acid, 4-[[[3S]-1,1-dioxido-4-oxo-3-[[phenylmethoxy)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-93-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-[[phenylmethoxy)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-97-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[[4-nitrophenyl)methyl]-5-[[2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346698-03-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-phenyl-5-[[2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346698-04-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-phenyl-5-[[3-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-05-3 HCAPLUS
CN Benzoic acid, 4-[[[3S]-1,1-dioxido-4-oxo-3-phenyl-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-98-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[[4-nitrophenyl)methyl]-5-[[3-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-99-2 HCAPLUS
CN Benzoic acid, 4-[[[3S]-3-[[4-nitrophenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-00-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-[[4-nitrophenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346698-06-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-phenyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346698-12-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[[4-methoxyphenyl)methyl]-4-[[[1S]-1-methylpropyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-14-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[[4-methoxyphenyl)methyl]-4-[[[1S]-1-methylpropyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10510026rtr

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 22 Dec 2000

ACCESSION NUMBER: 2000:898004 HCAPLUS

DOCUMENT NUMBER: 134:307088

TITLE: 1,2,5-Thiadiazolidin-3-one 1,1 Dioxide: A Powerful Scaffold for Probing the S' Subsites of (Chymo)trypsin-Like Serine Proteases
 AUTHOR(S): Groutas, William C.; Epp, Jeffrey B.; Kuang, Rongze; Ruan, Sumei; Chong, Lee S.; Venkataraman, Radhika;

Tu,

Juan; He, Shu; Yu, Hongyi; Fu, Qinghong; Li, Yue He; Truong, Tien M.; Vu, Nga T.

CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA

SOURCE: Archives of Biochemistry and Biophysics (2001), 385(1), 162-169

CODEN: ABBIA4; ISSN: 0003-9861

PUBLISHER: Academic Press

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold (I) embodies a motif that allows it to dock to the active site of (chymo)trypsin-like proteases

in a predictable and substrate-like fashion. Consequently, inhibitors derived from this heterocyclic scaffold interact with both the S and S' subsites of an enzyme. Exploitation of binding interactions with both

the S and S' subsites of a target enzyme may lead to compds. with greatly enhanced enzyme selectivity and inhibitory potency. This preliminary report describes the use of a series of compds. having the heterocyclic scaffold linked to various amino acids to probe the S' subsites of human leukocyte elastase (HLE), proteinase 3 (PR 3), and cathepsin G (Cat G). For comparative purposes, a series of compds. derived from a related scaffold, isothiazolidin-3-one 1,1 dioxide (II), was also generated. Several of the compds. were found to be highly potent and selective time-dependent inhibitors of HLE, PR 3, and Cat G. (c) 2001 Academic Press.

IT 334975-68-7P 334975-69-8P 334975-75-6P

334975-81-4P 334975-83-6P 334975-85-8P

334975-88-1P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)


(1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold for probing S' subsites of human leukocyte elastase, proteinase 3 and cathepsin G)

RN 334975-68-7 HCAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 334975-69-8 HCAPLUS

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 334975-75-6 HCAPLUS


CN L-Phenylalanine, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 334975-74-5

CMF C23 H29 N3 O5 S

Absolute stereochemistry.



L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 334975-81-4 HCAPLUS

CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 334975-83-6 HCAPLUS

CN L-Phenylalanine, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 334975-85-8 HCAPLUS

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 334975-88-1 HCAPLUS


CN D-Phenylalanine, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 334975-87-0

CMF C26 H27 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2




REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

10510026rtr


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Jul 2000
ACCESSION NUMBER: 2000:488727 HCAPLUS
DOCUMENT NUMBER: 133:277919
TITLE: Potent inhibition of serine proteases by heterocyclic
sulfide derivatives of 1,2,5-thiadiazolidin-3-one 1,1
dioxide
AUTHOR(S): He, S.; Kuang, R.; Venkataraman, R.; Tu, J.; Truong,
T. M.; Chan, H. K.; Groutas, W. C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University,
Wichita, KS, 67260, USA
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(7),
1713-1717
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:277919
AB The existence of subtle differences in the Sn' subsites of
closely-related
(chymo)trypsin-like serine proteases, and the fact that the
1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold docks to the active site
of (chymo)trypsin-like enzymes in a substrate-like fashion, suggested
that
the introduction of recognition elements that can potentially interact
with the Sn' subsites of these proteases might provide an effective means
for optimizing enzyme potency and selectivity. Accordingly, a series of
heterocyclic sulfide derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1
dioxide scaffold (I) was synthesized and the inhibitory activity and
selectivity of these compds. toward human leukocyte elastase (HLE),
proteinase 3 (PR 3) and cathepsin G (Cat G) were then determined
Compds. with
P1-isobutyl were found to be potent, time-dependent inhibitors of HLE
and,
to a lesser extent PR 3, while those with P1=benzyl inactivated Cat G
rapidly and irreversibly. This study has demonstrated that
1,2,5-thiadiazolidin-3-one 1,1 dioxide-based heterocyclic sulfides are
effective inhibitors of (chymo)trypsin-like serine proteases.
IT 220869-26-1P 220869-27-2P 220869-29-4P
220869-30-7P 220869-33-0P 220869-35-2P
220869-38-5P 220869-39-6P 220869-40-9P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(potent inhibition of serine proteases by heterocyclic sulfide derivs.
of thiadiazolidinone dioxide)
RN 220869-26-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4-(2-
methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-27-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-[(4,5-diphenyl-2-oxazolyl)thio]methyl]-4-(2-
methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-29-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(3-
phenyl-1,2,4-oxadiazol-5-yl)thio]methyl]-, 1,1-dioxide (9CI) (CA INDEX
NAME)




L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 220869-30-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzothiazolylthio)methyl]-4-(2-
methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-33-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(3-
phenyl-1,2,4-oxadiazol-5-yl)thio]methyl]-, 1,1-dioxide (9CI) (CA INDEX
NAME)




RN 220869-35-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(5-phenyl-2-
benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX
NAME)




RN 220869-38-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4,5-
bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-39-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[5-phenyl-1,3,4-oxadiazol-2-yl]thio]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-40-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[6-amino-2-benzoxazolyl]thio]methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



IT 300553-85-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of thiadiazolidinone dioxide derivative; potent inhibition
of
serine proteases by heterocyclic sulfide derivs. of thiadiazolidinone
dioxide)

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 15 Jun 2000

ACCESSION NUMBER: 2000:395930 HCAPLUS
DOCUMENT NUMBER: 133:159638
TITLE: Utilization of the 1,2,5-thiadiazolidin-3-one 1,1
dioxide scaffold in the design of potent inhibitors

of
serine proteases: SAR studies using carboxylates
AUTHOR(S): Kuang, R.; Epp, J. B.; Ruan, S.; Chong, L. S.;
Venkataraman, R.; Tu, J.; He, S.; Truong, T. M.;
Groutas, W. C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University,
Wichita, KS, 67260, USA
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(5),
1005-1016
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A series of carboxylate derivs. based on the 1,2,5-thiadiazolidin-3-one
1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds has been
synthesized and the inhibitory profile of these compds. toward human
leukocyte elastase (HLE), cathepsin G (Cat G) and proteinase 3 (PR 3) was
then determined. Most of the compds. were found to be potent,
time-dependent
inhibitors of elastase, with some of the compds. exhibiting k_{inact}/K_I
values as high as 4,928,300 M⁻¹ s⁻¹. The inhibitory potency of
carboxylate derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1 dioxide
platform was found to be influenced by both the pKa and the inherent
structure of the leaving group. Proper selection of the primary
specificity group was found to lead to selective inhibition of HLE over
Cat G, however, those compds. that inhibited HLE also inhibited PR 3,
albeit less efficiently. The predictable mode of binding of these

compds.
suggests that, among closely-related serine proteases, highly selective
inhibitors of a particular serine protease can be fashioned by exploiting
subtle differences in their S' subsites.

IT 247179-63-1P 287921-30-6P 287921-33-9P
287921-37-3P 287921-38-4P 287921-39-5P
287921-42-0P 287921-45-3P 287921-46-4P
287921-52-2P 287921-54-4P 287921-65-1P
287921-91-9P


RL: BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); SPN (Synthetic preparation); BIOL (Biological
study); PREP (Preparation)
(synthesis of thiadiazolidinone dioxides and isothiazolidinone
dioxides as serine protease inhibitors)

RN 247179-63-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-((acetyloxy)methyl)-4,5-bis(phenylmethyl)-,
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 300553-85-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-
(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 287921-30-6 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-,
[4-ethyl-1,1-dioxido-3-oxo-5-(phenylmethyl)-
1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)



RN 287921-33-9 HCAPLUS
CN Benzenecetic acid, 4-[[[3S]-5-[(2,2-dimethyl-1-oxopropoxy)methyl]-1,1-
dioxido-4-oxo-3-propyl-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA
INDEX
NAME)

Absolute stereochemistry.




RN 287921-37-3 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-,
[[4S]-4-(2-methylpropyl)-1,1-dioxido-3-oxo-
5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX
NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 287921-38-4 HCAPLUS
CN Benzeneacetic acid, 4-[[[(3S)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]-3-(2-methylpropyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287921-39-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-42-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(benzoyloxy)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzeneacetic acid, 4-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-54-4 HCAPLUS
CN Benzeneacetic acid, 4-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-65-7 HCAPLUS
CN Benzoic acid, 2,6-dichloro-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-91-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 287921-45-3 HCAPLUS
CN Benzoic acid, 2,6-dichloro-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-46-4 HCAPLUS
CN Benzeneacetic acid, 4-[[[(3S)-5-[(2,6-dichlorobenzoyloxy)methyl]-3-(2-methylpropyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287921-52-2 HCAPLUS


L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 212331-98-1P 212331-99-2P
Rt: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of thiadiazolidinone dioxides and isothiazolidinone dioxides as serine protease inhibitors)


RN 212331-98-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


10510026rtr

L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 19 May 2000
 ACCESSION NUMBER: 2000:324184 HCAPLUS
 DOCUMENT NUMBER: 133:105000
 TITLE: Solid-phase synthesis of sulfahydantoins
 AUTHOR(S): Albericio, Fernando; Garcia, Javier; Michelotti, Enrique L.; Nicolas, Ernesto; Tice, Colin M.
 CORPORATE SOURCE: Department of Organic Chemistry, University of Barcelona, Barcelona, 08028, Spain
 SOURCE: Tetrahedron Letters (2000), 41(17), 3161-3163
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:105000
 AB A 5-step solid-phase synthesis of 2-unsubstituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides, sulfahydantoins, from Nu-Fmoc amino acids and aromatic aldehydes is described. The key step is the base-mediated cyclization of a resin bound Nu-aminosulfonyl Nu-benzyl amino acid to afford the desired product. This synthesis allows the preparation of a diverse library of compds. based on this heterocycle.
 IT 283587-14-4P 283587-15-5P 283587-16-6P
 283587-18-8P 283587-19-9P 283587-21-3P
 283587-22-4P 283587-24-6P
 RL SPW (Synthetic Preparation); PREP (Preparation)
 (solid-phase synthesis of sulfahydantoin library)
 RN 283587-14-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 283587-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dichlorophenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 283587-16-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[(3-methylphenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 283587-18-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[(4-trifluoromethylphenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 283587-19-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 283587-21-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 283587-22-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4,4-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 283587-24-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-(2-methylthioethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


10510026rtr

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 27 Aug 1999
 ACCESSION NUMBER: 1999:536684 HCAPLUS
 DOCUMENT NUMBER: 131:296963
 TITLE: Human chymase inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold
 AUTHOR(S): Groutas, William C.; Schechter, Norman M.; He, Shu; Yu, Hongyi; Huang, Peng; Tu, Juan
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1999), 9(15), 2199-2204
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of comds. that utilize the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold was synthesized and shown to be highly effective inhibitors of recombinant human skin chymase.
 IT 170918-99-7 247178-41-2 247179-63-1
 247179-64-2 247179-65-3 247179-66-4
 247179-67-5 247179-68-6 247179-69-7
 247179-70-0 247179-71-1 247179-72-2
 247179-74-4 247179-75-5 247179-76-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (human chymase inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold)
 RN 170918-99-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 247178-41-2 HCAPLUS
 CN Benzoic acid, 4-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetic acid, hydroxy-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 247179-66-4 HCAPLUS
 CN Propanoic acid, 2-hydroxy-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 247179-67-5 HCAPLUS
 CN Benzeneacetic acid, α-hydroxy-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 247179-63-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 247179-64-2 HCAPLUS
 CN Propanedioic acid, mono[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl] ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 247179-65-3 HCAPLUS


L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 247179-68-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(methylsulfonyl)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 247179-69-7 HCAPLUS
 CN Acetic acid, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 247179-70-0 HCAPLUS
 CN Propanoic acid, 3-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 247179-71-1 HCAPLUS
CN Benzoic acid, 2-[[[4S]-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247179-72-2 HCAPLUS
CN Benzoic acid, 3-[[[4S]-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 247179-74-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[2-benzoxazolylthio]methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-75-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[6-amino-2-benzoxazolylthio]methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-76-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[5-phenyl-1,3,4-oxadiazol-2-yl]thio]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 25 Aug 1999
ACCESSION NUMBER: 1999:529836 HCAPLUS
DOCUMENT NUMBER: 131:296959
TITLE: A General Inhibitor Scaffold for Serine Proteases

with a (Chymotrypsin-Like Fold: Solution-Phase Construction and Evaluation of the First Series of Libraries of Mechanism-Based Inhibitors
AUTHOR(S): Kuang, Rongze; Epp, Jeffrey B.; Ruan, Sumei; Yu, Hongyi; Huang, Peng; He, Shu; Tu, Juan; Schechter, Norman M.; Turbov, Jane; Froelich, Christopher J.; Groutas, William C.

CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Journal of the American Chemical Society (1999), 121(35), 8128-8129
CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English


AB The authors demonstrate that the 1,2,5-thiadiazolidin-3-one 1,1 dioxide platform embodies a general motif that renders the platform capable of binding to the active site of many serine proteases with a (chymotrypsin-like fold in a predictable fashion and is amenable to the facile construction of libraries for lead identification and optimization.

IT 170918-99-7P 170919-03-6P 189124-02-5P
247178-39-8P 247178-40-1P 247178-41-2P
RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(inhibitor; general inhibitor scaffold for serine proteases with a (chymotrypsin-like fold with solution-phase construction and evaluation

of first series of libraries of mechanism-based inhibitors)
RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[phenylsulfonyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[[phenylsulfonyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 189124-02-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-(phenylmethyl)-2-((phenylsulfonyl)methyl)-4-
propyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247178-39-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((4-aminobutyl)-5-(phenylmethyl)-2-
((phenylsulfonyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Mar 1999
ACCESSION NUMBER: 1999:172588 HCAPLUS
DOCUMENT NUMBER: 130:209985
TITLE: Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives as serine protease inhibitors
INVENTOR(S): Groutas, William C.; Kuang, Rongze
PATENT ASSIGNEE(S): Wichita State University, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909977	A1	19990304	WO 1998-US17406	19980821
W: AU, BR, CA, IS, JP, MX, NZ				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6420401	B1	20020716	US 1997-916693	19970822
AU 9890298	A	19990316	AU 1998-90298	19980821
EP 1011668	A1	20000628	EP 1998-942192	19980821
R: DE, GB				
PRIORITY APPLN. INFO.:			US 1997-916693	A 19970822
			WO 1998-US17406	W 19980821

OTHER SOURCE(S): MARPAT 130:209985
GI




AB Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivs. I (R1, R3 = independently H, alkyl, aryl, aralkyl, alkaryl, substituted aryl; R2 = H, alkyl, aralkyl, alkylthioalkyl, hydroxyalkyl, amino acid side chain; R4 = H, alkyl, aryl, aralkyl, amino acid side chain, PO3R82, NCO, NHCHR7CO2R10, NHCO2R10, NHCONR12R13, CO-Q, -CHR7NHW, [CHR7NHCO]rR10, [CHR7CONH]rR10, NHG: Q = OR10, OJ, NR12R13, halo, (NHCHR7CO)qOR10, (NHCHR7CO)qNR10R16, OPN, NHPn; R5 = R1, halo; R6 = H, alkyl, aryl, aralkyl, NCO, COR9, COO1, NHCHR7CO2R11, NH2, NHG, NHCO2R11, NHCONR14R15, OZCCN2(OCN2CN2)ZOR, O-X; R = alkyl; Q1 = OR11, OJ, NR14R15, (NHCHR7CO)zOR11, halo; X = COR9, [COCHR7NH]zXp, CHR7NHV, CHR7[NHCOCHR7]pNHW1, [CONHCHR7]zCO2R11, CO2R11, S(O)nR9, N(SO2R18)COK; Pn = polymer; each W, W1 = H, G, CONHCHR7CO2R10; each q, r = 1-10; Xp = H, G; G = amino protecting group; J = carboxyl protecting group; Y = H, R9, COR9, G; z = 1-10; n = 0-2; K = R9, OR9, NHR9, OCHR7NHV, (NHCHR7CO)mOR9, (NHCHR7CO)mNR10R17; V = G, H, COCHR7NH2;

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 247178-40-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-acetic acid, 4-oxo-2-(phenylmethyl)-5-
((phenylsulfonyl)methyl)-, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247178-41-2 HCAPLUS
CN Benzoic acid, 4-(((4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl)sulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
= G, H; m = 1-2; each R7 = amino acid side chain; each R8, R9 = alkyl, aryl, aralkyl, alkaryl, heterocyclyl; each R10-R15 = H, any group R8; each R16, R17 = heterocyclylalkyl; R18 = any group R8, NHR19; R19 = alkyl, aryl, aralkyl; with proviso(s), oligomers and combinatorial libraries contg. them, and methods of using them, are disclosed. Thus, title compd.

II showed apparent second-order rate consts. Kinact/KI (M-1s-1) of 119,360, 27,400, and 60 for inhibition of human leukocyte elastase, proteinase 3, and cathepsin G, resp., by *in vitro* assays.
IT 220868-74-6DP, combinatorial library derivs. 220868-75-7DP, combinatorial library derivs. 220868-80-4DP, combinatorial library derivs. 220868-81-5DP, combinatorial library derivs. 220868-86-ODP, combinatorial library derivs. 220868-87-1DP, combinatorial library derivs. 220868-92-8DP, combinatorial library derivs. 220868-93-9DP, combinatorial library derivs. 220868-98-4DP, combinatorial library derivs. 220868-99-5DP, combinatorial library derivs. 220869-05-6P, 220869-06-7P, 220869-07-8P, 220869-14-7P, 220869-16-9P, 220869-19-2P, 220869-20-5P, 220869-26-1P, 220869-27-2P, 220869-29-4P, 220869-30-7P, 220869-33-0P, 220869-35-2P, 220869-38-5P, 220869-39-6P, 220869-40-9P, 220869-41-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study; unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amino acid-derived thiadiazolidinone dioxide derivs.

as serine protease inhibitors)


RN 220868-74-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-(chloromethyl)-5-((3-phenoxyphenyl)methyl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 220868-75-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-(chloromethyl)-5-((3-phenoxyphenyl)methyl)-,
1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220868-80-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-((acetyloxy)methyl)-5-((4-methoxyphenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220868-81-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-((acetyloxy)methyl)-5-((3-phenoxyphenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220868-86-0 HCAPLUS
CN Carbamic acid, [[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 220868-87-1 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-5-[(3-phenoxyphenyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220868-92-8 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl]methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220868-93-9 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[1,1-dioxido-3-oxo-5-[(3-phenoxyphenyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220868-98-4 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl]methyl]thio]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220868-99-5 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[1,1-dioxido-3-oxo-5-[(3-phenoxyphenyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-05-6 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 220869-06-7 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 220869-16-9 HCAPLUS
CN Carbamic acid, 2-[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 220869-19-2 HCAPLUS
CN Glycine, N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 220869-20-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2,2'-methylenebis[4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)


L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-07-8 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)-, butyl ester (9CI) (CA INDEX NAME)




RN 220869-14-7 HCAPLUS
CN Carbamic acid, 2-[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-26-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-27-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-29-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-30-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzothiazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-33-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(3-phenyl-1,2,4-oxadiazol-5-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-40-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(6-amino-2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-41-0 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, α-fluoro-3-oxo-4,5-bis(phenylmethyl)-, ethyl ester, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220869-64-7 220869-65-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid-derived thiadiazolidinone dioxide derivs.)


as serine protease inhibitors)

RN 220869-64-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-,


L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-35-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-2-[(5-phenyl-2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-38-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-39-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(5-phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220869-65-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220869-61-4P 220869-62-5P 220869-63-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid-derived thiadiazolidinone dioxide derivs.)

as serine protease inhibitors)

RN 220869-61-4 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-(2-methylpropyl)-3-oxo-5-(phenylmethyl)-, 1,1-dimethylethyl ester, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220869-62-5 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-(2-methylpropyl)-3-oxo-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-63-6 HCAPLUS
 CN 1,2,5-Thiadiazolidine-2-acetamide, 4-(2-methylpropyl)-3-oxo-N-(2-phenylethyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 02 Oct 1998
 ACCESSION NUMBER: 1998:622789 HCAPLUS
 DOCUMENT NUMBER: 129:289796
 TITLE: Kinetics of the hydrolysis of cyclic N-substituted sulfamides: 4-amino-2-cyclohexyl- and 4-amino-2-phenethyl-2,3-dihydro-3-oxo-1,2,5-thiadiazole 1,1-dioxides
 AUTHOR(S): Rozas, M. F.; Svartman, E. L.; Mirifico, M. V.; Vasini, E. J.
 CORPORATE SOURCE: Instituto de Investigaciones Fisicoquimicas Teóricas y
 Aplicadas (INIFTA), Facultad de Ciencias Exactas, Departamento de Química, Universidad Nacional de La Plata, La Plata, 1900, Argent.
 SOURCE: Journal of Physical Organic Chemistry (1998), 11(7), 489-494
 CODEN: JPOCEE; ISSN: 0894-3230
 PUBLISHER: John Wiley & Sons Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The hydrolysis reactions of 4-amino-2-phenethyl- and 4-amino-2-cyclohexyl-

2,3-dihydro-3-oxo-1,2,5-thiadiazole 1,1-dioxide (1a and 1b) were investigated at 24-73° in buffered aqueous solns. The observed rate consts. (kobs) are independent of pH in the range ca 1-4 pH, but increase with increase in pH above ca 4. A linear log kobs vs pH profile with

unit slope is observed from pH ca 4 up to the highest exptl. pH (ca 10). The products are the corresponding new compds.: 2-amino-2-[(N-substituted-sulfamoyl)imino]acetic acid salts. The C=N bond of these compds. hydrolyzes further, in a slow reaction, to the sulfamide and oxalic acid derivs. The substrates decompose to the final products without accumulation


of the acetic acid derivs. under these exptl. conditions. A mechanism is proposed. Rate consts. and activation parameters are given for the first reaction step. Owing to steric effects, the reaction rate is higher for the N-phenethyl-substituted derivative than for the 2-cyclohexyl-substituted derivative

IT 214216-09-8, 4-Amino-2-phenethyl-2,3-dihydro-3-oxo-1,2,5-thiadiazole 1,1-dioxide
 RL: PEP (Physical, engineering or chemical process); PRP (Properties);

RCT (Reactant); PROC (Process); RACT (Reactant or reagent)
 (hydrolysis of cyclic N-substituted sulfamides)

RN 214216-09-8 HCAPLUS
 CN 1,2,5-Thiadiazol-3-amine, 4,5-dihydro-5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 05 Aug 1998
 ACCESSION NUMBER: 1998:487562 HCAPLUS
 DOCUMENT NUMBER: 129:216561
 TITLE: Potent and specific inhibition of human leukocyte elastase, cathepsin G and proteinase 3 by sulfone derivatives employing the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold
 AUTHOR(S): Groutas, William C.; Kuang, Rongze; Ruan, Sumei; Epp, Jeffrey B.; Venkataraman, Radhika; Truong, Tien M.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry (1998), 6(6), 661-671
 CODEN: BMECEP; ISSN: 0960-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 G1



AB This paper describes the results of structure-activity relationship studies in a series of heterocyclic mechanism-based inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold (1; R1 = iso-Bu, benzyl; R2 = Bu, Me, benzyl, CH2COOCH3, etc.; L = SO2Ph, SO2C6H4Cl-4, etc.) and capable of interacting with the S1 and S1' subsites of a serine proteinase. Sulfone derivs. of 1 were found to be highly effective, time-dependent inhibitors of human leukocyte elastase (HLE), cathepsin G (Cat G) and proteinase 3 (PR 3). The judicious selection of an R1 group (accommodated at the primary specificity site S1) that is based on the known substrate specificity of a target serine proteinase, was found to yield highly selective inhibitors. The presence of a benzyl group (R2 = benzyl) at the S2 subsite was found to lead to a pronounced enhancement

in inhibitory potency. Furthermore, the effective use of computer graphics and modeling has led to the design of potent, water-soluble inhibitors.

The results of these studies demonstrate that the 1,2,5-thiadiazolidin-3-one 1,1-dioxide platform provides an effective means for appending recognition elements in a well-defined vector relationship, and in fashioning highly-selective and potent inhibitors of serine proteinases.


IT 212331-98-1P 212331-99-2P 212332-00-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(1,2,5-thiadiazolidin-3-one 1,1-dioxide inhibitors of human leukocyte elastase, cathepsin G and proteinase 3)

RN 212331-98-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212332-00-8 HCAPLUS
CN Benzeneacetic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylthio)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 212331-79-8P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation as inhibitor of human leukocyte elastase, cathepsin G and proteinase 3)
RN 212331-79-8 HCAPLUS


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.




RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-77-6 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212331-78-7 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 170918-99-7P 170919-01-4P 170919-03-6P
212331-77-6P 212331-78-7P 212331-80-1P
212331-81-2P 212331-82-3P 212331-83-4P
212331-86-7P 212331-87-8P 212331-90-3P
212331-92-5P 212331-94-7P 212331-95-8P
212331-97-0P

RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation as inhibitor of human leukocyte elastase, cathepsin G and proteinase 3)

RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170919-01-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(phenylmethyl)-5-[(2E)-3-phenyl-2-propenyl]-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 212331-80-1 HCAPLUS
CN Benzoic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-81-2 HCAPLUS
CN Benzoic acid, 2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212331-82-3 HCAPLUS
CN Benzoic acid, 2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



RN 212331-83-4 HCAPLUS
CN Benzeneacetic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 212331-86-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[[(4-chlorophenyl)sulfonyl)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 212331-92-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 212331-94-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.




RN 212331-95-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-bis(phenylmethyl)-2-

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 212331-87-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(2-phenylethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212331-90-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[[(4-chlorophenyl)sulfonyl)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-97-0 HCAPLUS
CN Benzeneacetic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

10510026rtr

L4 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 09 Apr 1998

ACCESSION NUMBER: 1998:200895 HCAPLUS

DOCUMENT NUMBER: 128:278642

TITLE: Use of the 1,2,5-thiadiazolidin-3-one 1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds in the design of potent inhibitors of serine proteinases

AUTHOR(S): Kuang, Rongze; Venkataraman, Radhika; Ruan, Sumel; Groutas, William C.

CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(5),

539-544

CODEN: BMCLEB; ISSN: 0960-894X

Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The attachment of a phosphate leaving group to the

1,2,5-thiadiazolidin-3-one 1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds was found to yield highly potent, time-dependent inhibitors of human leukocyte elastase (HLE).

IT 205932-85-OP 205932-87-2P 205932-88-3P

205932-89-4P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)

(use of the 1,2,5-thiadiazolidin-3-one 1,1 dioxide and

isothiazolidin-3-one 1,1 dioxide scaffolds in the design of potent


inhibitors of serine proteinases)

RN 205932-85-0 HCAPLUS

CN Phosphoric acid, dimethyl [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-

(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX

NAME)



RN 205932-87-2 HCAPLUS

CN Phosphoric acid, dibutyl [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-

(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX

NAME)

L4 ANSWER 29 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 30 Aug 1997

ACCESSION NUMBER: 1997:555602 HCAPLUS

DOCUMENT NUMBER: 127:257045

TITLE: Competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels

in mouse plasma

AUTHOR(S): Bright, Stuart W.; Tinsley, Frank C.; Dominianni, Samuel J.; Schmiegel, Klaus K.; Fitch, Lora L.; Gold, Gerald

CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA

JOURNAL OF IMMUNOLOGICAL METHODS (1997), 207(1),

23-31

CODEN: JIMMBC; ISSN: 0022-1759

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Two competitive particle concentration fluorescence immunoassays were

developed

to measure blood levels of analogs of antidiabetic drugs being tested in

diabetic mice. Ligands that contained the active pharmacophores were

conjugated to PPD for immunization and to B-phycoerythrin for use as

a tracer in the immunoassays. Approx. 90% of 262 compds. assayed were

detectable at less than 120 nM in plasma which was well below the

estimated

therapeutic level of 1 µM for lowering blood glucose. These data were

used to define the bioavailability of test compds. and assist in

decisions

of constructing active analogs. Of addnl. interest, we noted

crossreactivity of one monoclonal antibody for 3 different compound

classes

that are all known to bind with varying affinities to peroxisome

proliferator-activated receptors.

IT 196079-43-3

RL: ANT (Analyte); ANST (Analytical study)

(competitive particle concentration fluorescence immunoassays for

measuring


antidiabetic drug levels in mouse plasma)

RN 196079-43-3 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]-

1,1-dioxide (9CI) (CA INDEX NAME)


1,1-dioxide (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

FORMAT RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 205932-88-3 HCAPLUS

CN Phosphoric acid, [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-

1,2,5-thiadiazolidin-2-yl]methyl bis(phenylmethyl) ester (9CI) (CA INDEX


NAME)



RN 205932-89-4 HCAPLUS

CN Phosphoric acid, [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-

1,2,5-thiadiazolidin-2-yl]methyl diphenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR

THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 09 Apr 1997

ACCESSION NUMBER: 1997:226843 HCAPLUS

DOCUMENT NUMBER: 126:287581

TITLE: Structure-Based Design of a General Class of Mechanism-Based Inhibitors of the Serine Proteinases Employing a Novel Amino Acid-Derived Heterocyclic Scaffold

AUTHOR(S): Groutas, William C.; Kuang, Rongze; Venkataraman, Radhika; Epp, Jeffrey B.; Ruan, Sumel; Prakash, Om

CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA

BIOCHEMISTRY (1997), 36(16), 4739-4750

CODEN: BICHAJ; ISSN: 0006-2960

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We describe in this paper the structure-based design of a general class

of

heterocyclic mechanism-based inhibitors of the serine proteinases that

embody in their structure a novel peptidomimetic scaffold

(1,2,5-thiadiazolidin-3-one 1,1-dioxide). Sulfone derivs. of this class

were time-dependent, potent, and highly efficient irreversible inhibitors

of human leukocyte elastase, cathepsin G, and proteinase 3. The

partition

ratios for a select number of inhibitors were found to range between 0

and 1.

We furthermore demonstrate that these inhibitors exhibit remarkable

enzyme

selectivity that is dictated by the nature of the P1 residue and is

consistent with the known substrate specificity reported for these

enzymes. Thus, inhibitors with small hydrophobic side chains were

effective inhibitors of elastase, those with aromatic side chains of

cathepsin G, and those with a basic side chain of bovine trypsin. Taken

together, the findings cited herein reveal the emergence of a general

class of stable mechanism-based inhibitors of the serine proteinases

which

can be readily synthesized using amino acid precursors. Biochem. and

high-field NMR studies show that the interaction of this class of

inhibitors with a serine proteinase results in the formation of a stable

acyl complex(es) and the release of benzenesulfinate, formaldehyde, and a

low mol. weight heterocycle. The data are consistent with initial

formation

of a Michaelis-Menten complex, acylation of Ser195, and tandem loss of

the

leaving group. The initial HLE-inhibitor complex reacts with water

generating formaldehyde and a stable HLE-inhibitor complex. Whether the

initial HLE-inhibitor complex also reacts with His57 to form a third

complex is not known at this point. The desirable salient parameters

associated with this class of inhibitors, including the expeditious

generation of structurally diverse libraries of inhibitors based on I,

suggest that this class of mechanism-based inhibitors is of general

applicability and can be used in the development of inhibitors of human

and viral serine proteinases of clinical relevance.

IT 170918-99-7P 170919-03-6P 189124-00-3P

189124-02-5P 189124-04-7P 189124-06-9P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological

study, unclassified); SPN (Synthetic preparation); BIOL (Biological

study); PREP (Preparation)


(preparation and structure activity relations of mechanism-based

inhibitors)

10510026rtr


L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
of human leukocyte serine proteinases employing a novel amino
acid-derived heterocyclic scaffold)
RN 170910-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189124-00-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-ethyl-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 189124-02-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-4-
propyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189124-04-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(1-methylethyl)-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189124-06-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-butyl-5-(phenylmethyl)-2-

L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01 Dec 1995
ACCESSION NUMBER: 1995:954574 HCAPLUS
DOCUMENT NUMBER: 123:340140
TITLE: Novel serine protease inhibitors: derivatives of
isothiazolidin-3-one 1,1-dioxide and
3-oxo-1,2,5-thiadiazolidine 1,1-dioxide
INVENTOR(S): Groutas, William C.
PATENT ASSIGNEE(S): Wichita State University, USA
SOURCE: PCT Int. Appl., 93 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518797	A1	19950713	WO 1995-US236	19950103
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5550139	A	19960827	US 1994-177352	19940103
CA 2179913	A1	19950713	CA 1995-2179913	19950103
AU 9515998	A	19950801	AU 1995-15998	19950103
AU 686316	B2	19980205		
EP 739338	A1	19961030	EP 1995-908003	19950103
EP 739338	B1	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509922	T	19971007	JP 1995-518638	19950103
AT 215938	T	20020415	AT 1995-908003	19950103
NZ 329766	A	20010223	NZ 1998-329766	19980216
PRIORITY APPLN. INFO.:			US 1994-177352	A 19940103
			WO 1995-US236	W 19950103

OTHER SOURCE(S): MARPAT 123:340140
GI




AB Various isothiazolidin-3-one 1,1-dioxide and 3-oxo-1,2,5-thiadiazolidine 1,1-dioxide derivs., e.g. I [X = CH2, (un)substituted NH; R1 = H, alkyl, (un)substituted benzyl, indolylalkyl, etc.; Y = non-steroidal antiinflammatory residue, H, protected amino acid, acyloxy, etc.], and their use to reduce or inhibit the activity of serine proteinases, are claimed. The compds. are useful as anti-inflammatory and anti-metastatic agents. For example, 4-benzylisothiazolidin-3-one 1,1-dioxide underwent

10510026rtr


L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 M-alkylation with ClCH₂SPH and Et₃N in MeCN, followed by 5-oxidn. with
 m-ClC₆H₄C(O)OOH in CH₂Cl₂ (90%), to give title compd. II. In an in vitro
 assay, II had an apparent 2nd-order inactivation rate const. (kobs/[I])
 M-1 s-1) of 960 against cathepsin G. A variety of compds. were prepd. and/or
 tested against cathepsin G, human leukocyte elastase, and/or
 proteinase-3.
 IT 170919-16-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (intermediate; preparation of isothiazolidinone and oxothiadiazolidine
 dioxide derivs. as serine protease inhibitors)
 RN 170919-16-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(phenylmethyl)-5-(3-phenyl-2-propenyl)-2-
 [(phenylthio)methyl]-, 1,1-dioxide, [5-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




IT 170919-15-0P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT
 (Reactant or reagent); USES (Uses)
 (preparation of isothiazolidinone and oxothiadiazolidine dioxide
 derivs. as
 serine protease inhibitors)
 RN 170919-15-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 4,5-bis(phenylmethyl)-2-[(phenylthio)methyl]-,
 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 170919-03-6 170919-21-8 170919-22-9
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study);
 USES
 (Uses)
 (preparation of isothiazolidinone and oxothiadiazolidine dioxide
 derivs. as
 serine protease inhibitors)
 RN 170919-03-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-
 [(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170919-21-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-
 [(phenylsulfonyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 170919-22-9 HCAPLUS

L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


IT 153044-45-2P 170918-99-7P 170919-01-4P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of isothiazolidinone and oxothiadiazolidine dioxide
 derivs. as
 serine protease inhibitors)
 RN 153044-45-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-,
 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170918-99-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-
 [(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170919-01-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 4-(phenylmethyl)-5-[(2E)-3-phenyl-2-propenyl]-
 2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.




L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-,
 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 32 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 19 Mar 1994
 ACCESSION NUMBER: 1994:124451 HCAPLUS
 DOCUMENT NUMBER: 120:124451
 TITLE: Substituted 3-oxo-1,2,5-thiadiazolidine 1,1-dioxides:
 a new class of potential mechanism-based inhibitors
 of
 human leukocyte elastase and cathepsin G
 AUTHOR(S): Groutas, William C.; Kuang, Rongze; Venkataraman,
 Radhika
 CORPORATE SOURCE: Dep. Chem., Wichita State Univ., Wichita, KS, 67260,
 USA
 SOURCE: Biochemical and Biophysical Research Communications
 (1994), 198(1), 341-9
 CODEN: BBRCA9; ISSN: 0006-291X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A series of substituted 3-oxo-1,2,5-thiadiazolidine 1,1-dioxides (I, R =
 benzyl; R1 = H, Me, benzyl, CH2CO2-tert-Bu or CH2CO2-benzyl) was prepd,
 and their in vitro inhibitory activity toward human leukocyte elastase
 and
 cathepsin G was investigated. These compds. inactivated the 2 enzymes
 efficiently and in a time-dependent fashion.
 IT 153044-45-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of and human leukocyte elastase and cathepsin G
 inhibition by)
 RN 153044-45-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-,
 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 26 Jan 1991
 ACCESSION NUMBER: 1991:23940 HCAPLUS
 DOCUMENT NUMBER: 114:23940
 TITLE: Intra- and intermolecular α -sulfamidoalkylation
 reactions
 AUTHOR(S): Lee, Chai Ho; Kohn, Harold
 CORPORATE SOURCE: Dep. Chem., Univ. Houston, Houston, TX, 77204-5641,
 USA
 SOURCE: Journal of Organic Chemistry (1990), 55(25), 6098-104
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:23940
 GI

L4 ANSWER 32 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na



AB The utility of α -sulfamidoalkylation processes for the generation of
 sulfamides has been examined Both intra- and intermol. α -
 sulfamidoalkylation transformations were observed to proceed in moderate
 to
 good yields. The generality of these processes has been demonstrated
 using N,N'-di(aryl-substituted)sulfamides, and the utility of these
 reactions was examined for the preparation of cyclic sulfamides of novel
 structure. Thus, reaction of PhCH2NH5O2NH2 with EtO2CCH(OEt)2 in the
 presence of CF3CO2H gave 74% dithiatetrazocinedicarboxylate tetraoxide I,
 whereas reaction of 3-MeOC6H4CH2NH5O2NH2 with EtO2CCH(OEt)2 in CF3CO2H
 followed by methylation gave benzothiadiazepinecarboxylate dioxides II.
 The crystal structures of I and II were determined
 IT 130670-00-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclization of)
 RN 130670-00-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-hydroxy-5-(2-phenylethyl)-, 1,1-dioxide,
 monosodium salt (9CI) (CA INDEX NAME)

10510026rtr

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.69

340.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-24.75

-24.75

STN INTERNATIONAL LOGOFF AT 14:04:52 ON 21 DEC 2006

10510026rtr

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Expanded

Q₂ - ALL , L₁, L₂, Z, Q₁, R₁, R₂ - ALL

L₃ - ALL

X, Y = CH

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CAplus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8 SEP 25 CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CAplus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21 NOV 20 CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 22 NOV 20 CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 23 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 24 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 25 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 26 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 27 DEC 18 CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 28 DEC 18 CA/CAplus patent kind codes updated
NEWS 29 DEC 18 MARPAT to CA/CAplus accession number crossover limit increased to 50,000
NEWS 30 DEC 18 MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

10510026rtr

NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 14:02:27 ON 21 DEC 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 14:03:05 ON 21 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0

DICTIONARY FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TS/CA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10510026RTRExpand.str

10510026rtr



chain nodes :

7 9 18 19 22 23

ring nodes :

1 2 3 4 5 10 11 12 13 14 15

chain bonds :

1-22 1-23 2-7 4-18 4-19 5-9 9-10

ring bonds :

1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15

exact/norm bonds :

1-2 1-5 1-22 1-23 2-3 2-7 3-4 4-5 4-18 4-19 5-9

exact bonds :

9-10

normalized bonds :

10-11 10-15 11-12 12-13 13-14 14-15

G1:H,CH3

G2:O,S

G3:O,S,N

G4:H,CH3

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 9:CLASS 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 18:CLASS 19:CLASS 22:CLASS 23:CLASS


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10510026rtr



G1 H, Me

G2 O, S

G3 O, S, N

G4 H, Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 14:03:30 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 68 TO ITERATE

100.0% PROCESSED 68 ITERATIONS
SEARCH TIME: 00.00.01

50 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 866 TO 1854
PROJECTED ANSWERS: 576 TO 1424

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 14:03:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1124 TO ITERATE

100.0% PROCESSED 1124 ITERATIONS
SEARCH TIME: 00.00.01

766 ANSWERS

L3 766 SEA SSS FUL L1

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
166.94	167.15

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 14:03:44 ON 21 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

10510026rtr

The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 21 Dec 2006 VOL 145 ISS 26

FILE LAST UPDATED: 20 Dec 2006 (20061220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 33 L3

=> d ed ibib abs hitstr 1-33

10510026rtr

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 03 Aug 2006

ACCESSION NUMBER: 2006:765251 HCAPLUS

DOCUMENT NUMBER: 145:211037

TITLE: Preparation of pyrazolyl aryl ureas as modulators of the protein kinase activation state for treatment of inflammation and hyperproliferative diseases

INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.

PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, LLC, USA

SOURCE: PCT Int. Appl., 305pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006081034	A2	20060803	WO 2005-US47597	20051223
WO 2006081034	A3	20061123		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CM, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MM, MG, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPL. INFO.: US 2004-638987P P 20041223

OTHER SOURCE(S): MARPAT 145:211037

GI



II

AB Novel compds. and methods of using those compds. for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

embodiment, the compds. of the invention modulate the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein. The compds. of the invention 1 have general formula (R1-(X))m-A-NH-L-NH-D-(E)q-(Y)t-Q wherein R1 = aryl, heteroaryl, and heterocyclyl; X and Y = individually O, S, alkynyl, alkenyl, etc.; A = an arom., monocycloheterocyclic, or bicycloheterocyclic ring; D = Ph or a 5-6-membered heterocyclic ring; E = Ph, pyridinyl, or pyrimidinyl; L = -C(O)- or -S(O)2-; j,m,q,t = 0-1; and Q = a substituted ring or ring system. Over 500 compds. were prepd. for example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester provided the propionate, which was subsequently converted to the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentenenitrile afforded Me

3-[3-(3-tert-butyl-5-amino-1H-pyrazol-1-yl)phenyl]propionate, which was coupled with 1-naphthyl isocyanate and reduced to provide urea II. In a competition assay with SKF 86002 as a fluorescent probe, II inhibited p38 MAP kinase with IC50 of 45 nM.

IT 872171-35-2P, 1-[5-tert-Butyl-2-[3-[(S)-3-methyl-1,1,4-trioxo-

[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-37-4B, 1-[5-tert-Butyl-2-[3-[(R)-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-57-8P, N-[3-tert-Butyl-1-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-2-naphthalenecarboxamide 872171-62-5P, 1-[5-tert-Butyl-2-[3-

[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-63-6P, 1-[5-tert-Butyl-2-[3-

[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-chlorophenyl)urea 872171-73-8P, 1-[5-tert-Butyl-2-[3-

[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-methoxynaphthalen-1-yl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(p38 kinase inhibitor; preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflammation and hyperproliferative diseases)

RN 872171-35-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(3S)-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 872171-37-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(3R)-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872171-57-8 HCAPLUS


CN 2-Naphthalenecarboxamide, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 872171-62-5 HCAPLUS


CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 872171-63-6 HCAPLUS

CN Urea, N-(4-chlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 872171-73-8 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 872171-36-3P, 1-[5-tert-Butyl-2-[3-[[5-(4-methoxybenzyl)-(R)-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-39-6P, 1-[5-tert-Butyl-2-[3-[[5-(4-methoxybenzyl)-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea 872171-49-8P, 1-[5-tert-Butyl-2-[3-[[1,1,4-trioxo-(1,2,5)thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflammation and hyperproliferative diseases)
 RN 872171-36-3 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[[3R)-5-[(4-methoxyphenyl)methyl]-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872171-39-6 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 872171-49-8 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



10510026rtr


L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 28 Jul 2006
 ACCESSION NUMBER: 2006:739358 HCAPLUS
 DOCUMENT NUMBER: 145:377543
 TITLE: Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure-activity relationships of a peptide

scaffold
 AUTHOR(S): Yue, Eddy W.; Wayland, Brian; Douthy, Brent; Crawley, Matthew L.; McLaughlin, Erin; Takvorian, Amy; Wasserman, Zeld; Bower, Michael J.; Wei, Min; Li, Yanlong; Ala, Paul J.; Gonneville, Lucie; Wynn, Richard; Burn, Timothy C.; Liu, Phillip C. C.; Combs, Andrew P.
 CORPORATE SOURCE: Discovery Chemistry, Experimental Station, Incyte Corporation, Wilmington, DE, 19880, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(17), 5833-5849
 CODEN: BMECEP; ISSN: 0968-0896
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Oxo- and trioxo-substituted isothiazolidinylphenylalanines are prepared as tyrosine mimetics by Suzuki coupling reactions of chloroisothiazolidinones and chlorodioxoisothiazolidinones with N-Boc-4-borono-L-phenylalanine derivs.; the isothiazolidinylphenylalanines (with or without subsequent hydrogenation) are incorporated into dipeptides prepared as human protein tyrosine phosphatase 1B (PTP1B) inhibitors such as I. Of the comds. tested, I is the most potent inhibitor of PTP1B with an IC50 value of 40 nM; the corresponding mixture of isothiazolidinone diastereomers inhibits PTP1B with an IC50 value of 80 nM, and the separated (R)-isothiazolidinone diastereomer inhibits PTP1B with an IC50 value of 15.5 μM; the related dipeptides prepared inhibit PTP1B less potently than either I or the mixture of isothiazolidinone diastereomers containing I. Crystal structures of a

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 850315-21-8 HCAPLUS
 CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 850315-23-0 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dioxothiazolidinone-substituted dipeptide and a dioxoisothiazolidinone-substituted dipeptide bound to PTP1B are detd. by X-ray crystallog.; the low energy conformation found by ab initio calcns. for the satd. heterocycle more closely approaches the conformation obtained upon binding to PTP1B than that of the unsatd. heterocycle.

IT 850315-22-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of isothiazolone- and dioxoisothiazolone-substituted phenylalanine-containing dipeptide amides and their activities as human PTP1B inhibitors)


Absolute stereochemistry.



IT 850315-20-7P 850315-21-8P 850315-23-0P
 910606-95-0P 910606-97-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of isothiazolone- and dioxoisothiazolone-substituted phenylalanine-containing dipeptide amides and their activities as human PTP1B inhibitors)

Absolute stereochemistry.

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 910606-95-0 HCAPLUS
 CN Benzenepropanamide, α-amino-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 910606-94-9
 CMF C23 H30 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2




10510026rtr

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 910606-97-2 HCAPLUS
 CN L-Phenylalaninamide,
 L-phenylalanyl-4-[(1,1-dioxido-4-oxo-5-(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl)-N-pentyl-, mono(trifluoroacetate) (9CI) (CA
 INDEX NAME)
 CM 1
 CRN 910606-96-1
 CMF C32 H39 N5 O5 S

Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CMF C2 H F3 O2



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 29 Dec 2005
 ACCESSION NUMBER: 2005:1346235 HCAPLUS
 DOCUMENT NUMBER: 144:88279
 TITLE: Preparation of 1-pyrazolyl-3-phenylurea p38 MAP
 Kinase
 INVENTOR(S):
 PATENT ASSIGNEE(S): Flynn, Daniel L.; Petillo, Peter A.
 SOURCE: USA
 U.S. Pat. Appl. Publ., 214 pp., Cont.-in-part of U.S.
 Ser. No. 746,460.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288286	A1	20051229	US 2004-886329	20040706
US 2004180906	A1	20040916	US 2003-746460	20031224
US 7144911	B2	20061205		
WO 2006014290	A2	20060209	WO 2005-US23100	20050630
WO 2006014290	A3	20060427		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPL. INFO.:
 US 2003-746460 A2 20031224
 US 2002-437304P P 20021231
 US 2002-437403P P 20021231
 US 2002-437415P P 20021231
 US 2002-437487P P 20021231
 US 2003-463804P P 20030418
 US 2004-886329 A 20040706

OTHER SOURCE(S): MARPAT 144:88279
 GI

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. (R1Xj)mA(NH)pLn(NH)pDEqYtQ [I; wherein R1 = (un)substituted (hetero)aryl; X, Y = independently O, S, NR6, NR6SO2, NR6CO, alkynyl, alkenyl, alkylene, O(CH2)h, NR6(CH2)h, wherein for each alkylene, O(CH2)h, and NR6(CH2)h, one of the methylene groups may be substituted with CO; h = 1-4; A = (un)substituted aryl, hetero(bi)cyclyl; D = (un)substituted Ph, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, pyrimidyl; E = (un)substituted Ph, pyridinyl, pyrimidinyl; L = CO, SO2; m, n, p, q, t = independently 0, 1; Q = (un)substituted heterocyclyl, Ph, etc.; R6 = independently H, alkyl, allyl, TMS(CH2)2; with exceptions] were prepared as p38 MAP kinase inhibitors. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the α -C helix, the α -D helix, the catalytic loop, the switch control ligand sequence, or the C-lobe residues of the kinase protein with I (no data). Although the methods of preparation are not claimed, preps. and/or characterization data for approx.150 examples of I and many intermediates are included. For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester using 10% Pd/C in EtOH provided the propionate, which was treated with NaNO2 in the presence of 6N HCl and SnCl2 \cdot 2H2O to give the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentenenitrile in EtOH and 6N HCl afforded Me 3-[3-(3-tert-butyl-5-amino-1H-pyrazole-1-yl)phenyl]propionate. Coupling of the amine with 1-naphthyl isocyanate in CH2Cl2, followed by reduction with LiOH in THF/MeOH/H2O provided the urea II: In a competition assay with SKR 96002 as a fluorescent probe, the latter inhibited p38 MAP kinase with IC50 of 45 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory conditions (no data). IT 872171-35-2P, 1-[5-tert-Butyl-2-[3-[(3S)-3-methyl-1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-37-4P, 1-[5-tert-Butyl-2-[3-[(3R)-3-methyl-1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-57-8P, N-[3-tert-Butyl-1-[3-[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-2-naphthalenecarboxamide 872171-62-5P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-63-6P, 1-[5-tert-Butyl-2-[3-

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-chlorophenyl)urea 872171-73-8P, 1-[5-tert-Butyl-2-[3-

[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-methoxynaphthalen-1-yl)urea

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; prepn. of (pyrazolyl)(phenyl)urea p38 kinase inhibitors as antiinflammatory agents)


RN 872171-35-2 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(3S)-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872171-37-4 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(3R)-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872171-57-8 HCAPLUS

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Naphthalenecarboxamide, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)




RN 872171-62-5 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)



RN 872171-63-6 HCAPLUS
 CN Urea, N-(4-chlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 872171-36-3P, 1-[5-tert-Butyl-2-[3-[(5-(4-methoxybenzyl)-(R)-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-39-6P, 1-[5-tert-Butyl-2-[3-[(5-(4-methoxybenzyl)-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea 872171-49-8P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (pyrazolyl)(phenyl)urea p38 kinase inhibitors as antiinflammatory agents)

RN 872171-36-3 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(3R)-5-[(4-methoxyphenyl)methyl]-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872171-39-6 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(5-[(4-methoxyphenyl)methyl]-1,1-

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 872171-73-8 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 872171-49-8 HCAPLUS
 CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

PAGE 1-A






L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 26 Aug 2005
 ACCESSION NUMBER: 2005:904352 HCAPLUS
 DOCUMENT NUMBER: 143:248386
 TITLE: Preparation of substituted azole derivatives for treating diseases mediated by PTPase activity
 INVENTOR(S): Mjalli, Adnan M. M.; Polissetti, Dharma R.; Subramanian, Govindan; Quada, James C.; Arimilli, Murthy N.; Yarragunta, Ravindra R.; Andrews, Robert C.;
 Xie, Rongyuan
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 204 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187277	A1	20050825	US 2005-56498	20050211
AU 2005214349	A1	20050901	AU 2005-214349	20050211
CA 2551909	A1	20050901	CA 2005-2551909	20050211
WO 2005080346	A1	20050901	WO 2005-US4590	20050211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1730118	A1	20061213	EP 2005-723026	20050211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRIORITY APPLN. INFO.: US 2004-543971P P 20040212				
WO 2005-US4590 W 20050211				

OTHER SOURCE(S): MARPAT 143:248386
 GI




AB The title compds. I (a, b = 0-2; W = O, S, NR2 (wherein R2 = alkyl, etc.)).
 R1 = H, halo, CN, etc.; L1 = a direct bond, (un)substituted NMO, NMSO2, etc.; Ar1 = (un)substituted (hetero)aryl, fused cycloalkylaryl, etc.; Ar2 = (un)substituted (hetero)arylene, fused arylcycloalkylene, etc.; L2 = CH2, O, alkylene, etc.) which can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity such as type I diabetes and type II diabetes, were prepared

Thus, treating
 4-(2,4-dichlorophenyl)-2-[(2-(4-methoxyphenyl)-(E)-vinyl)-1H-imidazole with Me bromoacetate followed by ester hydrolysis afforded 56% (4-(2,4-dichlorophenyl)-2-[(2-(4-methoxyphenyl)-(E)-vinyl)-1H-imidazol-1-yl]acetic acid. The representative compds. I were tested for inhibition of PTP-1B. In general, the exemplified compds. I may inhibit PTP-1B with IC50 of less than 20 μ M. The pharmaceutical compns. comprising the compds. I, and their use in treating human or animal disorders are also disclosed.

IT 863243-91-8P 863245-57-2P 863245-74-3P
 863246-05-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of substituted azole derivs. for treating diseases mediated by


PTPase activity)
 RN 863243-91-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-4,4-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-57-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-74-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-05-3 HCAPLUS
 CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.

10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 863243-80-5P 863243-92-9P 863243-93-0P
863243-94-1P 863243-95-2P 863244-05-7P
863244-06-8P 863244-07-9P 863244-08-0P
863244-13-7P 863244-47-7P 863244-51-3P
863244-52-4P 863244-53-5P 863245-25-4P
863245-56-1P 863245-58-3P 863245-59-4P
863245-60-7P 863245-61-8P 863245-62-9P
863245-63-0P 863245-64-1P 863245-66-3P
863245-67-4P 863245-68-5P 863245-69-6P
863245-70-9P 863245-71-0P 863245-72-1P
863245-75-4P 863245-78-7P 863245-80-1P
863245-82-3P 863246-03-1P 863246-04-2P
863246-06-4P 863246-07-5P 863246-09-7P
863246-10-0P 863246-11-1P 863246-12-2P
863246-13-3P 863246-15-5P 863246-16-6P
863287-03-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted azole derivs. for treating diseases mediated by

PTPase activity)
RN 863243-80-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-difluorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Double bond geometry as shown.

PAGE 1-A




PAGE 2-A



RN 863243-94-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2-chlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863243-92-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-2,4,4-trimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863243-93-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-phenyl-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863243-95-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(4-chlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-05-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863244-06-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(3,4-dichlorophenyl)-2-[(1E)-2-{3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl}ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-07-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(3,4-difluorophenyl)-2-[(1E)-2-{3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl}ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-1-yl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 863244-47-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(3-(trifluoromethyl)phenyl)methyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 863244-51-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(2-(4-(trifluoromethyl)phenyl)ethyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.




RN 863244-08-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2-chloro-4-fluorophenyl)-2-[(1E)-2-{3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl}ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-13-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(3-(trifluoromethyl)phenyl)methyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-1H-imidazol-1-yl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 863244-52-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(2-(4-(trifluoromethyl)phenyl)ethyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 863244-53-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[2-[3-(trifluoromethoxy)(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 863245-25-4 HCAPLUS
 CN Benzoic acid,
 4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-56-1 HCAPLUS


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-[3'-chloro[1,1'-biphenyl]-4-yl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-60-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(1-methylethoxy)(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-61-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4'-(1-methylethylthio)(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-[3',5'-bis(trifluoromethyl)(1,1'-biphenyl)-4-yl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-58-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(2'-fluoro-5'-propoxy[1,1'-biphenyl]-4-yl]ethenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-59-4 HCAPLUS


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4'-(1,1-dimethylethyl)(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-62-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4'-(1,1-dimethylethyl)(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-63-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(1,1-dimethylethyl)-5'-methyl(1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-64-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-66-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-69-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-70-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-67-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-68-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-71-0 HCAPLUS
CN Carbamic acid, [4'-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl]-4-fluoro[1,1'-biphenyl]-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-72-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(5-chloro-2-thienyl)phenyl]ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-4-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-75-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[2-(trifluoromethyl)phenoxy]phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-78-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(4,4-trifluorobutoxy)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


(trifluoromethyl)phenoxy]phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863246-03-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-04-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[(1E)-2-[4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazol-2-yl]ethenyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.




RN 863245-80-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dimethylethyl)phenoxy]phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-82-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(4-tert-butylphenoxy)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-06-4 HCAPLUS
CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]-1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-07-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-09-7 HCAPLUS
 CN Carbamic acid, [4'-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl][1,1'-biphenyl]-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-10-0 HCAPLUS
 CN Carbamic acid, [4'-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl][1,1'-biphenyl]-3-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



RN 863246-13-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[(4-phenoxyphenyl)ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[(3-(trifluoromethyl)-1,1'-biphenyl]-4-yl)ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863246-11-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[(1-methylethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-12-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[(3'-methyl[1,1'-biphenyl]-4-yl)ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-16-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[(3-(trifluoromethyl)-1,1'-biphenyl]-4-yl)ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863287-03-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,6-dichlorophenyl)-2-[(1E)-2-[(3-(trifluoromethyl)-1,1'-biphenyl]-4-yl)ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 863247-41-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (Preparation of substituted azole derivs. for treating diseases mediated by PTPase activity)
 RN 863247-41-0 HCAPLUS
 CN Benzoic acid, 4-[(4-(2,4-dichlorophenyl)-2-yl)-2-(3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)(1,1'-biphenyl)-4-yl)ethenyl]-1H-imidazol-1-ylmethyl-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 03 May 2005

ACCESSION NUMBER: 2005:378875 HCAPLUS

DOCUMENT NUMBER: 143:19267

TITLE: Structure-based design of protein tyrosine phosphatase-1B inhibitors

AUTHOR(S): Black, Emma; Breed, Jason; Breeze, Alexander L.; Embrey, Kevin; Garcia, Robert; Gero, Thomas W.; Godfrey, Linda; Kenny, Peter W.; Morley, Andrew D.; Minshull, Claire A.; Pannifer, Andrew D.; Read, Jon; Rees, Amanda; Russell, Daniel J.; Toader, Dorin; Tucker, Julie

CORPORATE SOURCE: AstraZeneca, Cheshire, SK10 4TG, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(10), 2503-2507

CODEN: BMCLES; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:19267


AB Using structure-based design, a new class of inhibitors of protein tyrosine phosphatase-1B (PTP1B) has been identified, which incorporate the

1,2,5-thiadiazolidin-3-one-1,1-dioxide template.

IT 692765-80-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (Structure-based design of protein tyrosine phosphatase-1B inhibitors)

RN 692765-80-3 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-(3-bromophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



IT 612530-44-6P 692764-89-9P 692764-94-6P


852835-44-0P 852835-45-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (Structure-based design of protein tyrosine phosphatase-1B inhibitors)


RN 612530-44-6 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-89-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692764-94-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[1,1'-biphenyl]-3-yl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 852835-44-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 852835-45-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 850315-36-5 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-4-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-35-4
CMF C25 H19 F6 N5 O5 S2

Absolute stereochemistry.



CM 2


CRN 76-05-1

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzenesulfonamide, N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-43-4
CMF C26 H18 F9 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-48-9 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-47-8
CMF C25 H19 F6 N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C2 H F3 O2




RN 850315-40-1 HCAPLUS
CN Benzenesulfonamide, 4-bromo-N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-39-8
CMF C25 H18 Br F6 N5 O6 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-44-5 HCAPLUS

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-63-8 HCAPLUS
CN [1,1'-Biphenyl]-4-sulfonamide, N-[(1S)-2-[3-chloro-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 850315-62-7
CMF C30 H23 Cl F3 N5 O5 S2

Absolute stereochemistry.

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850315-65-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-4-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850315-64-9
CMF C25 H18 Cl F6 N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850315-69-4 HCAPLUS
CN Benzenesulfonamide, 4-bromo-N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850315-68-3
CMF C25 H17 Br Cl F6 N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850315-73-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850315-72-9
CMF C26 H17 Cl F9 N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-65-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-[5-chloro-1H-benzimidazol-2-yl]-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-64-9
CMF C23 H19 Cl2 N5 O5 S2

Absolute stereochemistry.



CM 2

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-67-2 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyano-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-66-1
CMF C24 H18 Cl2 N6 O5 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850327-69-4 HCAPLUS

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850327-73-0 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxy-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-72-9
CMF C25 H23 Cl2 N5 O7 S2

Absolute stereochemistry.


L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyano-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-68-3
CMF C24 H18 Cl2 N6 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-71-8 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxy-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-70-7
CMF C29 H23 Cl2 N5 O6 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850327-75-2 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethyl-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 850327-74-1
CMF C25 H23 Cl2 N5 O5 S2

Absolute stereochemistry.

10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-77-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-76-3
CMF C23 H20 Cl N5 O5 S2


Absolute stereochemistry.



L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-80-9
CMF C24 H19 Cl N6 O5 S2

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-83-2 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-82-1
CMF C29 H24 Cl N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-79-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-78-5
CMF C24 H19 Cl N6 O5 S2

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-81-0 HCAPLUS

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-85-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-84-3
CMF C25 H24 Cl N5 O7 S2

Absolute stereochemistry.



10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-87-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-86-5
CMF C25 H24 Cl N5 O5 S2


Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2



L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-93-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-92-3
CMF C23 H19 Cl2 N5 O5 S2

Absolute stereochemistry.




CM 2

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 850327-89-8 HCAPLUS
CN Benzenesulfonamide, 3-chloro-N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-88-7
CMF C23 H18 Cl3 N5 O5 S2

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-91-2 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-90-1
CMF C23 H18 Cl2 F N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CRN 76-05-1
CMF C2 H F3 O2



RN 850327-95-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-94-5
CMF C23 H19 Cl F N5 O5 S2

Absolute stereochemistry.




CM 2
CRN 76-05-1
CMF C2 H F3 O2



IT 850315-20-7P, [(S)-2-[4-(5-Benzyl-1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]-1-(pentylcarbamoyl)ethyl]carbamamic acid tert-butyl ester 850315-21-8P, [(1S)-1-[(1S)-2-[4-(5-Benzyl-1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]-1-(pentylcarbamoyl)ethyl]carbamoyl]-2-phenylethyl]carbamamic acid tert-butyl


L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ester 850315-23-OP, (2S)-3-[4-(5-Benzyl-1,1,4-trioxo(1,2,5)thiadiazolidin-2-yl)phenyl]-2-[[[(2S)-2-[[2-(4-methoxyphenyl)acetyl]amino]-3-phenylpropionyl]amino]-N-pentylpropionamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 1-oxo and 1,1-dioxoisothiazolone and related modulators of proteins such as phosphatases that bind phosphorylated peptides and proteins)
 RN 850315-20-7 HCAPLUS
 CN Carbamic acid, [(1S)-1-[[[4-(1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 850315-21-8 HCAPLUS
 CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-[(1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850315-23-0 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-[(1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 11 Apr 2005
 ACCESSION NUMBER: 2005:308290 HCAPLUS
 DOCUMENT NUMBER: 143:7658
 TITLE: Expedient syntheses of sulfonylhydantoins and two six-membered analogs
 AUTHOR(S): Campbell, Andrew D.; Birch, Alan M.
 CORPORATE SOURCE: Research and Development, AstraZeneca, Cheshire, SK10 4TG, UK
 SOURCE: Synlett (2005), (5), 834-838
 CODEN: SYNLES; ISSN: 0936-5214
 PUBLISHER: Georg Thieme Verlag
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:7658
 GI




AB A range of α -amino esters can be turned into sulfonylhydantoins in a single, atom-economic step using sulfamide and DBU. E.g., reaction of BnNHCH₂CO₂Et with sulfamide and DBU gave 6% sulfonylhydantoin I. This procedure obviates the need for a three- or four-step sequence utilized by traditional procedures. Two new six-membered analogs [5-aryl-1,2,6-thiadiazinan-3-one 1,1-dioxides and 5-aryl-1,2-thiazinan-3-one 1,1-dioxides], e.g. II and III, have also been prepared utilizing novel synthetic protocols.

IT 612528-23-1P 612529-46-1P 612530-69-5P
 852358-50-OP 852358-51-1P 852358-53-3P
 852358-54-4P 852358-56-6P 852358-57-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)


L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (prepn. of sulfonylhydantoins via reaction of amino acid esters with sulfamide and DBU)
 RN 612528-23-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-46-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-69-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 852358-50-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 852358-51-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((2-methoxyphenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 852358-53-3 HCAPLUS
CN Benzonitrile, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 852358-54-4 HCAPLUS

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 4-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 852358-56-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-([1,1'-biphenyl]-3-ylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 852358-57-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-methyl-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 08 Mar 2005
ACCESSION NUMBER: 2005:202894 HCAPLUS
DOCUMENT NUMBER: 142:366767
TITLE: 1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides are potent inhibitors of human trypsin
AUTHOR(S): Wong, Tzutshin; Groutas, Christopher S.; Mohan, Swathi; Lai, Zhong; Alliston, Kevin R.; Vu, Nga; Schechter, Norman M.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Archives of Biochemistry and Biophysics (2005), 436(1), 1-7
CODEN: ABBIA4; ISSN: 0003-9861
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The authors describe herein the design, synthesis, and in vitro biochem. evaluation of a series of potent, time-dependent inhibitors of the mast cell-derived serine protease trypsin. The inhibitors were readily obtained by attaching various heterocyclic thiols, as well as a basic primary specificity residue P1, to the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold. The inhibitors were found to be devoid of any inhibitory activity toward a neutral (elastase) or cysteine (papain) protease, however they were also fairly efficient inhibitors of bovine trypsin. The differential inhibition observed with trypsin suggests that enzyme selectivity can be optimized by exploiting differences in the S' subsites of the two enzymes. The results described herein demonstrate the versatility of the heterocyclic scaffold in fashioning mechanism-based inhibitors of neutral, basic, and acidic (chymo)trypsin-like serine proteases.
IT 849415-30-1P 849415-31-2P 849415-32-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
are (1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides are potent inhibitors of human trypsin)
RN 849415-30-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((4-aminobutyl)-2-[[[(2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.




RN 849415-31-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((4-aminobutyl)-5-(phenylmethyl)-2-[[[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 849415-32-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(4-aminobutyl)-5-(phenylmethyl)-2-[(3-phenyl-1,2,4-oxadiazol-5-yl)thio]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 849415-24-3P 849415-25-4P 849415-26-5P
849415-27-6P 849415-28-7P 849415-29-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides)


are potent inhibitors of human tryptase)

RN 849415-24-3 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 849415-28-7 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-29-8 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[(3-phenyl-1,2,4-oxadiazol-5-yl)thio]methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 849415-25-4 HCAPLUS
CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[(phenylthio)methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849415-26-5 HCAPLUS
CN Carbamic acid, [4-[(3S)-5-(chloromethyl)-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-27-6 HCAPLUS
CN Carbamic acid, [4-[(3S)-5-[(2-benzoxazolylthio)methyl]-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Aug 2004
ACCESSION NUMBER: 2004:677210 HCAPLUS
DOCUMENT NUMBER: 141:235669
TITLE: Potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-3-one 1,1-dioxide-based
sulfonamide derivatives
AUTHOR(S): Lai, Zhong; Gan, Xiangdong; Wei, Liqing; Alliston,
Kevin R.; Yu, Hongyi; Li, Yue H.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University,
Wichita, KS, 67260, USA
SOURCE: Archives of Biochemistry and Biophysics (2004),
429(2), 191-197
CODEN: ABBIA4; ISSN: 0003-9861
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:235669
AB The design, synthesis, and in vitro biochem. evaluation of a class of
mechanism-based inhibitors of human leukocyte elastase (HLE) that
incorporate in their structure a 1,2,5-thiadiazolidin-3-one 1,1-dioxide
scaffold with appropriate recognition and reactivity elements appended to
it is described. The synthesized compds. were found to be efficient,
time-dependent inhibitors of HLE. The interaction of the inhibitors with
HLE is postulated to lead to the formation of a highly reactive
N-sulfonyl
imine (a Michael acceptor) that arises from an enzyme-induced sulfonamide
fragmentation cascade. Subsequent reaction ultimately leads to the
formation of a relatively stable acyl enzyme. The results cited herein
demonstrate convincingly the superiority of the
1,2,5-thiadiazolidin-3-one
1,1-dioxide scaffold over other scaffolds (e.g., saccharin) in the design
of inhibitors of (chymotrypsin-like serine proteases.
IT 749866-31-7P 749866-32-8P 749866-33-9P
749866-34-0P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); USES (Uses)
(potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-
3-one 1,1-dioxide-based sulfonamide derivs.)
RN 749866-31-7 HCAPLUS
CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]sulfonyl]-, methyl ester
(9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).


L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 749866-32-8 HCAPLUS
CN D-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]sulfonyl]-, methyl ester
(9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).




RN 749866-33-9 HCAPLUS
CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]sulfonyl]-, phenylmethyl
ester (9CI) (CA INDEX NAME)
Absolute stereochemistry. Rotation (-).




RN 749866-34-0 HCAPLUS
CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]sulfonyl]- (9CI) (CA
INDEX NAME)
Absolute stereochemistry. Rotation (-).


L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 212331-99-2P 749866-30-6P
RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP
(Preparation); RACT (Reactant or reagent)
(potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-
3-one 1,1-dioxide-based sulfonamide derivs.)
RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-
(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)
Absolute stereochemistry.



RN 749866-30-6 HCAPLUS
CN Ethanedithioic acid, S-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-
(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl] ester (9CI) (CA INDEX
NAME)
Absolute stereochemistry.




IT 220869-64-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(potent inhibition of human leukocyte elastase by
1,2,5-thiadiazolidin-
3-one 1,1-dioxide-based sulfonamide derivs.)
RN 220869-64-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-,

L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR
THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

10510026rtr

L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ED Entered STN: 30 Jul 2004
 ACCESSION NUMBER: 2004:610081 HCAPLUS
 DOCUMENT NUMBER: 141:157120
 TITLE: Preparation of sulfahydantoin as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
 INVENTOR(S): Saunders, Jeffrey O.; Miknis, Gregory F.; Blake, James
 F.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 62 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004062664	A1	20040729	WO 2003-US41630	20031230	
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW:	BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG	CA 2511818	A1	20040729	CA 2003-2511818	20031230
AU 2003300447	A1	20040810	AU 2003-300447	20031230	
US 2004167187	A1	20040826	US 2003-749121	20031230	
EP 1594497	A1	20051116	EP 2003-815258	20031230	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200514960	T	20060518	JP 2004-566641	20031230	
PRIORITY APPL. INFO.:			US 2002-437572P	P 20021230	
			WO 2003-US41630	W 20031230	

OTHER SOURCE(S): MARPAT 141:157120
 GI


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 4-[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)benzoic acid methyl ester
 729600-47-9P 729600-48-0P 729600-49-1P
 729600-50-4P 729600-51-5P 729600-52-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of sulfahydantoin as phosphate isosteres for use as protein or phosphatase inhibitors in treatment of cancer and autoimmune disorders)

RN 612527-99-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612530-69-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 729600-44-6 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB The invention relates to compds. having a sulfahydantoin or a reverse sulfahydantoin moiety (I) and (II) or pharmaceutically acceptable salts thereof [Q = each (un)substituted C1-8 aliphatic group, C6-10 aryl, heteroaryl having 5-10 ring atoms, heterocyclyl having 3-10 ring atoms; T = C1-6 alkylidene chain wherein one or two nonadjacent methylene units of T are optionally and independently replaced by O, NR, S, CO, CONR, NRCO, NRCONR, SO, SO2, NRSO2, SO2NR, or NRSO2NR; m = 0, 1; X = CH2, CO, CF2; R = H or (un)substituted C1-8 aliphatic group or two R groups bound to the


same nitrogen are taken together with the nitrogen to form a 3-7 membered heterocyclic ring having 0-2 heteroatoms in addition to the nitrogen, wherein

Said heteroatoms are independently selected from N, O, or S, uses thereof, and related methods. These compds. are inhibitors of phosphatases, particularly inhibitors of protein tyrosine phosphatase SHP-2 and are used in the treatment of various phosphatase mediated diseases such as proliferative diseases, autoimmune disorders, angiogenic disorders, and cancer. The autoimmune disease is selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease. The proliferative disease is selected from acute myelogenous leukemia, chronic


myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HTLV-1-mediated tumorigenesis. The angiogenic disorder is selected from solid tumors, ocular neovascularization, and infantile haemangiomas. The cancer is selected from colon, breast, stomach, and ovarian cancer. Thus, N-alkylation of Me 4-aminobenzoate by Et bromoacetate in the presence of Et3N at 60° for 2.5 days gave 4-[(ethoxycarbonyl)methyl]amino]benzoic acid Me ester which underwent N-sulfamoylation by sulfamoyl chloride in the presence of Et3N in CH2Cl2 at room temperature overnight to give 4-[N-[(ethoxycarbonyl)methyl]-N-sulfamoylamino]benzoic acid Me ester (III). Cyclization of III by treatment with NaOMe/MeOH at room temperature overnight gave 4-[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)benzoic acid Me ester (IV). IV showed IC50 of 1.0-100 μM against protein tyrosine phosphatase SHP-2.

IT 612527-99-8P 612530-69-5P 729600-44-6P,


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 729600-47-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-naphthalenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 729600-48-0 HCAPLUS
 CN Benzoic acid, 3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 729600-49-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3-phenyl-2-propenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 729600-50-4 HCAPLUS
 CN Benzamide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 729600-51-5 HCAPLUS
 CN Benzamide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 729600-52-6 HCAPLUS
 CN Benzamide, N-butyl-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 23 Jul 2004

ACCESSION NUMBER: 2004:589375 HCAPLUS

DOCUMENT NUMBER: 141:140459

TITLE: Preparation of sulfamides as anti-cancer agents

INVENTOR(S): Flynn, Daniel L.; Petrillo, Peter A.

PATENT ASSIGNER(S): Deciphera Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 168 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	WO 2004060305	A2	20040722	WO 2003-US41425	20031226
	WO 2004060305	A3	20050210		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TJ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD			
TG	US 2004171075	A1	20040902	US 2003-746545	20031224
	US 2004176395	A1	20040909	US 2003-746607	20031224
	CA 2511840	A1	20040722	CA 2003-2511840	20031226
	AU 2003303639	A1	20040729	AU 2003-303639	20031226
	EP 1590344	A2	20051102	EP 2003-814980	20031226
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003017863	A	20051206	BR 2003-17863	20031226
	CN 1756849	A	20060405	CN 2003-80110049	20031226
	CN 1791596	A	20060621	CN 2003-80110048	20031226
	JP 200619765	T	20060831	JP 2005-508623	20031226
PRIORITY APPLN. INFO.:				US 2002-437304P	P 20021231
				US 2002-437403P	P 20021231
				US 2002-437415P	P 20021231
				US 2002-437487P	P 20021231
				US 2003-463804P	P 20030418
				US 2003-746545	A 20031224
				US 2003-746607	A 20031224
				WO 2003-US41425	W 20031226

OTHER SOURCE(S): MARPAT 141:140459
 GI

L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Sulfamides, such as I, were prepared for use as anticancer agents which

act

by modulating the activation states of abl or bcr-abl α -kinase proteins. Thus, 4-HO2CC6H4CH2NHSO2NHCOR [R = pyrrolidino], prepared from 4-MeO2CC6H4CH2NH2 and pyrrolidine, was treated with the pyrimidinylaminoaniline fragment to give I, which showed 10% inhibition

of

non-phosphorylated abl kinase at 10 μ M.

726192-44-5P 726192-45-6P 726192-60-5P

726192-61-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU


(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of sulfamides as anti-cancer agents)

RN 726192-44-5 HCAPLUS


CN Benzamide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)-N-(4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 726192-45-6 HCAPLUS


10510026rtr

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[4-methyl-3-[(4-phenyl-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 726192-60-5 HCAPLUS
 CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[4-methyl-3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726192-61-6 HCAPLUS
 CN Urea, N-[4-[(3,3-dimethyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N'-[4-methyl-3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 612527-99-8P 612528-00-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of sulfamides as anti-cancer agents)
 RN 612527-99-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-00-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 18 Jun 2004
 ACCESSION NUMBER: 2004:493693 HCAPLUS
 DOCUMENT NUMBER: 141:54348
 TITLE: Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives as inhibitors of protein tyrosine phosphatase 1B
 INVENTOR(S): Kenny, Peter Wedderburn; Morley, Andrew David; Russell, Daniel John; Toader, Dorin
 PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004050646	A1	20040617	WO 2003-GB5120	20031126
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG	AU 2003302626	A1	AU 2003-302626	20031126
PRIORITY APPLN. INFO.:			GB 2002-27813	A 20021129
			WO 2003-GB5120	W 20031126

OTHER SOURCE(S): MARPAT 141:54348
 GI




AB Title compds. I [wherein R1 = H, (halogeno)alkyl, (hydroxy)alkoxy, alkylamino, etc.; R2 = H, (halogeno)alkyl, halogeno, alkoxy; R3 = alkylamino or (un)substituted alkyl; R4 = H, alkyl, (hetero)aryl; R5 = H]


L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-61-7 HCAPLUS
 CN Butanamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-67-3 HCAPLUS
 CN Benzenepropanamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-methyl- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 or alkyl; and pharmaceutically acceptable salts thereof] were prepd. as inhibitors of protein tyrosine phosphatase 1B (PTB1B). For example, 5-[4-(acetamidomethyl)-2-methoxyphenyl]-1,2,5-thiadiazolidin-3-one 1,1-dioxide (II) was given in multi-step synthesis starting from 3-methoxy-4-nitrobenzyl alc. II showed inhibition of human PTB1B with IC50 value of 44μM. Thus, I and their pharmaceutical compns. are useful as inhibitors of protein tyrosine phosphatase 1B for the treatment of diabetes mellitus.


IT 705256-50-4P 705256-54-8P 705256-55-9P
 705256-61-7P 705256-67-3P 705256-72-0P
 705256-78-6P 705256-82-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-phenyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivs. as

inhibitors of protein tyrosine phosphatase 1B)


RN 705256-50-4 HCAPLUS

CN Acetamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 705256-54-8 HCAPLUS

CN Benzenecetonitrile, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)




RN 705256-55-9 HCAPLUS

L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 705256-72-0 HCAPLUS
 CN Benzenepentanamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 705256-78-6 HCAPLUS

CN Acetamide, N-[[4-[(3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-82-2 HCAPLUS

CN Acetamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 21 May 2004
ACCESSION NUMBER: 2004:412929 HCAPLUS
DOCUMENT NUMBER: 140:423678
TITLE: Preparation of 5-(substituted
phenyl)thiadiazolidin-3-
ones as inhibitors of protein tyrosine phosphatase 1B
INVENTOR(S): Birch, Alan Martin; Kenny, Peter Wedderburn; Morley,
Andrew David; Russell, Daniel John; Toader, Dorin
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
SOURCE: PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041799	A1	20040521	WO 2003-GB4721	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DL, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
PG				
AU 2003278392	A1	20040607	AU 2003-278392	20031103
PRIORITY APPLN. INFO.:			GB 2002-25986	A 20021107
			WO 2003-GB4721	W 20031103

OTHER SOURCE(S): MARPAT 140:423678
GI




AB The title compds. (I) or pharmaceutically acceptable salts thereof [R1 = H, halo, Cl-6 alkyl, Cl-6 alkythio, Cl-6 alkythio, halo-Cl-6 alkyl, halo-Cl-6 alkythio, or halo and R3 = aryl, biaryl, heteroaryl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, arylcarbonyl, heteroarylcarbonyl, aryl-C2-6 alkenyl, aryl-C2-6 alkynyl, or heteroaryl-C2-6 alkenyl; or (ii) R4 = H, Cl-6 alkyl, Cl-6 alkythio, or halo and R3 = aryl, biaryl, heteroaryl, C2-6 alkenyl, C3-7 cycloalkyl, arylcarbonyl, heteroarylcarbonyl, aryl-C2-6 alkenyl, aryl-C2-6 alkynyl or heteroaryl-C2-6 alkenyl; R5 = H, Cl-6 alkyl, Cl-6 alkythio, halo-Cl-6 alkyl, halo; R6 = H, Cl-6 alkyl; wherein any aryl, biaryl or heteroaryl group is optionally substituted] are prepd. These compds. are useful as inhibitors of protein tyrosine phosphatase PTP1B for the treatment of diabetes mellitus. Thus, 4-tolylboronic acid was coupled with 5-(4-bromophenyl)-1,2,5-thiadiazolidin-3-one in the presence of tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] and cesium carbonate in a mixt. of DMF, DME, EtOH, and H2O at 170° for 600 s to give 5-(4'-Methyl-1,1'-biphenyl-4-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide.

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
alkoxy, Cl-6 alkoxy-Cl-6 alkoxy, aryloxy, aryl-Cl-6 alkoxy, aryloxy-Cl-6 alkoxy, heteroaryl-Cl-6 alkoxy, heteroaryloxy, heteroaryloxy-Cl-6 alkoxy, Cl-6 alkoxy-Cl-6 alkythio, Cl-6 alkythio-Cl-6 alkoxy, Cl-6 alkythio-Cl-6 alkythio, or halo and R3 = aryl, biaryl, heteroaryl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, arylcarbonyl, heteroarylcarbonyl, aryl-C2-6 alkenyl, aryl-C2-6 alkynyl or heteroaryl-C2-6 alkenyl; R5 = H, Cl-6 alkyl, Cl-6 alkythio, halo-Cl-6 alkyl, halo; R6 = H, Cl-6 alkyl; wherein any aryl, biaryl or heteroaryl group is optionally substituted] are prepd. These compds. are useful as inhibitors of protein tyrosine phosphatase PTP1B for the treatment of diabetes mellitus. Thus, 4-tolylboronic acid was coupled with 5-(4-bromophenyl)-1,2,5-thiadiazolidin-3-one in the presence of tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] and cesium carbonate in a mixt. of DMF, DME, EtOH, and H2O at 170° for 600 s to give 5-(4'-Methyl-1,1'-biphenyl-4-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide.


IT
R1: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(Preparation of phenylthiadiazolidinones as inhibitors of protein tyrosine phosphatase 1B (PTP1B) for treatment of diabetes mellitus)

RN 692765-08-5 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)



RN 692765-17-6 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 692764-76-4P 692764-77-5P 692764-78-6P
692764-79-7P 692764-80-0P 692764-81-1P
692764-82-2P 692764-83-3P 692764-84-4P
692764-85-5P 692764-86-6P 692764-87-7P
692764-88-8P 692764-89-9P 692764-90-2P
692764-91-3P 692764-92-4P 692764-93-5P
692764-94-6P 692764-95-7P 692764-96-8P
692764-97-9P 692764-98-0P 692764-99-1P
692765-00-7P 692765-01-8P 692765-02-9P
692765-03-0P 692765-04-1P 692765-05-2P
692765-06-3P 692765-07-4P 692765-09-6P
692765-10-9P 692765-11-0P 692765-12-1P
692765-13-2P 692765-14-3P 692765-15-4P
692765-16-5P 692765-18-7P 692765-19-8P
692765-20-1P 692765-21-2P 692765-22-3P
692765-23-4P 692765-24-5P 692765-25-6P
692765-26-7P 692765-27-8P 692765-28-9P
692765-29-0P 692765-30-3P 692765-31-4P
692765-32-5P 692765-33-6P 692765-34-7P
692765-35-8P 692765-36-9P 692765-37-0P
692765-38-1P 692765-39-2P 692765-40-5P
692765-41-6P 692765-42-7P 692765-43-8P
692765-44-9P 692765-45-0P 692765-46-1P
692765-47-2P 692765-48-3P 692765-49-4P
692765-50-7P 692765-51-8P 692765-52-9P
692765-53-0P 692765-54-1P 692765-55-2P
692765-56-3P 692765-57-4P 692765-58-5P
692765-59-6P 692765-60-9P 692765-61-0P
692765-62-1P 692765-63-2P 692765-64-3P
692765-65-4P 692765-66-5P 692765-67-6P
692765-68-7P 692765-69-8P 692765-70-1P
692765-71-2P 692765-72-3P 692765-73-4P
692765-74-5P 692765-75-6P
R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of phenylthiadiazolidinones as inhibitors of protein tyrosine phosphatase 1B (PTP1B) for treatment of diabetes mellitus)


RN 692764-76-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-methyl-1,1'-biphenyl-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-77-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-nitro[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-78-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-81-1 HCAPLUS
CN Acetamide, N-[4'-([1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl])[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 692764-82-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-83-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-79-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-methyl[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-80-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-methyl[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-84-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-methylthio[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-85-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-86-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-87-7 HCAPLUS
 CN Acetamide, N-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)]-[1,1'-biphenyl]-3-yl- (9CI) (CA INDEX NAME)




RN 692764-88-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[3-(2-benzofuranyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-89-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-93-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[1,1'-biphenyl]-4-yl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-94-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[1,1'-biphenyl]-3-yl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-95-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-90-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[3-(5-oxazolyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-91-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-cyclohexylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-92-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3-benzoylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-96-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4,4'-dimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-97-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-4'-phenoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-98-0 HCAPLUS
 CN [1,1'-Biphenyl]-3-carbonitrile, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-3'-nitro[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-00-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-01-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-hydroxy-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-02-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3',4',4'-trimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-03-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-04-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-(1,3-benzodioxol-5-yl)-2-methoxyphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-05-2 HCAPLUS
CN Acetamide, N-[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 692765-06-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-3'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-07-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-09-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-[(1E)-2-phenylethenyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 692765-10-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(2-naphthalenyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-11-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4'-(hydroxymethyl)-4-methoxy[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-12-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(4-methoxy-3'-(methoxymethyl)[1,1'-biphenyl]-
 3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-13-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(4-methoxy-3'-(phenylmethoxy)[1,1'-biphenyl]-
 3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-14-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(4-methoxy-4'-(phenylmethoxy)[1,1'-biphenyl]-
 3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-19-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(4-methoxy-3'-(methylthio)[1,1'-biphenyl]-3-
 yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-20-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-,
 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-21-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-,
 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-15-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(2-methoxy-5-[(12)-2-phenylethenyl]phenyl)-,
 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 692765-16-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4'-[(1,1-dimethylethoxy)methyl]-4-
 methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-18-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(4-methoxy-4'-(methoxymethyl)[1,1'-biphenyl]-
 3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-22-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3',5'-difluoro-4-methoxy[1,1'-biphenyl]-3-
 yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-23-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(5'-fluoro-2',4-dimethoxy[1,1'-biphenyl]-3-
 yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-24-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxy[1,1':3',1''-terphenyl]-3-yl)-,
 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-25-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-26-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-4'-(methylthio)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-27-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-(1,1-dimethylethyl)-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-31-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-32-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-[(1E)-2-(4-chlorophenyl)ethenyl]-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 692765-33-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-ethenyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-28-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1':4',1''-terphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-29-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-chloro-4'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-30-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-fluoro-4-methoxy[1,1':4',1''-terphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-34-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-(2-furanyl)-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-35-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-benzo[b]thien-2-yl-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-36-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-(2-benzofuranyl)-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-37-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-38-1 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide,
3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-
2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-39-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(1H-pyrazol-4-yl)phenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-40-5 HCAPLUS
CN Pyrrolidine, 1-[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-
methoxy[1,1'-biphenyl]-4-yl]carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-44-9 HCAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-3'-(1,1-dioxido-4-oxo-1,2,5-
thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-45-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-amino-4-methoxy[1,1'-biphenyl]-3-yl)-,
1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 692765-46-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[4'-(dimethylamino)-4-methoxy[1,1'-biphenyl]-
3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-41-6 HCAPLUS
CN [1,1'-Biphenyl]-4-propanoic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-
thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-42-7 HCAPLUS
CN Carbamic acid, [[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-
methoxy[1,1'-biphenyl]-3-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA
INDEX NAME)




RN 692765-43-8 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide,
3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-
2-yl)-4'-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-47-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(4-pyridinyl)phenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-48-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-(4'-hydroxy-4-methoxy[1,1'-biphenyl]-3-yl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-49-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-(1H-indol-6-yl)-2-methoxyphenyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-50-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(2-thienyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-51-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(phenylethynyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-52-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(3-phenyl-1-propynyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-53-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(5-ethynyl-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME) ;




RN 692765-54-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-55-2 HCAPLUS
 CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-56-3 HCAPLUS
 CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-57-4 HCAPLUS
 CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-58-5 HCAPLUS
 CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-59-6 HCAPLUS
 CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-60-9 HCAPLUS
 CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-61-0 HCAPLUS
 CN Benzoic acid, 2-[2-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-62-1 HCAPLUS
CN Benzoic acid, 2-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-63-2 HCAPLUS
CN Benzoic acid, 2-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]methoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-64-3 HCAPLUS
CN Benzoic acid, 2-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-68-7 HCAPLUS
CN Benzoic acid, 2-[2-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]carbonyl]amino]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-69-8 HCAPLUS
CN Benzoic acid, 2-[3-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]carbonyl]amino]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-70-1 HCAPLUS
CN Benzoic acid, 2-[5-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]carbonyl]amino]pentyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-65-4 HCAPLUS
CN Benzoic acid, 2-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-66-5 HCAPLUS
CN Benzoic acid, 2-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]methoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-67-6 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)



RN 692765-71-2 HCAPLUS
CN Benzoic acid, 2-[[[6-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]carbonyl]amino]hexyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-72-3 HCAPLUS
CN Benzoic acid, 2-[2-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]carbonyl]amino]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-73-4 HCAPLUS
CN Benzoic acid, 2-[3-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-74-5 HCAPLUS
CN Benzoic acid,
2-[[[5-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]pentyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-75-6 HCAPLUS
CN Benzoic acid,
2-[[[6-[[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]carbonyl]amino]hexyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




IT 692765-79-OP 692765-80-3P 692765-84-7P
692765-85-8P 692765-86-9P 692766-02-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylthiadiazolidinones as inhibitors of protein tyrosine


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
methoxyphenyl]- (9CI) (CA INDEX NAME)



RN 692765-86-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692766-02-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-iodo-2-methoxyphenyl)-, 1,1-dioxide (9CI)
(CA INDEX NAME)




L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phosphatase 1B (PTP1B) for treatment of diabetes mellitus)


RN 692765-79-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-bromophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-80-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-bromophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-84-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-bromo-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-85-8 HCAPLUS
CN Boronic acid, [3-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4-

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 10 Oct 2003
ACCESSION NUMBER: 2003:796679 HCAPLUS
DOCUMENT NUMBER: 139:307766
TITLE: Preparation of substituted 1,1-dioxo-1,2,5-thiadiazolidine-3-ones as protein tyrosine phosphatase
1b
and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis
INVENTOR(S): Coppola, Gary Mark; Davies, John William; Jewell, Charles Francis, Jr.; Li, Yu-Chin; Wareing, James Richard; Sperbeck, Donald Mark; Stams, Travis Mathew; Topiol, Sidney Wolf; Vlattas, Isidoros
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 148 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082841	A1	20031009	WO 2003-EP3466	20030402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DE, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2480562	A1	20031009	CA 2003-2480562	20030402
AU 2003224030	A1	20031013	AU 2003-224030	20030402
US 2004023974	A1	20040205	US 2003-405728	20030402
EP 1492780	A1	20050105	EP 2003-720412	20030402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008974	A	20050215	BR 2003-8974	20030402
US 2005090502	A1	20050428	US 2003-510026	20030402
CN 1646508	A	20050727	CN 2003-807887	20030402
JP 2005535568	T	20051124	JP 2003-580308	20030402
NO 2004004745	A	20041214	NO 2004-4745	20041102
PRIORITY APPLN. INFO.:			US 2002-369779P	P 20020403
			US 2002-369930P	P 20020403
			WO 2003-EP3466	W 20030402


OTHER SOURCE(S): MARPAT 139:307766
GI

RN 612530-94-6 HCAPLUS
CN Benzoic acid,
4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-
thiadiazolidin-2-yl)methyl]-, [4-(methylsulfonyl)phenyl)methyl ester
(9CI)
(CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-95-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-((bromomethyl)phenyl)methyl]-2-[[4-(dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-96-8 HCAPLUS
CN Acetic acid, [[4-[[5-[[2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-98-0 HCAPLUS
CN Acetic acid, [[4-[[5-[[2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]methyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-((3-iodophenyl)methyl)-2-[[4-(dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-00-7 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-01-8 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-05-2 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-10-9 HCAPLUS
CN Benzaldehyde, 4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-02-9 HCAPLUS
CN Carbamic acid, [(1S)-1-[[3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-03-0 HCAPLUS
CN Benzene propanamide, α-amino-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-13-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[2,4-dimethoxyphenyl)methyl]-5-[[4-[(phenylmethyl)-1-piperazinyl)methyl]phenyl)methyl]-, 1,1-dioxido (9CI) (CA INDEX NAME)


PAGE 1-A



10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612531-22-3 HCAPLUS
CN Carbamic acid, [[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

RN 612531-23-4 HCAPLUS


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)phenyl)methyl]-2-[[2,4-dimethoxyphenyl)methyl]-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)



RN 612531-24-5 HCAPLUS
CN Carbamic acid, [2-[[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 612531-30-3 HCAPLUS
CN Benzoic acid, 4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 612531-31-4 HCAPLUS
CN Benzoic acid, 4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-32-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-[(1,1-dimethylethoxy)carbonyl]phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612531-34-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2,4-dimethoxyphenyl)methyl]-5-(2,4-dinitrophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-35-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-2-[(2,4-dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612531-36-9 HCAPLUS
CN Benzoic acid, 3-[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-61-0 HCAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-(phenylmethoxy)phenyl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 612531-63-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-iodophenyl)-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-64-3 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-65-4 HCAPLUS
CN D-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-68-7 HCAPLUS
CN Benzenepropanamide, α-amino-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-69-8 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-66-5 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-67-6 HCAPLUS
CN Carbamic acid, [(1S)-1-[(4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]phenyl)methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-70-1 HCAPLUS
CN L-Phenylalanine, 4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-71-2 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-72-3 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-73-4 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-N-[2-[4-[2-(1,1-dimethylethoxy)-2-oxoethyl]phenyl]ethyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-77-8 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612531-78-9 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-75-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-iodophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612531-76-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-iodophenyl)-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-79-0 HCAPLUS
CN Carbamic acid, [(1S)-1-[[[3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-80-3 HCAPLUS
CN Benzenepropanamide, α-amino-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612534-94-8 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 612527-93-2P 612530-46-8P 612530-49-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(invention compound; preparation of thiazolidinediones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)
RN 612527-93-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


612527-98-7P 612527-99-8P 612528-00-4P
612528-01-5P 612528-02-6P 612528-07-1P
612528-08-2P 612528-09-3P 612528-10-6P
612528-11-7P 612528-12-8P 612528-13-9P
612528-14-0P 612528-15-1P 612528-16-2P
612528-17-3P 612528-18-4P 612528-19-5P
612528-20-6P 612528-21-9P 612528-22-0P
612528-23-1P 612528-25-3P 612528-26-4P
612528-27-5P 612528-28-6P 612528-29-7P
612528-32-2P 612528-33-3P 612528-34-4P
612528-35-5P 612528-36-6P 612528-37-7P
612528-38-8P 612528-39-9P 612528-40-2P
612528-41-3P 612528-42-4P 612528-43-5P
612528-44-6P 612528-45-7P 612528-46-8P
612528-47-9P 612528-48-0P 612528-49-1P
612528-50-4P 612528-51-5P 612528-52-6P
612528-53-7P 612528-54-8P 612528-55-9P
612528-56-0P 612528-57-1P 612528-58-2P
612528-59-3P 612528-60-6P 612528-61-7P
612528-62-8P 612528-63-9P 612528-64-0P
612528-65-1P 612528-66-2P 612528-67-3P
612528-68-4P 612528-69-5P 612528-70-8P
612528-71-9P 612528-72-0P 612528-73-1P
612528-74-2P 612528-75-3P 612528-76-4P
612528-77-5P 612528-78-6P 612528-79-7P
612528-80-0P 612528-82-2P 612528-83-3P
612528-84-4P 612528-85-5P 612528-86-6P
612528-87-7P 612528-88-8P 612528-89-9P
612528-97-9P 612528-98-0P 612528-99-1P
612529-00-7P 612529-01-8P 612529-02-9P
612529-03-0P 612529-04-1P 612529-05-2P
612529-06-3P 612529-07-4P 612529-08-5P
612529-09-6P 612529-10-9P 612529-11-0P
612529-12-1P 612529-13-2P 612529-14-3P
612529-15-4P 612529-16-5P 612529-17-6P
612529-18-7P 612529-19-8P 612529-20-1P
612529-21-2P 612529-22-3P 612529-23-4P
612529-24-5P 612529-26-7P 612529-27-8P
612529-28-9P 612529-29-0P 612529-30-3P
612529-31-4P 612529-32-5P 612529-33-6P
612529-36-9P 612529-37-0P 612529-38-1P
612529-39-2P 612529-40-5P 612529-41-6P
612529-42-7P 612529-43-8P 612529-44-9P
612529-45-0P 612529-46-1P 612529-47-2P
612529-48-3P 612529-49-4P 612529-50-7P
612529-51-8P 612529-52-9P 612529-53-0P
612529-54-1P 612529-56-3P 612529-57-4P
612529-58-5P 612529-59-6P 612529-60-9P
612529-61-0P 612529-62-1P 612529-63-2P
612529-64-3P 612529-65-4P 612529-67-6P
612529-68-7P 612529-69-8P 612529-70-1P
612529-73-4P 612529-74-5P 612529-75-6P
612529-76-7P 612529-77-8P 612529-78-9P
612529-79-0P 612529-80-3P 612529-81-4P
612529-82-5P 612529-83-6P 612529-84-7P
612529-85-8P 612529-86-9P 612529-87-0P
612529-90-5P 612529-91-6P 612529-93-8P
612529-94-9P 612529-95-0P 612529-96-1P
612529-97-2P 612529-98-3P 612529-99-4P
612530-01-5P 612530-02-6P 612530-03-7P



RN 612530-46-8 HCAPLUS
CN Benzoic acid, 3-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 612530-49-1 HCAPLUS
CN Benzeneacetic acid, 2-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)




IT 612527-84-1P 612527-85-2P 612527-86-3P
612527-87-4P 612527-88-5P 612527-89-6P
612527-90-9P 612527-91-0P 612527-92-1P
612527-94-3P 612527-96-5P 612527-97-6P

612530-04-8P 612530-05-9P 612530-06-0P
612530-08-2P 612530-09-3P 612530-10-6P
612530-11-7P 612530-12-8P 612530-13-9P
612530-16-2P 612530-17-3P 612530-18-4P
612530-19-5P 612530-20-8P 612530-21-9P
612530-22-0P 612530-23-1P 612530-25-3P
612530-26-4P 612530-27-5P 612530-28-6P
612530-29-7P 612530-30-0P 612530-31-1P
612530-32-2P 612530-33-3P 612530-34-4P
612530-35-5P 612530-36-6P 612530-37-7P
612530-38-8P 612530-39-9P 612530-40-2P
612530-41-3P 612530-42-4P 612530-43-5P
612530-44-6P 612530-45-7P 612530-47-9P
612530-48-0P 612530-50-4P 612530-51-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compd.; prepn. of thiazolidinediones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)
RN 612527-84-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(1-naphthalenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-85-2 HCAPLUS
CN Acetamide, N-[(3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612527-86-3 HCAPLUS
 CN Carbamic acid, [[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 612527-87-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-88-5 HCAPLUS
 CN Acetamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612527-89-6 HCAPLUS
 CN Carbamic acid, [[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 612527-90-9 HCAPLUS
 CN Benzenepropanamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612527-91-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-iodophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-92-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-94-3 HCAPLUS
 CN Acetamide, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612527-96-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-97-6 HCAPLUS
 CN Butanamide, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 612527-98-7 HCAPLUS
 CN Urea, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N'-

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
propyl- (9CI) (CA INDEX NAME)




RN 612527-99-8 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612528-00-4 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 612528-07-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-08-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-amino-2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-09-3 HCAPLUS
CN Acetamide, N-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-01-5 HCAPLUS
CN Benzoic acid, 2-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612528-02-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-10-6 HCAPLUS
CN Methanesulfonamide, N-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 612528-11-7 HCAPLUS
CN Methanesulfonamide, N-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-12-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-13-9 HCAPLUS
CN Benzeneacetic acid, alpha-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-14-0 HCAPLUS
CN Benzeneacetamide, alpha-amino-2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-15-1 HCAPLUS
CN Benzeneacetamide, alpha-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-16-2 HCAPLUS
CN Benzeneacetamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl-alpha-[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)




RN 612528-17-3 HCAPLUS
CN Benzeneacetamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-alpha-[(methylsulfonyl)amino]-N-propyl- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-18-4 HCAPLUS
CN Benzenepropanamide, alpha-(acetylamino)-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-19-5 HCAPLUS
CN Propanedioic acid, (acetylamino)[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl-, diethyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-20-8 HCAPLUS
CN Benzenepropanamide, alpha-amino-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-21-9 HCAPLUS
CN Phenylalanine, N-acetyl-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)-, ethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-22-0 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-alpha-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-23-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-25-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(3,4-dimethoxyphenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-26-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(2-chlorophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-27-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(4-aminophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-28-6 HCAPLUS
CN Acetamide, N-[4-[2-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)ethyl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 612528-29-7 HCAPLUS
CN Butanamide, N-[4-[2-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-32-2 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-4-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-33-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(3-aminophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-37-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxy-7-quinolinyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-38-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-(2-methylpropoxy)-7-quinolinyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-39-9 HCAPLUS
CN Glycine, N-[2-(butylamino)-2-oxo-1-phenylethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-34-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-aminomethyl)-1-naphthalenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-35-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(1-ethyl-2-methyl-1H-benzimidazol-5-yl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-36-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methyl-1-(3-methylbutyl)-1H-benzimidazol-5-yl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-40-2 HCAPLUS
CN Glycine, N-[2-(butylamino)-1-(4-ethylphenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 612528-41-3 HCAPLUS
 CN Glycine, N-[2-(butylamino)-2-oxo-1-(3-phenoxyphenyl)ethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 612528-42-4 HCAPLUS
 CN Glycine, N-[2-(butylamino)-1-(4-methoxyphenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 612528-43-5 HCAPLUS
 CN Glycine, N-[1-(2-bromophenyl)-2-(butylamino)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)



PAGE 2-A

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



RN 612528-44-6 HCAPLUS
 CN Glycine, N-[2-(butylamino)-1-(2-naphthalenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




PAGE 2-A




RN 612528-45-7 HCAPLUS
 CN Glycine, N-[2-(butylamino)-1-(4-chlorophenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



RN 612528-46-8 HCAPLUS
 CN Glycine, N-[2-(butylamino)-2-oxo-1-[3-(phenylmethoxy)phenyl]ethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




PAGE 2-A

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-47-9 HCAPLUS
CN Glycine,
N-[(2E)-1-[(butylamino)carbonyl]-3-phenyl-2-propenyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 612528-48-0 HCAPLUS
CN Glycine,
N-[1-[(butylamino)carbonyl]-3-phenylpropyl]-N-[4-[(1,1-dioxido-4-


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612528-50-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612528-51-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-butylphenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 612528-49-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(methylsulfonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612528-52-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(hydroxymethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612528-53-7 HCAPLUS
CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]methyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-54-8 HCAPLUS
CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]methyl]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 612528-55-9 HCAPLUS
CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]methyl]phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[4-(difluoromethoxy)phenyl]methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 612528-56-0 HCAPLUS
CN 2-Thiopheneacetic acid, 5-[[4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]-u,u-difluoro- (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
612528-57-1 HCAPLUS
CN Acetic acid, [[4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 612528-58-2 HCAPLUS
CN Acetic acid, [[4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]thio]-, ethyl ester (9CI) (CA INDEX NAME)




RN 612528-59-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[[4-[[3-methylbutyl]thio]methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Me₂CH-CH₂-CH₂-S-CH₂


RN 612528-60-6 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-ethylbutyl ester (9CI) (CA INDEX NAME)




RN 612528-61-7 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclobutylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-64-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)




RN 612528-65-1 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclohexylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-66-2 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 1,2-dimethylpropyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-62-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclopentylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-63-9 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpentyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-67-3 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 612528-68-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)




RN 612528-69-5 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(methylthio)ethyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-70-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-[(carboxymethyl)thio]ethyl ester (9CI) (CA INDEX NAME)




RN 612528-71-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (5-nitro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-72-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 612528-73-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(hydroxymethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-74-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(methylsulfonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612528-75-3 HCAPLUS
CN Benzeneacetic acid, 4-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]butyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612528-76-4 HCAPLUS
CN Benzenecetic acid, 4-[[4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]propyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 612528-77-5 HCAPLUS
CN Benzoic acid, 4-[[4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-[[dimethylamino)methyl]-2-furanyl]methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 612528-78-6 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612528-79-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[1H-indol-5-ylmethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-80-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[[3,4,5-trimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612528-82-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[[4-[[[4-(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-83-3 HCAPLUS
CN Benzenecetic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612528-84-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[[4-benzoylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-85-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-naphthalenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-86-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(4-methyl-1-oxopentyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A

RN 612528-89-9 HCAPLUS
CN 2(1H)-Quinolinone, 6-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-1-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 612528-97-9 HCAPLUS
CN Acetamide, 2-amino-N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 612528-98-0 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-carboxyphenyl)methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-87-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(2-fluorophenoxy)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-88-8 HCAPLUS
CN Benzoic acid, 3-[2-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612528-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(phenoxy)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 612529-00-7 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 612529-01-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(hydroxymethyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-02-9 HCAPLUS
 CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-03-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-04-1 HCAPLUS
 CN Benzoic acid, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-5-nitro- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-05-2 HCAPLUS
 CN Benzoic acid, 5-amino-2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-06-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-methoxy-5-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 612529-07-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-08-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-methyl-2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-09-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-10-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3-phenylpropyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
INDEX NAME)



RN 612529-11-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-butoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-12-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-13-2 HCAPLUS
CN Benzoic acid, 3-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-16-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methyl-3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-17-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(5-methyl-2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-18-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-14-3 HCAPLUS
CN Benzenecarboxylic acid, 5-amino-2-[[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612529-15-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methyl-3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-19-8 HCAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612529-20-1 HCAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612529-21-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5,5'-[1,4-phenylenebis(methylene)]bis-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-22-3 HCAPLUS
CN Acetic acid, [[2-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 612529-23-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-24-5 HCAPLUS
CN Benzoic acid, 2-amino-4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-28-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-amino-5-(hydroxymethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-29-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-amino-4-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-30-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-amino-3-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-26-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-fluoro-2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-27-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(hydroxymethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-31-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-amino-2-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-32-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-amino-5-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-33-6 HCAPLUS
CN Acetamide, N-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-36-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3,4-dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-37-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-amino-5-hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-41-6 HCAPLUS
CN Benzoic acid, 2-amino-5-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-42-7 HCAPLUS
CN Benzoic acid, 2-(acetylamino)-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-43-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-(phenylmethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-38-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3,5-dimethylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-39-2 HCAPLUS
CN L-Phenylalanine, N-[[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612529-40-5 HCAPLUS
CN L-Phenylalanine, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-44-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-bis(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-45-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,6-trifluorophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-46-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-47-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5,5'-bis-[(1,1'-biphenyl)-2,2'-diylbis(methylene)]bis-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)




RN 612529-48-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(ethylamino)methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-49-4 HCAPLUS

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




Ph-CH₂-CH₂-NH-CH₂


RN 612529-52-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(diethylamino)methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-53-0 HCAPLUS
CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid,
2-(acetylamino)-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-50-7 HCAPLUS
CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 612529-51-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[[4-[[[(2-phenylethyl)amino]methyl]phenyl]met
hyl]-, 1,1-dioxide (9CI). (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612529-54-1 HCAPLUS
CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 612529-56-3 HCAPLUS
CN Benamide,
4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[2-[3-(trifluoromethyl)phenyl]ethyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PAGE 2-A




RN 612529-57-4 HCAPLUS
CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)



RN 612529-58-5 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-α-(phenylmethyl)-, 1,1-dioxide, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612529-59-6 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-α-(phenylmethyl)-, 1,1-dioxide, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-63-2 HCAPLUS
CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-64-3 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-60-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 612529-61-0 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 612529-62-1 HCAPLUS

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-65-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(carboxymethoxy)phenyl]methyl ester (9CI) (CA INDEX NAME)




PAGE 1-A

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 612529-67-6 HCAPLUS
CN Benzoic acid, 4-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612529-68-7 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-69-8 HCAPLUS
CN Acetic acid, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 612529-70-1 HCAPLUS
CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-73-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-74-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-75-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-76-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-ethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-77-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-78-9 HCAPLUS
CN Benzeneacetic acid, 4-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612529-79-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-80-3 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(phenylamino)ethyl ester (9CI) (CA INDEX NAME)




RN 612529-81-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-methoxyphenyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612529-82-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl ester (9CI) (CA INDEX NAME)




RN 612529-83-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-84-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-methoxy-2,2-dimethyl-3-oxopropyl ester (9CI) (CA INDEX NAME)




RN 612529-85-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,2,4-trimethylpentyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-86-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-(dimethylamino)-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 612529-87-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [(3aR,4S,5R,6aS)-5-(benzoyloxy)hexahydro-2-oxo-2H-cyclopenta[b]furan-4-yl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-90-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-methyl-4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612529-91-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-methyl-4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



PAGE 1-A


PAGE 2-A



RN 612529-93-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 6-ethoxy-6-oxohexyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-94-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-chlorophenyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2-[3-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612529-97-2 HCAPLUS
CN O-Phenylalanine, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612529-98-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(phenylmethyl)amino]methyl]phenyl]meth


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612529-95-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-methylphenyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612529-96-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-methylphenyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-99-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-methylphenyl)methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A




RN 612530-01-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(methoxycarbonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612530-02-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-cyclohexyl-2-methylpropyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 612530-03-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-phenoxypropyl ester (9CI) (CA INDEX NAME)



RN 612530-04-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612530-05-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612530-06-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(4-carboxyphenyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-08-2 HCAPLUS
 CN Benzoic acid, 3-[[4-[[[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]-phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-09-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[[4-[[[(2-methylpropyl)amino]methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-10-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[[4-[[[(2,2-dimethylpropyl)amino]methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-11-7 HCAPLUS
 CN Benzoic acid, 4-[[[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 1-naphthalenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-12-8 HCAPLUS
 CN Benzoic acid, 4-[[[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-13-9 HCAPLUS
 CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-16-2 HCAPLUS
 CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612530-17-3 HCAPLUS
 CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-[[carboxymethyl]amino]-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-18-4 HCAPLUS

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxylic acid, 5-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 612530-19-5 HCAPLUS
 CN Benzoic acid, 4-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [1,1'-biphenyl]-4-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 612530-20-8 HCAPLUS


10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-(acetylamino)phenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612530-21-9 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [2-(phenylmethyl)phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-22-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (2-methylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 612530-23-1 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (2-methylphenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (2-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612530-25-3 HCAPLUS
 CN Benzenecetic acid, 3-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxymethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-26-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612530-27-5 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
 (4-fluoro-2-(trifluoromethyl)phenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612530-28-6 HCAPLUS
 CN Benzoic acid,
 4-[(5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)methyl]-,
 (4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl)methyl ester (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


OMe

RN 612530-29-7 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
 (4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl)methyl ester (9CI)
 (CA INDEX NAME)



RN 612530-30-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
 (5-methyl-2-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me


RN 612530-31-1 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
 2-methylphenyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-32-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-[(carboxymethyl)methylamino]-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-33-3 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-37-7 HCAPLUS
CN 1-Piperazineacetic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl- (9CI) (CA INDEX NAME)




RN 612530-38-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-naphthalenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-34-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 5-[(2-methylpropyl)amino]carbonyl-2-thienylmethyl ester (9CI) (CA INDEX NAME)




RN 612530-35-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-naphthalenylmethyl ester (9CI) (CA INDEX NAME)




RN 612530-36-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-39-9 HCAPLUS
CN 2-Thiophenecarboxylic acid, 5-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-40-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 5-(aminocarbonyl)-2-thienylmethyl ester (9CI) (CA INDEX NAME)




RN 612530-41-3 HCAPLUS
CN Piperazine, 1-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-42-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-(1-oxo-3-phenylpropyl)-2-thienyl]methyl ester (9CI) (CA INDEX NAME)




RN 612530-43-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-[(phenylmethyl)amino]carbonyl]-2-thienyl]methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-48-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-(aminomethyl)phenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-50-4 HCAPLUS
CN Benzoic acid, 2-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)




RN 612530-51-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-dimethoxyphenyl)-, 1,1-dioxide, potassium salt (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-44-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-45-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-47-9 HCAPLUS
CN Benzoic acid, 3-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● K

IT 612530-52-6P 612530-53-7P 612530-54-8P
612530-55-9P 612530-56-0P 612530-57-1P
612530-58-2P 612530-59-3P 612530-60-6P
612530-61-7P 612530-62-8P 612530-63-9P
612530-64-0P 612530-65-1P 612530-66-2P
612530-67-3P 612530-68-4P 612530-69-5P
612530-71-9P 612530-72-0P 612530-73-1P
612530-74-2P 612530-75-3P 612530-77-5P
612530-78-6P 612534-93-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compound; preparation of thiazolidinetriones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)


RN 612530-52-6 HCAPLUS
CN Acetamide, 2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-methylphenoxy]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 612530-53-7 HCAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-hydroxyphenyl]methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NAME)




RN 612530-54-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-iodophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-55-9 HCAPLUS
CN L-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612530-56-0 HCAPLUS
CN L-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 612530-60-6 HCAPLUS
CN L-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-61-7 HCAPLUS
CN Benzenepropanamide, α-[(1,1'-biphenyl)-4-ylsulfonyl]amino]-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-57-1 HCAPLUS
CN L-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-58-2 HCAPLUS
CN L-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-59-3 HCAPLUS
CN L-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-62-8 HCAPLUS
CN Benzenepropanamide, α-[(1,1'-biphenyl)-4-ylsulfonyl]amino]-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-63-9 HCAPLUS
CN Benzenepropanamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl-α-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-64-0 HCAPLUS
CN Benzenepropanamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl-α-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-65-1 HCAPLUS
CN Benzenepropanamide,
4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(3,3-diphenylpropyl)-α-((phenylsulfonyl)amino)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-66-2 HCAPLUS
CN L-Phenylalaninamide,
N-acetyl-L-phenylalanyl-3-bromo-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-((Z)-(3-oxo-2(3H)-benzofuranylidene)methyl]phenyl)methyl]-, 1,1-dioxide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612527-96-5
CMF C9 H11 N3 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612530-72-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-((Z)-(3-oxo-2(3H)-benzofuranylidene)methyl]phenyl)methyl]-, 1,1-dioxide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612528-35-5
CMF C13 H16 N4 O3 S




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612530-67-3 HCAPLUS


CN Benzenepropanamide, 3-bromo-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)-α-((phenylsulfonyl)amino)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-68-4 HCAPLUS
CN L-Phenylalaninamide,
N-acetyl-L-phenylalanyl-3-bromo-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-69-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-71-9 HCAPLUS

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612530-73-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-((Z)-(3-oxo-2(3H)-benzofuranylidene)methyl]phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 612530-74-2 HCAPLUS
CN Ethanedione, [4-[[4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)phenyl]- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-75-3 HCAPLUS
CN 9,10-Anthracenedione, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)



RN 612530-77-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide, sodium salt (9CI)
(CA INDEX NAME)




● Na

RN 612530-78-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-, 1,1-dioxide, trifluoroacetate (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
REFERENCE COUNT: 4
THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1
CRN 612530-45-7
CMF C8 H10 N4 O3 S




CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 612534-93-7 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 31 Jul 2002
ACCESSION NUMBER: 2002:565367 HCAPLUS
DOCUMENT NUMBER: 137:232603
TITLE: Efficient Solid-Phase Synthesis of Sulfahydantoin
Tremblay, Melanie; Voyer, Normand; Boujabi, Sihem;
Dewynter, Georges F.
CORPORATE SOURCE: Centre de Recherche sur la Fonction, la Structure et
l'Ingénierie des Protéines, Département de Chimie,
Faculté des Sciences et de Génie, Université Laval,
Quebec, QC, G1K 7P4, Can.
SOURCE: Journal of Combinatorial Chemistry (2002), 4(5),
429-435
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 137:232603
GI



AB A novel solid-phase strategy allows the efficient preparation of
traceless
sulfahydantoin. A total of 28 derivs., with crude purity generally
higher than 85%, were prepared by parallel synthesis. Through reductive
alkylations, Mitsunobu reactions, and sulfamoylation reactions on oxime
resin, the synthetic strategy affords sulfahydantoin derivs. selectively
substituted at N2, e.g., I, N5, e.g., II, and N2, N5, e.g., III,
positions, although yields of disubstituted compds. are lower. The mild
reaction conditions involved, lead to sulfahydantoin without
racemization.


10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 459831-33-5P 459831-34-6P 459831-35-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of N2,N5-disubstituted sulfahydantoins)

via reductive alkylation of resin-bound phenylalanine with substituted benzaldehydes and subsequent sulfamoylation, Mitsunobu reaction, resin-cleavage, and cyclization)


RN 459831-33-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-2-
(2-propenyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-34-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-butyl-5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-35-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-2-
(3-phenylpropyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 283587-14-4P 459831-30-2P 459831-31-3P
459831-32-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of N5-substituted sulfahydantoins via

reductive alkylation of resin-bound phenylalanine with substituted benzaldehydes and subsequent sulfamoylation, resin-cleavage, and cyclization)


RN 283587-14-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(4-methoxyphenyl)methyl]-4-(phenylmethyl)-,
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-30-2 HCAPLUS
CN Benzonitrile, 4-[[[(3S)-1,1-dioxido-4-oxo-3-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459831-31-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-nitrophenyl)methyl]-4-(phenylmethyl)-,
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459831-32-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methylphenyl)methyl]-4-(phenylmethyl)-,
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 03 Oct 2001
ACCESSION NUMBER: 2001:735235 HCAPLUS
DOCUMENT NUMBER: 136:85785
TITLE: A one-step protocol for the N-chloromethylation of heterocyclic imides
AUTHOR(S): He, Shu; Yu, Hongyi; Fu, Qinghong; Kuang, Rongze; Epp, Jeff B.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Synthetic Communications (2001), 31(20), 3055-3058
CODEN: SYNCAR; ISSN: 0039-7911
PUBLISHER: Marcel Dekker, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 136:85785


AB A convenient single step methodol. for the N-chloromethylation of heterocyclic imides using a mixture of formaldehyde sodium bisulfite adduct and thionyl chloride is described. For example, the chloromethylation of 5-Butyl-3-propyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide gave.

IT 387859-83-8 387859-86-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of 2-(chloromethyl)-1,2,5-thiadiazolidin-3-one by chloromethylation of 1,2,5-thiadiazolidin-3-one using thionyl chloride and formaldehyde sodium bisulfite adduct)

RN 387859-83-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 387859-86-1 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 4-oxo-2-(phenylmethyl)-, phenylmethyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




IT 300553-85-9P 387859-88-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 2-(chloromethyl)-1,2,5-thiadiazolidin-3-one by

L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 chloromethylation of 1,2,5-thiadiazolidin-3-one using thionyl chloride
 and formaldehyde sodium bisulfite adduct)
 RN 300553-05-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 307059-00-3 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 5-(chloromethyl)-4-oxo-2-(phenylmethyl)-, phenylmethyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 13 Jun 2001
 ACCESSION NUMBER: 2001:426029 HCAPLUS
 DOCUMENT NUMBER: 135:282665
 TITLE: Inhibition of serine proteases by functionalized
 sulfonamides coupled to the
 1,2,5-thiadiazolidin-3-one
 1,1 dioxide scaffold
 AUTHOR(S): Groutas, W. C.; He, S.; Kuang, R.; Ruan, S.; Tu, J.;
 Chan, H.-K.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University,
 Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(6),
 1543-1548
 CODEN: BMCECP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A challenge associated with drug design is the development of selective
 inhibitors of proteases (serine or cysteine) that exhibit the same
 primary
 substrate specificity, i.e., show a preference for the same P1 residue.
 While these proteases have similar active sites, nevertheless there are
 subtle differences in their S and S' subsites which can be exploited. We
 describe herein for the first time the use of functionalized sulfonamides
 as a design and diversity element which, when coupled to the
 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold yields potent,
 time-dependent inhibitors of the serine proteases human leukocyte
 elastase
 (HLE), proteinase 3 (PR 3) and cathepsin G (Cat G). Our preliminary
 findings suggest that (a) appending to the 1,2,5-thiadiazolidin-3-one 1,1
 dioxide scaffold recognition and diversity elements that interact with
 both the S and S' subsites of a target protease may result in optimal
 enzyme selectivity and potency and, (b) functionalized sulfonamides
 constitute a powerful design and diversity element with low intrinsic
 chemical reactivity and potentially wide applicability. Potent
 inhibitors of
 human leukocyte elastase, proteinase 3 and cathepsin G that interact with
 the S and S' subsites are realized by using functional sulfonamides
 coupled to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold.
 IT 220869-05-6P 220869-07-8P 220869-14-7P
 220869-16-9P 365216-39-3P 365216-41-7P
 365216-42-8P 365216-43-9P
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (Inhibition of serine proteases by functionalized sulfonamides coupled
 to 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold)
 RN 220869-05-6 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, methyl ester (9CI) (CA
 INDEX NAME)


L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-07-8 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl](methylsulfonyl)-, butyl ester (9CI) (CA
 INDEX NAME)




RN 220869-14-7 HCAPLUS
 CN Carbamic acid,
 [2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-,
 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 220869-16-9 HCAPLUS
 CN Carbamic acid,
 [2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-


L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-,
 phenylmethyl ester (9CI) (CA INDEX NAME)



RN 365216-39-3 HCAPLUS
 CN Benzamide,
 N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 365216-41-7 HCAPLUS
 CN Glycine,
 N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]carbonyl]-, ethyl ester
 (9CI) (CA INDEX NAME)



RN 365216-42-8 HCAPLUS


10510026rtr

L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Carbamic acid, [(1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl](phenylsulfonyl)-, butyl ester (9CI) (CA INDEX NAME)



RN 365216-43-9 HCAPLUS
 CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 24 Apr 2001
 ACCESSION NUMBER: 2001:288468 HCAPLUS
 DOCUMENT NUMBER: 135:76831
 TITLE: Synthesis of a Sulfahydantoin Library
 AUTHOR(S): Albericio, Fernando; Bryman, Lois M.; Garcia, Javier; Michelotti, Enrique L.; Nicolas, Ernesto; Tice, Colin M.
 CORPORATE SOURCE: Department of Organic Chemistry, University of Barcelona, Barcelona, 08028, Spain
 SOURCE: Journal of Combinatorial Chemistry (2001), 3(3), 290-300
 CODEN: JCCHFF; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:76831
 AB A five-step solid-phase synthesis of sulfahydantoins from α -amino acids and aldehydes was developed. The synthetic method allows the use of


hindered amino acids, including Val, Phe, and Aib, and use of aromatic aldehydes substituted with electron-withdrawing and -donating groups. Some limitations were encountered with amino acids with reactive side chains. A small but diverse library of compds. was produced for biol. testing.

IT 283587-14-4P 283587-15-5P 283587-16-6P
 283587-18-8P 283587-19-9P 283587-21-3P
 283587-22-4P 283587-24-6P 346697-35-6P
 346697-36-7P 346697-37-8P 346697-38-9P
 346697-39-0P 346697-40-3P 346697-41-4P
 346697-42-5P 346697-43-6P 346697-44-7P
 346697-45-8P 346697-46-9P 346697-47-0P
 346697-48-1P 346697-49-2P 346697-50-5P
 346697-51-6P 346697-53-8P 346697-54-9P
 346697-55-0P 346697-56-1P 346697-57-2P
 346697-58-3P 346697-59-4P 346697-60-7P
 346697-62-9P 346697-63-0P 346697-64-1P
 346697-65-2P 346697-69-6P 346697-71-0P
 346697-72-1P 346697-73-2P 346697-74-3P
 346697-75-4P 346697-76-5P 346697-77-6P
 346697-79-8P 346697-80-1P 346697-81-2P
 346697-82-3P 346697-83-4P 346697-84-5P
 346697-85-6P 346697-86-7P 346697-87-8P
 346697-88-9P 346697-89-0P 346697-90-3P
 346697-91-4P 346697-92-5P 346697-93-6P
 346697-97-0P 346697-98-1P 346697-99-2P
 346698-00-8P 346698-03-1P 346698-04-2P
 346698-05-3P 346698-06-4P 346698-12-2P
 346698-14-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of a sulfahydantoin library from amino acids and aldehydes)


RN 283587-14-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




RN 283587-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dichlorophenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-16-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[(3-methylphenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-18-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[(4-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 283587-19-9 HCAPLUS


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-21-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-22-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4,4-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 283587-24-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-35-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(3-chlorophenyl)methyl]-4-(1-methylethyl)-,
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-36-7 HCAPLUS
CN Acetamide, N-[4-[[[(3S)-3-(1-methylethyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-37-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
4-(1-methylethyl)-5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-42-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[(4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-43-6 HCAPLUS
CN Acetamide, N-[4-[[[(3S)-1,1,1-dioxido-4-oxo-3-[[4-(phenylmethoxy)phenyl]methyl]-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-44-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-[(4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-38-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-39-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-40-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-41-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[(4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-45-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[(4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-46-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[(4-(phenylmethoxy)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-47-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[(2-methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-48-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[(2-methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-49-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[(2-methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-50-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-4-[(2-methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-55-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-56-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-57-2 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(3-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-58-3 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-(acetamino)phenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-51-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-53-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-54-9 HCAPLUS
CN Acetamide, N-[4-[(3R)-1,1-dioxido-4-oxo-3-[(phenylmethyl)thio]methyl]-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-59-4 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-chloro-3-nitrophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-60-7 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-62-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chlorophenyl)methyl]-4-[(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-63-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[[2-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-64-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-65-2 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(1-methylethyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-73-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-74-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methylphenyl]methyl]-4-[[1-(phenylmethyl)-1H-imidazol-4-yl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-75-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methylphenyl]methyl]-4-[[1-(phenylmethyl)-1H-imidazol-4-yl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-69-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methylphenyl]methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-71-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[4-(phenylmethoxy)phenyl]methyl]-5-[[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-72-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(trifluoromethyl)phenyl]methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
5-[[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-76-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,3-dihydro-1,4-benzodioxin-6-yl]methyl]-4-[[1-(phenylmethyl)-1H-imidazol-4-yl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-77-6 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[[3-methylphenyl]methyl]-4-oxo-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-79-8 HCAPLUS


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 4-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-80-1 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-oxo-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-81-2 HCAPLUS
 CN Acetamide, N-[4-[[[(3S)-3-[2-(methylthio)ethyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-82-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[2-(methylthio)ethyl]-5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-86-7 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-87-8 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-88-9 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-83-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chlorophenyl)methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-84-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-85-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-89-0 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-90-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(phenylmethoxy)methyl]-5-[[2-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-91-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(phenylmethoxy)methyl]-5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-92-5 HCAPLUS
CN Benzoic acid, 4-[[3-(1,1-dioxido-4-oxo-3-[(phenylmethoxy)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-93-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-[(phenylmethoxy)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-97-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(4-nitrophenyl)methyl]-5-[(2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346698-03-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-phenyl-5-[(2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346698-04-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-phenyl-5-[(3-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-05-3 HCAPLUS
CN Benzoic acid, 4-[[3-(1,1-dioxido-4-oxo-3-phenyl-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-98-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(4-nitrophenyl)methyl]-5-[(3-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-99-2 HCAPLUS
CN Benzoic acid, 4-[[3-(1,1-dioxido-4-oxo-3-[(4-nitrophenyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346698-00-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-[(4-nitrophenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346698-06-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-phenyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346698-12-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-[(1S)-1-methylpropyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-14-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-[(1S)-1-methylpropyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD FORMAT

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 22 Dec 2000
 ACCESSION NUMBER: 2000:898004 HCAPLUS
 DOCUMENT NUMBER: 134:307088
 TITLE: 1,2,5-Thiadiazolidin-3-one 1,1 Dioxide: A Powerful Scaffold for Probing the S' Subsites of (Chymo)trypsin-Like Serine Proteases
 AUTHOR(S): Groutas, William C.; Epp, Jeffrey B.; Kuang, Rongze; Ruan, Sumei; Chong, Lee S.; Venkataraman, Radhika;
 TU, Juan; He, Shu; Yu, Hongyi; Fu, Qinghong; Li, Yue Re; Truong, Tien M.; Vu, Nga T.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Archives of Biochemistry and Biophysics (2001), 385(1), 162-169
 CODEN: ABBT44; ISSN: 0003-9861
 PUBLISHER: Academic Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB The 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold (I) embodies a motif that allows it to dock to the active site of (chymo)trypsin-like proteases in a predictable and substrate-like fashion. Consequently, inhibitors derived from this heterocyclic scaffold interact with both the S and S' subsites of an enzyme. Exploitation of binding interactions with both the S and S' subsites of a target enzyme may lead to compds. with greatly enhanced enzyme selectivity and inhibitory potency. This preliminary report describes the use of a series of compds. having the heterocyclic scaffold linked to various amino acids to probe the S' subsites of human leukocyte elastase (HLE), proteinase 3 (PR 3), and cathepsin G (Cat G). For comparative purposes, a series of compds. derived from a related scaffold, isochiazolidin-3-one 1,1 dioxide (II), was also generated. Several of the compds. were found to be highly potent and selective time-dependent inhibitors of HLE, PR 3, and Cat G. (c) 2001 Academic Press.
 IT 334975-68-7P 334975-69-8P 334975-75-6P
 334975-81-4P 334975-83-6P 334975-85-8P
 334975-88-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold for probing S' subsites of human leukocyte elastase, proteinase 3 and cathepsin G)
 RN 334975-68-7 HCAPLUS
 CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CM 2
 CRN 76-05-1
 CHF C2 H F3 O2



RN 334975-81-4 HCAPLUS
 CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 334975-83-6 HCAPLUS
 CN L-Phenylalanine, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




● HCl

RN 334975-85-8 HCAPLUS


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 334975-69-8 HCAPLUS
 CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




RN 334975-75-6 HCAPLUS
 CN L-Phenylalanine, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 CM 1
 CRN 334975-74-5
 CHF C23 H29 N3 O5 S
 Absolute stereochemistry.



L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)
 Absolute stereochemistry.



RN 334975-88-1 HCAPLUS
 CN D-Phenylalanine, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)
 CM 1
 CRN 334975-87-0
 CHF C26 H27 N3 O5 S
 Absolute stereochemistry.



CM 2
 CRN 76-05-1
 CHF C2 H F3 O2




REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS

10510026rtr


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Jul 2000
ACCESSION NUMBER: 2000:488727 HCAPLUS
DOCUMENT NUMBER: 133:277919
TITLE: Potent inhibition of serine proteases by heterocyclic sulfide derivatives of 1,2,5-thiadiazolidin-3-one 1,1 dioxide
AUTHOR(S): Ha, S.; Kuang, R.; Venkataraman, R.; Tu, J.; Truong, T. M.; Chan, H. K.; Groutas, W. C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(7), 1713-1717
CODEN: BMCEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 133:277919
AB The existence of subtle differences in the Sn' subsites of closely-related (chymo)trypsin-like serine proteases, and the fact that the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold docks to the active site of (chymo)trypsin-like enzymes in a substrate-like fashion, suggested that the introduction of recognition elements that can potentially interact with the Sn' subsites of these proteases might provide an effective means for optimizing enzyme potency and selectivity. Accordingly, a series of heterocyclic sulfide derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold (I) was synthesized and the inhibitory activity and selectivity of these compds. toward human leukocyte elastase (HLE), proteinase 3 (PR 3) and cathepsin G (Cat G) were then determined. Compds. with P1-isobutyl were found to be potent, time-dependent inhibitors of HLE and, to a lesser extent PR 3, while those with P1-benzyl inactivated Cat G rapidly and irreversibly. This study has demonstrated that 1,2,5-thiadiazolidin-3-one 1,1 dioxide-based heterocyclic sulfides are effective inhibitors of (chymo)trypsin-like serine proteases.
IT 220869-26-1P 220869-27-2P 220869-29-4P
220869-30-7P 220869-33-0P 220869-35-2P
220869-38-5P 220869-39-6P 220869-40-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(potent inhibition of serine proteases by heterocyclic sulfide derivs. of thiadiazolidinone dioxide)
RN 220869-26-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-27-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(4,5-diphenyl-2-oxazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-29-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(5-phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 220869-30-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzothiazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-33-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(3-phenyl-1,2,4-oxadiazol-5-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-35-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-2-[(5-phenyl-2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-38-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-39-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[5-phenyl-1,3,4-oxadiazol-2-yl]thio]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-40-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[6-amino-2-benzoxazolyl]thio]methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



IT 300553-85-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of thiadiazolidinone dioxide derivative; potent inhibition of serine proteases by heterocyclic sulfide derivs. of thiadiazolidinone dioxide)

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 15 Jun 2000
ACCESSION NUMBER: 2000:395930 HCAPLUS
DOCUMENT NUMBER: 133:159638
TITLE: Utilization of the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold in the design of potent inhibitors of serine proteases: SAR studies using carboxylates
AUTHOR(S): Kuang, R.; Epp, J. B.; Ruan, S.; Chong, L. S.; Venkataraman, R.; Tu, J.; He, S.; Truong, T. M.; Groutas, W. C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(5), 1005-1016
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of carboxylate derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1-dioxide and isothiazolidin-3-one 1,1-dioxide scaffolds has been synthesized and the inhibitory profile of these compds. toward human leukocyte elastase (HLE), cathepsin G (Cat G) and proteinase 3 (PR 3) was then determined. Most of the compds. were found to be potent, time-dependent inhibitors of elastase, with some of the compds. exhibiting K_{inact}/K_I values as high as 4,928,300 M⁻¹ s⁻¹. The inhibitory potency of carboxylate derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1-dioxide platform was found to be influenced by both the pKa and the inherent structure of the leaving group. Proper selection of the primary specificity group was found to lead to selective inhibition of HLE over Cat G, however, those compds. that inhibited HLE also inhibited PR 3, albeit less efficiently. The predictable mode of binding of these compds. suggests that, among closely-related serine proteases, highly selective inhibitors of a particular serine protease can be fashioned by exploiting subtle differences in their 5' subsites.

IT 247179-63-1P 287921-30-6P 287921-33-9P 287921-37-3P 287921-38-4P 287921-39-5P 287921-42-0P 287921-45-3P 287921-46-4P 287921-52-2P 287921-54-4P 287921-65-7P 287921-91-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(synthesis of thiadiazolidinone dioxides and isothiazolidinone dioxides as serine protease inhibitors)

RN 247179-63-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[acetyloxy]methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 300553-85-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 287921-30-6 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [4-ethyl-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)



RN 287921-33-9 HCAPLUS
CN Benzeneacetic acid, 4-[[[(3S)-5-[[2,2-dimethyl-1-oxopropoxy]methyl]-1,1-dioxido-4-oxo-3-propyl-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-37-3 HCAPLUS
CN Propanoic acid, 2,2-dimethyl-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 287921-38-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[[(3S)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]-3-(2-methylpropyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287921-39-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-42-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(benzoyloxy)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzenepropanoic acid, 4-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-54-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-65-7 HCAPLUS
CN Benzoic acid, 2,6-dichloro-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-91-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 287921-45-3 HCAPLUS
CN Benzoic acid, 2,6-dichloro-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-46-4 HCAPLUS
CN Benzenepropanoic acid, 4-[[[(3S)-5-[(2,6-dichlorobenzoyloxy)methyl]-3-(2-methylpropyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287921-52-2 HCAPLUS


L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 212331-98-1P 212331-99-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of thiadiazolidinone dioxides and isothiazolidinone dioxides as serine protease inhibitors)


RN 212331-98-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RECORD.

10510026rtr

L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 19 May 2000
 ACCESSION NUMBER: 2000:324184 HCAPLUS
 DOCUMENT NUMBER: 133:105000
 TITLE: Solid-phase synthesis of sulfahydantoina
 AUTHOR(S): Albericio, Fernando; Garcia, Javier; Michelotti,
 Enrique L.; Nicolas, Ernesto; Tice, Colin M.
 CORPORATE SOURCE: Department of Organic Chemistry, University of
 Barcelona, Barcelona, 08028, Spain
 SOURCE: Tetrahedron Letters (2000), 41(17), 3161-3163
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:105000
 AB A 5-step solid-phase synthesis of 2-unsubstituted 1,2,5-thiadiazolidin-3-
 one 1,1-dioxides, sulfahydantoina, from N α -Fmoc amino acids and
 aromatic aldehydes is described. The key step is the base-mediated
 cyclative
 cleavage of a resin bound N α -aminosulfonyl N α -benzyl amino
 acid to afford the desired product. This synthesis allows the
 preparation of a
 diverse library of compds. based on this heterocycle.
 IT 283587-14-4P 283587-15-5P 283587-16-6P
 283587-18-8P 283587-19-9P 283587-21-3P
 283587-22-4P 283587-24-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of sulfahydantoin library)
 RN 283587-14-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(4-methoxyphenyl)methyl]-4-(phenylmethyl)-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 283587-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dichlorophenyl)methyl]-4-
 (phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 283587-16-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 4-(1-methylethyl)-5-[(3-methylphenyl)methyl]-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-18-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(1-methylethyl)-5-[(4-
 (trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



RN 283587-19-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-
 (1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 283587-21-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[(2-chlorophenyl)methyl]-4-(1-methylethyl)-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-22-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4,4-dimethyl-
 1,1-dioxide (9CI) (CA INDEX NAME)



RN 283587-24-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-(2-
 methylthioethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR
 THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

10510026rtr

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 27 Aug 1999
 ACCESSION NUMBER: 1999:536684 HCAPLUS
 DOCUMENT NUMBER: 131:296963
 TITLE: Human chymase inhibitors based on the
 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold
 Groutas, William C.; Schechter, Norman M.; He, Shu;
 Yu, Hongyi; Huang, Peng; Tu, Juan
 CORPORATE SOURCE: Department of Chemistry, Wichita State University,
 Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1999),
 9(15), 2199-2204
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of compds. that utilize the 1,2,5-thiadiazolidin-3-one 1,1
 dioxide scaffold was synthesized and shown to be highly effective
 IT 170918-99-7 247178-41-2 247179-63-1
 247179-64-2 247179-65-3 247179-66-4
 247179-67-5 247179-68-6 247179-69-7
 247179-70-0 247179-71-1 247179-72-2
 247179-74-4 247179-75-5 247179-76-6
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
 (human chymase inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1
 dioxide scaffold)
 RN 170918-99-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-
 [(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247178-41-2 HCAPLUS
 CN Benzoic acid, 4-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetic acid, hydroxy-,
 [[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-66-4 HCAPLUS
 CN Propanoic acid, 2-hydroxy-,
 [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247179-67-5 HCAPLUS
 CN Benzenesacetic acid, α-hydroxy-, [(4S)-1,1-dioxido-3-oxo-4,5-
 bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 247179-63-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247179-64-2 HCAPLUS
 CN Propanedioic acid, mono[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247179-65-3 HCAPLUS

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 247179-68-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(methylsulfonyl)methyl]-4,5-
 bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-69-7 HCAPLUS
 CN Acetic acid, [[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247179-70-0 HCAPLUS
 CN Propanoic acid, 3-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 247179-71-1 HCAPLUS
CN Benzoic acid, 2-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247179-72-2 HCAPLUS
CN Benzoic acid, 3-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 247179-74-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-75-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[6-amino-2-benzoxazolyl]thio]methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-76-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[5-phenyl-1,3,4-oxadiazol-2-yl]thio]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN


ED Entered STN: 25 Aug 1999
ACCESSION NUMBER: 1999:529836 HCAPLUS
DOCUMENT NUMBER: 131:296959
TITLE: A General Inhibitor Scaffold for Serine Proteases

with
a (Chymo)trypsin-Like Fold: Solution-Phase Construction and Evaluation of the First Series of Libraries of Mechanism-Based Inhibitors
AUTHOR(S): Kuang, Rongze; Epp, Jeffrey B.; Ruan, Sumei; Yu, Hongyi; Huang, Peng; He, Shu; Tu, Juan; Schechter, Norman M.; Turbov, Jane; Froelich, Christopher J.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Journal of the American Chemical Society (1999), 121(35), 8128-8129
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors demonstrate that the 1,2,5-thiadiazolidin-3-one 1,1 dioxide platform embodies a general motif that renders the platform capable of binding to the active site of many serine proteases with a (chymo)trypsin-like fold in a predictable fashion and is amenable to the facile construction of libraries for lead identification and optimization.
IT 170918-99-7P 170919-03-6P 189124-02-5P
247178-39-6P 247178-40-1P 247178-41-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(inhibitor; general inhibitor scaffold for serine proteases with a (chymo)trypsin-like fold with solution-phase construction and evaluation
of first series of libraries of mechanism-based inhibitors)

RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 189124-02-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-4-
propyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247178-39-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(4-aminobutyl)-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Mar 1999
ACCESSION NUMBER: 1999:172588 HCAPLUS
DOCUMENT NUMBER: 130:209985
TITLE: Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide
derivatives as serine protease inhibitors
INVENTOR(S): Groutas, William C.; Kuang, Rongze
PATENT ASSIGNEE(S): Wichita State University, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909977	A1	19990304	WO 1998-US17406	19980821
W: AU, BR, CA, IS, JP, MX, NZ				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6420401	B1	20020716	US 1997-916693	19970822
AU 980298	A	19990316	AU 1998-90298	19980821
EP 1011668	A1	20000628	EP 1998-942192	19980821
R: DE, GB				
PRIORITY APPLN. INFO.:			US 1997-916693	A 19970822
			WO 1998-US17406	W 19980821

OTHER SOURCE(S): MARPAT 130:209985
GI




AB Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivs. I [R1, R3 = independently H, alkyl, aryl, aralkyl, alkaryl, substituted aryl; R2 = H, alkyl, aralkyl, alkylthioalkyl, hydroxyalkyl, amino acid side chain; R4 = H, alkyl, aryl, aralkyl, amino acid side chain, PO3R2, NCO, NHCHR7CO2R10, NHCONR12R13, CO-Q, -CHR7NHW, [CHR7NHCO]:R10, [CHR7CONH]:R10, NHG; Q = OR10, OJ, NR12R13, halo, [NHCHR7CO]qOR10, [NHCHR7CO]qNR10R16, OPN, NHFN; R5 = R1, halo; R6 = H, alkyl, aryl, aralkyl, NCO, COR9, COO1, NHCHR7CO2R11, NH2, NHG, NHCO2R11, NHCONR14R15, O2CCH2[OCH2CH2]2OR, O-X; R = alkyl; Q1 = OR11, OJ, NR14R15, [NHCHR7CO]zOR11, halo; X = COR9, [COCHR7NH]zXp, CHR7NHV, CHR7[NHCOCHR7]pNHW1, [CONHCHR7]zCO2R11, CO2R11, S(O)nR9, N(SO2R18)COK; Pn = polymer; each W, W1 = H, G, CONHCHR7CO2R10; each q, z = 1-10; Xp = H, G; G = amino protecting group; J = carboxyl protecting group; Y = H, R9, COR9, G; z = 1-10; n = 0-2; K = R9, OR9, NHR9, OCHR7NHV, [NHCHR7CO]mOR9, [NHCHR7CO]mNR10R17; V = G, H, COCHR7NHZ;

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 247178-40-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-acetic acid, 4-oxo-2-(phenylmethyl)-5-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247178-41-2 HCAPLUS
CN Benzoic acid, 4-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
= G, H; m = 1-2; each R7 = amino acid side chain; each R8, R9 = alkyl, aryl, aralkyl, alkaryl, heterocyclyl; each R10-R15 = H, any group R8; each

R16, R17 = heterocyclalkyl; R18 = any group R8, NHR19; R19 = alkyl, aryl, aralkyl; with provisos], oligomers and combinatorial libraries contg. them, and methods of using them, are disclosed. Thus, title compd.


II showed apparent second-order rate consts. Kinact/KI (M-1s-1) of 119,360, 27,400, and 60 for inhibition of human leukocyte elastase, proteinase 3, and cathepsin G, resp., by in vitro assays.

IT 220868-74-6DP, combinatorial library derivs. 220868-75-7DP, combinatorial library derivs. 220868-80-4DP, combinatorial library derivs. 220868-81-5DP, combinatorial library derivs. 220868-86-0DP, combinatorial library derivs. 220868-87-1DP, combinatorial library derivs. 220868-92-8DP, combinatorial library derivs. 220868-93-9DP, combinatorial library derivs. 220868-98-4DP, combinatorial library derivs. 220868-99-5DP, combinatorial library derivs. 220869-05-6P, 220869-06-7P 220869-07-8P 220869-14-7P 220869-16-9P 220869-19-2P 220869-20-5P 220869-26-1P 220869-27-2P 220869-29-4P 220869-30-7P 220869-33-0P 220869-35-2P 220869-38-5P 220869-39-6P 220869-40-9P 220869-41-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amino acid-derived thiadiazolidinone dioxide derivs.

as serine protease inhibitors)


RN 220868-74-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-(chloromethyl)-5-[(4-methoxyphenyl)methyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 220868-75-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-(chloromethyl)-5-[(3-phenoxyphenyl)methyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220868-80-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-((acetyloxy)methyl)-5-((4-methoxyphenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220868-81-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-((acetyloxymethyl)-5-((3-phenoxyphenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220868-86-0 HCAPLUS
CN Carbamic acid, [[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 220868-87-1 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-5-[(3-phenoxyphenyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220868-92-8 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220868-93-9 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[1,1-dioxido-3-oxo-5-[(3-phenoxyphenyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220868-98-4 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 220868-99-5 HCAPLUS
CN L-Phenylalanine, 4-chloro-N-[[[1,1-dioxido-3-oxo-5-[(3-phenoxyphenyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-05-6 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 220869-06-7 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 220869-16-9 HCAPLUS
 CN Carbamic acid, [2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 220869-19-2 HCAPLUS
 CN Glycine, N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 220869-20-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2,2'-methylenebis[4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)


L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-07-8 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)-, butyl ester (9CI) (CA INDEX NAME)




RN 220869-14-7 HCAPLUS
 CN Carbamic acid, [2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-26-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[[2-benzoxazolylthio]methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-27-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[[[4,5-diphenyl-2-oxazolyl]thio]methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-29-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[[5-

10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-30-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzothiazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-33-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(2-methylpropyl)-5-(phenylmethyl)-2-[(3-phenyl-1,2,4-oxadiazol-5-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-40-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(6-amino-2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-41-0 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, α -fluoro-3-oxo-4,5-bis(phenylmethyl)-, ethyl ester, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220869-64-7 220869-65-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid-derived thiadiazolidinone dioxide derivs.


as serine protease inhibitors)

RN 220869-64-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-,


L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-35-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-2-[(5-phenyl-2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-38-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-39-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(5-phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220869-65-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220869-61-4P 220869-62-5P 220869-63-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid-derived thiadiazolidinone dioxide derivs.

as serine protease inhibitors)

RN 220869-61-4 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-(2-methylpropyl)-3-oxo-5-(phenylmethyl)-, 1,1-dimethylethyl ester, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220869-62-5 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-(2-methylpropyl)-3-oxo-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-63-6 HCAPLUS
 CN 1,2,5-Thiadiazolidine-2-acetamide, 4-(2-methylpropyl)-3-oxo-N-(2-phenylethyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 02 Oct 1998

ACCESSION NUMBER: 1998:622789 HCAPLUS

DOCUMENT NUMBER: 129:289796

TITLE: Kinetics of the hydrolysis of cyclic N-substituted sulfamides: 4-amino-2-cyclohexyl- and 4-amino-2-phenethyl-2,3-dihydro-3-oxo-1,2,5-thiadiazole 1,1-dioxides
 Rozas, M. F.; Svartman, E. L.; Mirifico, M. V.; Vasini, E. J.

CORPORATE SOURCE: Instituto de Investigaciones Fisicoquimicas Teóricas y

Aplicadas (INIFTA), Facultad de Ciencias Exactas, Departamento de Química, Universidad Nacional de La Plata, La Plata, 1900, Argent.

SOURCE: Journal of Physical Organic Chemistry (1998), 11(7), 489-494

CODEN: JPOCEE; ISSN: 0894-3230

PUBLISHER: John Wiley & Sons Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The hydrolysis reactions of 4-amino-2-phenethyl- and 4-amino-2-cyclohexyl-

2,3-dihydro-3-oxo-1,2,5-thiadiazole 1,1-dioxide (Ia and Ib) were investigated at 24-73° in buffered aqueous solns. The observed rate consts. (kobs) are independent of pH in the range ca 1-4 pH, but increase with increase in pH above ca 4. A linear log kobs vs pH profile with

unit slope is observed from pH ca 4 up to the highest exptl. pH (ca 10). The products are the corresponding new compds.: 2-amino-2-[(N-substituted-sulfamoyl)amino]acetic acid salts. The C-N bond of these compds. hydrolyzes further, in a slow reaction, to the sulfamide and oxalic acid derivs. The substrates decompose to the final products without

accumulation of the acetic acid derivs. under these exptl. conditions. A mechanism is proposed. Rate consts. and activation parameters are given for the first reaction step. Owing to steric effects, the reaction rate is higher for the N-phenethyl-substituted derivative than for the

2-cyclohexyl-substituted

derivative
 IT 214216-09-8, 4-Amino-2-phenethyl-2,3-dihydro-3-oxo-1,2,5-thiadiazole 1,1-dioxide

RL: PEP (Physical, engineering or chemical process); PRP (Properties);

RCT (Reactant); PROC (Process); RACT (Reactant or reagent) (hydrolysis of cyclic N-substituted sulfamides)

RN 214216-09-8 HCAPLUS

CN 1,2,5-Thiadiazol-3-amine, 4,5-dihydro-5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 05 Aug 1998

ACCESSION NUMBER: 1998:487562 HCAPLUS

DOCUMENT NUMBER: 129:216561

TITLE: Potent and specific inhibition of human leukocyte elastase, cathepsin G and proteinase 3 by sulfone derivatives employing the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold
 Groutas, William C.; Kuang, Rongze; Ruan, Sumei; Epp, Jeffrey S.; Venkataraman, Radhika; Truong, Tien M.

CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 Bioorganic & Medicinal Chemistry (1998), 6(6),


SOURCE: 661-671
 CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB This paper describes the results of structure-activity relationship studies in a series of heterocyclic mechanism-based inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold (I; R1 = iso-Bu, benzyl; R2 = Bu, Me, benzyl, CH2COOMe, etc.; L = SO2Ph, SO2C6H4Cl-4, etc.) and capable of interacting with the Sn and S'n subsites of a serine proteinase. Sulfone derivs. of I were found to be highly effective, time-dependent inhibitors of human leukocyte elastase (HLE), cathepsin G (Cat G) and proteinase 3 (PR 3). The judicious selection of an R1 group (accommodated at the primary specificity site S1) that is based on the known substrate specificity of a target serine proteinase, was found to yield highly selective inhibitors. The presence of a benzyl group (R2 = benzyl) at the S2 subsite was found to lead to a pronounced enhancement

in inhibitory potency. Furthermore, the effective use of computer graphics and modeling has led to the design of potent, water-soluble inhibitors.

The results of these studies demonstrate that the 1,2,5-thiadiazolidin-3-one 1,1-dioxide platform provides an effective means for appending

recognition elements in a well-defined vector relationship, and in fashioning highly-selective and potent inhibitors of serine proteinases.

IT 212331-98-1P 212331-99-2P 212332-00-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(1,2,5-thiadiazolidin-3-one 1,1-dioxide inhibitors of human leukocyte elastase, cathepsin G and proteinase 3)

RN 212331-98-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212332-00-8 HCAPLUS
CN Benzenesulfonic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylthio)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 212331-79-9P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(Preparation as inhibitor of human leukocyte elastase, cathepsin G and proteinase 3)
RN 212331-79-8 HCAPLUS


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.




RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-77-6 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212331-78-7 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 170918-99-7P 170919-01-4P 170919-03-6P
212331-77-6P 212331-78-7P 212331-80-1P
212331-81-2P 212331-82-3P 212331-83-4P
212331-86-7P 212331-87-8P 212331-90-3P
212331-92-5P 212331-94-7P 212331-95-8P
212331-97-0P
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Preparation as inhibitor of human leukocyte elastase, cathepsin G and proteinase 3)

RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170919-01-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(2E)-3-phenyl-2-propenyl]-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 212331-80-1 HCAPLUS
CN Benzoic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-81-2 HCAPLUS
CN Benzoic acid, 2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212331-82-3 HCAPLUS
CN Benzoic acid, 2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-83-4 HCAPLUS
CN Benzenecetic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 212331-86-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[(4-chlorophenyl)sulfonyl)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 212331-87-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(2-phenylethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212331-90-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[(4-chlorophenyl)sulfonyl)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 212331-92-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



RN 212331-94-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]


Absolute stereochemistry.



RN 212331-95-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-97-0 HCAPLUS
CN Benzenecetic acid, 4-[[[(3S)-1,1-dioxido-4-oxo-3-(phenylmethyl)-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)]

Absolute stereochemistry.



REFERENCE COUNT: 15
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 09 Apr 1998
 ACCESSION NUMBER: 1998:200895 HCAPLUS
 DOCUMENT NUMBER: 128:278642
 TITLE: Use of the 1,2,5-thiadiazolidin-3-one 1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds in the design of potent inhibitors of serine proteinases


AUTHOR(S): Kuang, Rongze; Venkateraman, Radhika; Ruan, Sumel; Groutas, William C.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(5), 539-544
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The attachment of a phosphate leaving group to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds was found to yield highly potent, time-dependent inhibitors of human leukocyte elastase (HLE).

IT 205932-85-OP 205932-87-2P 205932-88-3P
 205932-89-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (use of the 1,2,5-thiadiazolidin-3-one 1,1 dioxide and isothiazolidin-3-one 1,1 dioxide scaffolds in the design of potent inhibitors of serine proteinases)

RN 205932-85-0 HCAPLUS
 CN Phosphoric acid, dimethyl [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)



RN 205932-87-2 HCAPLUS
 CN Phosphoric acid, dibutyl [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 29 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 30 Aug 1997
 ACCESSION NUMBER: 1997:555602 HCAPLUS
 DOCUMENT NUMBER: 127:257045
 TITLE: Competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels in mouse plasma
 AUTHOR(S): Bright, Stuart W.; Tinsley, Frank C.; Dominianni, Samuel J.; Schmieg, Klaus K.; Fitch, Lora L.; Gold, Gerald
 CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46295, USA
 SOURCE: Journal of Immunological Methods (1997), 207(1), 23-31
 CODEN: JIMMGG; ISSN: 0022-1759

PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Two competitive particle concentration fluorescence immunoassays were developed to measure blood levels of analogs of antidiabetic drugs being tested in diabetic mice. Ligands that contained the active pharmacophores were conjugated to PPD for immunization and to β -phycoerythrin for use as a tracer in the immunoassays. Approx. 90% of 262 compds. assayed were detectable at less than 120 nM in plasma which was well below the


estimated therapeutic level of 1 μ M for lowering blood glucose. These data were used to define the bioavailability of test compds. and assist in decisions

of constructing active analogs. Of addnl. interest, we noted crossreactivity of one monoclonal antibody for 3 different compound

classes that are all known to bind with varying affinities to peroxisome proliferator-activated receptors.


IT 196079-43-3
 RL: ANT (Analyte); ANST (Analytical study)
 measuring competitive particle concentration fluorescence immunoassays for antidiabetic drug levels in mouse plasma)

RN 196079-43-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[(2-phenyl-4-oxazolyl)ethoxy]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 13
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205932-88-3 HCAPLUS
 CN Phosphoric acid, [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 205932-89-4 HCAPLUS
 CN Phosphoric acid, [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl diphenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 09 Apr 1997
 ACCESSION NUMBER: 1997:226843 HCAPLUS
 DOCUMENT NUMBER: 126:287581
 TITLE: Structure-Based Design of a General Class of Mechanism-Based Inhibitors of the Serine Proteinases Employing a Novel Amino Acid-Derived Heterocyclic Scaffold

AUTHOR(S): Groutas, William C.; Kuang, Rongze; Venkateraman, Radhika; Epp, Jeffrey B.; Ruan, Sumel; Prakash, Om
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Biochemistry (1997), 36(16), 4739-4750
 CODEN: BICHAW; ISSN: 0006-2960

PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We describe in this paper the structure-based design of a general class of

heterocyclic mechanism-based inhibitors of the serine proteinases that embody in their structure a novel peptidomimetic scaffold (1,2,5-thiadiazolidin-3-one 1,1-dioxide). Sulfone derivs. of this class were time-dependent, potent, and highly efficient irreversible inhibitors of human leukocyte elastase, cathepsin G, and proteinase 3. The

partition ratios for a select number of inhibitors were found to range between 0 and 1.

We furthermore demonstrate that these inhibitors exhibit remarkable enzyme selectivity that is dictated by the nature of the P1 residue and is consistent with the known substrate specificity reported for these enzymes. Thus, inhibitors with small hydrophobic side chains were effective inhibitors of elastase, those with aromatic side chains of cathepsin G, and those with a basic side chain of bovine trypsin. Taken together, the findings cited herein reveal the emergence of a general class of stable mechanism-based inhibitors of the serine proteinases

which can be readily synthesized using amino acid precursors. Biochem. and high-field NMR studies show that the interaction of this class of inhibitors with a serine proteinase results in the formation of a stable acyl complex(es) and the release of benzenesulfinate, formaldehyde, and a low mol. weight heterocycle. The data are consistent with initial formation of a Michaelis-Menten complex, acylation of Ser195, and tandem loss of the


leaving group. The initial HLE-inhibitor complex reacts with water generating formaldehyde and a stable HLE-inhibitor complex. Whether the initial HLE-inhibitor complex also reacts with His57 to form a third complex is not known at this point. The desirable salient parameters associated with this class of inhibitors, including the expeditious generation of structurally diverse libraries of inhibitors based on I, suggest that this class of mechanism-based inhibitors is of general applicability and can be used in the development of inhibitors of human and viral serine proteinases of clin. relevance.

IT 170918-99-7P 170919-03-6P 189124-00-3P
 189124-02-5P 189124-04-7P 189124-06-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 inhibitors (preparation and structure activity relations of mechanism-based inhibitors)

10510026rtr


L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
of human leukocyte serine proteinases employing a novel amino
acid-derived heterocyclic scaffold)
RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189124-00-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-ethyl-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 189124-02-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-4-
propyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189124-04-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(1-methylethyl)-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 189124-06-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-butyl-5-(phenylmethyl)-2-

L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 01 Dec 1995
ACCESSION NUMBER: 1995:954574 HCAPLUS
DOCUMENT NUMBER: 123:340140
TITLE: Novel serine protease inhibitors: derivatives of
isothiazolidin-3-one 1,1-dioxide and
3-oxo-1,2,5-thiadiazolidine 1,1-dioxide
Groutas, William C.
INVENTOR(S): Wichita State University, USA
PATENT ASSIGNEE(S): PCT Int. Appl., 93 pp.
SOURCE: CODEN: PIXXKD
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518797	A1	19950713	WO 1995-US236	19950103
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5550139	A	19960827	US 1994-177352	19940103
CA 2179913	A1	19950713	CA 1995-2179913	19950103
AU 9515998	A	19950801	AU 1995-15998	19950103
AU 686316	B2	19980205		
EP 739338	A1	19961030	EP 1995-908003	19950103
EP 739338	B1	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509922	T	19971007	JP 1995-518638	19950103
AT 215938	T	20020415	AT 1995-908003	19950103
NZ 329766	A	20010223	NZ 1998-329766	19980216
PRIORITY APPLN. INFO.:			US 1994-177352	A 19940103
			WO 1995-US236	W 19950103

OTHER SOURCE(S): MARPAT 123:340140
GI



AB Various isothiazolidin-3-one 1,1-dioxide and 3-oxo-1,2,5-thiadiazolidine 1,1-dioxide derivs., e.g. I [X = CH2, (un)substituted NR; R1 = H, alkyl, (un)substituted benzyl, indolylalkyl, etc.; Y = non-steroidal antiinflammatory residue, H, protected amino acid, acyloxy, etc.], and their use to reduce or inhibit the activity of serine proteases, are claimed. The compds. are useful as anti-inflammatory and anti-metastatic agents. For example, 4-benzylisothiazolidin-3-one 1,1-dioxide underwent

10510026rtr


L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
N-alkylation with ClCH₂SPh and Et₃N in MeCN, followed by S-oxidn. with m-ClC₆H₄C(O)OOH in CH₂Cl₂ (90%), to give title compd. II. In an in vitro assay, II had an apparent 2nd-order inactivation rate const. (kobs/[I])

M-1 s-1) of 960 against cathepsin G. A variety of compds. were prepd. and/or tested against cathepsin G, human leukocyte elastase, and/or proteinase-3.

IT 170919-16-1P
RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of isothiazolidinone and oxothiadiazolidine dioxides derivs. as serine protease inhibitors)

RN 170919-16-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(phenylmethyl)-5-(3-phenyl-2-propenyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (S)-(E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.




IT 170919-15-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of isothiazolidinone and oxothiadiazolidine dioxides derivs. as serine protease inhibitors)

RN 170919-15-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 170919-03-6 170919-21-8 170919-22-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of isothiazolidinone and oxothiadiazolidine dioxides derivs. as serine protease inhibitors)

RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170919-21-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 170919-22-9 HCAPLUS

L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 153044-45-2P 170918-99-7P 170919-01-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of isothiazolidinone and oxothiadiazolidine dioxides derivs. as serine protease inhibitors)


RN 153044-45-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170919-01-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(phenylmethyl)-5-[(2E)-3-phenyl-2-propenyl]-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
Double bond geometry as shown.

L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 32 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 19 Mar 1994
 ACCESSION NUMBER: 1994:124451 HCAPLUS
 DOCUMENT NUMBER: 120:124451
 TITLE: Substituted 3-oxo-1,2,5-thiadiazolidine 1,1-dioxides:
 a new class of potential mechanism-based inhibitors
 of
 human leukocyte elastase and cathepsin G
 AUTHOR(S): Groutas, William C.; Kuang, Rongze; Venkataraman,
 Radhika
 CORPORATE SOURCE: Dep. Chem., Wichita State Univ., Wichita, KS, 67260,
 USA
 SOURCE: Biochemical and Biophysical Research Communications
 (1994), 198(1), 341-9
 CODEN: BBRCAS; ISSN: 0006-291X
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A series of substituted 3-oxo-1,2,5-thiadiazolidine 1,1-dioxides (I, R =
 benzyl; R1 = H, Me, benzyl, CH2CO2-tert-Bu or CH2CO2-benzyl) was prepd,
 and their in vitro inhibitory activity toward human leukocyte elastase
 and
 cathepsin G was investigated. These compds. inactivated the 2 enzymes
 efficiently and in a time-dependent fashion.
 IT 153044-45-2P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of and human leukocyte elastase and cathepsin G
 inhibition by)
 RN 153044-45-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-,
 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




L4 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 26 Jan 1991
 ACCESSION NUMBER: 1991:23940 HCAPLUS
 DOCUMENT NUMBER: 114:23940
 TITLE: Intra- and intermolecular α -sulfamidoalkylation
 reactions
 AUTHOR(S): Lee, Chai Ho; Kohn, Harold
 CORPORATE SOURCE: Dep. Chem., Univ. Houston, Houston, TX, 77204-5641,
 USA
 SOURCE: Journal of Organic Chemistry (1990), 55(25), 6098-104
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:23940
 GI

L4 ANSWER 32 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L4 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na



I



II

AB The utility of α -sulfamidoalkylation processes for the generation of
 sulfamides has been examined. Both intra- and intermol. α -
 sulfamidoalkylation transformations were observed to proceed in moderate
 to
 good yields. The generality of these processes has been demonstrated
 using N,N'-di(aryl-substituted)sulfamides, and the utility of these
 reactions was examined for the preparation of cyclic sulfamides of novel
 structure. Thus, reaction of PhCH2NHSO2NH2 with EtO2CCH(OEt)2 in the
 presence of CF3CO2H gave 74% dithiatetrazocinedicarboxylate tetraoxide I,
 whereas reaction of 3-MeOC6H4CH2NHSO2NH2 with EtO2CCH(OEt)2 in CF3CO2H
 followed by methylation gave benzothiadiazepinecarboxylate dioxide II.
 The crystal structures of I and II were determined
 IT 130670-00-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclization of)
 RN 130670-00-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-hydroxy-5-(2-phenylethyl)-, 1,1-dioxide,
 monosodium salt (9CI) (CA INDEX NAME)

10510026rtr

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.69

340.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-24.75

-24.75

STN INTERNATIONAL LOGOFF AT 14:04:52 ON 21 DEC 2006

10510026rtr

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANAG1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 AUG 09 INSPEC enhanced with 1898-1968 archive
NEWS 4 AUG 28 ADISCTI Reloaded and Enhanced
NEWS 5 AUG 30 CA(SM)/CPlus(SM) Austrian patent law changes
NEWS 6 SEP 11 CA/CPlus enhanced with more pre-1907 records
NEWS 7 SEP 21 CA/CPlus fields enhanced with simultaneous left and right
truncation
NEWS 8 SEP 25 CA(SM)/CPlus(SM) display of CA Lexicon enhanced
NEWS 9 SEP 25 CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10 SEP 25 CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11 SEP 28 CEABA-VTB classification code fields reloaded with new
classification scheme
NEWS 12 OCT 19 LOGOFF HOLD duration extended to 120 minutes
NEWS 13 OCT 19 E-mail format enhanced
NEWS 14 OCT 23 Option to turn off MARPAT highlighting enhancements available
NEWS 15 OCT 23 CAS Registry Number crossover limit increased to 300,000 in
multiple databases
NEWS 16 OCT 23 The Derwent World Patents Index suite of databases on STN
has been enhanced and reloaded
NEWS 17 OCT 30 CHEMLIST enhanced with new search and display field
NEWS 18 NOV 03 JAPIO enhanced with IPC 8 features and functionality
NEWS 19 NOV 10 CA/CPlus F-Term thesaurus enhanced
NEWS 20 NOV 10 STN Express with Discover! free maintenance release Version
8.01c now available
NEWS 21 NOV 20 CAS Registry Number crossover limit increased to 300,000 in
additional databases
NEWS 22 NOV 20 CA/CPlus to MARPAT accession number crossover limit increased
to 50,000
NEWS 23 DEC 01 CAS REGISTRY updated with new ambiguity codes
NEWS 24 DEC 11 CAS REGISTRY chemical nomenclature enhanced
NEWS 25 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated
NEWS 26 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and
functionality
NEWS 27 DEC 18 CA/CPlus pre-1967 chemical substance index entries enhanced
with preparation role
NEWS 28 DEC 18 CA/CPlus patent kind codes updated
NEWS 29 DEC 18 MARPAT to CA/CPlus accession number crossover limit increased
to 50,000
NEWS 30 DEC 18 MEDLINE updated in preparation for 2007 reload

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

10510026rtr

NEWS IPC8 For general information regarding STN implementation of IPC 8
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:18:58 ON 21 DEC 2006

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:19:08 ON 21 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0

DICTIONARY FILE UPDATES: 20 DEC 2006 HIGHEST RN 916134-56-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.



REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10510026RTR.str

10510026rtr



chain nodes :
7 9 18 19
ring nodes :
1 2 3 4 5 10 11 12 13 14 15
chain bonds :
2-7 4-18 4-19 5-9 9-10
ring bonds :
1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15
exact/norm bonds :
1-2 1-5 2-3 2-7 3-4 4-5 4-18 4-19 5-9
exact bonds :
9-10
normalized bonds :
10-11 10-15 11-12 12-13 13-14 14-15

G1:H,CH3

G2:O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 9:CLASS 10:Atom 11:Atom 12:Atom
13:Atom 14:Atom 15:Atom 18:CLASS 19:CLASS


L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR

10510026rtr



G1 H, Me

G2 O, S

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:19:35 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 62 TO ITERATE

100.0% PROCESSED 62 ITERATIONS

50 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 768 TO 1712

PROJECTED ANSWERS: 576 TO 1424

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:19:40 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 1006 TO ITERATE

100.0% PROCESSED 1006 ITERATIONS

770 ANSWERS

SEARCH TIME: 00.00.01

L3 770 SEA SSS FUL L1

=> fil hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.15

FILE 'HCAPLUS' ENTERED AT 12:19:44 ON 21 DEC 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

10510026rtr

FILE COVERS 1907 - 21 Dec 2006 VOL 145 ISS 26
FILE LAST UPDATED: 20 Dec 2006 (20061220/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3

L4 33 L3

=> d ed ibib abs hitstr 1-33

10510026rtr


L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 03 Aug 2006
 ACCESSION NUMBER: 2006:765251 HCAPLUS
 DOCUMENT NUMBER: 145:211037
 TITLE: Preparation of pyrazolyl aryl ureas as modulators of the protein kinase activation state for treatment of inflammation and hyperproliferative diseases
 INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.
 PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, LLC, USA
 SOURCE: PCT Int. Appl., 305pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006081034	A2'	20060803	WO 2005-US47597	20051223
WO 2006081034	A3	20061123		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KH, KR, KZ, LC, LK, LR, LS, LU, LV, LY, MA, MD, ME, MG, MK, MN, MU, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-638987P P 20041223

OTHER SOURCE(S): MARPAT 145:211037
 GI




AB Novel compds. and methods of using those compds. for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization are provided. In a preferred

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 embodiment, the compds. of the invention modulate the activation state of p38 kinase protein, abl kinase protein, bcr-abl kinase protein, braf kinase protein, VEGFR kinase protein, or PDGFR kinase protein. The compds. of the invention I have general formula (R1)-(X))m-A-NH-L-NH-D-(E)q-(Y)t-Q wherein R1 = aryl, heteroaryl, and heterocyclyl; X and Y = individually O, S, alkynyl, alkenyl, etc.; A = an arom., monocycloheterocyclic, or bicycloheterocyclic ring; D = Ph or a 5-6-membered heterocyclic ring; E = Ph, pyridinyl, or pyrimidinyl; L = -C(O)- or -S(O)2-; j,m,q,t = 0-1; and Q = a substituted ring or ring system. Over 500 compds. were prepd. For example, hydrogenation of 3-(3-aminophenyl)acrylic acid Me ester provided the propionate, which was subsequently converted to the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentenenitrile afforded Me
 3-[3-(3-tert-butyl-5-amino-1H-pyrazole-1-yl)phenyl]propionate, which was coupled with 1-naphthyl isocyanate and reduced to provide urea II. In a competition assay with SKF 86002 as a fluorescent probe, II inhibited p38 MAP kinase with IC50 of 45 nM.
 IT 897369-58-3P 903567-40-8P
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treating inflammation and proliferative disorders)
 RN 897369-58-3 HCAPLUS
 CN Urea,
 N-(4-chlorophenyl)-N'-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-3,4-dioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]- (9CI)
 (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 903567-40-8 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-3,4-dioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




IT 872171-35-2P, 1-[5-tert-Butyl-2-[3-[[[S]-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-37-4P, 1-[5-tert-Butyl-2-[3-[[[R]-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-67-8P, N-[3-tert-Butyl-1-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-2-naphthalenecarboxamide 872171-62-5P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-63-6P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-chlorophenyl)urea 872171-73-8P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-methoxynaphthalen-1-yl)urea
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (p38 kinase inhibitor; preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflammation and hyperproliferative diseases)
 RN 872171-35-2 HCAPLUS
 CN Urea, N-[3-[(1,1-dimethylethyl)-1-[3-[[[S]-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 872171-37-4 HCAPLUS
 CN Urea, N-[3-((1,1-dimethylethyl)-1-[3-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)phenyl]-1H-pyrazol-5-yl)-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872171-57-8 HCAPLUS
 CN 2-Naphthalenecarboxamide, N-[3-((1,1-dimethylethyl)-1-[3-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)phenyl]-1H-pyrazol-5-yl)-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 872171-73-8 HCAPLUS
 CN Urea, N-[3-((1,1-dimethylethyl)-1-[3-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)phenyl]-1H-pyrazol-5-yl)-N'-1-(4-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 872171-62-5 HCAPLUS
 CN Urea, N-[3-((1,1-dimethylethyl)-1-[3-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)phenyl]-1H-pyrazol-5-yl)-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 872171-63-6 HCAPLUS
 CN Urea, N-(4-chlorophenyl)-N'-[3-((1,1-dimethylethyl)-1-[3-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)phenyl]-1H-pyrazol-5-yl)-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 872171-36-3P, 1-[5-tert-Butyl-2-[3-[[5-(4-methoxybenzyl)-(R)-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl]methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-39-6P, 1-[5-tert-Butyl-2-[3-[[5-(4-methoxybenzyl)-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl]methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea 872171-49-8P, 1-[5-tert-Butyl-2-[3-[[1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl]methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrazolyl aryl ureas as modulators of protein kinase activation state for treatment of inflammation and hyperproliferative diseases)
 RN 872171-36-3 HCAPLUS
 CN Urea, N-[3-((1,1-dimethylethyl)-1-[3-[[5-(4-methoxybenzyl)methyl]-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]-1H-pyrazol-5-yl)-N'-1-naphthalenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 872171-39-6 HCAPLUS

10510026rtr


L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Urea, N-[(3-(1,1-dimethylethyl)-1-[3-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 872171-49-8 HCAPLUS
 CN Urea, N-[(3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 28 Jul 2006
 ACCESSION NUMBER: 2006:739358 HCAPLUS
 DOCUMENT NUMBER: 145:377543
 TITLE: Isothiazolidinone heterocycles as inhibitors of protein tyrosine phosphatases: Synthesis and structure-activity relationships of a peptide
 scaffold
 AUTHOR(S): Yue, Eddy W.; Wayland, Brian; Douty, Brent; Crawley, Matthew L.; McLaughlin, Erin; TakVorian, Amy; Wasserman, Zeld; Bower, Michael J.; Wei, Min; Li, Yanlong; Ala, Paul J.; Gonneville, Lucie; Wynn, Richard; Burn, Timothy C.; Liu, Phillip C. C.; Combs, Andrew P.
 CORPORATE SOURCE: Discovery Chemistry, Experimental Station, Incyte Corporation, Wilmington, DE, 19880, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(17), 5833-5849
 CODEN: BMCEP; ISSN: 0968-0896
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB Oxo- and trioxo-substituted isothiazolidinylphenylalanines are prepared as
 tyrosine mimetics by Suzuki coupling reactions of chloroisothiazolidinones and chlorodioxoisothiazolidinones with N-Boc-4-borono-L-phenylalanine derivs.; the isothiazolidinylphenylalanines (with or without subsequent hydrogenation) are incorporated into dipeptides prepared as human protein tyrosine phosphatase 1B (PTP1B) inhibitors such as I. Of the compds. tested, I is the most potent inhibitor of PTP1B with an IC50 value of 40 nM; the corresponding mixture of isothiazolidinone diastereomers inhibits PTP1B with an IC50 value of 80 nM, and the separated (R)-isothiazolidinone diastereomer inhibits PTP1B with an IC50 value of 15.5 μM; the related dipeptides prepared inhibit PTP1B less potently than either I or the mixture of isothiazolidinone diastereomers containing I. Crystal structures of a dioxoisothiazolidinone-substituted dipeptide and a dioxoisothiazolidinone-substituted dipeptide bound to PTP1B are determined by X-ray crystallog.; the low energy conformation found by ab initio calcs. for the saturated

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 heterocycle more closely approaches the conformation obtained upon binding to PTP1B than that of the unsatd. heterocycle.
 IT 850315-22-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of isothiazolone- and dioxoisothiazolone-substituted phenylalanine-containing dipeptide amides and their activities as human PTP1B inhibitors)
 RN 850315-22-9 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)
 Absolute stereochemistry.




IT 850315-20-7P 850315-21-8P 850315-23-0P
 910606-95-OP 910606-97-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of isothiazolone- and dioxoisothiazolone-substituted phenylalanine-containing dipeptide amides and their activities as human PTP1B inhibitors)
 RN 850315-20-7 HCAPLUS
 CN Carbamic acid, [(1S)-1-[[[4-[(1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]phenyl)methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 850315-21-8 HCAPLUS
 CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850315-23-0 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 910606-97-2 HCAPLUS
 CN L-Phenylalaninamide, L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 910606-96-1
 CMF C32 H39 N5 O5 S

Absolute stereochemistry.




CM 2

CRN 910606-96-1
 CMF C2 H F3 O2



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 2 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 910606-95-0 HCAPLUS
 CN Benzenepropanamide, 2-amino-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (aS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 910606-94-9
 CMF C23 H30 N4 O4 S

Absolute stereochemistry.



CM 2


CRN 76-05-1
 CMF C2 H F3 O2

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 07 Jul 2006
 ACCESSION NUMBER: 2006:655575 HCAPLUS
 DOCUMENT NUMBER: 145:124558
 TITLE: Preparation of pyrazolyl phenyl ureas as enzyme modulators
 INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.
 PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, LLC, USA
 SOURCE: PCT Int. Appl., 974 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006071940	A2	20060706	WO 2005-047270	20051223
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GH, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:		US 2004-638968P P 20041223		
		US 2004-638966P P 20041223		
		US 2004-638987P P 20041223		
		US 2004-639087P P 20041223		


OTHER SOURCE(S): MARPAT 145:124558
 GI



AB The invention relates to title compds. I [A2 = bicyclic fused aryl, bicyclic fused heteroaryl, and bicyclic fused heterocyclyl, etc.; A1 = pyrazolyl, Ph, pyridyl, pyrimidinyl, etc.; W, Y = CHR4, NR3 or O (wherein W and Y are not simultaneously O); X = O, S or NR3; D = Ph, heteroaryl,


10510026rtr

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
heterocyclyl, etc.; R3 = H, alkyl, cycloalkyl, Ph; R4 = H, alkyl, hydroxyalkyl, etc.) which are useful for the treatment of inflammatory conditions, hyperproliferative diseases, cancer, and diseases characterized by hypervascularization. Over 500 compds. I were prepd. E.g., a multi-step synthesis of 11, starting from m-aminobenzoic acid, was given. Compds. I were tested against various kinases (IC50 values were given for representative compds. I). In a preferred embodiment, modulation of the activation state of p38 kinase protein c-Abl kinase protein, Bcr-Abl kinase protein, B-raf kinase protein, VEGFR kinase protein, or PDGFR kinase protein comprises the step of contacting said kinase protein with the novel compds. I.
IT 897369-58-3P 897369-62-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of pyrazolyl Ph ureas as enzyme modulators for treating cancer and hyperproliferative diseases)
RN 897369-58-3 HCAPLUS
CN Urea,
N-(4-chlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-3,4-dioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]]- (9CI)
(CA INDEX NAME)




PAGE 1-A

L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
PAGE 2-A



RN 897369-62-9 HCAPLUS
CN Urea,
N-(2,3-dichlorophenyl)-N'-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-3,4-dioxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]]- (9CI)
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 3 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 29 Dec 2005
ACCESSION NUMBER: 2005:1346235 HCAPLUS
DOCUMENT NUMBER: 144:88279
TITLE: Preparation of 1-pyrazolyl-3-phenylurea p38 MAP kinase inhibitors as antiinflammatory medicaments
INVENTOR(S): Flynn, Daniel L.; Petillo, Peter A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 214 pp., Cont.-in-part of U.S. Ser. No. 746,460.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005288286	A1	20051229	US 2004-886329	20040706
US 2004180906	A1	20040916	US 2003-746460	20031224
US 7144911	B2	20061205		
WO 2006014290	A2	20060209	WO 2005-US23100	20050630
WO 2006014290	A3	20060427		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HN, HU, ID, IL, IN, IS, JP, KE, KG, KH, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:
US 2003-746460 A2 20031224
US 2002-437304P P 20021231
US 2002-437403P P 20021231
US 2002-437415P P 20021231
US 2002-437487P P 20021231
US 2003-463804P P 20030418
US 2004-886329 A 20040706

OTHER SOURCE(S): MARPAT 144:88279
GI

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title compds. (R1Xj)mA(NH)pLn(NH)pDEqYtQ [I: wherein R1 = (un)substituted (hetero)aryl; X, Y = independently O, S, NR6, NR6SO2, NR6CO, alkynyl, alkenyl, alkylene, O(CH2)h, NR6(CH2)h, wherein for each alkylene, O(CH2)h, and NR6(CH2)h, one of the methylene groups may be substituted with CO; h =

1-4; A = (un)substituted aryl, hetero(bi)cyclyl; D = (un)substituted Ph, pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, pyrimidinyl; E = (un)substituted Ph, pyridinyl, pyrimidinyl; L = CO, SO2; j, m, n, p, q, t = independently O, 1; Q = (un)substituted heterocyclyl, Ph, etc.; R6 = independently H, alkyl, allyl, TMS(CH2)2; with exceptions]

were prepared as p38 MAP kinase inhibitors. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the α -C helix, the α -D helix, the catalytic loop, the switch control ligand sequence, or the C-lobe residues of the kinase protein with I (no data). Although the methods of preparation are not

claimed, preps. and/or characterization data for .apprx.150 examples of I and many intermediates are included. For example, hydrogenation of

3-(3-aminophenyl)acrylic acid Me ester using 10% Pd/C in EtOH provided the propionate, which was treated with NaNO₂ in the presence of 6N HCl and SnCl₂·2H₂O to give the hydrazine. Reaction of the hydrazine with 4,4-dimethyl-3-oxopentenenitrile in EtOH and 6N HCl afforded Me 3-(3-(3-tert-butyl-5-amino-1H-pyrazol-1-yl)phenyl)propionate. Coupling of the amine with 1-naphthyl isocyanate in CH₂Cl₂, followed by reduction with

LiOH in THF/MeOH/H₂O provided the urea II. In a competition assay with SKF 86002 as a fluorescent probe, the latter inhibited p38 MAP kinase with

IC₅₀ of 45 nM. Thus, I and their pharmaceutical compns. are useful for the treatment of a wide variety of inflammatory conditions (no data). IT 872171-35-2P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-

[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-37-4P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-57-8P, N-[3-tert-Butyl-1-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-2-

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

naphthalenecarboxamide 872171-62-5P, 1-[5-tert-Butyl-2-[3-

[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-63-6P, 1-[5-tert-Butyl-2-[3-

[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-chlorophenyl)urea 872171-73-8P, 1-[5-tert-Butyl-2-[3-

[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-methoxynaphthalen-1-yl)urea


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

[p38 kinase inhibitor; prepn. of (pyrazolyl)(phenyl)urea p38 kinase inhibitors as antiinflammatory agents]

RN 872171-35-2 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 872171-37-4 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 872171-57-8 HCAPLUS


CN 2-Naphthalenecarboxamide, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



RN 872171-62-5 HCAPLUS

CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 872171-63-6 HCAPLUS


CN Urea, N-[4-chlorophenyl]-N'-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A


10510026rtr

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 872171-73-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-methoxy-1-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 872171-36-3P, 1-[5-tert-Butyl-2-[3-[(5-(4-methoxybenzyl)-(R)-3-methyl-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(naphthalen-1-yl)urea 872171-39-6P, 1-[5-tert-Butyl-2-[3-[(5-(4-methoxybenzyl)-1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea 872171-49-8P, 1-[5-tert-Butyl-2-[3-[(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yl)methyl]phenyl]-2H-pyrazol-3-yl]-3-(4-fluorophenyl)urea
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (pyrazolyl)(phenyl)urea p38 kinase inhibitors as antiinflammatory agents)
RN 872171-36-3 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(3R)-5-[(4-methoxyphenyl)methyl]-3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A




PAGE 2-A



L4 ANSWER 4 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 872171-39-6 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(5-(4-methoxybenzyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 872171-49-8 HCAPLUS
CN Urea, N-[3-(1,1-dimethylethyl)-1-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-1H-pyrazol-5-yl]-N'-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 26 Aug 2005
ACCESSION NUMBER: 2005:904352 HCAPLUS
DOCUMENT NUMBER: 143:248386
TITLE: Preparation of substituted azole derivatives for treating diseases mediated by PTPase activity
INVENTOR(S): Mjalli, Adnan M. M.; Polisetti, Dharma R.; Subramanian, Govindan; Quada, James C.; Arimilli, Murthy N.; Yarragunta, Ravindra R.; Andrews, Robert

C.: Xie, Rongyuan
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 204 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187277	A1	20050825	US 2005-56498	20050211
AU 2005214349	A1	20050901	AU 2005-214349	20050211
CA 2551909	A1	20050901	CA 2005-2551909	20050211
WO 2005080346	A1	20050901	WO 2005-US4590	20050211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BE, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1730118	A1	20061213	EP 2005-723026	20050211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
PRIORITY APPLN. INFO.:			US 2004-543971P	P 20040212
			WO 2005-US4590	W 20050211

OTHER SOURCE(S): MARPAT 143:248386
GI



AB The title compds. I [a, b = 0-2; W = O, S, NR2 (wherein R2 = alkyl, etc.);
R1 = H, halo, CN, etc.; L1 = a direct bond, (un)substituted NHCO, NHSO2,

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 etc.; Ar1 = (un)substituted (hetero)aryl, fused cycloalkylaryl, etc.; Ar2 = (un)substituted (hetero)arylene, fused cycloalkylarylene, etc.; L2 = CH2, O, alkylene, etc.) which can be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity such as type I diabetes and type II diabetes, were prepd. Thus, treating

4-(2,4-dichlorophenyl)-2-[2-(4-methoxyphenyl)-(E)-vinyl]-1H-imidazole with Me bromoacetate followed by ester hydrolysis afforded 564 (4-(2,4-dichlorophenyl)-2-[2-(4-methoxyphenyl)-(E)-vinyl]-1H-imidazol-1-yl)acetic acid. The representative compds. I were tested for inhibition of PTP-1B. In general, the exemplified compds. I may inhibit PTP-1B with IC50 of less than 20 µM. The pharmaceutical compns. comprising the compds. I, and their use in treating human or animal disorders are also disclosed.

IT 863243-91-8P 863245-57-2P 863245-74-3P

863246-05-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (Preparation of substituted azole derivs. for treating diseases mediated by

PTPase activity)

RN 863243-91-8 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-57-2 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



IT 863243-80-5P 863243-92-9P 863243-93-0P

863243-94-1P 863243-95-2P 863244-05-7P

863244-06-8P 863244-07-9P 863244-08-0P

863244-13-7P 863244-47-7P 863244-51-3P

863244-52-4P 863244-53-5P 863245-25-4P

863245-56-1P 863245-58-3P 863245-59-4P

863245-60-7P 863245-61-8P 863245-62-9P

863245-63-0P 863245-64-1P 863245-66-3P

863245-67-4P 863245-68-5P 863245-69-6P

863245-70-9P 863245-71-0P 863245-72-1P

863245-75-4P 863245-78-7P 863245-80-1P

863245-82-3P 863246-03-1P 863246-04-2P

863246-06-4P 863246-07-5P 863246-09-7P

863246-10-0P 863246-11-1P 863246-12-2P

863246-13-3P 863246-15-5P 863246-16-6P

863287-03-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of substituted azole derivs. for treating diseases mediated by


PTPase activity)

RN 863243-80-5 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-difluorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Double bond geometry as shown.



RN 863245-74-3 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[2-(trifluoromethyl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-05-3 HCAPLUS

CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863243-92-9 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863243-93-0 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-phenyl-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.

PAGE 1-A




PAGE 2-A




RN 863243-94-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2-chlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863243-95-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(4-chlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-05-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-06-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(3,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863244-07-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(3,4-difluorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863244-08-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2-chloro-4-fluorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 863244-13-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[[3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863244-47-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[[3-(trifluoromethyl)phenyl]methyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 863244-51-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[[2-(4-

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863244-53-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[[2-(3-(trifluoromethoxy)phenyl)-1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 863245-25-4 HCAPLUS
CN Benzoic acid, 4-[[4-(2,4-dichlorophenyl)-2-[[2-(3-(1,1-dioxido-4-oxo-


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethyl)phenyl]ethyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 863244-52-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[[2-(2-fluoro-4-(trifluoromethyl)phenyl)ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(trifluoromethyl)phenyl]ethyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 863245-56-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[[2-(3-(trifluoromethyl)phenyl)-1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-58-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[[2-(2-fluoro-5'-propoxy[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-59-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(3'-chloro[1,1'-biphenyl]-4-yl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-60-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(3'-chloro[1,1'-biphenyl]-4-yl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



RN 863245-63-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(3'-chloro[1,1'-biphenyl]-4-yl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-64-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(4-(5-chloro-2-thienyl)phenyl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.




RN 863245-61-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(3'-chloro[1,1'-biphenyl]-4-yl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-62-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(3'-chloro[1,1'-biphenyl]-4-yl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-66-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(4-(5-acetyl-2-thienyl)phenyl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-67-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[2-[(1E)-2-(3'-chloro[1,1'-biphenyl]-4-yl)ethenyl]-4-(2,4-dichlorophenyl)-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-68-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(3,3-dimethylbutoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-69-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(4,4,4-trifluorobutoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Double bond geometry as shown.



RN 863245-72-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-4-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863245-75-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[2-fluoro-4-(trifluoromethyl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-2-methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 863245-70-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-fluoro-4'-(4,4,4-trifluorobutoxy)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-71-0 HCAPLUS
CN Carbamic acid, [4'-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl]-4-fluoro[1,1'-biphenyl]-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863245-78-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(4,4,4-trifluorobutoxy)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863245-80-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dimethylethyl)phenoxy]phenyl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 863245-82-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[(1E)-2-[4-(4-chlorophenyl)phenyl]ethenyl]phenyl]methyl-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-03-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[(1E)-2-[4-(4-chlorophenyl)phenyl]ethenyl]phenyl]methyl-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 863246-07-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[(1E)-2-[4-(4-chlorophenyl)phenyl]ethenyl]phenyl]methyl-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-09-7 HCAPLUS
CN Carbanic acid, [4'-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl]biphenyl]-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
Double bond geometry as shown.



RN 863246-04-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[(1E)-2-[4-(2,4-dichlorophenyl)-1-ethyl-1H-imidazol-2-yl]ethenyl]phenyl]methyl-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-06-4 HCAPLUS
CN Benzoic acid, 4'-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethenyl]-1H-imidazol-1-yl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 863246-10-0 HCAPLUS
CN Carbanic acid, [4'-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl]biphenyl]-3-yl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 863246-11-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[(1E)-2-[4-(2,4-dichlorophenyl)-1-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]methyl]-1H-imidazol-2-yl]ethenyl]biphenyl]-3-yl]-, 1-methylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.


10510026rtr

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-12-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-(3'-methyl-1,1'-biphenyl)-4-yl]ethenyl]-1H-imidazol-1-yl]methylphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-13-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-{[4-(2,4-dichlorophenyl)-2-[(1E)-2-(4-phenoxyphenyl)ethenyl]-1H-imidazol-1-yl]methyl}phenyl]-, 1,1-dioxide
(9CI)
(CA INDEX NAME)


Double bond geometry as shown.

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Double bond geometry as shown.




RN 863287-03-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,6-dichlorophenyl)-2-[(1E)-2-[3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 863247-41-OP
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of substitutedazole derivs. for treating diseases
 mediated by
 PTase activity)
 RN 863247-41-0 HCAPLUS
 CN Benzoic acid,
 4-[4-(2,4-dichlorophenyl)-2-[(1E)-2-[3'-(1,1-dioxido-4-oxo-

L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 863246-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-{3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl)ethenyl]-1H-imidazol-1-yl)methyl]-2-methylphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 863246-16-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[[4-(2,4-dichlorophenyl)-2-[(1E)-2-{3'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl]methyl]phenyl]-4-propyl-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 5 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,2,5-thiadiazolidin-2-yl][1,1'-biphenyl]-4-yl]ethenyl]-1H-imidazol-1-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




10510026rtr

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN
 ED Entered STN: 03 May 2005
 ACCESSION NUMBER: 2005:378875 HCAPLUS
 DOCUMENT NUMBER: 143:19267
 TITLE: Structure-based design of protein tyrosine phosphatase-1B inhibitors
 AUTHOR(S): Black, Emma; Breed, Jason; Breese, Alexander L.; Embrey, Kevin; Garcia, Robert; Gero, Thomas W.; Godfrey, Linda; Kenny, Peter W.; Morley, Andrew D.; Minshull, Claire A.; Pannifer, Andrew D.; Read, Jon; Rees, Amanda; Russell, Daniel J.; Toader, Dorin; Tucker, Julie
 CORPORATE SOURCE: AstraZeneca, Cheshire, SK10 4TG, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(10), 2503-2507
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:19267
 AB Using structure-based design, a new class of inhibitors of protein tyrosine phosphatase-1B (PTP1B) has been identified, which incorporate the 1,2,5-thiadiazolidin-3-one-1,1-dioxide template.
 IT 692765-80-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (structure-based design of protein tyrosine phosphatase-1B inhibitors)
 RN 692765-80-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3-bromophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




IT 612530-44-6P 692764-89-9P 692764-94-6P
 852835-44-0P 852835-45-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (structure-based design of protein tyrosine phosphatase-1B inhibitors)
 RN 612530-44-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 852835-45-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 6 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 692764-89-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692764-94-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[1,1'-biphenyl]-3-yl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 852835-44-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN

ED Entered STN: 22 Apr 2005
 ACCESSION NUMBER: 2005:347030 HCAPLUS
 DOCUMENT NUMBER: 142:411350
 TITLE: Preparation of 1-oxo and 1,1-dioxoisothiazolones and related modulators of proteins such as phosphatases that bind phosphorylated peptides and proteins
 INVENTOR(S): Combs, Andrew P.; Yue, Eddy Wai Tsun; Bower, Michael; Jason, Zhu; Wenyu, Crawley, Matthew Lantz; Sparks, Richard Bruce; Pruitt, James Russell; Takvorian, Amy
 INCYTE CORPORATION, USA
 PATENT ASSIGNEE(S): INCYTE CORPORATION, USA
 SOURCE: PCT Int. Appl., 529 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005035551	A2	20050421	WO 2004-US33212	20041007
WO 2005035551	A3	20060908		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005272778	A1	20051208	US 2004-960344	20041007
US 7141596	B2	20061128		
PRIORITY APPL. INFO.:				
			US 2003-510002P	P 20031008
			US 2003-529372P	P 20031211
			US 2004-600506P	P 20040811

OTHER SOURCE(S): CASREACT 142:411350; MARPAT 142:411350
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention provides 1-oxo and 1,1-dioxoisothiazolones (shown as I-IV; also isothiazolidinone analogs of I-IV with R16 and R17 in place of R15 and R2 as a substituent at the 5 position of the isothiazolidinone ring; variables defined below; e.g. V) and related compds. that can modulate (no data) the activity of a target protein, such as a phosphatase, that selectively binds phosphorylated peptides or proteins. The present compds. can be useful (no data) in treating diseases or disorders, including, for example, diabetes and obesity, that are connected directly or indirectly to the activity of the target protein. Methods of preparation are claimed and hundreds of example preps. are included. For example, V was prepared in 12 steps (50, 62, 100, 59, not

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 detd., 100, 100, 99, not detd., not detd., 43, and 25 % yield) starting
 from N-tert-butyl-3-[2-(tert-butylcarbamoyl)ethyl]disulfanylpropionamide.
 For I-IV: a dashed line indicates an optional bond; Scl is a 1st mol.
 scaffold or is absent; Sc2 is a 2nd mol. scaffold or is absent, wherein

at least one of Scl and Sc2 is present; or Scl and Sc2 together with X1 and
 X2 or X4 and X5 form a 5-, 6-, or 7-membered fused carbocyclic ring or a
 5-, 6-, or 7-membered fused heterocarbocyclic ring; X1 is C or N when Scl
 is present; X1 is CR1, N, NR2, CO, CS, SO, or SO2 when Scl is absent; X2
 is C or N when Sc2 is present; X2 is CR1, N, NR2, CO, CS, SO, or SO2 when
 Sc2 is absent; X3 is C or N; each D1, D2, and D3 = CR1, N, NR2, CO, CS,
 SO, or SO2, wherein the ring formed by X1, X2, X3, D1, D2, and D3 is an
 arom. ring; X4 is C or N when Scl is present; X4 is O, S, CR3, N, NR4,

CO, CS, SO, or SO2 when Scl is absent; X5 is C or N when Sc2 is present; X5
 is O, S, CR3, N, NR4, CO, CS, SO, or SO2 when Sc2 is absent; X6 is C or N.
 Each E1 and E2 = O, S, CR3, N, NR4, CO, CS, SO, or SO2, wherein the ring
 formed by X4, X5, X6, E1, and E2 is an arom. ring; R2 is H, halo, Cl-C4
 alkyl, C3-C6 cycloalkyl, haloalkyl, OR28, SR28, NO2, CN, SO2R29,
 COR10, COR11, NR32R33, a 5- or 6-membered heterocarbocyclyl group, or
 tetrazolyl. R15 is H, halo, Cl-C4 alkyl, C3-C6 cycloalkyl, haloalkyl,

OH, Cl-C4 alkoxy, Cl-C4 haloalkoxy, SH, Cl-C4 thioalkoxy, CN, NO2, SO(Cl-C4
 alkyl), SO(Cl-C4 haloalkyl), SO(C3-C6 cycloalkyl), SONH2, SO3H, SO2(Cl-C4
 alkyl), SO2(Cl-C4 haloalkyl), SO2(C3-C6 cycloalkyl), SO2NH2, CHO, COOH,
 CO(Cl-C4 alkyl), CO(C3-C6 cycloalkyl), CO(Cl-C4 haloalkyl),
 CO(heterocarbocyclyl), COO(Cl-C4 alkyl), COO(C3-C6 cycloalkyl), COO(Cl-C4
 haloalkyl), CONH2, CONH(Cl-C4 alkyl), CON(Cl-C4 alkyl)2, CONH(C3-C6
 cycloalkyl), CON(C3-C6 cycloalkyl)2, NH2, NH(Cl-C4 alkyl), N(Cl-C4
 alkyl)2, NH(C3-C6 cycloalkyl), or N(C3-C6 cycloalkyl)2. R16 and R17 = H,
 halo, Cl-C4 alkyl, C3-C6 cycloalkyl, haloalkyl, OH, Cl-C4 alkoxy, Cl-C4
 haloalkoxy, SH, Cl-C4 thioalkoxy, CN, NO2, SO(Cl-C4 alkyl), SO(Cl-C4
 haloalkyl), SO(C3-C6 cycloalkyl), SONH2, SO3H, SO2(Cl-C4 alkyl),

SO2(Cl-C4 haloalkyl), SO2(C3-C6 cycloalkyl), SO2NH2, CHO, COOH, CO(Cl-C4 alkyl),
 CO(C3-C6 cycloalkyl), CO(Cl-C4 haloalkyl), CO(heterocarbocyclyl),
 COO(Cl-C4 alkyl), COO(C3-C6 cycloalkyl), COO(Cl-C4 haloalkyl), CONH2,
 CONH(Cl-C4 alkyl), CON(Cl-C4 alkyl)2, CONH(C3-C6 cycloalkyl), CON(C3-C6
 cycloalkyl)2, NH2, NH(Cl-C4 alkyl), N(Cl-C4 alkyl)2, NH(C3-C6
 cycloalkyl), or N(C3-C6 cycloalkyl)2; or R16 and R17 together with the C atom to which
 they are attached form a C3-C6 cycloalkyl group or a 3-7 membered
 heterocycloalkyl group; and q1 is 1 or 2; addnl. details are given in the
 claims.

IT 850315-19-4P, [(1S)-1-[(1S)-1-(Pentylcarbamoyl)-2-[4-(1,1,4-
 trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]ethyl]carbamoyl]-2-
 phenylethyl]carbamate acid tert-butyl ester 850315-22-9P,
 (2S)-2-[(1S)-2-[(1S)-2-[(4-Methoxyphenyl)acetyl]amino]-3-

phenylpropionyl]amino]-N-pentyl-3-[4-(1,1,4-trioxo[1,2,5]thiadiazolidin-2-
 yl)phenyl]propionamide 850315-24-1P, N-[(1S)-2-[4-(1,1-Dioxido-4-
 oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-
 benzimidazol-2-yl]ethyl]biphenyl-4-sulfonamide 850315-36-5P
 850315-40-1P, 4-Bromo-N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-


L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 850327-93-4P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-
 dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-
 chlorobenzene-sulfonamide trifluoroacetate 850327-95-6P,
 N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)phenyl]ethyl]-3-fluorobenzene-sulfonamide
 trifluoroacetate

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; prepn. of 1-oxo and 1,1-dioxolothiazolone and
 related modulators of proteins such as phosphatases that bind phosphorylated
 peptides and proteins)


RN 850315-19-4 HCAPLUS
 CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-
 (1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.



RN 850315-22-9 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-(1,1-
 dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850315-24-1 HCAPLUS
 CN [1,1'-Biphenyl]-4-sulfonamide, N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-
 yl]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 yl]ethyl]-2-(trifluoromethoxy)benzenesulfonamide trifluoroacetate
 850315-44-5P, N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-
 2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-
 bis(trifluoromethyl)benzenesulfonamide trifluoroacetate
 850315-48-9P, N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-
 2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-
 (trifluoromethoxy)benzenesulfonamide trifluoroacetate 850315-63-8P,
 N-[(1S)-2-[3-Chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]biphenyl-4-
 sulfonamide trifluoroacetate 850315-65-0P 850315-69-4P

4-Bromo-N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-
 (trifluoromethoxy)benzenesulfonamide trifluoroacetate 850315-73-0P,
 N-[(1S)-2-[3-Chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-
 bis(trifluoromethyl)benzenesulfonamide trifluoroacetate
 850327-65-0P 850327-67-2P, N-[(1S)-1-(5-Chloro-1H-

benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl]ethyl]-2-cyanobenzene-sulfonamide trifluoroacetate
 850327-69-4P, N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-
 chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-
 cyanobenzene-sulfonamide trifluoroacetate 850327-71-8P,

N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-
 1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxybenzenesulfonamide
 trifluoroacetate 850327-73-0P, N-[(1S)-1-(5-Chloro-1H-


benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl]ethyl]-3,4-dimethoxybenzenesulfonamide trifluoroacetate
 850327-75-2P, N-[(1S)-1-(5-Chloro-1H-benzimidazol-2-yl)-2-[3-
 chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-
 dimethylbenzenesulfonamide trifluoroacetate 850327-77-4P,
 N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)phenyl]ethyl]benzenesulfonamide trifluoroacetate
 850327-79-6P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-
 dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-
 cyanobenzene-sulfonamide trifluoroacetate 850327-81-0P,
 N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)phenyl]ethyl]-4-cyanobenzene-sulfonamide
 trifluoroacetate 850327-83-2P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-

2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-
 phenoxybenzenesulfonamide trifluoroacetate 850327-85-4P,
 N-[(1S)-1-(1H-Benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxybenzenesulfonamide
 trifluoroacetate 850327-87-6P, N-[(1S)-1-(1H-Benzimidazol-2-yl)-
 2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-
 3,5-dimethylbenzenesulfonamide trifluoroacetate 850327-89-8P,
 3-Chloro-N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-
 dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]benzenesulfonamide
 trifluoroacetate 850327-91-2P, N-[(1S)-1-(5-Chloro-1H-

benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl]ethyl]-3-fluorobenzene-sulfonamide trifluoroacetate

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

Absolute stereochemistry.




RN 850315-36-5 HCAPLUS
 CN Benzenesulfonamide,
 N-[(1S)-2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-
 yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-4-
 (trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-35-4
 CMF C25 H19 F6 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
 CMF C2 H F3 O2

10510026rtr

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 850315-40-1 HCAPLUS
CN Benzenesulfonamide, 4-bromo-N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-39-8
CMF C25 H18 Br F6 N5 O6 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-44-5 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-63-8 HCAPLUS
CN [1,1'-Biphenyl]-4-sulfonamide, N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-62-7
CMF C30 H23 Cl F3 N5 O5 S2


Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-43-4
CMF C26 H18 F9 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850315-48-9 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-2-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850315-47-8
CMF C25 H19 F6 N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850315-65-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-yl]ethyl]-4-(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 850315-64-9
CMF C25 H18 Cl F6 N5 O5 S2

Absolute stereochemistry.

10510026rtr

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850315-69-4 HCAPLUS
CN Benzenesulfonamide,
4-bromo-N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-
thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-
yl]ethyl]-2-(trifluoromethoxy)-, mono(trifluoroacetate) (9CI) (CA INDEX
NAME)

CM 1
CRN 850315-68-3
CMF C25 H17 Br Cl F6 N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2
CRN 76-05-1
CMF C2 H F3 O2




RN 850315-73-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-
thiadiazolidin-2-yl)phenyl]-1-[5-(trifluoromethyl)-1H-benzimidazol-2-
yl]ethyl]-3,5-bis(trifluoromethyl)-, mono(trifluoroacetate) (9CI) (CA
INDEX NAME)

CM 1
CRN 850315-72-9
CMF C26 H17 Cl F9 N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-65-0 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-
4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-64-9
CMF C23 H19 Cl2 N5 O5 S2

Absolute stereochemistry.



CM 2

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CRN 76-05-1
CMF C2 H F3 O2



RN 850327-67-2 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-
4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyano-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1
CRN 850327-66-1
CMF C24 H18 Cl2 N6 O5 S2

Absolute stereochemistry.



CM 2
CRN 76-05-1
CMF C2 H F3 O2



RN 850327-69-4 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-
4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyano-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1

CRN 850327-68-3
CMF C24 H18 Cl2 N6 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-71-8 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxy-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-70-7
CMF C29 H23 Cl2 N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-73-0 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxy-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-72-9
CMF C25 H23 Cl2 N5 O7 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-75-2 HCAPLUS
CN Benzenesulfonamide,
N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethyl-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-74-1
CMF C25 H23 Cl2 N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-77-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-,
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-76-3
CMF C23 H20 Cl N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1

10510026rtr

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CMF C2 H F3 O2




RN 850327-79-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-2-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-78-5
CMF C24 H19 Cl N6 O5 S2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850327-81-0 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-4-cyano-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-85-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,4-dimethoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-84-3
CMF C25 H24 Cl N5 O7 S2


Absolute stereochemistry.



L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CM 1

CRN 850327-80-9
CMF C24 H19 Cl N6 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850327-83-2 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-phenoxy-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-82-1
CMF C29 H24 Cl N5 O6 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-87-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3,5-dimethyl-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-86-5
CMF C25 H24 Cl N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850327-89-8 HCAPLUS
CN Benzenesulfonamide, 3-chloro-N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-88-7
CMF C23 H18 Cl3 N5 O5 S2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-91-2 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(5-chloro-1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-90-1
CMF C23 H18 Cl2 F N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 850327-95-6 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-fluoro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 850327-94-5
CMF C23 H19 Cl F N5 O5 S2

Absolute stereochemistry.



L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850327-93-4 HCAPLUS
CN Benzenesulfonamide, N-[(1S)-1-(1H-benzimidazol-2-yl)-2-[3-chloro-4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl]ethyl]-3-chloro-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850327-92-3
CMF C23 H19 Cl2 N5 O5 S2

Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2

CRN 76-05-1
CMF C2 H F3 O2




IT 850315-20-7P, [(S)-2-[4-(5-Benzyl-1,1,4-

trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]-1-(pentylcarbamoyl)ethyl]carbamic acid tert-butyl ester 850315-21-8P, [(1S)-1-[[[(1S)-2-[4-(5-Benzyl-1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]-1-(pentylcarbamoyl)ethyl]carbamoyl]-2-phenylethyl]carbamic acid tert-butyl ester 850315-23-0P, (2S)-3-[4-(5-Benzyl-1,1,4-trioxo[1,2,5]thiadiazolidin-2-yl)phenyl]-2-[[[(2S)-2-[[2-(4-methoxyphenyl)acetyl]amino]-3-phenylpropionyl]amino]-N-pentylpropionamide RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 1-oxo and 1,1-dioxoisothiazolone and related modulators of proteins such as phosphatases that bind phosphorylated peptides and proteins)

RN 850315-20-7 HCAPLUS
CN Carbamic acid, [(1S)-1-[[4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 850315-21-8 HCAPLUS
CN L-Phenylalaninamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-4-[1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 7 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 850315-23-0 HCAPLUS
 CN L-Phenylalaninamide, N-[(4-methoxyphenyl)acetyl]-L-phenylalanyl-4-[(1,1-dioxido-4-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)-N-pentyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 11 Apr 2005

ACCESSION NUMBER: 2005:308290 HCAPLUS

DOCUMENT NUMBER: 143:7658

TITLE: Expedient syntheses of sulfonylhydantoins and two

six-membered analogs

AUTHOR(S): Campbell, Andrew D.; Birch, Alan M.

CORPORATE SOURCE: Research and Development, AstraZeneca, Cheshire, SK10

4TG, UK

SOURCE: Synlett (2005), (5), 834-838

CODEN: SYNLES; ISSN: 0936-5214


PUBLISHER: Georg Thieme Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:7658

GI



AB A range of α -amino esters can be turned into sulfonylhydantoins in a single, atom-economic step using sulfamide and DBU. E.g., reaction of $\text{BnNHCH}_2\text{CO}_2\text{Et}$ with sulfamide and DBU gave 65% sulfonylhydantoin I. This procedure obviates the need for a three- or four-step sequence utilized

by

traditional procedures. Two new six-membered analogs [5-aryl-1,2,6-thiadiazinan-3-one 1,1-dioxides and 5-aryl-1,2-thiazinan-3-one 1,1-dioxides], e.g. II and III, have also been prepared utilizing novel synthetic protocols.

L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 612528-23-1P 612529-46-1P 612530-69-5P

852358-50-0P 852358-51-1P 852358-53-3P

852358-54-4P 852358-56-6P 852358-57-7P

RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of sulfonylhydantoins via reaction of amino acid esters

with

sulfamide and DBU)


RN 612528-23-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-46-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-69-5 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 852358-50-0 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852358-51-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 852358-53-3 HCAPLUS

CN Benzonitrile, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 852358-54-4 HCAPLUS


CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 852358-56-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-([1,1'-biphenyl]-3-ylmethyl)-, 1,1-dioxide
 (9CI) (CA INDEX NAME)



RN 852358-57-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-methyl-5-(phenylmethyl)-, 1,1-dioxide,
 (4S)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR
 THIS

L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 08 Mar 2005

ACCESSION NUMBER: 2005:202894 HCAPLUS
 DOCUMENT NUMBER: 142:366767
 TITLE: 1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides are potent inhibitors of human trypsin
 AUTHOR(S): Wong, Tzushin; Groutas, Christopher S.; Mohan, Swathi; Lai, Zhong; Alliston, Kevin R.; Vu, Nga; Schechter, Norman M.; Groutas, William C.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Archives of Biochemistry and Biophysics (2005), 436(1), 1-7
 CODEN: ABBIA4; ISSN: 0003-9861
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The authors describe herein the design, synthesis, and in vitro biochem. evaluation of a series of potent, time-dependent inhibitors of the mast cell-derived serine protease trypsin. The inhibitors were readily obtained by attaching various heterocyclic thiols, as well as a basic primary specificity residue P1, to the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold. The inhibitors were found to be devoid of any inhibitory activity toward a neutral (elastase) or cysteine (papain) protease, however they were also fairly efficient inhibitors of bovine trypsin. The differential inhibition observed with trypsin suggests that enzyme selectivity can be optimized by exploiting differences in the S' subsites of the two enzymes. The results described herein demonstrate


the versatility of the heterocyclic scaffold in fashioning mechanism-based inhibitors of neutral, basic, and acidic (chymo)trypsin-like serine proteases.

IT 849415-30-1P 849415-31-2P 849415-32-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides

are potent inhibitors of human trypsin)

RN 849415-30-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(4-aminobutyl)-2-[[2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-31-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(4-aminobutyl)-5-(phenylmethyl)-2-[[5-phenyl-1,3,4-oxadiazol-2-yl]thio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 849415-32-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(4-aminobutyl)-5-(phenylmethyl)-2-[[3-phenyl-1,2,4-oxadiazol-5-yl]thio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 849415-24-3P 849415-25-4P 849415-26-5P
 849415-27-6P 849415-28-7P 849415-29-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (1,2,5-Thiadiazolidin-3-one 1,1-dioxide-based heterocyclic sulfides

are potent inhibitors of human trypsin)

RN 849415-24-3 HCAPLUS
 CN Carbamic acid, [4-[[[3S]-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 849415-25-4 HCAPLUS
 CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[(phenylthio)methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-26-5 HCAPLUS
 CN Carbamic acid, [4-[(3S)-5-(chloromethyl)-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 849415-27-6 HCAPLUS
 CN Carbamic acid, [4-[(3S)-5-[(2-benzoxazolylthio)methyl]-1,1-dioxido-4-oxo-2-(phenylmethyl)-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L4 ANSWER 9 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 849415-28-7 HCAPLUS
 CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 849415-29-8 HCAPLUS
 CN Carbamic acid, [4-[(3S)-1,1-dioxido-4-oxo-2-(phenylmethyl)-5-[(5-phenyl-1,2,4-oxadiazol-5-yl)thio]methyl]-1,2,5-thiadiazolidin-3-yl]butyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 19 Aug 2004
 ACCESSION NUMBER: 2004:677210 HCAPLUS
 DOCUMENT NUMBER: 141:235669
 TITLE: Potent inhibition of human leukocyte elastase by 1,2,5-thiadiazolidin-3-one 1,1 dioxido-based sulfonamide derivatives
 AUTHOR(S): Lai, Zhong; Gan, Xiangdong; Wei, Liqing; Alliston, Kevin R.; Yu, Hongyi; Li, Yue H.; Groutas, William C.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Archives of Biochemistry and Biophysics (2004), 429(2), 191-197
 CODEN: ABBIA4; ISSN: 0003-9861
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 141:235669
 AB The design, synthesis, and in vitro biochem. evaluation of a class of mechanism-based inhibitors of human leukocyte elastase (HLE) that incorporate in their structure a 1,2,5-thiadiazolidin-3-one 1,1-dioxido-based scaffold with appropriate recognition and reactivity elements appended to it is described. The synthesized compds. were found to be efficient, time-dependent inhibitors of HLE. The interaction of the inhibitors with HLE is postulated to lead to the formation of a highly reactive N-sulfonyl imine (a Michael acceptor) that arises from an enzyme-induced sulfonamide fragmentation cascade. Subsequent reaction ultimately leads to the formation of a relatively stable acyl enzyme. The results cited herein demonstrate convincingly the superiority of the 1,2,5-thiadiazolidin-3-one 1,1 dioxido scaffold over other scaffolds (e.g., saccharin) in the design of inhibitors of (chymo)trypsin-like serine proteases.
 IT 749866-31-7P 749866-32-8P 749866-33-9P 749866-34-0P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (potent inhibition of human leukocyte elastase by 1,2,5-thiadiazolidin-3-one 1,1-dioxido-based sulfonamide derivs.)
 RN 749866-31-7 HCAPLUS
 CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 749866-32-8 HCAPLUS
 CN D-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-

10510026rtr


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl)sulfonyl]-, methyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 749866-33-9 HCAPLUS
 CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl)sulfonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 749866-34-0 HCAPLUS
 CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl)sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 212331-99-2P 749866-30-6P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (potent inhibition of human leukocyte elastase by
 1,2,5-thiadiazolidin-


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 10 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 3-one 1,1-dioxide-based sulfonamide derivs.)
 RN 212331-99-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 749866-30-6 HCAPLUS
 CN Ethanethioic acid, S-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 220869-64-7
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (potent inhibition of human leukocyte elastase by
 1,2,5-thiadiazolidin-
 3-one 1,1-dioxide-based sulfonamide derivs.)
 RN 220869-64-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 30 Jul 2004

ACCESSION NUMBER: 2004:610081 HCAPLUS

DOCUMENT NUMBER: 141:157120

TITLE: Preparation of sulfahydantoin as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders
 INVENTOR(S): Saunders, Jeffrey O.; Mikkis, Gregory F.; Blake, James


PATENT ASSIGNEE(S): F.
 SOURCE: Vertex Pharmaceuticals Incorporated, USA
 PCT Int. Appl., 62 pp.
 CODEN: PIXKD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004062664	A1	20040729	WO 2003-US41630	20031230
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
CA 2511818	A1	20040729	CA 2003-2511818	20031230
AU 2003300447	A1	20040810	AU 2003-300447	20031230
US 2004167187	A1	20040826	US 2003-749121	20031230
EP 1594497	A1	20051116	EP 2003-815258	20031230
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006514960	T	20060518	JP 2004-566641	20031230
PRIORITY APPLN. INFO.: US 2002-437572P P 20021230				
WO 2003-US41630 W 20031230				

OTHER SOURCE(S): MARPAT 141:157120
 GI

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB The invention relates to compds. having a sulfahydantoin or a reverse sulfahydantoin moiety (I) and (II) or pharmaceutically acceptable salts thereof [O = each (un)substituted C1-8 aliphatic group, C6-10 aryl, heteroaryl having 5-10 ring atoms, heterocyclyl having 3-10 ring atoms; T = C1-6 alkylidene chain wherein one or two nonadjacent methylene units of T are optionally and independently replaced by O, NR, S, CO, CONR, NRCO, NRCONR, SO, SO₂, NRSO₂, SO₂NR, or NRSO₂NR; m = 0,1; X = CH₂, CO, CF₂; R = H or (un)substituted C1-8 aliphatic group or two R groups bound to the

same nitrogen are taken together with the nitrogen to form a 3-7 membered heterocyclic ring having 0-2 heteroatoms in addition to the nitrogen, wherein said heteroatoms are independently selected from N, O, or S], uses thereof, and related methods. These compds. are inhibitors of phosphatases, particularly inhibitors of protein tyrosine phosphatase SHP-2 and are used in the treatment of various phosphatase mediated diseases such as proliferative diseases, autoimmune disorders, angiogenic disorders, and cancer. The autoimmune disease is selected from glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease. The proliferative disease is selected from acute myelogenous leukemia, chronic

myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, multiple myeloma, and HTLV-1-mediated tumorigenesis. The angiogenic disorder is selected from solid tumors, ocular neovascularization, and infantile hemangiomas. The cancer is selected from colon, breast, stomach, and ovarian cancer. Thus, N-alkylation of Me 4-aminobenzoate by Et bromoacetate in the presence of Et₃N at 60° for 2.5 days gave 4-[(ethoxycarbonyl)methylamino]benzoic acid Me ester which underwent N-sulfamoylation by sulfamoyl chloride in the presence of Et₃N in CH₂Cl₂ at room temperature overnight to give 4-[N-[(ethoxycarbonyl)methyl]-N-sulfamoylamino]benzoic acid Me ester (III). Cyclization of III by treatment with NaOMe/MeOH at room temperature overnight gave 4-[(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)benzoic acid Me ester (IV). IV showed IC₅₀ of 1.0-100 μM against protein tyrosine phosphatase SHP-2.

IT 612527-99-8P 612530-69-5P 729600-44-6P,

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

4-[(1,1,4-Trioxo-1,2,5)thiadiazolidin-2-yl]benzoic acid methyl ester 729600-47-9P 729600-48-0P 729600-49-1P 729600-50-4P 729600-51-5P 729600-52-6P


RL: PAC (Pharmacological activity); SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of sulfahydantoin as phosphate isosteres for use as protein

or phosphatase inhibitors in treatment of cancer and autoimmune disorders)


RN 612527-99-8 HCAPLUS

CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 612530-69-5 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 729600-44-6 HCAPLUS


CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 729600-47-9 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-(2-naphthalenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 729600-48-0 HCAPLUS


CN Benzoic acid, 3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 729600-49-1 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-(3-phenyl-2-propenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 729600-50-4 HCAPLUS

CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)



RN 729600-51-5 HCAPLUS

CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 729600-52-6 HCAPLUS

CN Benzamide, N-butyl-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 11 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 23 Jul 2004
ACCESSION NUMBER: 2004:589375 HCAPLUS
DOCUMENT NUMBER: 141:140459
TITLE: Preparation of sulfamides as anti-cancer agents
INVENTOR(S): Flynn, Daniel L.; Petrillo, Peter A.
PATENT ASSIGNEE(S): Deciphera Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 168 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004060305	A2	20040722	WO 2003-US41425	20031226
WO 2004060305	A3	20050210		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, WO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
US 2004171075	A1	20040902	US 2003-746545	20031224
US 2004176395	A1	20040909	US 2003-746607	20031224
CA 2511840	A1	20040722	CA 2003-2511840	20031226
AU 2003303639	A1	20040729	AU 2003-303639	20031226
EP 1590344	A2	20051102	EP 2003-814980	20031226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017863	A	20051206	BR 2003-17863	20031226
CN 1756849	A	20060405	CN 2003-80110049	20031226
CN 1791596	A	20060621	CN 2003-80110048	20031226
JP 2006519765	T	20060831	JP 2005-508623	20031226
PRIORITY APPLN. INFO.:				
			US 2002-437304P	P 20021231
			US 2002-437403P	P 20021231
			US 2002-437415P	P 20021231
			US 2002-437487P	P 20021231
			US 2003-463804P	P 20030418
			US 2003-746545	A 20031224
			US 2003-746607	A 20031224
			WO 2003-US41425	W 20031226

OTHER SOURCE(S): MARPAT 141:140459

L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
GI

AB Sulfamides, such as I, were prepared for use as anticancer agents which
act by modulating the activation states of abl or bcr-abl α -kinase proteins. Thus, 4-MeOCC6H4CH2NHSO2NHCO[R = pyrrolidino], prepared from 4-MeOCC6H4CH2NH2 and pyrrolidine, was treated with the pyrimidinylaminoaniline fragment to give I, which showed 10% inhibition


of non-phosphorylated abl kinase at 10 μ M.
IT 726192-44-5P 726192-45-6P 726192-60-5P

726192-61-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of sulfamides as anti-cancer agents)


RN 726192-44-5 HCAPLUS

CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[4-methyl-3-[(4-(3-pyridinyl)-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 726192-45-6 HCAPLUS
CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[4-methyl-3-[(4-phenyl-2-pyrimidinyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 726192-60-5 HCAPLUS
CN Benzamide, 4-[(3,3-dimethyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[4-methyl-3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 726192-61-6 HCAPLUS
 CN Urea, N-[4-[(3,3-dimethyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N'-[4-methyl-3-(2-pyrimidinylamino)phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




IT 612527-99-8P 612528-00-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of sulfamides as anti-cancer agents)
 RN 612527-99-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-00-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 18 Jun 2004

ACCESSION NUMBER: 2004:493693 HCAPLUS

DOCUMENT NUMBER: 141:54348

TITLE: Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives as inhibitors of protein tyrosine phosphatase 1B

INVENTOR(S): Kenny, Peter Wedderburn; Morley, Andrew David; Russell, Daniel John; Toader, Dorin

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 2004050646	A1	20040617	WO 2003-GB5120	20031126	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SE, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,					
TG	AU 2003302626	A1	20040623	AU 2003-302626	20031126
PRIORITY APPLN. INFO.:			GB 2002-27813	A	20021129
			WO 2003-GB5120	W	20031126

OTHER SOURCE(S): MARPAT 141:54348

GI



AB Title compds. I [wherein R1 = H, (halogeno)alkyl, (hydroxy)alkoxy, alkylamino, etc.; R2 = H, (halogeno)alkyl, halogeno, alkoxy; R3 = alkylamido or (un)substituted alkyl; R4 = H, alkyl, (hetero)aryl; R5 = H or alkyl; and pharmaceutically acceptable salts thereof] were prepared as inhibitors of protein tyrosine phosphatase 1B (PT1B). For example, 5-[4-(acetamidomethyl)-2-methoxyphenyl]-1,2,5-thiadiazolidin-3-one 1,1-dioxide (II) was given in multi-step synthesis starting from


10510026rtr

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
3-methoxy-4-nitrobenzyl alc. II showed inhibition of human PTB1B with
IC50 value of 44µM. Thus, I and their pharmaceutical compns. are
useful as inhibitors of protein tyrosine phosphatase 1B for the treatment
of diabetes mellitus.


IT 705256-50-4P 705256-54-8P 705256-55-9P
705256-61-7P 705256-67-3P 705256-72-0P
705256-78-6P 705256-82-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 5-phenyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide
derivs. as
inhibitors of protein tyrosine phosphatase 1B)

RN 705256-50-4 HCAPLUS
CN Acetamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)
phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 705256-54-8 HCAPLUS
CN Benzenecetonitrile, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-
(9CI) (CA INDEX NAME)




RN 705256-55-9 HCAPLUS
CN Acetamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-
methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 705256-61-7 HCAPLUS
CN Butanamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)
phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 705256-67-3 HCAPLUS
CN Benzenepropanamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-
methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 705256-72-0 HCAPLUS
CN Benzenepentanamide, N-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)
phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-78-6 HCAPLUS
CN Acetamide, N-[[4-(3-methyl-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)
phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 705256-82-2 HCAPLUS
CN Acetamide, N-[2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)
phenyl]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 13 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 21 May 2004
 ACCESSION NUMBER: 2004:412929 HCAPLUS
 DOCUMENT NUMBER: 140:423678
 TITLE: Preparation of 5-(substituted

phenylthiadiazolidin-3-

ones as inhibitors of protein tyrosine phosphatase 1B
 INVENTOR(S): Birch, Alan Martin; Kenny, Peter Wedderburn; Morley,
 Andrew David; Russell, Daniel John; Toader, Dorin
 PATENT ASSIGNER(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited
 SOURCE: PCT Int. Appl., 89 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041799	A1	20040521	WO 2003-GB4721	20031103
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,			
TG	AU 2003278392	A1	20040607	20031103
PRIORITY APPLN. INFO.:			GB 2002-25986	A 20021107
			WO 2003-GB4721	W 20031103

OTHER SOURCE(S):

MARPAT 140:423678


GI



I

AB The title compds. (I) or pharmaceutically acceptable salts thereof [R1 = H, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, halo-C1-6 alkyl, halo-C1-6 alkoxy, halo-C1-6 alkylthio, hydroxy-C1-6 alkoxy, dihydroxy-C1-6

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 692764-76-4P 692764-77-5P 692764-78-6P
 692764-79-7P 692764-80-0P 692764-81-1P
 692764-82-2P 692764-83-3P 692764-84-4P
 692764-85-5P 692764-86-6P 692764-87-7P
 692764-88-8P 692764-89-9P 692764-90-2P
 692764-91-3P 692764-92-4P 692764-93-5P
 692764-94-6P 692764-95-7P 692764-96-8P
 692764-97-9P 692764-98-0P 692764-99-1P
 692765-00-7P 692765-01-8P 692765-02-9P
 692765-03-0P 692765-04-1P 692765-05-2P
 692765-06-3P 692765-07-4P 692765-09-6P
 692765-10-9P 692765-11-0P 692765-12-1P
 692765-13-2P 692765-14-3P 692765-15-4P
 692765-16-5P 692765-18-7P 692765-19-8P
 692765-20-1P 692765-21-2P 692765-22-3P
 692765-23-4P 692765-24-5P 692765-25-6P
 692765-26-7P 692765-27-8P 692765-28-9P
 692765-29-0P 692765-30-3P 692765-31-4P
 692765-32-5P 692765-33-6P 692765-34-7P
 692765-35-8P 692765-36-9P 692765-37-0P
 692765-38-1P 692765-39-2P 692765-40-5P
 692765-41-6P 692765-42-7P 692765-43-8P
 692765-44-9P 692765-45-0P 692765-46-1P
 692765-47-2P 692765-48-3P 692765-49-4P
 692765-50-7P 692765-51-8P 692765-52-9P
 692765-53-0P 692765-54-1P 692765-55-2P
 692765-56-3P 692765-57-4P 692765-58-5P
 692765-59-6P 692765-60-9P 692765-61-0P
 692765-62-1P 692765-63-2P 692765-64-3P
 692765-65-4P 692765-66-5P 692765-67-6P
 692765-68-7P 692765-69-8P 692765-70-1P
 692765-71-2P 692765-72-3P 692765-73-4P
 692765-74-5P 692765-75-6P

RI: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of phenylthiadiazolidinones as inhibitors of protein tyrosine

phosphatase 1B (PTP1B) for treatment of diabetes mellitus)

RN 692764-76-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-methoxy[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 alkoxy, C1-6 alkoxy-C1-6 alkoxy, aryloxy, aryl-C1-6 alkoxy, aryloxy-C1-6 alkoxy, heteroaryl-C1-6 alkoxy, heteroaryloxy, heteroaryloxy-C1-6 alkoxy, C1-6 alkoxy-C1-6 alkylthio, C1-6 alkylthio-C1-6 alkoxy, C1-6 alkylsulfinyl-C1-6 alkoxy, C1-6 alkylsulfonyl-C1-6 alkoxy, aryl-C1-6 alkylthio, aryloxy-C1-6 alkylthio, etc.; R2 = H, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, halo; or R1 and R2 together with the carbon atoms to

which

they are attached form a 5-7 membered carbocyclic or heterocyclic ring;

R3

and R4 are selected such that (i) R3 = hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio or halo and R4 = aryl, biaryl, heteroaryl, C2-6 alkynyl, C3-7 cycloalkyl, arylcarbonyl, heteroarylcarbonyl, aryl-C2-6 alkenyl, aryl-C2-6 alkynyl or heteroaryl-C2-6 alkenyl; or (ii) R4 = H, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, or halo and R3 = aryl, biaryl, heteroaryl, C2-6 alkynyl, C3-7 cycloalkyl, arylcarbonyl, heteroarylcarbonyl, aryl-C2-6 alkenyl, aryl-C2-6 alkynyl or heteroaryl-C2-6 alkenyl; R5 = H, C1-6 alkyl,

C1-6 alkoxy, C1-6 alkylthio, halo-C1-6 alkyl, halo; R6 = H, C1-6 alkyl; wherein any aryl, biaryl or heteroaryl group is optionally substituted) are prepd. These compds. are useful as inhibitors of protein tyrosine

phosphatase PTP1B for the treatment of diabetes mellitus. Thus, 4-tolylboronic acid was coupled with 5-(4-bromophenyl)-1,2,5-thiadiazolidin-3-one in the presence of tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4] and cesium carbonate in a mixt. of DMF, DME, EtOH, and H2O at 170° for 600 s to give 5-(4'-Methyl-1,1'-biphenyl-4-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide.


IT 692765-08-5P 692765-17-6P

RI: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of phenylthiadiazolidinones as inhibitors of protein

tyrosine phosphatase 1B (PTP1B) for treatment of diabetes mellitus)

RN 692765-08-5 HCAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)



RN 692765-17-6 HCAPLUS


CN [1,1'-Biphenyl]-3-carboxylic acid, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-77-5 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-nitro[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-78-6 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-(3',5'-dichloro[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-79-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-methyl[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-80-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-methyl[1,1'-biphenyl]-4-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 692764-83-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692764-84-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4'-(methylthio)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-85-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-86-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692764-81-1 HCAPLUS
CN Acetamide, N-[4'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 692764-82-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-chloro[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-87-7 HCAPLUS
CN Acetamide, N-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 692764-88-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[3-(2-benzofuranyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-89-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-90-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[3-(5-oxazolyl)phenyl]-, 1,1-dioxide (9CI)
(CA INDEX NAME)




RN 692764-91-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-cyclohexylphenyl)-, 1,1-dioxide (9CI)
(CA INDEX NAME)




RN 692764-92-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-benzoylphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-96-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4,4'-dimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-97-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-4'-phenoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692764-98-0 HCAPLUS
CN [1,1'-Biphenyl]-3-carbonitrile, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4-methoxy- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-93-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[1,1'-biphenyl]-4-yl-, 1,1-dioxide (9CI)
(CA INDEX NAME)




RN 692764-94-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[1,1'-biphenyl]-3-yl-, 1,1-dioxide (9CI)
(CA INDEX NAME)




RN 692764-95-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692764-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-3'-nitro[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-00-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3',4'-dimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-01-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-hydroxy-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-02-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3',4,4'-trimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-03-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-04-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-(1,3-benzodioxol-5-yl)-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-09-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methoxy-5-((1E)-2-phenylethenyl)phenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 692765-10-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2-methoxy-5-(2-naphthalenyl)phenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-11-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-(hydroxymethyl)-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-05-2 HCAPLUS
CN Acetamide, N-[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




RN 692765-06-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-3'-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-07-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-12-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-3'-(methoxymethyl)[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-13-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-3'-(phenylmethoxy)[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-14-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy-4'-(phenylmethoxy)[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-15-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-((12)-2-phenylethenyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 692765-16-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4'-((1,1-dimethylethoxy)methyl)-4-methoxy[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-18-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-4'-(methoxymethyl)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-22-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3',5'-difluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-23-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(5'-fluoro-2',4-dimethoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-24-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1':3',1''-terphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-19-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-3'-(methylthio)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-20-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-21-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-25-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-26-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-4'-(methylthio)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-27-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4'-((1,1-dimethylethyl)-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-28-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methoxy[1,1':4',1''-terphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-29-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-chloro-4'-fluoro-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-30-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-fluoro-4-methoxy[1,1':4',1''-terphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-34-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-(2-furanyl)-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-35-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-benzo[b]thien-2-yl-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-36-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(5-(2-benzofuranyl)-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-37-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-acetyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-31-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-methoxy-3'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-32-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[5-[(1E)-2-(4-chlorophenyl)ethenyl]-2-methoxyphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 692765-33-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4'-ethenyl-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-38-1 HCAPLUS
CN [1,1'-Biphenyl]-3-carboxamide, 3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy-, (9CI) (CA INDEX NAME)




RN 692765-39-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(1H-pyrazol-4-yl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-40-5 HCAPLUS
CN Pyrrolidine, 1-[(3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-41-6 HCAPLUS
 CN [1,1'-Biphenyl]-4-propanoic acid, 3'--(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-42-7 HCAPLUS
 CN Carbamic acid, {[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]methyl}-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 692765-43-8 HCAPLUS
 CN [1,1'-Biphenyl]-3-carboxamide, 3'--(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-47-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(4-pyridinyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-48-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(4-pyridinyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-49-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[5-(1H-indol-6-yl)-2-methoxyphenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-44-9 HCAPLUS
 CN [1,1'-Biphenyl]-4-carboxamide, N-cyclohexyl-3'--(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy- (9CI) (CA INDEX NAME)




RN 692765-45-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3'-amino-4-methoxy[1,1'-biphenyl]-3-yl)-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 692765-46-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4'-(dimethylamino)-4-methoxy[1,1'-biphenyl]-


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 692765-50-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(2-thienyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-51-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(phenylethynyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-52-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(3-phenyl-1-propynyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 692765-53-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(5-ethynyl-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-54-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-methyl[1,1'-biphenyl]-3-yl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-55-2 HCAPLUS
 CN Benzoic acid, 2-[2-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy}-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-56-3 HCAPLUS
 CN Benzoic acid, 2-[2-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]ethoxy}-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-60-9 HCAPLUS
 CN Benzoic acid, 2-[2-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]ethoxy}-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-61-0 HCAPLUS
 CN Benzoic acid, 2-[2-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]ethoxy}-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-62-1 HCAPLUS
 CN Benzoic acid, 2-[3-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]propoxy}-6-hydroxy- (9CI) (CA INDEX NAME)




L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 INDEX NAME)




RN 692765-57-4 HCAPLUS
 CN Benzoic acid, 2-[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]methoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-58-5 HCAPLUS
 CN Benzoic acid, 2-[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]methoxy]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-59-6 HCAPLUS
 CN Benzoic acid, 2-[[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]methoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 692765-63-2 HCAPLUS
 CN Benzoic acid, 2-[3-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl]propoxy}-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-64-3 HCAPLUS
 CN Benzoic acid, 2-[3-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]propoxy}-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-65-4 HCAPLUS
 CN Benzoic acid, 2-[3-{[3'-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl]propoxy}-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-66-5 HCAPLUS
CN Benzoic acid, 2-[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)methoxy]-6-hydroxy- (9CI) (CA INDEX NAME)




RN 692765-67-6 HCAPLUS
CN (1,1'-Biphenyl)-3-carboxamide, 3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy-N-(2-phenoxyethyl)- (9CI) (CA INDEX NAME)




RN 692765-68-7 HCAPLUS
CN Benzoic acid, 2-[2-[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-[[6-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]hexyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 692765-72-3 HCAPLUS
CN Benzoic acid, 2-[2-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]amino]ethoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-73-4 HCAPLUS
CN Benzoic acid, 2-[3-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]amino]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-74-5 HCAPLUS
CN Benzoic acid, 2-[[5-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]pentyloxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 692765-69-8 HCAPLUS
CN Benzoic acid, 2-[3-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]propoxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-70-1 HCAPLUS
CN Benzoic acid, 2-[[5-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]pentyloxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




RN 692765-71-2 HCAPLUS


L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzoic acid, 2-[[5-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-3-yl)carbonyl]amino]pentyloxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)



RN 692765-75-6 HCAPLUS
CN Benzoic acid, 2-[[6-[[[3'-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4'-methoxy[1,1'-biphenyl]-4-yl)carbonyl]amino]hexyl]oxy]-6-hydroxy-, methyl ester (9CI) (CA INDEX NAME)




IT 692765-79-0P 692765-80-3P 692765-84-7P
692765-85-8P 692765-86-9P 692766-02-2P
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylthiadiazolidinones as inhibitors of protein tyrosine phosphatase 1B (PTP1B) for treatment of diabetes mellitus)
RN 692765-79-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(4-bromophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




10510026rtr

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 692765-80-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(3-bromophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692765-84-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(5-bromo-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 692765-85-8 HCAPLUS
 CN Boronic acid, [3-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-4-methoxyphenyl]- (9CI) (CA INDEX NAME)




RN 692765-86-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-

L4 ANSWER 14 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 dioxaborolan-2-yl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 692766-02-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(5-iodo-2-methoxyphenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 10 Oct 2003

ACCESSION NUMBER: 2003:796679 HCAPLUS

DOCUMENT NUMBER:

TITLE: Preparation of substituted 1,1-dioxo-1,2,5-thiadiazolidine-3-ones as protein tyrosine phosphatase

1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis

INVENTOR(S): Coppola, Gary Mark; Davies, John William; Jewell, Charles Francis, Jr.; Li, Yu-Chin; Wareing, James Richard; Sperbeck, Donald Mark; Stams, Travis Mathew; Topiol, Sidney Wolf; Vlattas, Isidoros

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 148 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082841	A1	20031009	WO 2003-EP3466	20030402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LV, MA, MD, ME, MG, MK, MN, MU, MV, MW, MY, MZ, NA, NG, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2480562	A1	20031009	CA 2003-2480562	20030402
AU 2003224030	A1	20031013	AU 2003-224030	20030402
US 2004023974	A1	20040205	US 2003-510026	20030402
EP 1492780	A1	20050105	EP 2003-510026	20030402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008974	A	20050215	BR 2003-8974	20030402
US 2005090502	A1	20050428	US 2003-510026	20030402
CN 1646508	A	20050727	CN 2003-510026	20030402
JP 2005535568	T	20051124	JP 2003-580308	20030402
NO 2004004745	A	20041214	NO 2004-4745	20041102
PRIORITY APPL. INFO.:			US 2002-369779P	P 20020403
			US 2002-369930P	P 20020403
			WO 2003-EP3466	W 20030402

OTHER SOURCE(S): MARPAT 139:307766
 GI


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Substituted thiazolidinetriones I [L1 = L2 = single bond; Q1 = single bond, H, (un)substituted alkyl, cycloalkyl, or aminocarbonyl, carboxy, R1OC(:O), R1OOC(:O), R1OS(:O)q; Q2 = O, S, R3N; R, R2 = (un)substituted alkyl, alkynyl, heteroalkyl, aryl, heteroaryl, aralkyl, alkoxy, aralkoxy, or aralkylthio, amino, halogen, nitro, carboxy, trifluoromethyl, etc.; R1 = (un)substituted alkyl, alkynyl, heteroalkyl, aryl, heteroaryl, aralkyl, alkoxy, aralkoxy, aralkylthio; R3 = H, HO, alkyl; R10 = (un)substituted alkyl, aryl, heteroaryl, aralkyl, heteroalkyl; R14 = H, (un)substituted alkyl, alkoxy, carbonyl, acyl, aryloxy, carbonyl, heteroaryloxy, carbonyl, carbamoyl, or sulfonyl; X, Y = CH, N, O, S, R14N; Z = (un)substituted alkyl, alkoxyalkyl, alkylthioalkyl, alkylaminoalkyl; Z1, Z2, Z3 = CH, N, N(:O), CR1, CR2; R1 and R2 can form an (un)substituted 5- or 6-membered aromatic or heteroarom. ring; R1 and L1 can form an (un)substituted 5-, 6- or 7-membered ring interrupted by nitrogen, oxygen or sulfur atoms] such as II are prepared as inhibitors of protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase for overcoming insulin resistance and modulating glucose levels in the treatment or prevention of metabolic diseases, such as diabetes, or atherosclerosis. II is prepared by treatment of Et bromoacetate with 1-naphthalenemethanamine, N-sulfamoylation with sulfamoyl chloride, and base-mediated cyclocondensation. No biol. data is provided.

IT 612530-89-9P 612530-90-2P 612530-92-4P
 612530-93-5P 612530-94-6P 612530-95-7P
 612530-96-8P 612530-98-0P 612530-99-1P
 612531-00-7P 612531-01-8P 612531-02-9P
 612531-03-0P 612531-05-2P 612531-10-9P
 612531-13-2P 612531-22-3P 612531-23-4P
 612531-24-5P 612531-30-3P 612531-31-4P
 612531-32-5P 612531-34-7P 612531-35-8P
 612531-36-9P 612531-61-0P 612531-63-2P
 612531-64-3P 612531-65-4P 612531-66-5P
 612531-67-6P 612531-68-7P 612531-69-8P
 612531-70-1P 612531-71-2P 612531-72-3P
 612531-73-4P 612531-75-6P 612531-76-7P
 612531-77-8P 612531-78-9P 612531-79-0P

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 612531-80-3P 612534-94-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; prepn. of thiazolidinetriones as protein tyrosine
 phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to
 mitigate insulin resistance in the treatment of diabetes or
 atherosclerosis)
 RN 612530-89-9 HCAPLUS
 CN Carbamic acid, [4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-
 1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

RN 612530-90-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 2-[[5-[(2,4-dimethoxyphenyl)methyl]-5-[(1-ethyl-2-
 methyl-1H-benzimidazol-5-yl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-92-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 2-[[5-[(2,4-dimethoxyphenyl)methyl]-5-[(4-methoxy-
 7-quinolinyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-93-5 HCAPLUS
 CN Benzoic acid,
 4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)methyl]-, [4-(methylthio)phenyl]methyl ester (9CI)
 (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-94-6 HCAPLUS
 CN Benzoic acid,
 4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-
 thiadiazolidin-2-yl)methyl]-, [4-(methylsulfonyl)phenyl]methyl ester
 (9CI)
 (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-95-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(bromomethyl)phenyl]methyl]-2-[[2,4-
 dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-96-8 HCAPLUS
CN Acetic acid, [[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]thio]-, ethyl ester (9CI)
(CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 612530-98-0 HCAPLUS
CN Acetic acid, [[4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]sulfonyl]-, ethyl ester (9CI)
(CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A


RN 612530-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-iodophenyl)methyl]-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI)
(CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-00-7 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 612531-01-8 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-02-9 HCAPLUS
CN Carbamic acid,
[(1S)-1-[(3-[(5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-03-0 HCAPLUS
CN Benzenepropanamide, α-amino-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N-pentyl-, (αS)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-05-2 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-10-9 HCAPLUS
CN Benzaldehyde,
4-[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-13-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2,4-dimethoxyphenyl)methyl]-5-[[4-[(4-phenylmethyl)-1-piperazinyl)methyl]phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612531-22-3 HCAPLUS
CN Carbamic acid, [[4-[(5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 612531-23-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)phenyl)methyl]-2-[(2,4-dimethoxyphenyl)methyl]-, 1,1-dioxide, monohydrochloride (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-24-5 HCAPLUS
CN Carbamic acid,
[2-[[[4-[[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

RN 612531-30-3 HCAPLUS
CN Benzoic acid,
4-[[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A


RN 612531-31-4 HCAPLUS
CN Benzoic acid,
4-[[[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 612531-32-5 HCAPLUS
CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-[[[1,1-dimethylethoxy]carbonyl]phenyl)methyl ester (9CI) (CA INDEX NAME)







RN 612531-34-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(2,4-dimethoxyphenyl)methyl]-5-(2,4-dinitrophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612531-35-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-2-[(2,4-dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612531-36-9 HCAPLUS
CN Benzoic acid, 3-[5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, methyl ester (9CI) (CA INDEX NAME)



RN 612531-61-0 HCAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-(phenylmethoxy)phenyl]methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)




RN 612531-63-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612531-64-3 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-65-4 HCAPLUS
CN D-Phenylalanine, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612531-66-5 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 612531-67-6 HCAPLUS
CN Carbamic acid,
[(1S)-1-[[[4-[[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-68-7 HCAPLUS
CN Benzenepropanamide, α-amino-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-69-8 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-72-3 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612531-73-4 HCAPLUS
CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-N-[2-[4-[2-[(1,1-dimethylethoxy)-2-oxoethyl]phenyl]ethyl]-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 612531-70-1 HCAPLUS
CN L-Phenylalanine, 4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612531-71-2 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanyl-4-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612531-75-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-iodophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612531-76-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(3-iodophenyl)-2-[(4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-77-8 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612531-78-9 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612534-94-8 HCAPLUS
CN L-Phenylalanine, N-acetyl-L-phenylalanine-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 612527-93-2P 612530-46-8P 612530-49-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(invention compound; preparation of thiazolidinetriones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)
RN 612527-93-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612531-79-0 HCAPLUS
CN Carbanic acid, [(1S)-1-[[[3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]phenyl]methyl]-2-oxo-2-(pentylamino)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612531-80-3 HCAPLUS
CN Benzenepropanamide, α-amino-3-[5-[(4-methoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]-N-pentyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-46-8 HCAPLUS
CN Benzoic acid, 3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)



RN 612530-49-1 HCAPLUS
CN Benzenecetic acid, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-, methyl ester (9CI) (CA INDEX NAME)



IT 612527-84-1P 612527-85-2P 612527-86-3P
612527-87-4P 612527-88-5P 612527-89-6P
612527-90-9P 612527-91-0P 612527-92-1P
612527-94-3P 612527-96-5P 612527-97-6P
612527-98-7P 612527-99-8P 612528-00-4P
612528-01-5P 612528-02-6P 612528-07-1P
612528-08-2P 612528-09-3P 612528-10-6P
612528-11-7P 612528-12-8P 612528-13-9P
612528-14-0P 612528-15-1P 612528-16-2P

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

612520-17-3P 612520-18-4P 612520-19-5P
 612520-20-8P 612520-21-9P 612520-22-0P
 612520-23-1P 612520-25-3P 612520-26-4P
 612520-27-5P 612520-28-6P 612520-29-7P
 612520-32-2P 612520-33-3P 612520-34-4P
 612520-35-5P 612520-36-6P 612520-37-7P
 612520-38-8P 612520-39-9P 612520-40-2P
 612520-41-3P 612520-42-4P 612520-43-5P
 612520-44-6P 612520-45-7P 612520-46-8P
 612520-47-9P 612520-48-0P 612520-49-1P
 612520-50-4P 612520-51-5P 612520-52-6P
 612520-53-7P 612520-54-8P 612520-55-9P
 612520-56-0P 612520-57-1P 612520-58-2P
 612520-59-3P 612520-60-6P 612520-61-7P
 612520-62-8P 612520-63-9P 612520-64-0P
 612520-65-1P 612520-66-2P 612520-67-3P
 612520-68-4P 612520-69-5P 612520-70-8P
 612520-71-9P 612520-72-0P 612520-73-1P
 612520-74-2P 612520-75-3P 612520-76-4P
 612520-77-5P 612520-78-6P 612520-79-7P
 612520-80-0P 612520-82-2P 612520-83-3P
 612520-84-4P 612520-85-5P 612520-86-6P
 612520-87-7P 612520-88-8P 612520-89-9P
 612520-97-9P 612520-98-0P 612520-99-1P
 612529-00-7P 612529-01-8P 612529-02-9P
 612529-03-0P 612529-04-1P 612529-05-2P
 612529-06-3P 612529-07-4P 612529-08-5P
 612529-09-6P 612529-10-9P 612529-11-0P
 612529-12-1P 612529-13-2P 612529-14-3P
 612529-15-4P 612529-16-5P 612529-17-6P
 612529-18-7P 612529-19-8P 612529-20-1P
 612529-21-2P 612529-22-3P 612529-23-4P
 612529-24-5P 612529-26-7P 612529-27-8P
 612529-28-9P 612529-29-0P 612529-30-3P
 612529-31-4P 612529-32-5P 612529-33-6P
 612529-36-9P 612529-37-0P 612529-38-1P
 612529-39-2P 612529-40-5P 612529-41-6P
 612529-42-7P 612529-43-8P 612529-44-9P
 612529-45-0P 612529-46-1P 612529-47-2P
 612529-48-3P 612529-49-4P 612529-50-7P
 612529-51-8P 612529-52-9P 612529-53-0P
 612529-54-1P 612529-56-3P 612529-57-4P
 612529-58-5P 612529-59-6P 612529-60-9P
 612529-61-0P 612529-62-1P 612529-63-2P
 612529-64-3P 612529-65-4P 612529-67-6P
 612529-68-7P 612529-69-8P 612529-70-1P
 612529-73-4P 612529-74-5P 612529-75-6P
 612529-76-7P 612529-77-8P 612529-78-9P
 612529-79-0P 612529-80-3P 612529-81-4P
 612529-82-5P 612529-83-6P 612529-84-7P
 612529-85-8P 612529-86-9P 612529-87-0P
 612529-90-5P 612529-91-6P 612529-93-8P
 612529-94-9P 612529-95-0P 612529-96-1P
 612529-97-2P 612529-98-3P 612529-99-4P
 612530-01-5P 612530-02-6P 612530-03-7P
 612530-04-8P 612530-05-9P 612530-06-0P

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


612530-08-2P 612530-09-3P 612530-10-6P
 612530-11-7P 612530-12-8P 612530-13-9P
 612530-16-2P 612530-17-3P 612530-18-4P
 612530-19-5P 612530-20-8P 612530-21-9P
 612530-22-0P 612530-23-1P 612530-25-3P
 612530-26-4P 612530-27-5P 612530-28-6P
 612530-29-7P 612530-30-0P 612530-31-1P
 612530-32-2P 612530-33-3P 612530-34-4P
 612530-35-5P 612530-36-6P 612530-37-7P
 612530-38-8P 612530-39-9P 612530-40-2P
 612530-41-3P 612530-42-4P 612530-43-5P
 612530-44-6P 612530-45-7P 612530-47-9P
 612530-48-0P 612530-50-4P 612530-51-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(invention compd.; prepn. of thiazolidinetriones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)

RN 612527-84-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 5-[(1-naphthalenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612527-85-2 HCAPLUS

CN Acetamide, N-[[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612527-86-3 HCAPLUS

CN Carbamic acid, [[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 612527-87-4 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612527-88-5 HCAPLUS


CN Acetamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612527-89-6 HCAPLUS

CN Carbamic acid, [[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 612527-90-9 HCAPLUS


CN Benzenepropanamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612527-91-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-iodophenyl)methyl]-, 1,1-dioxide (9CI)
(CA INDEX NAME)




RN 612527-92-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-nitrophenyl)methyl]-, 1,1-dioxide (9CI)
(CA INDEX NAME)



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612527-98-7 HCAPLUS
CN Urea,
N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N'-
propyl- (9CI) (CA INDEX NAME)




RN 612527-99-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612527-94-3 HCAPLUS
CN Acetamide, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 612527-96-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-aminophenyl)methyl]-, 1,1-dioxide (9CI)
(CA INDEX NAME)




RN 612527-97-6 HCAPLUS
CN Butanamide, N-[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-00-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-
(9CI) (CA INDEX NAME)




RN 612528-01-5 HCAPLUS
CN Benzoic acid, 2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-
(9CI) (CA INDEX NAME)




RN 612528-02-6 HCAPLUS

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-methylphenyl)methyl]-, 1,1-dioxide
 (9CI) (CA INDEX NAME)




RN 612528-07-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-, 1,1-dioxide
 (9CI) (CA INDEX NAME)




RN 612528-08-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-amino-2-bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-09-3 HCAPLUS
 CN Acetamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 612528-10-6 HCAPLUS
 CN Methanesulfonamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-11-7 HCAPLUS
 CN Methanesulfonamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612528-12-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methylphenyl)methyl]-, 1,1-dioxide
 (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-13-9 HCAPLUS
 CN Benzenesulfonamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 612528-14-0 HCAPLUS
 CN Benzenesulfonamide, N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-15-1 HCAPLUS

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzenacetamide, α -amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-16-2 HCAPLUS
 CN Benzenacetamide,
 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-
 N-propyl- α -[(trifluoroacetyl)amino]- (9CI) (CA INDEX NAME)



RN 612528-17-3 HCAPLUS
 CN Benzenacetamide,
 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-
 α -[(methylsulfonyl)amino]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-20-8 HCAPLUS
 CN Benzenepropanamide, α -amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-21-9 HCAPLUS
 CN Phenylalanine, N-acetyl-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-18-4 HCAPLUS
 CN Benzenepropanamide, α -(acetylamino)-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 612528-19-5 HCAPLUS
 CN Propanedioic acid, (acetylamino)[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl-, diethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-22-0 HCAPLUS
 CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo- α -phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-23-1 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-one, 5-(2-phenylethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-25-3 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-one, 5-[2-(3,4-dimethoxyphenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-26-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(2-chlorophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-27-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(4-aminophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-32-2 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo- α -(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-33-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[2-(3-aminophenyl)ethyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-34-4 HCAPLUS

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-28-6 HCAPLUS
CN Acetamide, N-[4-[2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)ethyl]phenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 612528-29-7 HCAPLUS
CN Butanamide, N-[4-[2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)ethyl]phenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)-1-naphthalenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612528-35-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)-1-naphthalenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-36-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)-1-naphthalenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-37-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(aminomethyl)-1-naphthalenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-38-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[[4-(2-methylpropoxy)-7-quinolinyl]methyl]-,
1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-39-9 HCAPLUS
CN Glycine, N-[2-(butylamino)-2-oxo-1-phenylethyl]-N-[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 612528-40-2 HCAPLUS
CN Glycine, N-[2-(butylamino)-1-(4-ethylphenyl)-2-oxoethyl]-N-[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-42-4 HCAPLUS
CN Glycine, N-[2-(butylamino)-1-(4-methoxyphenyl)-2-oxoethyl]-N-[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 612528-41-3 HCAPLUS
CN Glycine, N-[2-(butylamino)-2-oxo-1-(3-phenoxyphenyl)ethyl]-N-[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612528-43-5 HCAPLUS
CN Glycine, N-[1-(2-bromophenyl)-2-(butylamino)-2-oxoethyl]-N-[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612528-44-6 HCAPLUS
CN Glycine, N-[2-(butylamino)-1-(2-naphthalenyl)-2-oxoethyl]-N-[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-45-7 HCAPLUS
CN Glycine, N-[2-(butylamino)-1-(4-chlorophenyl)-2-oxoethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Double bond geometry as shown.



RN 612528-48-0 HCAPLUS
CN Glycine,
N-[1-[(butylamino)carbonyl]-3-phenylpropyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)



RN 612528-49-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(methylsulfonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612528-46-8 HCAPLUS
CN Glycine, N-[2-(butylamino)-2-oxo-1-[3-(phenylmethoxy)phenyl]ethyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612528-47-9 HCAPLUS
CN Glycine,
N-[(2E)-1-[(butylamino)carbonyl]-3-phenyl-2-propenyl]-N-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612528-50-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-chlorophenyl)methyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-51-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-butylphenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-52-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(hydroxymethyl)phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612528-53-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [2-(2-phenylethyl)phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-54-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [1,1'-biphenyl]-2-ylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-55-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(difluoromethoxy)phenyl)methyl ester (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-56-0 HCAPLUS
CN 2-Thiophenylacetic acid,
5-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- α,α -difluoro- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-59-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[[4-[(3-methylbutylthio)methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




Me₂CH-CH₂-CH₂-S-CH₂

RN 612528-60-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-ethylbutyl ester (9CI) (CA INDEX NAME)




RN 612528-61-7 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclobutylmethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-57-1 HCAPLUS
CN Acetic acid, [[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]sulfonyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 612528-58-2 HCAPLUS
CN Acetic acid, [[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]thio-, ethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-62-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclopentylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-63-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpentyl ester (9CI) (CA INDEX NAME)




RN 612528-64-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,4,4-trimethylpentyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-65-1 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclohexylmethyl ester (9CI) (CA INDEX NAME)




RN 612528-66-2 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 1,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-69-5 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(methylthio)ethyl ester (9CI) (CA INDEX NAME)




RN 612528-70-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-[(carboxymethyl)thio]ethyl ester (9CI) (CA INDEX NAME)




RN 612528-71-9 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (5-nitro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-67-3 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, cyclopentyl ester (9CI) (CA INDEX NAME)




RN 612528-68-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylbutyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-72-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-pyridinylmethyl ester (9CI) (CA INDEX NAME)



RN 612528-73-1 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(hydroxymethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612528-74-2 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-
 [3-(methylsulfonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612528-75-3 HCAPLUS
 CN Benzoic acid, 4-[(4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]butyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612528-76-4 HCAPLUS
 CN Benzoic acid, 4-[(4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]propyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612528-77-5 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-
 [5-[(dimethylamino)methyl]-2-furanyl]methyl ester (9CI) (CA INDEX NAME)




RN 612528-78-6 HCAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-pentyl- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 612528-79-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(1H-indol-5-ylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-80-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3,4,5-trimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-82-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(phenylmethyl)-1-piperazinyl]methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-85-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2-naphthalenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-86-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(4-methyl-1-oxopentyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612528-87-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(2-fluorophenoxy)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-83-3 HCAPLUS
CN Benzeneacetic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612528-84-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-benzoylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612528-88-8 HCAPLUS
CN Benzoic acid, 3-[2-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

PAGE 1-A




HO₂C

PAGE 2-A


RN 612528-89-9 HCAPLUS
CN 2-[1H]-Quinolinone, 6-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-1-(3-methylbutyl)- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612528-97-9 HCAPLUS
CN Acetamide, 2-amino-N-[[4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 612528-98-0 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-carboxyphenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612528-99-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-phenoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-00-7 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 612529-01-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(hydroxymethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-02-9 HCAPLUS
CN Benzoic acid, 2-amino-4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-03-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-04-1 HCAPLUS
CN Benzoic acid, 2-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-5-nitro- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-05-2 HCAPLUS
CN Benzoic acid, 5-amino-2-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-06-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-10-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-phenylpropyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-11-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-(4-butoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-12-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-07-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-(2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-08-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-methyl-2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-09-6 HCAPLUS


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-13-2 HCAPLUS
CN Benzoic acid, 3-amino-4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-14-3 HCAPLUS
CN Benzenebutanoic acid, 5-amino-2-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-15-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-methyl-3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-16-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methyl-3-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-17-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(5-methyl-2-nitrophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-22-3 HCAPLUS
 CN Acetic acid, [(2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 612529-23-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-24-5 HCAPLUS
 CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 612529-18-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-aminophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-19-8 HCAPLUS
 CN 1H-Indole-1,3(2H)-dione, 2-[(4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-20-1 HCAPLUS
 CN 1H-Indole-1,3(2H)-dione, 2-[(3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-21-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5,5'-[1,4-phenylenebis(methylene)]bis-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-26-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-fluoro-2-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-27-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-(hydroxymethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-28-9 HCAPLUS

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-amino-5-(hydroxymethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-29-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-amino-4-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-30-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-amino-3-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-36-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3,4-dimethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-37-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-amino-5-hydroxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-31-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-amino-2-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-32-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-amino-5-methylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-33-6 HCAPLUS
 CN Acetamide, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 612529-38-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(3,5-dimethylphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-39-2 HCAPLUS
 CN L-Phenylalanine, N-[[[3-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612529-40-5 HCAPLUS
 CN L-Phenylalanine, N-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612529-41-6 HCAPLUS
 CN Benzoic acid, 2-amino-5-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-42-7 HCAPLUS
CN Benzoic acid,
2-(acetylamino)-4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-43-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-(phenylmethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 612529-46-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-(bromophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-47-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5,5'-[[1,1'-biphenyl]-2,2'-diylbis(methylene)]bis-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)




RN 612529-48-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-((ethylamino)methyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-49-4 HCAPLUS


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-44-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,4-bis(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-45-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,4,6-trifluorophenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612529-46-1 HCAPLUS
CN Benzoic acid,
2-(acetylamino)-4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)




RN 612529-50-7 HCAPLUS
CN Benzoic acid, 2-amino-4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 612529-51-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[[2-(phenylethyl)amino]methyl]phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-52-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-[(diethylamino)methyl]phenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-53-0 HCAPLUS
CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-54-1 HCAPLUS
CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 612529-56-3 HCAPLUS
CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-[2-(3-(trifluoromethyl)phenyl)ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612529-57-4 HCAPLUS
CN Benamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(3-methylbutyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-58-5 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-α-(phenylmethyl)-, 1,1-dioxide, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612529-59-6 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-oxo-α-(phenylmethyl)-, 1,1-dioxide, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 612529-60-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-61-0 HCAPLUS
CN Acetic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]- (9CI) (CA INDEX NAME)




RN 612529-62-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-63-2 HCAPLUS
CN Benzoic acid, 2-amino-4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-64-3 HCAPLUS
CN Acetic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-65-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 4-(carboxymethoxy)phenyl methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612529-67-6 HCAPLUS
CN Benzoic acid, 4-[2-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methylaminoethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612529-68-7 HCAPLUS
CN Acetic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxy]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-69-8 HCAPLUS
CN Acetic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenoxyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 612529-70-1 HCAPLUS
CN Benzamide, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-73-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, methyl ester (9CI) (CA INDEX NAME)




RN 612529-74-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-75-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-3-nitro-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612529-76-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-ethoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-77-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612529-78-9 HCAPLUS
CN Benzeneacetic acid, 4-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612529-79-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-phenylethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-80-3 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(phenylamino)ethyl ester (9CI) (CA INDEX NAME)



RN 612529-81-4 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-methoxyphenyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612529-82-5 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenylmethyl ester (9CI) (CA INDEX NAME)




RN 612529-83-6 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-84-7 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-methoxy-2,2-dimethyl-3-oxopropyl ester (9CI) (CA INDEX NAME)




RN 612529-85-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2,2,4-trimethylpentyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-86-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-(dimethylamino)-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)



RN 612529-87-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [(3aR,4S,5R,6aS)-5-(benzoyloxy)hexahydro-2-oxo-2H-cyclopenta[b]furan-4-yl)methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-90-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-methyl-4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612529-91-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (3-chloro-4-methylphenyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612529-93-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 6-ethoxy-6-oxohexyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612529-94-9 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-chlorophenyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612529-95-0 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(3-methylphenyl)ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 612529-96-1 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
2-[3-(trifluoromethyl)phenyl]ethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612529-97-2 HCAPLUS
CN D-Phenylalanine, N-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612529-98-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(phenylmethyl)amino]methyl]phenyl]methyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612529-99-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-methylphenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-01-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(methoxycarbonyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-02-6 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-cyclohexyl-2-methylpropyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-03-7 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-phenoxypentyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 612530-04-8 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 2-A



RN 612530-05-9 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [3-(trifluoromethyl)phenyl]methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612530-06-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-(4-carboxyphenyl)ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-08-2 HCAPLUS
 CN Benzoic acid, 3-[[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A




RN 612530-09-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[[[4-[(2-methylpropyl)amino]methyl]phenyl]me
 thyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




RN 612530-10-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[[[4-[(2,2-dimethylpropyl)amino]methyl]phenyl]
 methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



Me3C-CH2-NH-CH2

RN 612530-11-7 HCAPLUS
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
 1-naphthalenylmethyl ester (9CI) (CA INDEX NAME)


PAGE 2-A




RN 612530-12-8 HCAPLUS
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-,
 (4-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-13-9 HCAPLUS
 CN Benzenecetic acid, 4-[2-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]amino]ethyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-16-2 HCAPLUS
 CN Benzoic acid, 4-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]- (3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 2-A




RN 612530-17-3 HCAPLUS
 CN Benzoic acid, 4-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-[(carboxymethyl)amino]-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-18-4 HCAPLUS

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 2-Thiophenecarboxylic acid, 5-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 612530-19-5 HCAPLUS
 CN Benzoic acid, 4-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [1,1'-biphenyl]-4-ylmethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 612530-20-8 HCAPLUS

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-(acetylamino)phenyl)methyl ester (9CI) (CA INDEX NAME)




PAGE 1-A




PAGE 2-A

RN 612530-21-9 HCAPLUS
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [2-(phenylmethyl)phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-22-0 HCAPLUS
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (2-methylphenyl)methyl ester (9CI) (CA INDEX NAME)



RN 612530-23-1 HCAPLUS
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (2-methylphenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (2-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




PAGE 1-A



PAGE 2-A

RN 612530-25-3 HCAPLUS
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)



PAGE 1-A




PAGE 2-A


RN 612530-26-4 HCAPLUS
 CN Benzoic acid, 4-[[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-methyl-3-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A




RN 612530-27-5 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (4-fluoro-2-(trifluoromethyl)phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A



RN 612530-28-6 HCAPLUS
 CN Benzoic acid, 4-[(5-[(2,4-dimethoxyphenyl)methyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


PAGE 1-A



PAGE 1-B

OMe


RN 612530-29-7 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)phenyl)methyl ester (9CI) (CA INDEX NAME)



RN 612530-30-0 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, (5-methyl-2-nitrophenyl)methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

PAGE 1-A




PAGE 2-A

Me


RN 612530-31-1 HCAPLUS
 CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-methylphenyl ester (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-32-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 3-[(carboxymethyl)methylamino]-2,2-dimethylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-33-3 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, phenyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-37-7 HCAPLUS
CN 1-Piperazineacetic acid, 4-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]- (9CI) (CA INDEX NAME)




RN 612530-38-8 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-naphthalenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-34-4 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-[(2-methylpropyl)amino]carbonyl]-2-thienylmethyl ester (9CI) (CA INDEX NAME)




RN 612530-35-5 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, 2-naphthalenylmethyl ester (9CI) (CA INDEX NAME)




RN 612530-36-6 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-N,N-bis(2-methylpropyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-39-9 HCAPLUS
CN 2-Thiophenecarboxylic acid, 5-[[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]oxy]methyl]-, 2-methylpropyl ester (9CI) (CA INDEX NAME)




RN 612530-40-2 HCAPLUS
CN Benzoic acid, 4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-(aminocarbonyl)-2-thienyl]methyl ester (9CI) (CA INDEX NAME)




RN 612530-41-3 HCAPLUS
CN Piperazine, 1-[4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]benzoyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-42-4 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-(1-oxo-3-phenylpropyl)-2-thienyl)methyl ester (9CI) (CA INDEX NAME)




RN 612530-43-5 HCAPLUS
CN Benzoic acid, 4-[[1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]-, [5-[[[(phenylmethyl)amino]carbonyl]-2-thienyl)methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-48-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[4-(aminomethyl)phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-50-4 HCAPLUS
CN Benzenecetic acid, 2-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)




RN 612530-51-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-dimethoxyphenyl)-, 1,1-dioxide, potassium salt (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-44-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-45-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 612530-47-9 HCAPLUS
CN Benzoic acid, 3-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




● K

IT 612530-52-6P 612530-53-7P 612530-54-8P
612530-55-9P 612530-56-0P 612530-57-1P
612530-58-2P 612530-59-3P 612530-60-6P
612530-61-7P 612530-62-8P 612530-63-9P
612530-64-0P 612530-65-1P 612530-66-2P
612530-67-3P 612530-68-4P 612530-69-5P
612530-71-9P 612530-72-0P 612530-73-1P
612530-74-2P 612530-75-3P 612530-77-5P
612530-78-6P 612534-93-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(invention compound; preparation of thiazolidinetriones as protein tyrosine phosphatase 1b and T-cell protein tyrosine phosphatase inhibitors to mitigate insulin resistance in the treatment of diabetes or atherosclerosis)
RN 612530-52-6 HCAPLUS
CN Acetamide, 2-[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-methylphenoxy]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 612530-53-7 HCAPLUS
CN 1H-1,4-Benzodiazepine-2,5-dione, 3-[[4-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-3-hydroxyphenyl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 612530-54-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(4-iodophenyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-55-9 HCAPLUS
 CN L-Phenylalanine, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))- , phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612530-56-0 HCAPLUS
 CN L-Phenylalanine, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 612530-60-6 HCAPLUS
 CN L-Phenylalaninamide, N-benzoyl-O-(dicarboxymethyl)-L-tyrosyl-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-61-7 HCAPLUS
 CN Benzenepropanamide, α-([1,1'-biphenyl]-4-ylsulfonyl)amino]-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))-N-pentyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-57-1 HCAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-58-2 HCAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 612530-59-3 HCAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-N-[2-((4-(carboxymethyl)phenyl)ethyl)-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))- (9CI) (CA INDEX NAME)


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-62-8 HCAPLUS
 CN Benzenepropanamide, α-([1,1'-biphenyl]-4-ylsulfonyl)amino]-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))-N-(4-phenylbutyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-63-9 HCAPLUS
 CN Benzenepropanamide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))-N-pentyl-α-([phenylsulfonyl]amino)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-64-0 HCAPLUS
 CN Benzenepropanamide, 4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl))-N-(4-phenylbutyl)-α-([phenylsulfonyl]amino)-, (αS)- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 612530-65-1 HCAPLUS
CN Benzenepropanamide,
4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(3,3-diphenylpropyl)-α-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-66-2 HCAPLUS
CN L-Phenylalaninamide,
N-acetyl-L-phenylalanyl-3-bromo-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 1,2,5-Thiadiazolidin-3-one, 5-((4-aminophenyl)methyl)-, 1,1-dioxide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612527-96-5
CMF C9 H11 N3 O3 S



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 612530-72-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-((1-ethyl-2-methyl-1H-benzimidazol-5-yl)methyl)-, 1,1-dioxide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 612528-35-5
CMF C13 H16 N4 O3 S




L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 612530-67-3 HCAPLUS


CN Benzenepropanamide, 3-bromo-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-(4-phenylbutyl)-α-[(phenylsulfonyl)amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 612530-68-4 HCAPLUS
CN L-Phenylalaninamide,
N-acetyl-L-phenylalanyl-3-bromo-4-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 612530-69-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 612530-71-9 HCAPLUS

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 612530-73-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-[(Z)-(3-oxo-2(3H)-benzofuranylidene)methyl]phenyl]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 612530-74-2 HCAPLUS
CN Ethanedione, [4-[(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]phenyl- (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 612530-75-3 HCAPLUS
 CN 9,10-Anthracenedione, 2-((1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl)- (9CI) (CA INDEX NAME)



RN 612530-77-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-phenyl-, 1,1-dioxide, sodium salt (9CI)
 (CA INDEX NAME)




● Na
 RN 612530-78-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-(2,4-diaminophenyl)-, 1,1-dioxide, trifluoroacetate (9CI) (CA INDEX NAME)

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 15 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 1
 CRN 612530-45-7
 CMF C8 H10 N4 O3 S




CM 2
 CRN 76-05-1
 CMF C2 H F3 O2




RN 612534-93-7 HCAPLUS
 CN L-Phenylalaninamide, N-acetyl-L-phenylalanyl-3-(1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 31 Jul 2002
 ACCESSION NUMBER: 2002:565367 HCAPLUS
 DOCUMENT NUMBER: 137:232603
 TITLE: Efficient Solid-Phase Synthesis of Sulfahydantoins
 AUTHOR(S): Tremblay, Melanie; Voyer, Normand; Boujabi, Sihem; Dewynter, Georges F.
 CORPORATE SOURCE: Centre de Recherche sur la Fonction, la Structure et l'Ingénierie des Protéines, Département de Chimie, Faculté des Sciences et de Génie, Université Laval, Québec, QC, G1K 7P4, Can.
 SOURCE: Journal of Combinatorial Chemistry (2002), 4(5), 429-435
 CODEN: JCCHFF; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 137:232603
 GI



AB A novel solid-phase strategy allows the efficient preparation of traceless sulfahydantoins. A total of 28 derivs., with crude purity generally higher than 85%, were prepared by parallel synthesis. Through reductive alkylations, Mitsunobu reactions, and sulfamoylation reactions on oxime resin, the synthetic strategy affords sulfahydantoin derivs. selectively substituted at N2, e.g., I, N5, e.g., II, and N2, N5, e.g., III, positions, although yields of disubstituted compds. are lower. The mild reaction conditions involved, lead to sulfahydantoins without racemization.


10510026rtr

L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IT 459831-33-5P 459831-34-6P 459831-35-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (stereoselective preparation of N2,N5-disubstituted sulfahydantoins via

reductive alkylation of resin-bound phenylalanine with substituted benzaldehydes and subsequent sulfamoylation, Mitsunobu reaction, resin-cleavage, and cyclization)


RN 459831-33-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[[4-methylphenyl)methyl]-4-(phenylmethyl)-2-
 (2-propenyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-34-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-butyl-5-[[4-methylphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-35-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[[4-methylphenyl)methyl]-4-(phenylmethyl)-2-
 (3-phenylpropyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 16 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IT 283587-14-4P 459831-30-2P 459831-31-3P
 459831-32-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (stereoselective preparation of N5-substituted sulfahydantoins via

reductive alkylation of resin-bound phenylalanine with substituted benzaldehydes and subsequent sulfamoylation, resin-cleavage, and cyclization)


RN 283587-14-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one,
 5-[[4-methoxyphenyl)methyl]-4-(phenylmethyl)-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 459831-30-2 HCAPLUS
 CN Benzonitrile, 4-[[[(3S)-1,1-dioxido-4-oxo-3-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459831-31-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-nitrophenyl)methyl]-4-(phenylmethyl)-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 459831-32-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-methylphenyl)methyl]-4-(phenylmethyl)-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 09 OCT 2001

ACCESSION NUMBER: 2001:735235 HCAPLUS

DOCUMENT NUMBER: 136:85785

TITLE: A one-step protocol for the N-chloromethylation of heterocyclic imides

AUTHOR(S): He, Shu; Yu, Hongyi; Fu, Qinghong; Kuang, Rongze; Epp,

CORPORATE SOURCE: Jeff B. Groutas, William C. Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA

SOURCE: Synthetic Communications (2001), 31(20), 3055-3058

CODEN: SYNCAV; ISSN: 0039-7911

PUBLISHER: Marcel Dekker, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 136:85785

AB A convenient single step method. for the N-chloromethylation of heterocyclic imides using a mixture of formaldehyde sodium bisulfite adduct

and thionyl chloride is described. For example, the chloromethylation of 5-Butyl-3-propyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide gave.


IT 387859-83-8 387859-86-1

RL: RCT (Reactant); RACT (Reactant or reagent)


(preparation of 2-(chloromethyl)-1,2,5-thiadiazolidin-3-one by chloromethylation of 1,2,5-thiadiazolidin-3-one using thionyl chloride and formaldehyde sodium bisulfite adduct)

RN 387859-83-8 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-,
 1,1-dioxide (9CI) (CA INDEX NAME)




RN 387859-86-1 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 4-oxo-2-(phenylmethyl)-,
 phenylmethyl
 ester, 1,1-dioxide (9CI) (CA INDEX NAME)




IT 300553-85-9P 387859-88-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of 2-(chloromethyl)-1,2,5-thiadiazolidin-3-one by

L4 ANSWER 17 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 chloromethylation of 1,2,5-thiadiazolidin-3-one using thionyl chloride
 and formaldehyde sodium bisulfite adduct)
 RN 300553-85-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 387859-88-3 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 5-(chloromethyl)-4-oxo-2-(phenylmethyl)-, phenylmethyl ester, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 13 Jun 2001
 ACCESSION NUMBER: 2001:426029 HCAPLUS
 DOCUMENT NUMBER: 135:282665
 TITLE: Inhibition of serine proteases by functionalized sulfonamides coupled to the
 1,2,5-thiadiazolidin-3-one
 1,1 dioxide scaffold
 AUTHOR(S): Groutas, W. C.; He, S.; Kuang, R.; Ruan, S.; Tu, J.; Chan, H.-K.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2001), 9(6), 1543-1548
 CODEN: BMCECP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A challenge associated with drug design is the development of selective inhibitors of proteases (serine or cysteine) that exhibit the same primary substrate specificity, i.e., show a preference for the same P1 residue. While these proteases have similar active sites, nevertheless there are subtle differences in their S and S' subsites which can be exploited. We describe herein for the first time the use of functionalized sulfonamides as a design and diversity element which, when coupled to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold yields potent, time-dependent inhibitors of the serine proteases human leukocyte elastase (HLE), proteinase 3 (PR 3) and cathepsin G (Cat G). Our preliminary findings suggest that (a) appending to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold recognition and diversity elements that interact with both the S and S' subsites of a target protease may result in optimal enzyme selectivity and potency and, (b) functionalized sulfonamides constitute a powerful design and diversity element with low intrinsic chemical reactivity and potentially wide applicability. Potent inhibitors of human leukocyte elastase, proteinase 3 and cathepsin G that interact with the S and S' subsites are realized by using functional sulfonamides coupled to the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold.
 IT 220869-05-6P 220869-07-8P 220869-14-7P
 220869-16-9P 365216-39-3P 365216-41-7P
 365216-42-8P 365216-43-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Inhibition of serine proteases by functionalized sulfonamides coupled to 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold)
 RN 220869-05-6 HCAPLUS
 CN Carbamic acid, [(1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl](phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-07-8 HCAPLUS
 CN Carbamic acid, [(1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)-, butyl ester (9CI) (CA INDEX NAME)




RN 220869-14-7 HCAPLUS
 CN Carbamic acid, [(2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 220869-16-9 HCAPLUS
 CN Carbamic acid, [(2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 365216-39-3 HCAPLUS
 CN Benzamide,
 N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 365216-41-7 HCAPLUS
 CN Glycine,
 N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 365216-42-8 HCAPLUS


10510026rtr

L4 ANSWER 18 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, butyl ester (9CI) (CA INDEX NAME)



RN 365216-43-9 HCAPLUS
 CN L-Phenylalanine, N-[[[(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 24 Apr 2001
 ACCESSION NUMBER: 2001:288468 HCAPLUS
 DOCUMENT NUMBER: 135:76831
 TITLE: Synthesis of a Sulfahydantoin Library
 AUTHOR(S): Albericio, Fernando; Bryman, Lois M.; Garcia, Javier; Michelotti, Enrique L.; Nicolas, Ernesto; Tice, Colin M.
 CORPORATE SOURCE: Department of Organic Chemistry, University of Barcelona, Barcelona, 08028, Spain
 SOURCE: Journal of Combinatorial Chemistry (2001), 3(3), 290-300
 CODEN: JCCHFF; ISSN: 1520-4766
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:76831
 AB A five-step solid-phase synthesis of sulfahydantoins from α -amino acids and aldehydes was developed. The synthetic method allows the use of


hindered amino acids, including Val, Phe, and Aib, and use of aromatic aldehydes substituted with electron-withdrawing and -donating groups. Some limitations were encountered with amino acids with reactive side chains. A small but diverse library of compds. was produced for biol. testing.

IT 283587-14-4P 283587-15-5P 283587-16-6P
 283587-18-8P 283587-19-9P 283587-21-3P
 283587-22-4P 283587-24-6P 346697-35-6P
 346697-36-7P 346697-37-8P 346697-38-9P
 346697-39-0P 346697-40-3P 346697-41-4P
 346697-42-5P 346697-43-6P 346697-44-7P
 346697-45-8P 346697-46-9P 346697-47-0P
 346697-48-1P 346697-49-2P 346697-50-5P
 346697-51-6P 346697-53-8P 346697-54-9P
 346697-55-0P 346697-56-1P 346697-57-2P
 346697-58-3P 346697-59-4P 346697-60-7P
 346697-62-9P 346697-63-0P 346697-64-1P
 346697-65-2P 346697-69-6P 346697-71-0P
 346697-72-1P 346697-73-2P 346697-74-3P
 346697-75-4P 346697-76-5P 346697-77-6P
 346697-78-8P 346697-80-1P 346697-81-2P
 346697-82-3P 346697-83-4P 346697-84-5P
 346697-85-6P 346697-86-7P 346697-87-8P
 346697-88-9P 346697-89-0P 346697-90-3P
 346697-91-4P 346697-92-5P 346697-93-6P
 346697-97-0P 346697-98-1P 346697-99-2P
 346698-00-8P 346698-03-1P 346698-04-2P
 346698-05-3P 346698-06-4P 346698-12-2P
 346698-14-4P

RL: SEN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of a sulfahydantoin library from amino acids, and aldehydes)


RN 283587-14-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-methoxyphenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Absolute stereochemistry.




RN 283587-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,4-dichlorophenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-16-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(1-methylethyl)-5-[[3-methylphenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-18-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(1-methylethyl)-5-[[4-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 283587-19-9 HCAPLUS


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-21-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-chlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-22-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[4-methoxyphenyl)methyl]-4,4-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 283587-24-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-chlorophenyl)methyl]-4-(2-methylthio)ethyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-35-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(3-chlorophenyl)methyl]-4-(1-methylethyl)-,
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-36-7 HCAPLUS
CN Acetamide, N-[4-[[[(3S)-3-(1-methylethyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-37-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
4-(1-methylethyl)-5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-42-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-43-6 HCAPLUS
CN Acetamide, N-[4-[[[(3S)-1,1-dioxido-4-oxo-3-[[4-(phenylmethoxy)phenyl]methyl]-1,2,5-thiadiazolidin-2-yl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-44-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-38-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-39-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-40-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-41-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-45-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-46-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-47-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-48-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-49-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-50-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chloro-5-(trifluoromethyl)phenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-55-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-56-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chloro-3-nitrophenyl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-57-2 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-58-3 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[[4-(acetylamino)phenyl]methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-51-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-53-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(3-chlorophenyl)methyl]-4-[[phenylmethyl]thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-54-9 HCAPLUS
CN Acetamide, N-[4-[[[(3R)-1,1-dioxido-4-oxo-3-[[phenylmethyl]thio]methyl]-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-59-4 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-chloro-3-nitrophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-60-7 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-62-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-63-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[[2-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-64-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-65-2 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(1-methylethyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-73-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-74-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(methylphenyl)methyl]-4-[[1-(phenylmethyl)-1H-imidazol-4-yl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-75-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[1-(phenylmethyl)-1H-imidazol-4-yl]methyl]-

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-69-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[3-(methylphenyl)methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-71-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[4-(phenylmethoxy)phenyl]methyl]-5-[[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-72-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,3-dihydro-1,4-benzodioxin-6-yl]methyl]-4-[[4-(phenylmethoxy)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
5-[[4-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-76-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[[2,3-dihydro-1,4-benzodioxin-6-yl]methyl]-4-[[1-(phenylmethyl)-1H-imidazol-4-yl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-77-6 HCAPLUS
CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[[3-(methylphenyl)methyl]-4-oxo-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-79-8 HCAPLUS


L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 4-oxo-2-[[4-(trifluoromethyl)phenyl]methyl]-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-80-1 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-oxo-, methyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-81-2 HCAPLUS
 CN Acetamide, N-[4-[[[(3S)-3-[2-(methylthio)ethyl]-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-82-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[2-(methylthio)ethyl]-5-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-86-7 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(2-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-87-8 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(4-chlorophenyl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-88-9 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[(6-nitro-1,3-benzodioxol-5-yl)methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-83-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-chlorophenyl)methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-84-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dimethoxy-3-methylphenyl)methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346697-85-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-[[[(phenylmethyl)thio]methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-89-0 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3-acetic acid, 2-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-4-oxo-, phenylmethyl ester, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346697-90-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(phenylmethoxy)methyl]-5-[[2-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-91-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(phenylmethoxy)methyl]-5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346697-92-5 HCAPLUS
CN Benzoic acid, 4-[[3-(4-(trifluoromethyl)phenyl)methyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-93-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-[(phenylmethoxy)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-97-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[(4-nitrophenyl)methyl]-5-[[2-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 346698-03-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-phenyl-5-[[2-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346698-04-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-phenyl-5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-05-3 HCAPLUS
CN Benzoic acid, 4-[[3-(4-(trifluoromethyl)phenyl)methyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346697-98-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-[[4-(4-nitrophenyl)methyl]-5-[[3-(trifluoromethyl)phenyl]methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346697-99-2 HCAPLUS
CN Benzoic acid, 4-[[3-(4-(trifluoromethyl)phenyl)methyl]-1,1-dioxide-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-00-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-[(4-nitrophenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 19 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 346698-06-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dichlorophenyl)methyl]-4-phenyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 346698-12-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-[(1S)-1-methylpropyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 346698-14-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4-[(1S)-1-methylpropyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

10510026rtr

14 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 22 Dec 2000
ACCESSION NUMBER: 2000:898004 HCAPLUS
DOCUMENT NUMBER: 134:307008
TITLE: 1,2,5-Thiadiazolidin-3-one 1,1 Dioxide: A Powerful
Scaffold for Probing the S' Subsites of
(Chymo)trypsin-Like Serine Proteases
AUTHOR(S): Groutas, William C.; Epp, Jeffrey B.; Kuang, Rongze;
Ruan, Sumei; Chong, Lee S.; Venkataraman, Radhika;
Tu, Juan; He, Shu; Yu, Hongyi; Fu, Qinghong; Li, Yue He;
Truong, Tien M.; Vu, Nga T.
CORPORATE SOURCE: Department of Chemistry, Wichita State University,
Wichita, KS, 67260, USA
SOURCE: Archives of Biochemistry and Biophysics (2001),
385(1), 162-169
CODEN: ABBI44; ISSN: 0003-9861
PUBLISHER: Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold (I) embodies a motif
that allows it to dock to the active site of (chymo)trypsin-like
proteases
In a predictable and substrate-like fashion. Consequently, inhibitors
derived from this heterocyclic scaffold interact with both the S and S'
subsites of an enzyme. Exploitation of binding interactions with both
the S and S' subsites of a target enzyme may lead to compds. with greatly
enhanced enzyme selectivity and inhibitory potency. This preliminary
report describes the use of a series of compds. having the heterocyclic
scaffold linked to various amino acids to probe the S' subsites of human
leukocyte elastase (HLE), proteinase 3 (PR 3), and cathepsin G (Cat G).
For comparative purposes, a series of compds. derived from a related
scaffold, isothiazolidin-3-one 1,1 dioxide (II), was also generated.
Several of the compds. were found to be highly potent and selective
time-dependent inhibitors of HLE, PR 3, and Cat G. (c) 2001 Academic
Press.
IT 334975-66-7P 334975-69-8P 334975-75-6P
334975-81-4P 334975-83-6P 334975-85-8P
334975-88-1P
RL BAC (Biological activity or effector, except adverse); BSU
(Biological
study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOH
(Biological study); PREP (Preparation)
(1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold for probing S'
subsites of human leukocyte elastase, proteinase 3 and cathepsin G)
RN 334975-68-7 HCAPLUS
CN L-Phenylalanine, N-([1,1-dimethylethoxy]carbonyl)-, [(4S)-4-(2-
methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-
yl]methyl ester (9CI) (CA INDEX NAME)
Absolute stereochemistry.

L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 334975-81-4 HCAPLUS
CN L-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 334975-83-6 HCAPLUS
CN L-Phenylalanine, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


BN 334975-05-8 HCAPLUS

L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 334975-69-8 HCAPLUS
CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 334975-75-6 HCAPLUS
CN L-Phenylalanine, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl ester, mono(trifluoroacetate) {9CI} (CA INDEX NAME)

CM 1


CRN 334975-74-5
CMF C23 H29 N3 O5 S

Absolute stereochemistry.



L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN D-Phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 334975-88-1 HCAPLUS
CN D-Phenylalanine, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 334975-87-0
CMF C26 H27 N3 O5 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2




REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS


L4 ANSWER 20 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 19 Jul 2000
 ACCESSION NUMBER: 2000:488727 HCAPLUS
 DOCUMENT NUMBER: 133:277919
 TITLE: Potent inhibition of serine proteases by heterocyclic sulfide derivatives of 1,2,5-thiadiazolidin-3-one 1,1 dioxide
 AUTHOR(S): He, S.; Kuang, R.; Venkataraman, R.; Tu, J.; Truong, T. M.; Chan, H. K.; Groutas, W. C.
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(7), 1713-1717
 CODEN: BMCEP; ISSN: 0968-0896
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:277919
 AB The existence of subtle differences in the Sn' subsites of closely-related (chymo)trypsin-like serine proteases, and the fact that the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold docks to the active site of (chymo)trypsin-like enzymes in a substrate-like fashion, suggested that the introduction of recognition elements that can potentially interact with the Sn' subsites of these proteases might provide an effective means for optimizing enzyme potency and selectivity. Accordingly, a series of heterocyclic sulfide derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold (I) was synthesized and the inhibitory activity and selectivity of these compds. toward human leukocyte elastase (HLE), proteinase 3 (PR 3) and cathepsin G (Cat G) were then determined. Compds. with Pi-isobutyl were found to be potent, time-dependent inhibitors of HLE and, to a lesser extent PR 3, while those with Pi-benzyl inactivated Cat G rapidly and irreversibly. This study has demonstrated that 1,2,5-thiadiazolidin-3-one 1,1 dioxide-based heterocyclic sulfides are effective inhibitors of (chymo)trypsin-like serine proteases.
 IT 220869-26-1P 220869-27-2P 220869-29-4P
 220869-30-7P 220869-33-0P 220869-35-2P
 220869-38-5P 220869-39-6P 220869-40-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (potent inhibition of serine proteases by heterocyclic sulfide derivs. of thiadiazolidinone dioxide)
 RN 220869-26-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-27-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(4,5-diphenyl-2-oxazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-29-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(5-phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 220869-30-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzothiazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-33-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(3-phenyl-1,2,4-oxadiazol-5-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-35-2 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-2-[(5-phenyl-2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-38-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr


L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-39-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[(5-phenyl-1,3,4-oxadiazol-2-yl)thio]methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-40-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[(6-amino-2-benzoxazolyl)thio]methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



IT 300553-85-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(synthesis of thiadiazolidinone dioxide derivative; potent inhibition of serine proteases by heterocyclic sulfide derivs. of thiadiazolidinone dioxide)

L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 15 Jun 2000

ACCESSION NUMBER: 2000:395930 HCAPLUS

DOCUMENT NUMBER: 133:159638

TITLE: Utilization of the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold in the design of potent inhibitors of

AUTHOR(S): serine proteases: SAR studies using carboxylates
Kuang, R.; Epp, J. B.; Ruan, S.; Chong, L. S.; Venkataraman, R.; Tu, J.; He, S.; Truong, T. M.; Groutas, W. C.

CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA

SOURCE: Bioorganic & Medicinal Chemistry (2000), 8(5), 1005-1016

CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A series of carboxylate derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1-dioxide and isothiazolidin-3-one 1,1-dioxide scaffolds has been synthesized and the inhibitory profile of these compds. toward human leukocyte elastase (HLE), cathepsin G (Cat G) and proteinase 3 (PR 3) was then determined. Most of the compds. were found to be potent, time-dependent

inhibitors of elastase, with some of the compds. exhibiting K_i/K_I values as high as 4,928,300 M⁻¹ s⁻¹. The inhibitory potency of carboxylate derivs. based on the 1,2,5-thiadiazolidin-3-one 1,1-dioxide platform was found to be influenced by both the pKa and the inherent structure of the leaving group. Proper selection of the primary specificity group was found to lead to selective inhibition of HLE over Cat G, however, those compds. that inhibited HLE also inhibited PR 3, albeit less efficiently. The predictable mode of binding of these compds. suggests that, among closely-related serine proteases, highly selective inhibitors of a particular serine protease can be fashioned by exploiting subtle differences in their S' subsites.

IT 247179-63-1P 287921-30-6P 287921-33-9P 287921-37-3P 287921-38-4P 287921-39-5P 287921-42-0P 287921-45-3P 287921-46-4P 287921-52-2P 287921-54-4P 287921-65-7P 287921-91-9P

RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of thiadiazolidinone dioxides and isothiazolidinone dioxides as serine protease inhibitors)

RN 247179-63-1 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

as serine protease inhibitors)

RN 247179-63-1 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 21 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 300553-85-9 HCAPLUS

CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS

FORMAT


RECORD. ALL CITATIONS AVAILABLE IN THE RE

L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 287921-30-6 HCAPLUS


CN Propanoic acid, 2,2-dimethyl-, [4-ethyl-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)



RN 287921-33-9 HCAPLUS

CN Benzeneacetic acid, 4-[[[(3S)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]-1,1-dioxido-4-oxo-3-propyl-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287921-37-3 HCAPLUS


CN Propanoic acid, 2,2-dimethyl-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-38-4 HCAPLUS
CN Benzenecetic acid, 4-[[[(3S)-5-[(2,2-dimethyl-1-oxopropoxy)methyl]-3-(2-methylpropyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287921-39-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-42-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(benzoyloxy)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 22 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN Benzenepropanoic acid, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-54-4 HCAPLUS
CN Benzenecetic acid, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-65-7 HCAPLUS
CN Benzoic acid, 2,6-dichloro-, [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-91-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 287921-45-3 HCAPLUS
CN Benzoic acid, 2,6-dichloro-, [(4S)-4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-46-4 HCAPLUS
CN Benzenecetic acid, 4-[[[(3S)-5-[(2,6-dichlorobenzoyloxy)methyl]-3-(2-methylpropyl)-1,1-dioxido-4-oxo-1,2,5-thiadiazolidin-2-yl]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287921-52-2 HCAPLUS



IT 212331-98-1P 212331-99-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of thiadiazolidinone dioxides and isothiazolidinone dioxides as serine protease inhibitors)


RN 212331-98-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

10510026rtr

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 19 May 2000
 ACCESSION NUMBER: 2000:324184 HCAPLUS
 DOCUMENT NUMBER: 133:105000
 TITLE: Solid-phase synthesis of sulfahydantoin
 AUTHOR(S): Albericio, Fernando; Garcia, Javier; Michelotti, Enrique L.; Nicolas, Ernesto; Tice, Colin M.
 CORPORATE SOURCE: Department of Organic Chemistry, University of Barcelona, Barcelona, 08028, Spain
 SOURCE: Tetrahedron Letters (2000), 41(17), 3161-3163
 CODEN: TELEAY; ISSN: 0040-4039
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 133:105000
 AB A 5-step solid-phase synthesis of 2-unsubstituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides, sulfahydantoin, from Nu-Fmoc amino acids and aromatic aldehydes is described. The key step is the base-mediated cyclization of a resin bound Nu-aminosulfonyl Nu-benzyl amino acid to afford the desired product. This synthesis allows the preparation of a diverse library of compds. based on this heterocycle.
 IT 283587-14-4P 283587-15-5P 283587-16-6P
 283587-18-8P 283587-19-9P 283587-21-3P
 283587-22-4P 283587-24-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid-phase synthesis of sulfahydantoin library)
 RN 283587-14-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(4-methoxyphenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 283587-15-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,4-dichlorophenyl)methyl]-4-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 283587-16-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[(3-methylphenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 283587-18-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-[(4-(trifluoromethyl)phenyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 283587-19-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 283587-21-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-(1-methylethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 283587-22-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(4-methoxyphenyl)methyl]-4,4-dimethyl-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 283587-24-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[(2-chlorophenyl)methyl]-4-[2-(methylthio)ethyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 23 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 27 Aug 1999
 ACCESSION NUMBER: 1999:536684 HCAPLUS
 DOCUMENT NUMBER: 131:296963
 TITLE: Human chymase inhibitors based on the
 1,2,5-thiadiazolidin-3-one 1,1 dioxide scaffold
 Groutas, William C.; Schechter, Norman M.; He, Shu;
 Yu, Hongyi; Huang, Peng; Tu, Juan
 CORPORATE SOURCE: Department of Chemistry, Wichita State University,
 Wichita, KS, 67260, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1999),
 9(15), 2199-2204
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of compds. that utilize the 1,2,5-thiadiazolidin-3-one 1,1
 dioxide scaffold was synthesized and shown to be highly effective
 inhibitors of recombinant human skin chymase..
 IT 170918-99-7 247179-41-2 247179-63-1
 247179-64-2 247179-65-3 247179-66-4
 247179-67-5 247179-68-6 247179-69-7
 247179-70-0 247179-71-1 247179-72-2
 247179-74-4 247179-75-5 247179-76-6
 RL: BAC (Biological activity or effector, except adverse); BSU
 (Biological
 study, unclassified); PRP (Properties); BIOL (Biological study)
 (human chymase inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1
 dioxide scaffold)
 RN 170918-99-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-
 [(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247179-41-2 HCAPLUS
 CN Benzoic acid, 4-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Acetic acid, hydroxy-,
 [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-66-4 HCAPLUS
 CN Propanoic acid, 2-hydroxy-,
 [(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247179-67-5 HCAPLUS
 CN Benzeneacetic acid, α-hydroxy-, [(4S)-1,1-dioxido-3-oxo-4,5-
 bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl ester (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 247179-63-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(acetyloxy)methyl]-4,5-bis(phenylmethyl)-,
 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247179-64-2 HCAPLUS
 CN Propanedioic acid, mono[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-
 1,2,5-thiadiazolidin-2-yl]methyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 247179-65-3 HCAPLUS

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 247179-68-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-[(methylsulfonyl)methyl]-4,5-
 bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-69-7 HCAPLUS
 CN Acetic acid, [[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247179-70-0 HCAPLUS
 CN Propanoic acid, 3-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-
 thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.



RN 247179-71-1 HCAPLUS
CN Benzoic acid, 2-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 247179-72-2 HCAPLUS
CN Benzoic acid, 3-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl]sulfonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR
THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 24 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 247179-74-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[(2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-75-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[(6-amino-2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247179-76-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[(5-phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 25 Aug 1999
ACCESSION NUMBER: 1999:529836 HCAPLUS
DOCUMENT NUMBER: 131:296959
TITLE: A General Inhibitor Scaffold for Serine Proteases

With
a (Chymo)trypsin-Like Fold: Solution-Phase Construction and Evaluation of the First Series of Libraries of Mechanism-Based Inhibitors
AUTHOR(S): Kuang, Rongye; Epp, Jeffrey B.; Ruan, Sumei; Yu, Hongyi; Huang, Peng; He, Shu; Tu, Juan; Schechter, Norman M.; Turbov, Jane; Froelich, Christopher J.; Groutas, William C.
CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
SOURCE: Journal of the American Chemical Society (1999), 121(35), 8128-8129
CODEN: JACSAT; ISSN: 0002-7863
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The authors demonstrate that the 1,2,5-thiadiazolidin-3-one 1,1 dioxide platform embodies a general motif that renders the platform capable of binding to the active site of many serine proteases with a (chymo)trypsin-like fold in a predictable fashion and is amenable to the facile construction of libraries for lead identification and optimization.
IT 170918-99-7P 170919-03-6P 189124-02-5P
247178-39-8P 247178-40-1P 247178-41-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(inhibitor; general inhibitor scaffold for serine proteases with a (chymo)trypsin-like fold with solution-phase construction and evaluation of first series of libraries of mechanism-based inhibitors)
RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


10510026rtr

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
Absolute stereochemistry.




RN 189124-02-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((phenylsulfonyl)methyl)-2-phenyl-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247178-39-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((4-aminobutyl)-5-(phenylmethyl)-2-((phenylsulfonyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 16 Mar 1999
ACCESSION NUMBER: 1999:172588 HCAPLUS
DOCUMENT NUMBER: 130:209985
TITLE: Preparation of 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives as serine protease inhibitors
INVENTOR(S): Groutas, William C.; Kuang, Rongze
PATENT ASSIGNEE(S): Wichita State University, USA
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909977	A1	19990304	WO 1998-US17406	19980821
W: AU, BR, CA, IS, JP, MX, NZ				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 6420401	B1	20020716	US 1997-916693	19970822
US 9890298	A	19990316	AU 1998-90298	19980821
EP 1011668	A1	20000628	EP 1998-942192	19980821
R: DE, GB				
PRIORITY APPLN. INFO.:			US 1997-916693	A 19970822
			WO 1998-US17406	W 19980821

OTHER SOURCE(S): MARPAT 130:209985
GI




AB Substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxide derivs. I [R1, R3 = independently H, alkyl, aryl, aralkyl, alkaryl, substituted aryl; R2 = H, alkyl, aralkyl, alkylthioalkyl, hydroxyalkyl, amino acid side chain; R4 = H, alkyl, aryl, aralkyl, amino acid side chain, PO3R82, NCO, NHCHR7CO2R10, NHCONR12R13, CO-O, -CHRTNHM, [CHRTNHCO]R10, [CHRTCONH]R10, NHG, Q = OR10, OJ, NR12R13, halo, (NHCHR7CO)qOR10, (NHCHR7CO)qNR10R16, OPn, NHFR, R5 = R1, halo; R6 = H, alkyl, aryl, aralkyl, NCO, COR9, COQ1, NHCHR7CO2R11, NH2, NHG, NHCO2R11, NHCONR14R15, O2CCH2(OCN2CH2)2OR, O-X; R = alkyl; Q1 = OR11, OJ, NR14R15, (NHCHR7CO)OR11, halo; X = COR9, (COCHR7NH)Xp, CHRTNH, CHRT(NHCOCHR7)PnHW1, (CONHCHR7)zCO2R11, CO2R11, S(O)nR9, N(SO2R18)COK; Pn = polymer; each W, W1 = H, G, CONHCHR7CO2R10; each q, z = 1-10; Xp = H, G; G = amino protecting group; J = carboxyl protecting group; Y = H, R9, COR9, G; z = 1-10; n = 0-2; K = R9, OR9, NHR9, OCHR7NHV, (NHCHR7CO)mOR9, (NHCHR7CO)mNR10R17; V = G, H, COCHR7NHZ;

L4 ANSWER 25 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 247178-40-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-acetic acid, 4-oxo-2-(phenylmethyl)-5-((phenylsulfonyl)methyl)-, 1,1-dioxide, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 247178-41-2 HCAPLUS
CN Benzoic acid, 4-[[[(4S)-1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl]sulfonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
= G, H; m = 1-2; each R7 = amino acid side chain; each R8, R9 = alkyl, aryl, aralkyl, alkaryl, heterocyclyl; each R10-R15 = H, any group R8; each R16, R17 = heterocyclylalkyl; R18 = any group R8, NHR19; R19 = alkyl, aryl, aralkyl; with provisos, oligomers and combinatorial libraries contg. them, and methods of using them, are disclosed. Thus, title compd.

II showed apparent second-order rate consts. Kinact/KI (M⁻¹s⁻¹) of 119,360, 27,400, and 60 for inhibition of human leukocyte elastase, proteinase 3, and cathepsin G, resp., by in Vitro assays.
IT 220868-74-6DP, combinatorial library derivs. 220868-75-7DP, combinatorial library derivs. 220868-80-4DP, combinatorial library derivs. 220868-81-5DP, combinatorial library derivs. 220868-86-0DP, combinatorial library derivs. 220868-87-1DP, combinatorial library derivs. 220868-92-8DP, combinatorial library derivs. 220868-93-9DP, combinatorial library derivs. 220868-98-4DP, combinatorial library derivs. 220868-99-5DP, combinatorial library derivs. 220869-05-6P, 220869-06-7P, 220869-07-8P, 220869-14-7P, 220869-16-9P, 220869-19-2P, 220869-20-5P, 220869-26-1P, 220869-27-2P, 220869-29-4P, 220869-30-7P, 220869-33-0P, 220869-35-2P, 220869-38-5P, 220869-39-6P, 220869-40-9P, 220869-41-0P
RL: BAC (Biological activity or effector, except adverse): BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of amino acid-derived thiadiazolidinone dioxide derivs.


as serine protease inhibitors)
RN 220868-74-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-5-[[[4-methoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220868-75-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-5-[[[3-phenoxyphenyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

10510026rtr

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220868-80-4 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-((acetyloxy)methyl)-5-((4-methoxyphenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220868-81-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 2-((acetyloxy)methyl)-5-((3-phenoxyphenyl)methyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220868-86-0 HCAPLUS
 CN Carbamic acid, [[5-((4-methoxyphenyl)methyl)-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 220868-87-1 HCAPLUS
 CN Carbamic acid, [[1,1-dioxido-3-oxo-5-[(3-phenoxyphenyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl](methylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220868-92-8 HCAPLUS
 CN L-Phenylalanine, 4-chloro-N-[[[5-((4-methoxyphenyl)methyl)-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220868-93-9 HCAPLUS
 CN L-Phenylalanine, 4-chloro-N-[[[5-((4-methoxyphenyl)methyl)-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220868-98-4 HCAPLUS
 CN L-Phenylalanine, 4-chloro-N-[[[5-((4-methoxyphenyl)methyl)-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220868-99-5 HCAPLUS
 CN L-Phenylalanine, 4-chloro-N-[[[5-((4-methoxyphenyl)methyl)-1,1-dioxido-3-oxo-1,2,5-thiadiazolidin-2-yl)methyl]thio]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10510026rtr

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-05-6 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 220869-06-7 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 220869-16-9 HCAPLUS
CN Carbamic acid,
[2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 220869-19-2 HCAPLUS
CN Glycine,
N-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](phenylsulfonyl)amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 220869-20-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2,2'-methylenebis[4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1,1',1'-tetraoxide (9CI) (CA INDEX NAME)


L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-07-8 HCAPLUS
CN Carbamic acid, [[1,1-dioxido-3-oxo-4,5-bis(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)-, butyl ester (9CI) (CA INDEX NAME)




RN 220869-14-7 HCAPLUS
CN Carbamic acid,
[2-[[[4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl]methyl](methylsulfonyl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-26-1 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[2-benzoxazolylthio]methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-27-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
2-[[[4,5-diphenyl-2-oxazolyl]thio]methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-29-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[5-

10510026rtr

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-30-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[2-benzothiazolylthio)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-33-0 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((2-methylpropyl)-5-(phenylmethyl)-2-[[3-phenyl-1,2,4-oxadiazol-5-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 220869-40-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[6-amino-2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-41-0 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, alpha-fluoro-3-oxo-4,5-bis(phenylmethyl)-, ethyl ester, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220869-64-7 220869-65-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of amino acid-derived thiadiazolidinone dioxide derivs.


as serine protease inhibitors)

RN 220869-64-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((2-methylpropyl)-5-(phenylmethyl)-,


L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-35-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((2-methylpropyl)-2-[[5-phenyl-2-benzoxazolylthio)methyl]-5-(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 220869-38-5 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[2-benzoxazolylthio)methyl]-4,5-bis(phenylmethyl)-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 220869-39-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[[5-phenyl-1,3,4-oxadiazol-2-ylthio)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)


L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220869-65-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 220869-61-4P 220869-62-5P 220869-63-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid-derived thiadiazolidinone dioxide derivs.

as serine protease inhibitors)

RN 220869-61-4 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-((2-methylpropyl)-3-oxo-5-(phenylmethyl)-, 1,1-dimethylethyl ester, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220869-62-5 HCAPLUS
CN 1,2,5-Thiadiazolidine-2-acetic acid, 4-((2-methylpropyl)-3-oxo-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10510026rtr

L4 ANSWER 26 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 220869-63-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-3-oxo-N-(2-phenylethyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 05 Aug 1998

ACCESSION NUMBER: 129:216561 HCAPLUS

DOCUMENT NUMBER: 129:216561

TITLE: Potent and specific inhibition of human leukocyte elastase, cathepsin G and proteinase 3 by sulfone derivatives employing the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold

AUTHOR(S): Groutas, William C.; Kuang, Rongze; Ruan, Sumei; Epp, Jeffrey B.; Venkataraman, Radhika; Truong, Tien M. Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA


SOURCE: Bioorganic & Medicinal Chemistry (1998), 6(6), 661-671

PUBLISHER: CODEN: BMECEP; ISSN: 0968-0896

DOCUMENT TYPE: Elsevier Science Ltd.

LANGUAGE: Journal

GI English



AB This paper describes the results of structure-activity relationship studies in a series of heterocyclic mechanism-based inhibitors based on the 1,2,5-thiadiazolidin-3-one 1,1-dioxide scaffold (I; R1 = iso-Bu, benzyl; R2 = Bu, Me, benzyl, CH2COOCMe3, etc.; L = SO2Ph, SO2C6H4Cl-4, etc.) and capable of interacting with the Sn and S'n subsites of a serine proteinase. Sulfone derivs. of I were found to be highly effective, time-dependent inhibitors of human leukocyte elastase (HLE), cathepsin G (Cat G) and proteinase 3 (PR 3). The judicious selection of an R1 group (accommodated at the primary specificity site S1) that is based on the known substrate specificity of a target serine proteinase, was found to yield highly selective inhibitors. The presence of a benzyl group (R2 = benzyl) at the S2 subsite was found to lead to a pronounced enhancement

in inhibitory potency. Furthermore, the effective use of computer graphics and modeling has led to the design of potent, water-soluble inhibitors.

The results of these studies demonstrate that the 1,2,5-thiadiazolidin-3-one 1,1-dioxide platform provides an effective means for appending recognition elements in a well-defined vector relationship, and in fashioning highly-selective and potent inhibitors of serine proteinases.

IT 212331-98-1P 212331-99-2P 212332-00-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(1,2,5-thiadiazolidin-3-one 1,1-dioxide inhibitors of human leukocyte elastase, cathepsin G and proteinase 3)

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 212331-98-1 HCAPLUS


CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-((phenylthio)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212331-99-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(chloromethyl)-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212332-00-8 HCAPLUS
CN Benzenecetic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylthio)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 212331-79-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) (preparation as inhibitor of human leukocyte elastase, cathepsin G and proteinase 3)

RN 212331-79-8 HCAPLUS

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzoic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylsulfonyl)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 170918-99-7P 170919-01-4P 170919-03-6P
212331-77-6P 212331-78-7P 212331-80-1P
212331-81-2P 212331-82-3P 212331-83-4P
212331-86-7P 212331-87-8P 212331-90-3P
212331-92-5P 212331-94-7P 212331-95-8P
212331-97-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (preparation as inhibitor of human leukocyte elastase, cathepsin G and proteinase 3)

RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis((phenylmethyl)-2-((phenylsulfonyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170919-01-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(phenylmethyl)-5-((2E)-3-phenyl-2-propenyl)-2-((phenylsulfonyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


10510026rtr

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((2-methylpropyl)-5-(phenylmethyl)-2-((phenylsulfonyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212331-77-6 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylsulfonyl)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212331-78-7 HCAPLUS
CN Benzoic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylsulfonyl)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 212331-82-3 HCAPLUS
CN Benzoic acid, 2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylsulfonyl)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-83-4 HCAPLUS
CN Benzenesacetic acid, 4-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylsulfonyl)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212331-86-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[(4-chlorophenyl)sulfonyl)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.



RN 212331-80-1 HCAPLUS
CN Benzoic acid, 3-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylsulfonyl)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 212331-81-2 HCAPLUS
CN Benzoic acid, 2-[[[(3S)-3-(2-methylpropyl)-1,1-dioxido-4-oxo-5-((phenylsulfonyl)methyl)-1,2,5-thiadiazolidin-2-yl)methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 212331-87-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-((2-methylpropyl)-5-(2-phenylethyl)-2-((phenylsulfonyl)methyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-90-3 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-[[[(4-chlorophenyl)sulfonyl)methyl]-4-(2-methylpropyl)-5-(phenylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




10510026rtr

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 212331-92-5 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[[3-phenylpropyl)sulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 212331-94-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[[[3-(trifluoromethyl)phenyl)sulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 212331-95-8 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 27 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 212331-97-0 HCAPLUS
 CN Benzeneacetic acid, 4-[[[3S)-1,1-dioxido-4-oxo-3-(phenylmethyl)-5-[(phenylsulfonyl)methyl]-1,2,5-thiadiazolidin-2-yl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L4 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN

ED Entered STN: 09 Apr 1998

ACCESSION NUMBER: 1998:200895 HCAPLUS

DOCUMENT NUMBER: 128:278642

TITLE: Use of the 1,2,5-thiadiazolidin-3-one 1,1 dioxido and isothiazolidin-3-one 1,1 dioxido scaffolds in the design of potent inhibitors of serine proteinases
 AUTHOR(S): Kuang, Rongze; Venkataraman, Radhika; Ruan, Sumei; Groutas, William C.

CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(5),

539-544

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The attachment of a phosphate leaving group to the 1,2,5-thiadiazolidin-3-one 1,1 dioxido and isothiazolidin-3-one 1,1 dioxido scaffolds was found to yield highly potent, time-dependent inhibitors of human leukocyte elastase (HLE).

IT 205932-85-OP 205932-87-2P 205932-88-3P

205932-89-4P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (use of the 1,2,5-thiadiazolidin-3-one 1,1 dioxido and isothiazolidin-3-one 1,1 dioxido scaffolds in the design of potent inhibitors of serine proteinases)

RN 205932-85-0 HCAPLUS
 CN Phosphoric acid, dimethyl [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl ester (9CI) (CA INDEX NAME)




RN 205932-87-2 HCAPLUS
 CN Phosphoric acid, dibutyl [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 28 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 205932-88-3 HCAPLUS
 CN Phosphoric acid, [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl bis(phenylmethyl) ester (9CI) (CA INDEX NAME)




RN 205932-89-4 HCAPLUS
 CN Phosphoric acid, [4-(2-methylpropyl)-1,1-dioxido-3-oxo-5-(phenylmethyl)-1,2,5-thiadiazolidin-2-yl)methyl diphenyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

10510026rtr

L4 ANSWER 29 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 30 Aug 1997
 ACCESSION NUMBER: 1997:555602 HCAPLUS
 DOCUMENT NUMBER: 127:257045
 TITLE: Competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels in mouse plasma
 AUTHOR(S): Bright, Stuart W.; Tinsley, Frank C.; Dominianni, Samuel J.; Schmiegel, Klaus K.; Fitch, Lora L.; Gold, Gerald
 CORPORATE SOURCE: Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SOURCE: Journal of Immunological Methods (1997), 207(1), 23-31
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Two competitive particle concentration fluorescence immunoassays were developed to measure blood levels of analogs of antidiabetic drugs being tested in diabetic mice. Ligands that contained the active pharmacophores were conjugated to PPD for immunization and to β -phycoerythrin for use as a tracer in the immunoassays. Approx. 90% of 262 compds. assayed were detectable at less than 120 nM in plasma which was well below the estimated therapeutic level of 1 μ M for lowering blood glucose. These data were used to define the bioavailability of test compds. and assist in decisions of constructing active analogs. Of addnl. interest, we noted crossreactivity of one monoclonal antibody for 3 different compound classes that are all known to bind with varying affinities to peroxisome proliferator-activated receptors.
 IT 196079-43-3
 RL: ANT (Analyte); ANST (Analytical study)
 (competitive particle concentration fluorescence immunoassays for measuring antidiabetic drug levels in mouse plasma)
 RN 196079-43-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 5-[4-[2-(2-phenyl-4-oxazolyl)ethoxy]phenyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS

L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 09 Apr 1997
 ACCESSION NUMBER: 1997:226843 HCAPLUS
 DOCUMENT NUMBER: 126:287581
 TITLE: Structure-Based Design of a General Class of Mechanism-Based Inhibitors of the Serine Proteinases Employing a Novel Amino Acid-Derived Heterocyclic Scaffold
 AUTHOR(S): Groutas, William C.; Kuang, Rongze; Venkataraman, Radhika; Epp, Jeffrey B.; Ruan, Sumei; Prakash, Om
 CORPORATE SOURCE: Department of Chemistry, Wichita State University, Wichita, KS, 67260, USA
 SOURCE: Biochemistry (1997), 36(16), 4739-4750
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB We describe in this paper the structure-based design of a general class of heterocyclic mechanism-based inhibitors of the serine proteinases that embody in their structure a novel peptidomimetic scaffold (1,2,5-thiadiazolidin-3-one 1,1-dioxide). Sulfone derivs. of this class were time-dependent, potent, and highly efficient irreversible inhibitors of human leukocyte elastase, cathepsin G, and proteinase 3. The partition ratios for a select number of inhibitors were found to range between 0 and 1. We furthermore demonstrate that these inhibitors exhibit remarkable enzyme selectivity that is dictated by the nature of the P1 residue and is consistent with the known substrate specificity reported for these enzymes. Thus, inhibitors with small hydrophobic side chains were effective inhibitors of elastase, those with aromatic side chains of cathepsin G, and those with a basic side chain of bovine trypsin. Taken together, the findings cited herein reveal the emergence of a general class of stable mechanism-based inhibitors of the serine proteinases which can be readily synthesized using amino acid precursors. Biochem. and high-field NMR studies show that the interaction of this class of inhibitors with a serine proteinase results in the formation of a stable acyl complex(es) and the release of benzenesulfinate, formaldehyde, and a low mol. weight heterocycle. The data are consistent with initial formation of a Michaelis-Menten complex, acylation of Ser195, and tandem loss of the leaving group. The initial HLE-inhibitor complex reacts with water generating formaldehyde and a stable HLE-inhibitor complex. Whether the initial HLE-inhibitor complex also reacts with His57 to form a third complex is not known at this point. The desirable salient parameters associated with this class of inhibitors, including the expeditious generation of structurally diverse libraries of inhibitors based on I, suggest that this class of mechanism-based inhibitors is of general applicability and can be used in the development of inhibitors of human and viral serine proteinases of clin. relevance.
 IT 170918-99-7P 170919-03-6P 189124-00-3P 189124-02-5P 189124-04-7P 189124-06-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and activity relations of mechanism-based inhibitors)

L4 ANSWER 29 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT


L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 of human leukocyte serine proteinases employing a novel amino acid-derived heterocyclic scaffold)
 RN 170918-99-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170919-03-6 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189124-00-3 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-ethyl-5-(phenylmethyl)-2-[(phenylsulfonyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 189124-02-5 HCAPLUS

10510026rtr


L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-(phenylmethyl)-2-
 5-(phenylsulfonylmethyl)-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 189124-04-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-[(1-methylethyl)-5-(phenylmethyl)-2-
 5-(phenylsulfonylmethyl)-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 189124-06-9 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-butyl-5-(phenylmethyl)-2-
 5-(phenylsulfonylmethyl)-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ED Entered STN: 01 Dec 1995
 ACCESSION NUMBER: 1995:954574 HCAPLUS
 DOCUMENT NUMBER: 123:340140
 TITLE: Novel serine protease inhibitors: derivatives of
 isothiazolidin-3-one 1,1-dioxide and
 3-oxo-1,2,5-thiadiazolidine 1,1-dioxide
 Groutas, William C.
 INVENTOR(S): Wichita State University, USA
 PATENT ASSIGNEE(S):
 SOURCE: PCT Int. Appl., 93 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9518797	A1	19950713	WO 1995-US236	19950103
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5550139	A	19960827	US 1994-177352	19940103
CA 2179913	A1	19950713	CA 1995-2179913	19950103
AU 9515998	A	19950801	AU 1995-15998	19950103
AU 686316	B2	19980205		
EP 739338	B1	19961030	EP 1995-908003	19950103
EP 739338	B1	20020410		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09509922	T	19971007	JP 1995-518638	19950103
AT 215938	T	20020415	AT 1995-908003	19950103
NZ 329766	A	20010223	NZ 1998-329766	19980216
PRIORITY APPL. INFO.:			US 1994-177352	A 19940103
			WO 1995-US236	W 19950103

OTHER SOURCE(S): MARPAT 123:340140
 GI



AB Various isothiazolidin-3-one 1,1-dioxide and 3-oxo-1,2,5-thiadiazolidine 1,1-dioxide deriva., e.g. I [X = CH₂, (un)substituted NH; R₁ = H, alkyl, (un)substituted benzyl, indolylalkyl, etc.; Y = non-steroidal antiinflammatory residue, H, protected amino acid, acyloxy, etc.], and their use to reduce or inhibit the activity of serine proteases, are claimed. The compds. are useful as anti-inflammatory and anti-metastatic agents. For example, 4-benzylisothiazolidin-3-one 1,1-dioxide underwent


L4 ANSWER 30 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 N-alkylation with ClCH₂SPh and Et₃N in MeCN, followed by S-oxidn. With m-ClC₆H₄C(O)OOH in CH₂Cl₂ (90%), to give title compd. II. In an in vitro assay, II had an apparent 2nd-order inactivation rate const. (k_{obs}/[I])
 M-1 s-1) of 960 against cathepsin G. A variety of compds. were prepd. and/or tested against cathepsin G, human leukocyte elastase, and/or proteinase-3.
 IT 170919-16-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (intermediate; preparation of isothiazolidinone and oxothiadiazolidine dioxide derivs. as serine protease inhibitors)
 RN 170919-16-1 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-(phenylmethyl)-5-(3-phenyl-2-propenyl)-2-
 5-(phenylthiomethyl)-, 1,1-dioxide, [S-(E)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
 Double bond geometry as shown.



IT 170919-15-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of isothiazolidinone and oxothiadiazolidine dioxide derivs. as serine protease inhibitors)
 RN 170919-15-0 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-[(phenylthio)methyl]-, 1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 153044-45-2P 170918-99-7P 170919-01-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified)

10510026rtr


L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of isothiazolidinone and oxothiadiazolidine dioxide derivs. as
serine protease inhibitors)
RN 153044-45-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-,
1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 170918-99-7 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4,5-bis(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 170919-01-4 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one,
4-(phenylmethyl)-5-[(2E)-3-phenyl-2-propenyl]-
2-[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 170919-03-6 170919-21-8 170919-22-9
RL: BAC (Biological activity or effector, except adverse); BSU
(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study);
USES
(Uses)
(preparation of isothiazolidinone and oxothiadiazolidine dioxide
derivs. as
serine protease inhibitors)


RN 170919-03-6 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 170919-21-8 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 4-(2-methylpropyl)-5-(phenylmethyl)-2-
[(phenylsulfonyl)methyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)

L4 ANSWER 31 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 170919-22-9 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-,
1,1-dioxide (9CI) (CA INDEX NAME)



L4 ANSWER 32 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN


ED Entered STN: 19 Mar 1994
ACCESSION NUMBER: 1994:124451 HCAPLUS
DOCUMENT NUMBER: 120:124451
TITLE: Substituted 3-oxo-1,2,5-thiadiazolidine 1,1-dioxides:
a new class of potential mechanism-based inhibitors
of
human leukocyte elastase and cathepsin G
AUTHOR(S): Groutas, William C.; Kuang, Rongze; Venkataraman,
Radhika
CORPORATE SOURCE: Dep. Chem., Wichita State Univ., Wichita, KS, 67260,
USA
SOURCE: Biochemical and Biophysical Research Communications
(1994), 198(1), 341-9
CODEN: BBRCA9; ISSN: 0006-291X
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB A series of substituted 3-oxo-1,2,5-thiadiazolidine 1,1-dioxides (I, R =
benzyl; R1 = H, Me, benzyl, CH2CO2-tert-Bu or CH2CO2-benzyl) was prepd.
and their in vitro inhibitory activity toward human leukocyte elastase
and
cathepsin G was investigated. These compds. inactivated the 2 enzymes
efficiently and in a time-dependent fashion.



IT 153044-45-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of and human leukocyte elastase and cathepsin G
inhibition by)
RN 153044-45-2 HCAPLUS
CN 1,2,5-Thiadiazolidin-3-one, 2-(fluoromethyl)-4,5-bis(phenylmethyl)-,
1,1-dioxide, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



10510026rtr

L4 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN
 ED Entered STN: 26 Jan 1991
 ACCESSION NUMBER: 1991:23940 HCAPLUS
 DOCUMENT NUMBER: 114:23940
 TITLE: Intra- and intermolecular α -sulfamidoalkylation reactions
 AUTHOR(S): Lee, Chai Ho; Kohn, Harold
 CORPORATE SOURCE: Dep. Chem., Univ. Houston, Houston, TX, 77204-5641, USA
 SOURCE: Journal of Organic Chemistry (1990), 55(25), 6098-104
 CODEN: JOCEAH; ISSN: 0022-3263
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 114:23940
 GI




AB The utility of α -sulfamidoalkylation processes for the generation of sulfamides has been examined. Both intra- and intermol. α -sulfamidoalkylation transformations were observed to proceed in moderate

to good yields. The generality of these processes has been demonstrated using N,N' -di(aryl-substituted)sulfamides, and the utility of these reactions was examined for the preparation of cyclic sulfamides of novel structure. Thus, reaction of $\text{PhCH}_2\text{NHSO}_2\text{NH}_2$ with $\text{EtO}_2\text{CCH}(\text{OEt})_2$ in the presence of $\text{CF}_3\text{CO}_2\text{H}$ gave 74% dithiatetrazocinedicarboxylate tetraoxide I, whereas reaction of 3-MeOC₆H₄CH₂NHSO₂NH₂ with $\text{EtO}_2\text{CCH}(\text{OEt})_2$ in $\text{CF}_3\text{CO}_2\text{H}$ followed by methylation gave benzothiadiazepinecarboxylate dioxide II. The crystal structures of I and II were determined.


IT 130670-00-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of)
 RN 130670-00-7 HCAPLUS
 CN 1,2,5-Thiadiazolidin-3-one, 4-hydroxy-5-(2-phenylethyl)-, 1,1-dioxide, monosodium salt (9CI) (CA INDEX NAME)

L4 ANSWER 33 OF 33 HCAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● Na

IT 130669-99-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydride reduction of)
 RN 130669-99-7 HCAPLUS
 CN 1,2,5-Thiadiazolidine-3,4-dione, 2-(2-phenylethyl)-, 1,1-dioxide, sodium salt (9CI) (CA INDEX NAME)



● Na

10510026rtr

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

173.69

340.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-24.75

-24.75

STN INTERNATIONAL LOGOFF AT 12:20:59 ON 21 DEC 2006